{"caa570dadcc721c6bd0b9121ce4501bfe6e644f1": [["IntroductionGlobal warming and climate change have generated a tremendous challenge to our society in the last decades [1] .", [["Global warming", "TREATMENT", 12, 26], ["a tremendous challenge", "TREATMENT", 61, 83]]], ["The challenge of reducing environmental pollution and obtaining sustainable development is an important issue for governments, organizations, researchers, and practitioners [2] .", [["reducing environmental pollution", "TREATMENT", 17, 49]]], ["Green purchases and green food consumption are core issues that contribute to such a challenge [3] .IntroductionVarious studies have examined the issue of green purchases and green food consumption in the current literature.", [["core issues", "PROBLEM", 47, 58], ["Various studies", "TEST", 112, 127], ["green food", "OBSERVATION", 20, 30]]], ["Li et al. [1] investigated gender inequality that affects a household's decision to adopt green consumption.", [["green", "ORGANISM_SUBDIVISION", 90, 95]]], ["Zhang et al. [6] determined the impact of haze pollution on residents' green consumption behavior.", [["haze", "DISEASE", 42, 46], ["green", "ORGANISM_SUBDIVISION", 71, 76], ["haze", "OBSERVATION", 42, 46]]], ["Furthermore, several studies have determined socioeconomic factors (e.g., gender, age, family size, and income) that influence green food purchase behavior [1, 4] .", [["several studies", "TEST", 13, 28], ["socioeconomic factors", "PROBLEM", 45, 66]]], ["Prior studies have provided substantial evidence on the 2 of 14 factors that influence green purchases and green food consumption.", [["Prior studies", "TEST", 0, 13]]], ["However, further research should explore additional factors and mechanisms that affect green food consumption and their impact on human physiological and psychological outcomes [3, 4, 7] .IntroductionSocial ideal theory believes that an individual expects an ideal society [8] [9] [10] .", [["human", "ORGANISM", 130, 135], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 130, 135]]], ["People who expect an ideal society often think and act in ways that generate benefits and bring goodwill to society [9] .", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["For example, those people tend to engage in charitable donation and philanthropy behavior [10] .", [["people", "ORGANISM", 19, 25], ["people", "SPECIES", 19, 25]]], ["Therefore, this study investigates the relationship between perceived consumer effectiveness and psychological wellbeing with the mediating role of green food consumption, drawing upon the theoretical foundation of social ideal theory.IntroductionIn addition, social trust theory states that people who hold a high level of social trust tend to be optimistic about the future and confident in society, and they tend to trust in others [14, 15] .", [["people", "ORGANISM", 292, 298], ["people", "SPECIES", 292, 298], ["this study", "TEST", 11, 21]]], ["Consequently, social trust may play an important role in enhancing people's perceptions of their ability to solve environmental and social problems.", [["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73]]], ["Social trust may also influence people's behavior toward consuming green products [16, 17] .", [["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38]]], ["Thus, this study also investigates the moderating role of social trust in the relationship between perceived consumer effectiveness and green food consumption.", [["food", "ORGANISM_SUBDIVISION", 142, 146], ["this study", "TEST", 6, 16]]], ["Moreover, this study examines the moderating role of social trust in the indirect effect of perceived consumer effectiveness on psychological wellbeing through green food consumption.IntroductionIn sum, this study focusses on social ideal theory and social trust theory to investigate the mediating role of green food consumption and the moderating role of social trust in the relationship between perceived consumer effectiveness and psychological wellbeing.", [["food", "ORGANISM_SUBDIVISION", 166, 170], ["this study", "TEST", 10, 20], ["this study", "TEST", 203, 213]]], ["The objective is to provide new insights into the antecedent and consequence of green food consumption.IntroductionThe structure of this paper is organized as follows.", [["food", "ORGANISM_SUBDIVISION", 86, 90]]], ["Section 3 discusses the research design and sample procedure.", [["sample procedure", "TREATMENT", 44, 60]]], ["People who hold high perceptions of effectiveness tend to believe that they can influence and improve environmental and social problems.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Higueras-Castillo et al. [13] also reported that perceived consumer effectiveness is an important predictor of consumers' attitudes toward electromobility.Perceived Consumer EffectivenessIn sum, prior studies have provided substantial evidence to explain the predictive ability of perceived consumer effectiveness on socially responsible behavior.Psychological WellbeingWellbeing refers to a physical, mental, and psychological state in which individuals experience a sense of happiness, satisfaction, and pleasure [25, 26] .", [["electromobility", "DISEASE", 139, 154], ["individuals", "ORGANISM", 443, 454], ["prior studies", "TEST", 195, 208]]], ["Three important scientific disciplines have been critical for the study of psychological wellbeing: developmental psychology often studies the psychological wellbeing of human life across different lifespans [25] .", [["human", "ORGANISM", 170, 175], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175]]], ["Clinical psychology emphasizes the association between mental illness and psychological wellbeing [28] .", [["illness", "DISEASE", 62, 69], ["mental illness", "PROBLEM", 55, 69]]], ["Several studies have reported important factors that affect life satisfaction, including personality, self-esteem, age, experience, personal values, culture, family, and career [25, [29] [30] [31] .", [["Several studies", "TEST", 0, 15]]], ["In this study, social life satisfaction is treated as a key factor that reflects the psychological wellbeing of consumers [26, 28, 30 ].Perceived Consumer Effectiveness and Psychological WellbeingSocial ideal theory states that people tend to expect an ideal society in which they can enjoy justice, goodwill, and wellbeing [8] [9] [10] .", [["people", "ORGANISM", 228, 234], ["people", "SPECIES", 228, 234], ["this study", "TEST", 3, 13]]], ["Social ideal theory provides directions and guidelines to drive people's attitudes and behavior toward positive activities that are beneficial to society [32] .", [["people", "ORGANISM", 64, 70], ["people", "SPECIES", 64, 70]]], ["People who hold high expectations about an ideal society often favor living in a harmonious and peaceful environment.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Hartmann and Apaolaze-Ibanez [37] stated that consumers' intention to purchase green energy brands could also be viewed as green consumption.", [["Hartmann", "TREATMENT", 0, 8]]], ["Green food consumption is often viewed as a type of green consumption, which reflects consumers' purchase behavior toward green food products that are perceived as healthy, safe, and environmentally friendly [39] .Mediating Role of Green Food ConsumptionSocial ideal theory can provide a solid theoretical foundation to explain the relationship between perceived consumer effectiveness, green food consumption, and psychological wellbeing.", [["food consumption", "OBSERVATION", 6, 22]]], ["For example, consumers may engage in donations to help other people.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67]]], ["For example, the behavior of consumers purchasing and consuming organic and green foods contributes to their health because these types of foods provide additional nutrition and are safe to human health than traditional foods.", [["human", "ORGANISM", 190, 195], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195], ["additional nutrition", "TREATMENT", 153, 173]]], ["Green food consumption also reduces the negative impact of farming and processing on the environment [39] .", [["food consumption", "OBSERVATION", 6, 22]]], ["Consequently, when consumers perceive that their green food consumption contributes to the goodwill of human health, environment, and society, they tend to feel happy and satisfied with their behavior and lives [40] .", [["human", "ORGANISM", 103, 108], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108]]], ["The following hypothesis is proposed.Hypothesis (H2):Green food consumption positively mediates the relationship between perceived consumer effectiveness and psychological wellbeing.Moderating Role of Social TrustSocial trust theory states the tendency that people hold a positive belief about the social world.", [["people", "ORGANISM", 258, 264], ["people", "SPECIES", 258, 264], ["psychological wellbeing", "PROBLEM", 158, 181]]], ["These people tend to be optimistic and trust others in their society [14, 15] .", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12]]], ["Social trust reflects an individual's general belief that people will avoid behaving in ways that disadvantage others and take actions that benefit others [41] .", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64]]], ["However, this study followed Day and Settersten Jr.'s [16] suggestions and focused on several aspects of social trust, including confidence in society, optimism about the future, and general trust in others.", [["this study", "TEST", 9, 19]]], ["Furthermore, social trust theory states that beliefs about society shape and influence a person's view about the benevolence of other human beings [17] .", [["human", "ORGANISM", 134, 139], ["person", "SPECIES", 89, 95], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139]]], ["People who hold different perceptions of social trust tend to think and act differently [16] .", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["For example, people with low social trust are likely to be pessimistic, uncooperative, and egoistic.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["uncooperative", "PROBLEM", 72, 85], ["low", "OBSERVATION_MODIFIER", 25, 28], ["likely to be", "UNCERTAINTY", 46, 58]]], ["These people are less likely to help others [44] .", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12]]], ["By contrast, trusting people tend to be optimistic, cooperative, tolerant, and altruistic.", [["people", "ORGANISM", 22, 28], ["people", "SPECIES", 22, 28]]], ["They often engage in activities that bring benefits and positive results for others [45] .Moderating Role of Social TrustAccording to social trust theory, the influence of perceived consumer effectiveness on green food consumption may differ between people who trust and do not trust their society.", [["people", "ORGANISM", 250, 256], ["people", "SPECIES", 250, 256]]], ["Considering that people who hold a high level of social trust tend to be optimistic and altruistic, they may believe that they are useful, and their actions will bring benefits to the environment, society, and other people [46] .", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23], ["people", "SPECIES", 216, 222]]], ["Hence, these people may actively engage in green food consumption because they believe that their green food consumption will create additional values for society [4, 47] .", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19]]], ["For example, when consumers trust their society and other people, consumers may think that if they purchase environmentally friendly foods, then their purchase behavior will generate goodwill for the society.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64]]], ["By contrast, people who hold a low level of social trust may be pessimistic and lack confidence.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19]]], ["These people may believe that they are not able to contribute to society.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12]]], ["Hence, the lack of trust people may behave in egoistic manners and even take actions that harm others and society [44, 47] .", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31]]], ["In other words, when people hold a low level of social trust, they do not believe in their ability to improve social and environmental issues.", [["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27]]], ["Therefore, the influence of perceived consumer effectiveness on green food consumption will likely vary between people who hold a high level of social trust as compared with those who hold a low level of social trust.", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118]]], ["The following hypothesis is proposed.Hypothesis (H3):Social trust moderates the relationship between perceived consumer effectiveness and green food consumption such that the relationship is strong when social trust is high and vice versa.Hypothesis (H3):This study proposed a research model, as shown in Figure 1 .", [["This study", "TEST", 255, 265], ["a research model", "TREATMENT", 275, 291]]], ["As stated above, green food consumption is argued to have a mediating effect on the relationship between perceived consumer effectiveness and psychological wellbeing.", [["psychological wellbeing", "PROBLEM", 142, 165]]], ["Moreover, social trust is hypothesized to moderate the relationship between perceived consumer effectiveness and green food consumption.", [["food", "ORGANISM_SUBDIVISION", 119, 123]]], ["Thus, social trust will moderate the indirect effect of perceived consumer effectiveness on psychological wellbeing through green food consumption.", [["food", "ORGANISM_SUBDIVISION", 130, 134]]], ["In other words, when people hold a low level of social trust, they do not believe in their ability to improve social and environmental issues.", [["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27]]], ["Therefore, the influence of perceived consumer effectiveness on green food consumption will likely vary between people who hold a high level of social trust as compared with those who hold a low level of social trust.", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118]]], ["The following hypothesis is proposed.H3.", [["H3", "GENE_OR_GENE_PRODUCT", 37, 39], ["H3", "PROTEIN", 37, 39], ["H3", "PROBLEM", 37, 39]]], ["Social trust moderates the relationship between perceived consumer effectiveness and green food consumption such that the relationship is strong when social trust is high and vice versa.This study proposed a research model, as shown in Figure 1 .", [["This study", "TEST", 186, 196], ["a research model", "TEST", 206, 222]]], ["As stated above, green food consumption is argued to have a mediating effect on the relationship between perceived consumer effectiveness and psychological wellbeing.", [["psychological wellbeing", "PROBLEM", 142, 165]]], ["Moreover, social trust is hypothesized to moderate the relationship between perceived consumer effectiveness and green food consumption.", [["food", "ORGANISM_SUBDIVISION", 119, 123]]], ["Thus, social trust will moderate the indirect effect of perceived consumer effectiveness on psychological wellbeing through green food consumption.", [["food", "ORGANISM_SUBDIVISION", 130, 134]]], ["The following hypothesis is proposed.Measures of VariablesThis study adopted measurement items of variables in prior studies.", [["This study", "TEST", 58, 68], ["prior studies", "TEST", 111, 124]]], ["Green food consumption was measured using four items from Mohd et al. [4] .", [["food consumption", "OBSERVATION", 6, 22]]], ["These constructs were measured using a five-point Likert scale from 1 (strongly disagree) to 5 (strongly agree).", [["Likert scale", "TEST", 50, 62]]], ["This construct was measured using a five-point scale from 1 (never) to 5 (every day).", [["a five-point scale", "TREATMENT", 34, 52]]], ["Psychological wellbeing was measured using four items from Diener et al. [49] .", [["Psychological wellbeing", "PROBLEM", 0, 23]]], ["This construct was measured using a five-point Likert scale from 1 (strongly disagree) to 5 (strongly agree).", [["Likert scale", "TEST", 47, 59]]], ["Table 1 shows the details of the items and variables.Green food consumptionPsychological wellbeingSocial trustPerceived consumer effectivenessHypothesis (H4):Social trust moderates the indirect effect of perceived consumer effectiveness on psychological wellbeing through green food consumption such that the indirect effect is strong when social trust is high and weaker when social trust is low.Measures of VariablesThis study adopted measurement items of variables in prior studies.", [["This study", "TEST", 418, 428], ["prior studies", "TEST", 471, 484]]], ["Green food consumption was measured using four items from Mohd et al. [4] .", [["food consumption", "OBSERVATION", 6, 22]]], ["These constructs were measured using a five-point Likert scale from 1 (strongly disagree) to 5 (strongly agree).", [["Likert scale", "TEST", 50, 62]]], ["This construct was measured using a five-point scale from 1 (never) to 5 (every day).", [["a five-point scale", "TREATMENT", 34, 52]]], ["Psychological wellbeing was measured using four items from Diener et al. [49] .", [["Psychological wellbeing", "PROBLEM", 0, 23]]], ["This construct was measured using a five-point Likert scale from 1 (strongly disagree) to 5 (strongly agree).", [["Likert scale", "TEST", 47, 59]]], ["Each consumer can have a positive effect on society by purchasing products sold by socially responsible companies.", [["positive effect", "OBSERVATION_MODIFIER", 25, 40]]], ["Given that one person cannot have any effect on pollution and natural resource problems, what I do doesn't make any difference (r).Perceived consumer effectiveness[48]Perceived consumer effectivenessGreen food consumption I always buy green food.", [["person", "SPECIES", 15, 21]]], ["[16] Psychological wellbeingSample ProcedureThis study used a questionnaire survey to collect data.", [["Psychological wellbeingSample Procedure", "TREATMENT", 5, 44], ["This study", "TEST", 44, 54], ["a questionnaire survey", "TEST", 60, 82], ["collect data", "TEST", 86, 98]]], ["A forward and backward language translation was conducted to ensure the meaning of measurement items.", [["A forward and backward language translation", "PROBLEM", 0, 43]]], ["Moreover, a pilot test was conducted at a large supermarket with the participation of 30 consumers.", [["a pilot test", "TEST", 10, 22]]], ["The purpose of this pilot test is to modify and ensure the clarity of the questionnaire.", [["this pilot test", "TEST", 15, 30]]], ["We randomly selected 10 physical stores to collect the sample data.", [["the sample data", "TEST", 51, 66]]], ["We adopted a systematic sampling technique in which one of the three consumers was selected, considering that the list of consumers was not available.", [["a systematic sampling technique", "TREATMENT", 11, 42]]], ["Among the 800 questionnaires distributed, 520 were returned, and 514 were valid, with a response rate of 64.25%.", [["a response rate", "TEST", 86, 101]]], ["Only six questionnaires were invalid and excluded from the final sample because of missing values.", [["missing values", "PROBLEM", 83, 97]]], ["The ideal sample size should be 1:10 (1 measurement item requires 10 cases).", [["sample", "ANATOMY", 10, 16], ["size", "OBSERVATION_MODIFIER", 17, 21]]], ["In this study, the total measurement is was 14; hence, the number of sample sizes should be 140 cases.", [["this study", "TEST", 3, 13], ["the total measurement", "TEST", 15, 36]]], ["Thus, the sample size of 514 is considered adequate in this study.Ethical ConsiderationsThis study conducted a survey that involves human activity.", [["human", "ORGANISM", 132, 137], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["the sample size", "TEST", 6, 21], ["this study", "TEST", 55, 65], ["This study", "TEST", 88, 98], ["size", "OBSERVATION_MODIFIER", 17, 21]]], ["Considering ethical standards, this study was conducted with the approval of the Major Project of The National Social Science Fund of China (20ZDA084).", [["this study", "TEST", 31, 41]]], ["Therefore, this study ensured the privacy and security of the respondents.Analytical MethodsThis study used SPSS statistical software (IBM, Armonk, NY, United States) to analyze the descriptive statistics and reliability of the measures.", [["this study", "TEST", 11, 21], ["This study", "TEST", 92, 102]]], ["Furthermore, partial least square structural equation modeling (PLS-SEM) was adopted to perform the measurement model, which is used to test the validity of the measures.", [["the measurement model", "TEST", 96, 117], ["partial", "OBSERVATION_MODIFIER", 13, 20], ["least", "OBSERVATION_MODIFIER", 21, 26], ["square", "OBSERVATION_MODIFIER", 27, 33], ["structural equation", "OBSERVATION", 34, 53]]], ["In addition, PLS-SEM was used to test the hypotheses in this study.", [["PLS", "TEST", 13, 16], ["this study", "TEST", 56, 66]]], ["Specifically, basic PLS-SEM was used to perform a confirmatory factor analysis (CFA).", [["basic PLS", "TEST", 14, 23], ["a confirmatory factor analysis", "TEST", 48, 78]]], ["Based on the results of this CFA, the values of composite reliability (CR), the average variance extracted (AVE), and square roots of AVE were calculated to test the convergent and discriminant validity.", [["CR", "TEST", 71, 73], ["the average variance", "TEST", 76, 96]]], ["Furthermore, PLS-SEM with the maximum likelihood estimation method was used to test all hypotheses in a single model.", [["PLS", "TEST", 13, 16]]], ["Structural equation modeling (SEM) is a combination of path and factor analyses.", [["factor analyses", "TEST", 64, 79]]], ["Several multiple regression analyses were combined into a single model so that the standard errors were controlled in SEM.", [["Several multiple regression analyses", "PROBLEM", 0, 36], ["the standard errors", "PROBLEM", 79, 98], ["multiple", "OBSERVATION_MODIFIER", 8, 16], ["regression", "OBSERVATION", 17, 27]]], ["PLS-SEM has been widely used in business and management studies [50] .", [["management studies", "TEST", 45, 63]]], ["Results show that perceived consumer effectiveness was positively associated with green food consumption (r = 0.53, p < 0.01) and psychological wellbeing (r = 0.41, p < 0.01).", [["psychological wellbeing", "TEST", 130, 153]]], ["In addition, social trust was positively associated with green food consumption (r = 0.51, p < 0.01) and psychological wellbeing (r = 0.47, p < 0.01).Measurement ModelThe results of the measurement model in this study indicate a good model fit of the hypothesized model.", [["psychological wellbeing", "TEST", 105, 128], ["the measurement model", "TEST", 182, 203], ["this study", "TEST", 207, 217], ["good", "OBSERVATION", 229, 233]]], ["Specifically, all goodness of fit index of the measurement model met the required threshold: \u03c7 2 /d.f. = 2.93 which was less than 3; Comparative Fit Index -CFI = 0.94, Goodness-of-fit Index-GFI = 0.91, and Tucker Lewis Index -TLI = 0.92 which were all greater than 0.90; and Root Mean Square Error of Approximation -RMSEA = 0.07 which was less than 0.08 [50] .Measurement ModelThis study used Cronbach's alpha to measure reliability.", [["Cronbach's alpha", "GENE_OR_GENE_PRODUCT", 393, 409], ["Comparative Fit Index", "TEST", 133, 154], ["CFI", "TEST", 156, 159], ["Goodness", "TEST", 168, 176], ["fit Index", "TEST", 180, 189], ["GFI", "TEST", 190, 193], ["Tucker Lewis Index", "TEST", 206, 224], ["TLI", "TEST", 226, 229], ["Root", "TEST", 275, 279], ["Approximation", "TEST", 301, 314], ["RMSEA", "TEST", 316, 321], ["Measurement ModelThis study", "TEST", 360, 387], ["Cronbach's alpha", "TEST", 393, 409]]], ["Results in Table 4 show that Cronbach's alpha of all variables ranged from 0.77 to 0.90, which exceeded the cutoff value of 0.60 [51] .", [["Cronbach's alpha", "GENE_OR_GENE_PRODUCT", 29, 45], ["Cronbach's alpha", "TEST", 29, 45], ["the cutoff value", "TEST", 104, 120]]], ["Thus, the measures in this study show good reliability.", [["this study", "TEST", 22, 32], ["good", "OBSERVATION_MODIFIER", 38, 42], ["reliability", "OBSERVATION", 43, 54]]], ["Convergent validity was tested using CR and AVE in this study.", [["CR", "TEST", 37, 39], ["this study", "TEST", 51, 61]]], ["Hair et al. [51] suggested that the CR value must be greater than 0.70, and AVE values must be greater than 0.50.", [["the CR value", "TEST", 32, 44], ["AVE values", "TEST", 76, 86]]], ["Results indicate that CR and AVE values of all variables were all greater than the threshold value.", [["CR", "TEST", 22, 24], ["AVE values", "TEST", 29, 39], ["greater", "OBSERVATION_MODIFIER", 66, 73]]], ["Thus, the measures in this study have good convergent reliability.Measurement ModelDiscriminant validity was tested by comparing the square roots of AVE and Pearson correlations of all variables.", [["this study", "TEST", 22, 32], ["Measurement ModelDiscriminant validity", "TEST", 66, 104]]], ["Hair et al. [51] suggested that square roots of AVE must be greater than all correlation coefficients of all variables.", [["roots", "ANATOMY", 39, 44], ["AVE", "MULTI-TISSUE_STRUCTURE", 48, 51]]], ["Table 3 shows that the square roots of AVE were greater than all Pearson correlation, thereby providing evidence for the good discriminant validity of the measures in this study.Common Method BiasFollowing Podsakoff et al. [52] , this study conducted Harman's one-factor test to detect the problem of common method bias.", [["roots", "ANATOMY", 30, 35], ["this study", "TEST", 167, 177], ["this study", "TEST", 230, 240], ["factor test", "TEST", 264, 275]]], ["Results of the unrotated solution of principle component analysis show that four factors emerged with 64.24% of the variance, and the first factor accounted for only 17.02% of the variance.", [["principle component analysis", "TEST", 37, 65], ["the variance", "TEST", 112, 124]]], ["Furthermore, results of one-factor model of CFA indicate a poor model fit (\u03c7 2 /d.f. = 11.47, CFI = 0.76, GFI = 0.74, TLI = 0.734, and RMSEA = 0.14).", [["CFI", "TEST", 94, 97], ["GFI", "TEST", 106, 109], ["TLI", "TEST", 118, 121], ["RMSEA", "TEST", 135, 140]]], ["Thus, the common method bias may not seriously affect the results of hypothesis testing in this study.Structural ModelThis study used PLS-SEM to test the hypotheses.", [["hypothesis testing", "TEST", 69, 87], ["this study", "TEST", 91, 101], ["Structural ModelThis study", "TEST", 102, 128], ["PLS", "TEST", 134, 137]]], ["Results in Figure 2 show that perceived consumer effectiveness was positively related to psychological wellbeing (\u03b2 = 0.119, p <0.01), thereby supporting Hypothesis (H1).", [["psychological wellbeing", "TEST", 89, 112]]], ["Furthermore, perceived consumer effectiveness was positively related to green food consumption (\u03b2 = 0.532, p < 0.001) which in turn was positively related to psychological wellbeing (\u03b2 = 0.425, p < 0.001).", [["psychological wellbeing", "TEST", 158, 181]]], ["We followed Preacher et al. [53] to conduct a bootstrap analysis with 1000 bootstrap samples to confirm this indirect effect.", [["a bootstrap analysis", "TEST", 44, 64], ["bootstrap samples", "TEST", 75, 92]]], ["Results indicate that the indirect effect of perceived consumer effectiveness on psychological wellbeing through green food consumption was statistically significant (perceived consumer effectiveness \u2192 green food consumption \u2192 psychological wellbeing: \u03b2 = 0.328, p < 0.01, 95% CI = [0.252, 0.419]).", [["CI", "TEST", 277, 279]]], ["Thus, H3 was supported.Structural ModelThis study followed Edward and Lambert's [54] procedure to test the moderating effect of social trust on the indirect effect of perceived consumer effectiveness on psychological wellbeing through green food consumption.", [["H3", "GENE_OR_GENE_PRODUCT", 6, 8], ["food", "ORGANISM_SUBDIVISION", 241, 245], ["H3", "PROTEIN", 6, 8], ["Structural ModelThis study", "TEST", 23, 49], ["procedure", "TREATMENT", 85, 94]]], ["Thus, H4 was supported.", [["H4", "GENE_OR_GENE_PRODUCT", 6, 8], ["H4", "PROTEIN", 6, 8]]], ["This study followed Edward and Lambert's [54] procedure to test the moderating effect of social trust on the indirect effect of perceived consumer effectiveness on psychological wellbeing through green food consumption.", [["food", "ORGANISM_SUBDIVISION", 202, 206], ["This study", "TEST", 0, 10], ["procedure", "TREATMENT", 46, 55]]], ["The results provide important implications for researchers and managers.Research ImplicationsFirst, this study argues for the direct influence of perceived consumer effectiveness on psychological wellbeing based on social ideal theory.", [["this study", "TEST", 100, 110], ["psychological wellbeing", "TREATMENT", 182, 205]]], ["The findings of this study provide new insights into the relationship between perceived consumer effectiveness and psychological wellbeing.", [["this study", "TEST", 16, 26], ["psychological wellbeing", "PROBLEM", 115, 138]]], ["Thus, our study provides new knowledge and advances our understanding of the impact of perceived consumer effectiveness on psychological wellbeing.Research ImplicationsSecond, our findings demonstrate the mediating role of green food consumption in the relationship between perceived consumer effectiveness and psychological wellbeing.", [["our study", "TEST", 6, 15], ["green food", "OBSERVATION", 223, 233]]], ["Prior studies often determined the antecedents of green food consumption.", [["food", "ORGANISM_SUBDIVISION", 56, 60], ["Prior studies", "TEST", 0, 13]]], ["However, this study extends social ideal theory and provides new evidence on the mediating mechanism of green food consumption into the relationship between perceived consumer effectiveness and psychological wellbeing.", [["this study", "TEST", 9, 19]]], ["The findings of this study provide a theoretical foundation for researchers who may be interested in studying the role of social ideal theory in green food consumption.Research ImplicationsThird, this study found the moderating role of social trust in the relationship between perceived consumer effectiveness and green food consumption.", [["food", "ORGANISM_SUBDIVISION", 151, 155], ["green", "ORGANISM_SUBDIVISION", 314, 319], ["food", "ORGANISM_SUBDIVISION", 320, 324], ["this study", "TEST", 16, 26], ["this study", "TEST", 196, 206]]], ["This finding indicates that consumers who trust other people in their society often feel optimistic and also tend to engage in altruistic activities [14, 15] .", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60]]], ["They are less likely to engage in green food consumption behavior due to the lack of confidence and beliefs in others [44, 47] .", [["less likely", "UNCERTAINTY", 9, 20]]], ["Thus, the findings of this study provide new evidence on the moderating mechanism of social trust.", [["this study", "TEST", 22, 32]]], ["Our findings help to extend social trust theory and clarify the role of social trust in green food consumption research.Research ImplicationsLast, the research model in this study is unique and deals with the relationship among variables that have been greatly ignored in prior literature.", [["this study", "TEST", 169, 179]]], ["The mediating mechanism of green food consumption behavior in the relationship between perceived consumer effectiveness and psychological wellbeing helps to advance our knowledge about the antecedent of green food consumption and the impact of green food consumption on consumers' psychological wellbeing.", [["psychological wellbeing", "PROBLEM", 124, 147], ["green food", "OBSERVATION", 27, 37]]], ["To our best knowledge, none of the prior studies have determined the influence of green food consumption on consumers' psychological wellbeing.", [["the prior studies", "TEST", 31, 48]]], ["Furthermore, the moderating mechanism of social trust is unique in our research model.", [["social trust", "OBSERVATION", 41, 53]]], ["Findings in this study clarify the role of social trust in enhancing consumers' beliefs and behavior toward their ability to improve social and environmental problems.", [["this study", "TEST", 12, 22]]], ["Thus, the mediating and moderating mechanisms in this study provide new insight into our knowledge and understanding of green food consumption behavior in the current literature.Practical ImplicationsBased on empirical findings, this study provides several suggestions for business managers and policymakers.", [["this study", "TEST", 49, 59], ["empirical findings", "TEST", 209, 227], ["this study", "TEST", 229, 239]]], ["When consumers hold the belief that they can improve and change social and environmental problems, they will actively engage in green food consumption behavior.", [["food", "ORGANISM_SUBDIVISION", 134, 138]]], ["For example, marketing advertising may trigger consumers' perceptions of environmental protection and combine this with their green food purchasing behavior (e.g., combining organic food consumption with environmental protection and bridging green food purchases with reducing pollution).", [["environmental protection", "TREATMENT", 73, 97], ["environmental protection", "TREATMENT", 204, 228]]], ["Furthermore, policymakers should launch different strategies to persuade consumers to engage in green food consumption.", [["food", "ORGANISM_SUBDIVISION", 102, 106]]], ["The findings of this study also provide implications for individual consumers.", [["this study", "TEST", 16, 26]]], ["We can experience a happy life and create value for our entire society by engaging in green food consumption.ConclusionsTo the best of the researchers' knowledge, this study is the first attempt to examine a mediating and moderating mechanism in the relationship between perceived consumer effectiveness and psychological wellbeing.", [["food", "ORGANISM_SUBDIVISION", 92, 96], ["this study", "TEST", 163, 173], ["psychological wellbeing", "PROBLEM", 308, 331]]], ["Empirical results reveal several fresh insights.", [["several", "OBSERVATION_MODIFIER", 25, 32], ["fresh insights", "OBSERVATION", 33, 47]]], ["Green food consumption appears to have a mediating effect on the relationship between perceived consumer effectiveness and psychological wellbeing.", [["psychological wellbeing", "PROBLEM", 123, 146], ["food consumption", "OBSERVATION", 6, 22]]], ["Furthermore, social trust has a moderating effect on the relationship between perceived consumer effectiveness and green food consumption.", [["food", "ORGANISM_SUBDIVISION", 121, 125]]], ["Notably, social trust also moderates the indirect effect of perceived consumer effectiveness on psychological wellbeing through green food consumption.ConclusionsSome limitations should be acknowledged and overcome in future research.", [["food", "ORGANISM_SUBDIVISION", 134, 138]]], ["For example, cross-sectional data may affect the causal relationship among variables in this study.", [["cross-sectional data", "TEST", 13, 33], ["this study", "TEST", 88, 98]]], ["Hence, future research should collect longitudinal data to validate such a relationship to overcome this limitation.", [["longitudinal data", "TEST", 38, 55]]], ["Furthermore, cross-sectional data may generate a common method bias that influences the results of the hypothesis testing.", [["cross-sectional data", "TEST", 13, 33], ["the hypothesis testing", "TEST", 99, 121]]], ["In addition, this study analyzed data from consumers in China only, which may limit the generalizability of the results.", [["this study", "TEST", 13, 23]]]], "f9a7674c9052c8a2db502ec640a9e9cd1d6cef34": [["BackgroundAlthough great efforts have been made by Chinese government over the last three decades, HIV and AIDS remains an important public health concern in China [1, 2] .", [["AIDS", "DISEASE", 107, 111], ["HIV", "SPECIES", 99, 102], ["HIV", "SPECIES", 99, 102], ["HIV", "PROBLEM", 99, 102], ["AIDS", "PROBLEM", 107, 111]]], ["In 2014, more than half a million people living with HIV and 0.2 million AIDS cases were reported, and there were more than 0.1 million new HIV infections [3] .", [["HIV", "DISEASE", 53, 56], ["AIDS", "DISEASE", 73, 77], ["HIV infections", "DISEASE", 140, 154], ["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40], ["HIV", "SPECIES", 53, 56], ["HIV", "SPECIES", 140, 143], ["HIV", "TREATMENT", 53, 56], ["new HIV infections", "PROBLEM", 136, 154]]], ["Since the first AIDS case was reported in early 1980's, China had initiated a set of measures to combat this emerging health problem.", [["AIDS", "DISEASE", 16, 20], ["a set of measures", "TREATMENT", 76, 93]]], ["HIV and AIDS surveillance started in 1985.", [["HIV and", "DISEASE", 0, 7], ["AIDS", "DISEASE", 8, 12], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "PROBLEM", 0, 3], ["AIDS surveillance", "TREATMENT", 8, 25]]], ["In 1995, the China Ministry of Health and the National Center for AIDS established 42 national sentinel sites in 23 of the 31 provinces [4] .", [["AIDS", "DISEASE", 66, 70], ["AIDS", "PROBLEM", 66, 70]]], ["However, the system had issues related to its accessibility and accuracy, which hampered timely understanding of the HIV and AIDS epidemic pattern and effectiveness of HIV and AIDS prevention measures.BackgroundThe outbreak of severe acute respiratory syndromes (SARS) in 2003 revealed some shortcomings of China's infectious disease prevention system and triggered a rapid mobilization of public health policies for a broader range of health challenges.", [["AIDS", "DISEASE", 125, 129], ["AIDS", "DISEASE", 176, 180], ["acute respiratory syndromes", "DISEASE", 234, 261], ["SARS", "DISEASE", 263, 267], ["infectious disease", "DISEASE", 315, 333], ["HIV", "SPECIES", 117, 120], ["HIV", "SPECIES", 168, 171], ["accuracy", "TEST", 64, 72], ["the HIV", "PROBLEM", 113, 120], ["AIDS epidemic pattern", "PROBLEM", 125, 146], ["HIV", "TREATMENT", 168, 171], ["AIDS prevention measures", "TREATMENT", 176, 200], ["severe acute respiratory syndromes", "PROBLEM", 227, 261], ["China's infectious disease prevention system", "PROBLEM", 307, 351], ["a rapid mobilization of public health policies", "TREATMENT", 366, 412], ["outbreak", "OBSERVATION_MODIFIER", 215, 223], ["severe", "OBSERVATION_MODIFIER", 227, 233], ["acute", "OBSERVATION_MODIFIER", 234, 239], ["respiratory syndromes", "OBSERVATION", 240, 261]]], ["In particular, the HIV response has been strengthened by an influx of new funds and political support such as the \"Four Free and One Care\" policy [5] .", [["HIV", "SPECIES", 19, 22], ["political support", "TREATMENT", 84, 101]]], ["A web-based HIV reporting system was established in 2005 and integrated the HIV and AIDS surveillance system [6] , which provides a unique opportunity to comprehensively understand the epidemiological features of HIV and AIDS in China.BackgroundAccording to a recent study based on data collected from a routine infectious disease reporting system,~20% (10/45) infectious diseases showed a significantly increasing trend in incidence from 2004 to 2013.", [["AIDS", "DISEASE", 84, 88], ["HIV and", "DISEASE", 213, 220], ["AIDS", "DISEASE", 221, 225], ["infectious disease", "DISEASE", 312, 330], ["infectious diseases", "DISEASE", 361, 380], ["HIV", "ORGANISM", 213, 216], ["HIV", "SPECIES", 213, 216], ["HIV", "SPECIES", 12, 15], ["HIV", "SPECIES", 76, 79], ["HIV", "SPECIES", 213, 216], ["HIV", "PROBLEM", 213, 216], ["AIDS", "PROBLEM", 221, 225], ["a recent study", "TEST", 258, 272], ["infectious diseases", "PROBLEM", 361, 380], ["significantly", "OBSERVATION_MODIFIER", 390, 403], ["increasing", "OBSERVATION_MODIFIER", 404, 414], ["trend", "OBSERVATION_MODIFIER", 415, 420]]], ["HIV infection showed the fastest growth with annual percentage change of 16.3% in reporting incidence [7] , but the study did not provide province-specific and age-specific results.BackgroundTo better understand the epidemiological characteristics of HIV and AIDS in China, we used the surveillance data, by province, sex, and age, to determine the temporal trend of HIV and AIDS incidence in the country from 2004 to 2014, and the changing patterns of HIV and AIDS incidence across provinces and age groups.", [["HIV infection", "DISEASE", 0, 13], ["HIV and", "DISEASE", 251, 258], ["AIDS", "DISEASE", 259, 263], ["AIDS", "DISEASE", 375, 379], ["AIDS", "DISEASE", 461, 465], ["HIV", "ORGANISM", 0, 3], ["HIV", "ORGANISM", 251, 254], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 251, 254], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 251, 254], ["HIV", "SPECIES", 367, 370], ["HIV", "SPECIES", 453, 456], ["HIV infection", "PROBLEM", 0, 13], ["the fastest growth", "PROBLEM", 21, 39], ["annual percentage change", "TEST", 45, 69], ["the study", "TEST", 112, 121], ["HIV", "PROBLEM", 251, 254], ["AIDS", "PROBLEM", 259, 263], ["the surveillance data", "TEST", 282, 303], ["HIV", "PROBLEM", 367, 370], ["HIV", "PROBLEM", 453, 456], ["infection", "OBSERVATION", 4, 13], ["fastest", "OBSERVATION_MODIFIER", 25, 32], ["growth", "OBSERVATION_MODIFIER", 33, 39]]], ["Moreover, we collected the mortality data to assess the HIV and AIDS disease burden in the same period.", [["AIDS", "DISEASE", 64, 68], ["HIV", "SPECIES", 56, 59], ["HIV", "SPECIES", 56, 59], ["the mortality data", "TEST", 23, 41], ["the HIV", "PROBLEM", 52, 59], ["AIDS disease burden", "PROBLEM", 64, 83]]], ["All these will assist evidence-based and region-specific planning and evaluation of the effectiveness of current treatment and prevention strategies, as well as the assessment of future tendency and subsequent allocation of limited health resources.Data collectionA routine reporting system for selected infectious diseases covered 31 provinces in mainland China was established by the Chinese government in 1950s [8] .", [["infectious diseases", "DISEASE", 304, 323], ["evaluation", "TEST", 70, 80], ["current treatment", "TREATMENT", 105, 122], ["prevention strategies", "TREATMENT", 127, 148], ["the assessment", "TEST", 161, 175], ["future tendency", "PROBLEM", 179, 194], ["selected infectious diseases", "PROBLEM", 295, 323]]], ["The number of notifiable infectious diseases in this system increased from 18 before 1978 to 39 after 2003.", [["infectious diseases", "DISEASE", 25, 44], ["notifiable infectious diseases", "PROBLEM", 14, 44], ["notifiable", "OBSERVATION_MODIFIER", 14, 24], ["infectious", "OBSERVATION", 25, 35]]], ["The notifiable infectious diseases were divided into Classes A, B and C. According to the Infectious Disease Prevention Act, all epidemic reports are time-sensitive.", [["infectious diseases", "DISEASE", 15, 34], ["Infectious Disease", "DISEASE", 90, 108], ["The notifiable infectious diseases", "PROBLEM", 0, 34], ["infectious", "OBSERVATION", 15, 25], ["Infectious", "OBSERVATION", 90, 100]]], ["All Class A infectious diseases as well as pulmonary anthrax and SARS in Class B should be reported through the system within 2 h after diagnosis, and other disease in Class B and Class C infectious diseases should be reported within 24 h after diagnosis.", [["pulmonary", "ANATOMY", 43, 52], ["infectious diseases", "DISEASE", 12, 31], ["pulmonary anthrax", "DISEASE", 43, 60], ["SARS", "DISEASE", 65, 69], ["infectious diseases", "DISEASE", 188, 207], ["pulmonary", "ORGAN", 43, 52], ["Class B", "CANCER", 168, 175], ["pulmonary anthrax", "PROBLEM", 43, 60], ["other disease in Class B and Class C infectious diseases", "PROBLEM", 151, 207], ["infectious", "OBSERVATION", 12, 22], ["pulmonary", "ANATOMY", 43, 52], ["infectious", "OBSERVATION", 188, 198]]], ["We extracted HIV and AIDS data from 2004 and 2014 from the Science Data Center of Public Health (http://www.phsciencedata.cn).", [["AIDS", "DISEASE", 21, 25], ["HIV", "SPECIES", 13, 16], ["AIDS data", "TEST", 21, 30]]], ["AIDS patients in our study were those who had a previous HIV diagnosis, which had been identified or not, and then progressed to late stage.Statistical analysis Incident trend decompositionEmpirical mode decomposition (EMD), an adaptive model for non-liner and non-stationary time series data [9] , was used to identify the temporal trend of HIV and AIDS incidence from 2004 to 2014.", [["AIDS", "DISEASE", 0, 4], ["AIDS", "DISEASE", 350, 354], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 342, 345], ["our study", "TEST", 17, 26], ["Statistical analysis", "TEST", 140, 160], ["HIV", "PROBLEM", 342, 345], ["late stage", "OBSERVATION_MODIFIER", 129, 139], ["HIV", "OBSERVATION", 342, 345]]], ["The EMD method decomposed original data into several oscillatory components, corresponding to some physical phenomenon underlying the data, and the residue of decomposition is the unbiased surrogate of the true trend of the data [10] .", [["some physical phenomenon", "PROBLEM", 94, 118]]], ["The physical phenomenon varied across different scenarios and therefore hardly to be specified here.", [["The physical phenomenon", "PROBLEM", 0, 23]]], ["For example, if the data were time series of HIV incidence, the physical phenomenon included the effect size of infected people, the using rate of condom, and the HIV/AIDS polices etc.Patterns of time changes in incidence and mortality of HIV and AIDSIn order to investigate the changing patterns of HIV and AIDS epidemic and to specify a mathematical model that allows comparisons among sexes, different provinces and age groups [11] , we processed the original incidence and mortality data with a logit transformation and then assessed secular changes via polynomial and spline models (in our surveillance system, the incidence and mortality rate was calculated by population as denominator).", [["AIDS", "DISEASE", 167, 171], ["AIDS", "DISEASE", 308, 312], ["people", "ORGANISM", 121, 127], ["HIV", "ORGANISM", 300, 303], ["people", "SPECIES", 121, 127], ["HIV", "SPECIES", 163, 166], ["HIV", "SPECIES", 300, 303], ["HIV", "SPECIES", 45, 48], ["HIV", "SPECIES", 163, 166], ["HIV", "SPECIES", 239, 242], ["HIV", "SPECIES", 300, 303], ["HIV incidence", "PROBLEM", 45, 58], ["the physical phenomenon", "PROBLEM", 60, 83], ["condom", "TREATMENT", 147, 153], ["the HIV/AIDS polices", "TREATMENT", 159, 179], ["time changes", "PROBLEM", 196, 208], ["HIV", "PROBLEM", 239, 242], ["HIV", "PROBLEM", 300, 303], ["AIDS epidemic", "PROBLEM", 308, 321], ["mortality data", "TEST", 477, 491], ["a logit transformation", "PROBLEM", 497, 519], ["secular changes", "PROBLEM", 538, 553], ["polynomial and spline models", "TREATMENT", 558, 586], ["mortality rate", "TEST", 634, 648], ["size", "OBSERVATION_MODIFIER", 104, 108], ["infected", "OBSERVATION", 112, 120]]], ["As linear trends were observed in most provinces and age groups, a linear model was applied for incidence data on the logit scale.", [["a linear model", "TREATMENT", 65, 79], ["incidence data", "TEST", 96, 110], ["the logit scale", "TEST", 114, 129]]], ["Relative changes in HIV and AIDS incidence or mortality were presented by odds ratio (OR) as compared with 2004.", [["AIDS", "DISEASE", 28, 32], ["HIV", "ORGANISM", 20, 23], ["HIV", "SPECIES", 20, 23], ["HIV", "SPECIES", 20, 23], ["Relative changes", "PROBLEM", 0, 16], ["HIV", "PROBLEM", 20, 23], ["AIDS incidence", "PROBLEM", 28, 42], ["HIV", "OBSERVATION", 20, 23]]], ["In addition, we also calculated average annual percentage change (AAPC) in HIV and AIDS RIs [12] .", [["AIDS", "DISEASE", 83, 87], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 75, 78], ["HIV", "PROBLEM", 75, 78]]], ["All analyses were conducted using R (version 3.3.3).Patterns of time changes in incidence and mortality of HIV and AIDSIn the current analysis, \"HIV infection\" referred to the presence of HIV infection at the time of reporting.", [["HIV infection", "DISEASE", 145, 158], ["HIV infection", "DISEASE", 188, 201], ["HIV", "ORGANISM", 188, 191], ["HIV", "SPECIES", 107, 110], ["HIV", "SPECIES", 145, 148], ["HIV", "SPECIES", 107, 110], ["HIV", "SPECIES", 145, 148], ["HIV", "SPECIES", 188, 191], ["All analyses", "TEST", 0, 12], ["time changes", "PROBLEM", 64, 76], ["HIV", "PROBLEM", 107, 110], ["HIV infection", "PROBLEM", 145, 158], ["HIV infection", "PROBLEM", 188, 201], ["infection", "OBSERVATION", 192, 201]]], ["\"AIDS\" cases were newly diagnosed AIDS patients.ResultsTemporal trends of HIV and AIDS incidence Fig. 3 ).ResultsChanging patterns of HIV and AIDS incidence stratified by age 54.78% of all new diagnosed AIDS cases.", [["AIDS", "DISEASE", 1, 5], ["AIDS", "DISEASE", 34, 38], ["AIDS", "DISEASE", 82, 86], ["AIDS", "DISEASE", 142, 146], ["AIDS", "DISEASE", 203, 207], ["patients", "ORGANISM", 39, 47], ["HIV", "ORGANISM", 134, 137], ["patients", "SPECIES", 39, 47], ["HIV", "SPECIES", 74, 77], ["HIV", "SPECIES", 74, 77], ["HIV", "SPECIES", 134, 137], ["HIV", "PROBLEM", 74, 77], ["AIDS incidence Fig.", "PROBLEM", 82, 101], ["HIV", "PROBLEM", 134, 137], ["HIV", "OBSERVATION", 74, 77]]], ["However, the numbers of newly infected HIV and diagnosed AIDS cases unexpectedly increased among people aged 55 years or above between 2004 and 2014 (Fig. 4) .", [["newly infected HIV", "DISEASE", 24, 42], ["AIDS", "DISEASE", 57, 61], ["HIV", "ORGANISM", 39, 42], ["people", "ORGANISM", 97, 103], ["HIV", "SPECIES", 39, 42], ["people", "SPECIES", 97, 103], ["HIV", "SPECIES", 39, 42], ["newly infected HIV", "PROBLEM", 24, 42], ["newly", "OBSERVATION_MODIFIER", 24, 29], ["infected", "OBSERVATION_MODIFIER", 30, 38], ["HIV", "OBSERVATION", 39, 42], ["increased", "OBSERVATION_MODIFIER", 81, 90]]], ["In order to further investigate the HIV and AIDS changing patterns associated with age, we divided age into 18 groups stratified by gender.ResultsThe overall relative changes of reported HIV incidence among males and females were 1.12 (95% CI 1.11-1.14) and 1.10 (95% CI 1.06-1.13), respectively.", [["AIDS", "DISEASE", 44, 48], ["HIV", "ORGANISM", 187, 190], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 187, 190], ["the HIV", "PROBLEM", 32, 39], ["AIDS changing patterns", "PROBLEM", 44, 66], ["CI", "TEST", 240, 242], ["CI", "TEST", 268, 270]]], ["Males and females had a similar changing pattern of HIV incidence ( Table 2 ).", [["HIV", "ORGANISM", 52, 55], ["HIV", "SPECIES", 52, 55], ["HIV", "OBSERVATION", 52, 55]]], ["Most age groups experienced an increase in HIV infection from 2004 to 2014 (Fig. 5) .ResultsIn males, the highest incidence of HIV infection in 2004 was found in people aged 30-34 years (5.02 per 100,000), but the relative increase was low (OR = 1.02, 95% CI 1.00-1.05, p = 0.027).", [["HIV infection", "DISEASE", 43, 56], ["HIV infection", "DISEASE", 127, 140], ["HIV", "ORGANISM", 43, 46], ["HIV", "ORGANISM", 127, 130], ["people", "ORGANISM", 162, 168], ["people", "SPECIES", 162, 168], ["HIV", "SPECIES", 43, 46], ["HIV", "SPECIES", 127, 130], ["HIV infection", "PROBLEM", 43, 56], ["HIV infection", "PROBLEM", 127, 140], ["CI", "TEST", 256, 258], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["HIV infection", "OBSERVATION", 43, 56], ["HIV", "OBSERVATION_MODIFIER", 127, 130], ["infection", "OBSERVATION", 131, 140], ["increase", "OBSERVATION_MODIFIER", 223, 231]]], ["The largest relative increase was observed in men aged 80-84 (OR = 1.42, 95% CI 1.32-1.53), albeit the lowest incidence in 2004 (0.07 per 100,000).", [["men", "ORGANISM", 46, 49], ["men", "SPECIES", 46, 49], ["CI", "TEST", 77, 79], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["relative", "OBSERVATION_MODIFIER", 12, 20], ["increase", "OBSERVATION_MODIFIER", 21, 29]]], ["The highest incidence of HIV infection in 2004 was found in women aged 25-29 years (1.36 per 100,000), but the incidence remained stable in the study period (OR = 1.03, 95% CI 0.99-1.07).", [["HIV infection", "DISEASE", 25, 38], ["HIV", "ORGANISM", 25, 28], ["women", "ORGANISM", 60, 65], ["women", "SPECIES", 60, 65], ["HIV", "SPECIES", 25, 28], ["HIV infection", "PROBLEM", 25, 38], ["CI", "TEST", 173, 175], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["HIV", "OBSERVATION_MODIFIER", 25, 28], ["infection", "OBSERVATION", 29, 38], ["stable", "OBSERVATION_MODIFIER", 130, 136]]], ["The highest relative increase was detected in women aged 75-79 (OR = 1.50, 95% CI 1.32-1.70) with the HIV infection incidence being 0.02 per 100,000 in 2004.ResultsFor AIDS incidence, the relative increases in males and females were 1.31 (95% CI 1.26-1.36) and 1.22 (95% CI 1.17-1.28), respectively (Table 3 ; Fig. 5 ).", [["HIV infection", "DISEASE", 102, 115], ["AIDS", "DISEASE", 168, 172], ["women", "ORGANISM", 46, 51], ["women", "SPECIES", 46, 51], ["HIV", "SPECIES", 102, 105], ["CI", "TEST", 79, 81], ["the HIV infection", "PROBLEM", 98, 115], ["AIDS incidence", "PROBLEM", 168, 182], ["CI", "TEST", 243, 245], ["CI", "TEST", 271, 273], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["HIV", "OBSERVATION_MODIFIER", 102, 105], ["infection", "OBSERVATION", 106, 115], ["increases", "OBSERVATION_MODIFIER", 197, 206]]], ["All age groups except the age group of 10-14 years showed an increasing trend.", [["an increasing trend", "PROBLEM", 58, 77], ["increasing", "OBSERVATION_MODIFIER", 61, 71], ["trend", "OBSERVATION_MODIFIER", 72, 77]]], ["In 2004, the highest AIDS incidence was found in people aged 30-34 years in both genders, but the relative increase was low for both males (OR = 1.23, 95% CI 1.16-1.29) and females (OR = 1.16, 95% CI 1.11-1.23).", [["AIDS", "DISEASE", 21, 25], ["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55], ["CI", "TEST", 155, 157], ["females", "TEST", 173, 180], ["CI", "TEST", 197, 199]]], ["The largest relative increase was observed in older people (age \u2265 55 years) for both sexes.", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["relative", "OBSERVATION_MODIFIER", 12, 20], ["increase", "OBSERVATION_MODIFIER", 21, 29]]], ["In males, the largest OR was observed in the age group of 80-84 years (OR = 1.57, 95% CI 1.48-1.67).", [["CI", "TEST", 86, 88], ["males", "OBSERVATION", 3, 8], ["largest", "OBSERVATION_MODIFIER", 14, 21]]], ["In females, the largest OR was detected in the age group of 70-74 years (OR = 1.49, 95% CI 1.41-1.58).Changing patterns of HIV and AIDS mortalityOverall, the mortality rate for HIV and AIDS in China was increasing ( Fig. 3 and Table 1 in Appendix).", [["AIDS", "DISEASE", 131, 135], ["HIV and", "DISEASE", 177, 184], ["AIDS", "DISEASE", 185, 189], ["HIV", "ORGANISM", 123, 126], ["HIV", "SPECIES", 123, 126], ["HIV", "SPECIES", 177, 180], ["HIV", "SPECIES", 123, 126], ["HIV", "SPECIES", 177, 180], ["CI", "TEST", 88, 90], ["HIV", "PROBLEM", 123, 126], ["AIDS mortality", "PROBLEM", 131, 145], ["the mortality rate", "TEST", 154, 172], ["HIV", "PROBLEM", 177, 180], ["AIDS in China", "PROBLEM", 185, 198], ["largest", "OBSERVATION_MODIFIER", 16, 23], ["HIV", "OBSERVATION", 123, 126], ["Appendix", "ANATOMY", 238, 246]]], ["The relative increase was 1.29 (95% CI 1.18-1.40) nationwide.", [["CI", "TEST", 36, 38], ["increase", "OBSERVATION_MODIFIER", 13, 21]]], ["Geographically, the largest OR was found in Xinjiang (OR = 1.64, 95% CI 1.37-1.97).", [["CI", "TEST", 69, 71], ["largest", "OBSERVATION_MODIFIER", 20, 27]]], ["Henan was the only province where HIV and AIDS mortality remained stable from 2004 to 2014 (OR = 1.07, 95% CI 0.96-1.19).", [["AIDS", "DISEASE", 42, 46], ["HIV", "SPECIES", 34, 37], ["HIV", "SPECIES", 34, 37], ["HIV", "PROBLEM", 34, 37], ["AIDS mortality", "PROBLEM", 42, 56], ["CI", "TEST", 107, 109]]], ["Moreover, HIV and AIDS mortality showed an increasing trend among all age groups except for the age group of 20-24 years in both genders ( Table 2 in Appendix).Changing patterns of HIV and AIDS mortalityThe results of AAPC were presented in Tables 3, 4 , 5 and 6 in Appendix.", [["AIDS", "DISEASE", 18, 22], ["AIDS", "DISEASE", 189, 193], ["HIV", "ORGANISM", 181, 184], ["AAPC", "CANCER", 218, 222], ["HIV", "SPECIES", 10, 13], ["HIV", "SPECIES", 181, 184], ["HIV", "SPECIES", 10, 13], ["HIV", "SPECIES", 181, 184], ["HIV", "PROBLEM", 10, 13], ["AIDS mortality", "PROBLEM", 18, 32], ["HIV", "PROBLEM", 181, 184], ["AIDS mortality", "PROBLEM", 189, 203], ["AAPC", "TEST", 218, 222], ["increasing", "OBSERVATION_MODIFIER", 43, 53], ["Appendix", "ANATOMY", 150, 158], ["HIV", "OBSERVATION", 181, 184], ["AAPC", "OBSERVATION", 218, 222], ["Appendix", "ANATOMY", 266, 274]]], ["No significant difference was detected.DiscussionSince the first report of HIV and AIDS case in China, the HIV and AIDS epidemic has been changing both geographically and temporally [13] [14] [15] [16] [17] [18] [19] .", [["HIV and AIDS", "DISEASE", 75, 87], ["AIDS", "DISEASE", 115, 119], ["HIV", "ORGANISM", 75, 78], ["[13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 182, 216], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 107, 110], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 107, 110], ["significant difference", "PROBLEM", 3, 25], ["HIV", "PROBLEM", 75, 78], ["the HIV", "PROBLEM", 103, 110], ["AIDS epidemic", "PROBLEM", 115, 128], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["In this study, we provided a comprehensive overview of HIV and AIDS epidemic in China, and assessed secular changes among provinces and age groups for the period of 2004-2014.", [["HIV and", "DISEASE", 55, 62], ["AIDS", "DISEASE", 63, 67], ["HIV", "ORGANISM", 55, 58], ["HIV", "SPECIES", 55, 58], ["this study", "TEST", 3, 13], ["HIV", "PROBLEM", 55, 58], ["secular changes", "PROBLEM", 100, 115]]], ["The lowest relative increase of HIV and AIDS incidence was detected in provinces with a high HIV and AIDS incidence in 2004.", [["AIDS", "DISEASE", 40, 44], ["AIDS", "DISEASE", 101, 105], ["HIV", "ORGANISM", 32, 35], ["HIV", "SPECIES", 32, 35], ["HIV", "SPECIES", 93, 96], ["HIV", "PROBLEM", 32, 35], ["AIDS incidence", "PROBLEM", 40, 54], ["a high HIV", "PROBLEM", 86, 96], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["HIV", "OBSERVATION", 32, 35]]], ["Some Northwestern provinces such as Qinghai and Shaanxi had the strongest relative increase of HIV and AIDS incidence.", [["increase of HIV and", "DISEASE", 83, 102], ["AIDS", "DISEASE", 103, 107], ["HIV", "ORGANISM", 95, 98], ["HIV", "SPECIES", 95, 98], ["HIV", "SPECIES", 95, 98], ["HIV", "PROBLEM", 95, 98], ["AIDS incidence", "PROBLEM", 103, 117]]], ["In addition, young men and women aged 20-34 years who had the highest HIV and AIDS incidence in 2004 experienced the lowest relative increase during the study period.", [["AIDS", "DISEASE", 78, 82], ["men", "ORGANISM", 19, 22], ["women", "ORGANISM", 27, 32], ["men", "SPECIES", 19, 22], ["women", "SPECIES", 27, 32], ["HIV", "SPECIES", 70, 73], ["HIV", "SPECIES", 70, 73], ["increase", "OBSERVATION_MODIFIER", 133, 141]]], ["Older men and women (age \u2265 55 years) showed the largest increase of HIV and AIDS incidence.DiscussionThe HIV and AIDS surveillance/reporting system has been improving, which may explain part of the observed increases of HIV and AIDS incidence and mortality.", [["AIDS", "DISEASE", 76, 80], ["AIDS", "DISEASE", 113, 117], ["AIDS", "DISEASE", 228, 232], ["men", "ORGANISM", 6, 9], ["women", "ORGANISM", 14, 19], ["HIV", "ORGANISM", 68, 71], ["men", "SPECIES", 6, 9], ["women", "SPECIES", 14, 19], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 105, 108], ["HIV", "SPECIES", 220, 223], ["HIV", "PROBLEM", 68, 71], ["AIDS incidence", "PROBLEM", 76, 90], ["AIDS surveillance", "TEST", 113, 130], ["HIV", "PROBLEM", 220, 223], ["AIDS incidence", "PROBLEM", 228, 242], ["largest", "OBSERVATION_MODIFIER", 48, 55], ["increase", "OBSERVATION_MODIFIER", 56, 64]]], ["China has more than 1800 sentinel sites for HIV and AIDS surveillance [15] .", [["AIDS", "DISEASE", 52, 56], ["HIV", "SPECIES", 44, 47], ["HIV", "PROBLEM", 44, 47], ["AIDS surveillance", "TEST", 52, 69]]], ["By the end of 2014, there were 455 HIV testing and confirmation labs and 25,762 screening labs in China, covering 96.5% of the country [20] , and 21,210 medical and health institutions conducted 130 million person-times of HIV antibody tests, increasing from 84 million in 2011 [20] .DiscussionChina has achieved a substantial progress in combatting with HIV and AIDS.", [["HIV and AIDS", "DISEASE", 355, 367], ["HIV", "ORGANISM", 223, 226], ["person", "SPECIES", 207, 213], ["HIV", "SPECIES", 355, 358], ["HIV", "SPECIES", 35, 38], ["HIV", "SPECIES", 223, 226], ["HIV", "SPECIES", 355, 358], ["HIV testing", "TEST", 35, 46], ["confirmation labs", "TEST", 51, 68], ["screening labs", "TEST", 80, 94], ["HIV antibody tests", "TEST", 223, 241], ["HIV", "PROBLEM", 355, 358]]], ["For instance, AIDS incidence showed a plateau after 2013, which might imply a near-future decrease of AIDS cases with the persistent expansion of availability of highly active anti-retroviral therapy (HAART) [21] .", [["AIDS", "DISEASE", 14, 18], ["AIDS", "DISEASE", 102, 106], ["AIDS cases", "PROBLEM", 102, 112], ["highly active anti-retroviral therapy (HAART)", "TREATMENT", 162, 207], ["persistent", "OBSERVATION_MODIFIER", 122, 132], ["expansion", "OBSERVATION_MODIFIER", 133, 142], ["active", "OBSERVATION_MODIFIER", 169, 175], ["anti-retroviral therapy", "OBSERVATION", 176, 199]]], ["Also, the control of HIV and AIDS epidemic in Henan, Xinjiang, Guangxi and Yunnan might be an indication for the effectiveness of preventive strategies and measures after the SARS outbreak, and these areas used to be the \"hot-spots\" of HIV and AIDS in China [22] .", [["HIV and", "DISEASE", 21, 28], ["AIDS", "DISEASE", 29, 33], ["SARS", "DISEASE", 175, 179], ["HIV and", "DISEASE", 236, 243], ["AIDS", "DISEASE", 244, 248], ["HIV", "ORGANISM", 21, 24], ["HIV", "SPECIES", 21, 24], ["HIV", "SPECIES", 236, 239], ["HIV", "SPECIES", 21, 24], ["HIV", "SPECIES", 236, 239], ["HIV", "PROBLEM", 21, 24], ["AIDS epidemic", "PROBLEM", 29, 42], ["Yunnan", "TREATMENT", 75, 81], ["preventive strategies", "TREATMENT", 130, 151], ["the SARS outbreak", "PROBLEM", 171, 188], ["HIV", "PROBLEM", 236, 239]]], ["In the first two decades of HIV and AIDS era in China, Henan, Guangxi, Yunnan and Xinjiang had high HIV and AIDS prevalence [23] , but had different transmission modes.", [["AIDS", "DISEASE", 36, 40], ["AIDS", "DISEASE", 108, 112], ["HIV", "ORGANISM", 28, 31], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 100, 103], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 100, 103], ["HIV", "PROBLEM", 28, 31], ["high HIV", "PROBLEM", 95, 103], ["HIV", "OBSERVATION", 28, 31]]], ["After dramatically cracking down the illegal blood trade in Henan [24, 25] , HIV and AIDS incidence showed the lowest relative change there.", [["blood", "ANATOMY", 45, 50], ["AIDS", "DISEASE", 85, 89], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["HIV", "ORGANISM", 77, 80], ["HIV", "SPECIES", 77, 80], ["HIV", "SPECIES", 77, 80], ["HIV", "PROBLEM", 77, 80], ["AIDS incidence", "PROBLEM", 85, 99], ["dramatically", "OBSERVATION_MODIFIER", 6, 18], ["cracking", "OBSERVATION_MODIFIER", 19, 27], ["change", "OBSERVATION", 127, 133]]], ["Guangxi and Yunnan are close to the \"Golden Triangle\" in Burma, where intravenous drug use was once the major source of HIV transmission, but unprotected sex was found to be a main source of HIV transmission recently [26, 27] .", [["intravenous", "ANATOMY", 70, 81], ["HIV transmission", "DISEASE", 120, 136], ["Guangxi", "ORGANISM", 0, 7], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 81], ["HIV", "ORGANISM", 120, 123], ["HIV", "ORGANISM", 191, 194], ["HIV", "SPECIES", 120, 123], ["HIV", "SPECIES", 191, 194], ["Guangxi", "PROBLEM", 0, 7], ["intravenous drug use", "TREATMENT", 70, 90], ["HIV transmission", "PROBLEM", 120, 136]]], ["In this study, Guangxi and Yunnan had a relatively slow increasing trend for both HIV infection and AIDS incidence, which might ascribe to substantial targeted endeavors combating HIV and AIDS in the last decade.", [["HIV infection", "DISEASE", 82, 95], ["AIDS", "DISEASE", 100, 104], ["HIV and", "DISEASE", 180, 187], ["AIDS", "DISEASE", 188, 192], ["HIV", "ORGANISM", 82, 85], ["HIV", "SPECIES", 82, 85], ["HIV", "SPECIES", 180, 183], ["HIV", "SPECIES", 82, 85], ["HIV", "SPECIES", 180, 183], ["this study", "TEST", 3, 13], ["Guangxi", "PROBLEM", 15, 22], ["a relatively slow increasing trend", "PROBLEM", 38, 72], ["both HIV infection", "PROBLEM", 77, 95], ["AIDS incidence", "PROBLEM", 100, 114], ["HIV", "PROBLEM", 180, 183], ["AIDS", "PROBLEM", 188, 192], ["infection", "OBSERVATION", 86, 95]]], ["A similar changing pattern was observed in Xinjiang, where the HIV and AIDS incidence was high in 2004, but the relative increase was low during the study period.DiscussionHowever, it should be noted that some new HIV and AIDS \"hot-spots\" including Sichuan and Chongqing have appeared recently according to our analyses.", [["AIDS", "DISEASE", 71, 75], ["AIDS", "DISEASE", 222, 226], ["HIV", "SPECIES", 63, 66], ["HIV", "SPECIES", 214, 217], ["the HIV", "PROBLEM", 59, 66], ["AIDS incidence", "PROBLEM", 71, 85], ["some new HIV", "PROBLEM", 205, 217], ["high", "OBSERVATION_MODIFIER", 90, 94], ["increase", "OBSERVATION_MODIFIER", 121, 129], ["new", "OBSERVATION_MODIFIER", 210, 213], ["HIV", "OBSERVATION", 214, 217]]], ["Additionally, Inner Mongolia, Qinghai and Shaanxi showed great relative increases in the HIV and AIDS incidence.", [["increases in the HIV and", "DISEASE", 72, 96], ["AIDS", "DISEASE", 97, 101], ["HIV", "SPECIES", 89, 92], ["HIV", "SPECIES", 89, 92], ["Shaanxi", "TREATMENT", 42, 49], ["the HIV", "PROBLEM", 85, 92], ["AIDS incidence", "PROBLEM", 97, 111], ["Inner", "OBSERVATION_MODIFIER", 14, 19], ["Mongolia", "OBSERVATION_MODIFIER", 20, 28], ["great", "OBSERVATION_MODIFIER", 57, 62], ["relative", "OBSERVATION_MODIFIER", 63, 71], ["increases", "OBSERVATION_MODIFIER", 72, 81], ["HIV", "OBSERVATION", 89, 92]]], ["We should pay much more attention to the prevention and control of HIV and AIDS in these provinces.DiscussionThere were also substantial changes in HIV and AIDS incidence associated with age.", [["HIV", "DISEASE", 67, 70], ["AIDS", "DISEASE", 75, 79], ["AIDS", "DISEASE", 156, 160], ["HIV", "ORGANISM", 148, 151], ["HIV", "SPECIES", 67, 70], ["HIV", "SPECIES", 148, 151], ["HIV", "SPECIES", 67, 70], ["HIV", "SPECIES", 148, 151], ["the prevention", "TREATMENT", 37, 51], ["HIV", "PROBLEM", 67, 70], ["AIDS", "PROBLEM", 75, 79], ["HIV", "PROBLEM", 148, 151], ["AIDS incidence", "PROBLEM", 156, 170]]], ["Men and women aged 20-34 years had the lowest relative increase, while those aged 55 years or above had the highest relative increase.", [["Men", "ORGANISM", 0, 3], ["women", "ORGANISM", 8, 13], ["Men", "SPECIES", 0, 3], ["women", "SPECIES", 8, 13], ["increase", "OBSERVATION_MODIFIER", 55, 63]]], ["The results suggested the effectiveness of measures that focused on young adults but also indicated a potential upsurge of HIV and AIDS epidemic among older people.", [["AIDS", "DISEASE", 131, 135], ["HIV", "ORGANISM", 123, 126], ["people", "ORGANISM", 157, 163], ["people", "SPECIES", 157, 163], ["HIV", "SPECIES", 123, 126], ["HIV", "PROBLEM", 123, 126]]], ["Globally, previous evidence has suggested a considerable burden of HIV and AIDS among older adults [28] [29] [30] .", [["AIDS", "DISEASE", 75, 79], ["HIV", "ORGANISM", 67, 70], ["HIV", "SPECIES", 67, 70], ["HIV", "SPECIES", 67, 70], ["HIV", "PROBLEM", 67, 70], ["considerable", "OBSERVATION_MODIFIER", 44, 56], ["burden", "OBSERVATION_MODIFIER", 57, 63]]], ["Thus, it is important to further investigate the risk factors of HIV infection and to prioritize the prevention and control of HIV and AIDS among older adults.DiscussionSurprisingly, an increased mortality of HIV and AIDS was detected in the present study.", [["HIV infection", "DISEASE", 65, 78], ["HIV", "DISEASE", 127, 130], ["AIDS", "DISEASE", 135, 139], ["HIV and", "DISEASE", 209, 216], ["AIDS", "DISEASE", 217, 221], ["HIV", "ORGANISM", 65, 68], ["HIV", "ORGANISM", 127, 130], ["HIV", "ORGANISM", 209, 212], ["HIV", "SPECIES", 65, 68], ["HIV", "SPECIES", 127, 130], ["HIV", "SPECIES", 209, 212], ["HIV", "SPECIES", 65, 68], ["HIV", "SPECIES", 127, 130], ["HIV", "SPECIES", 209, 212], ["HIV infection", "PROBLEM", 65, 78], ["HIV", "PROBLEM", 127, 130], ["HIV", "PROBLEM", 209, 212], ["AIDS", "PROBLEM", 217, 221], ["the present study", "TEST", 238, 255], ["infection", "OBSERVATION", 69, 78], ["increased", "OBSERVATION_MODIFIER", 186, 195]]], ["We speculate that the increase of HIV and AIDS mortality may be partially explained by the accumulation of AIDS cases, since the cumulative AIDS-related mortality rates significantly increased over time after diagnosis [31] .", [["AIDS", "DISEASE", 42, 46], ["AIDS", "DISEASE", 107, 111], ["AIDS", "DISEASE", 140, 144], ["HIV", "ORGANISM", 34, 37], ["HIV", "SPECIES", 34, 37], ["HIV", "PROBLEM", 34, 37], ["AIDS mortality", "PROBLEM", 42, 56], ["AIDS cases", "PROBLEM", 107, 117], ["the cumulative AIDS", "PROBLEM", 125, 144], ["mortality rates", "PROBLEM", 153, 168], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["increased", "OBSERVATION_MODIFIER", 183, 192]]], ["Meanwhile, the inadequate provision of treatment services and difficulty with adherence were also likely to contribute to the increased mortality, particularly before 2003.", [["treatment services", "TREATMENT", 39, 57], ["the increased mortality", "PROBLEM", 122, 145], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["mortality", "OBSERVATION", 136, 145]]], ["Therefore, the accumulation in HIV infections and improved survival time among AIDS patients could result in an increasing burden of HIV and AIDS [32, 33] .DiscussionSome limitations of our study should be mentioned.", [["HIV infections", "DISEASE", 31, 45], ["AIDS", "DISEASE", 79, 83], ["HIV", "DISEASE", 133, 136], ["AIDS", "DISEASE", 141, 145], ["HIV", "ORGANISM", 31, 34], ["patients", "ORGANISM", 84, 92], ["HIV", "SPECIES", 31, 34], ["patients", "SPECIES", 84, 92], ["HIV", "SPECIES", 31, 34], ["HIV", "SPECIES", 133, 136], ["the accumulation in HIV infections", "PROBLEM", 11, 45], ["HIV", "PROBLEM", 133, 136], ["AIDS", "PROBLEM", 141, 145], ["our study", "TEST", 186, 195], ["accumulation", "OBSERVATION_MODIFIER", 15, 27], ["HIV infections", "OBSERVATION", 31, 45], ["increasing", "OBSERVATION_MODIFIER", 112, 122], ["burden", "OBSERVATION_MODIFIER", 123, 129]]], ["First, since the data were retrieved from a passive surveillance system, there might be some under reporting, especially during earlier years of the system.", [["the data", "TEST", 13, 21], ["a passive surveillance system", "TEST", 42, 71]]], ["Second, the incidence could also be underestimated because of ascertainment bias by self-selection that individuals at high risk of HIV and AIDS were more reluctant to screening.", [["AIDS", "DISEASE", 140, 144], ["HIV", "ORGANISM", 132, 135], ["HIV", "SPECIES", 132, 135], ["HIV", "SPECIES", 132, 135], ["ascertainment bias", "PROBLEM", 62, 80], ["HIV", "PROBLEM", 132, 135], ["AIDS", "PROBLEM", 140, 144], ["could also be", "UNCERTAINTY", 22, 35]]], ["Third, the increase of HIV and AIDS reporting incidence among older adults might be ascribed to the detection of long-standing infections, though more investigations should be warranted in the near future.", [["AIDS", "DISEASE", 31, 35], ["infections", "DISEASE", 127, 137], ["HIV", "ORGANISM", 23, 26], ["HIV", "SPECIES", 23, 26], ["HIV", "PROBLEM", 23, 26], ["long-standing infections", "PROBLEM", 113, 137], ["increase", "OBSERVATION_MODIFIER", 11, 19]]], ["Finally, key affected populations (e.g. the men who have sex with men) have not been particularized in our study due to the inaccessibility of corresponding surveillance data.DiscussionEstimation of the incidence of most infectious diseases is challenging, because infection might have occurred several years before symptoms arise or a diagnosis is made [34, 35] .", [["infectious diseases", "DISEASE", 221, 240], ["infection", "DISEASE", 265, 274], ["men", "ORGANISM", 44, 47], ["men", "ORGANISM", 66, 69], ["men", "SPECIES", 44, 47], ["men", "SPECIES", 66, 69], ["our study", "TEST", 103, 112], ["corresponding surveillance data", "TEST", 143, 174], ["most infectious diseases", "PROBLEM", 216, 240], ["infection", "PROBLEM", 265, 274], ["symptoms", "PROBLEM", 316, 324], ["infectious", "OBSERVATION", 221, 231]]], ["Fortunately, the surveillance data can serve as good proxy to quantify the temporal trends of infectious diseases.", [["infectious diseases", "DISEASE", 94, 113], ["the surveillance data", "TEST", 13, 34], ["infectious diseases", "PROBLEM", 94, 113], ["infectious", "OBSERVATION", 94, 104]]], ["The China Information System for Disease Control and Prevention (CISDCP) is currently the largest web-based surveillance system in the world, and it stores the nationwide validated reporting data daily.", [["Disease Control", "TREATMENT", 33, 48]]], ["Despite these challenges, our analysis is based on a large sample of people diagnosed with HIV and AIDS across 31 provinces and over 11 years, which strengthens the reliability of our findings.ConclusionsWe used a longitudinal surveillance dataset spanning 11 years in China to investigate changes in the epidemiological characteristics of HIV and AIDS after SARS outbreak.", [["HIV and AIDS", "DISEASE", 91, 103], ["HIV", "DISEASE", 340, 343], ["AIDS", "DISEASE", 348, 352], ["SARS", "DISEASE", 359, 363], ["people", "ORGANISM", 69, 75], ["HIV", "ORGANISM", 340, 343], ["people", "SPECIES", 69, 75], ["HIV", "SPECIES", 91, 94], ["HIV", "SPECIES", 340, 343], ["HIV", "SPECIES", 91, 94], ["HIV", "SPECIES", 340, 343], ["our analysis", "TEST", 26, 38], ["HIV", "PROBLEM", 91, 94], ["AIDS", "PROBLEM", 99, 103], ["a longitudinal surveillance dataset", "TEST", 212, 247], ["HIV", "PROBLEM", 340, 343], ["AIDS", "PROBLEM", 348, 352], ["SARS outbreak", "PROBLEM", 359, 372]]], ["HIV and AIDS incidence showed a significant increasing trend in the last decade, but the epidemic has been well controlled among provinces where the HIV and AIDS incidence were high, and among young adults.", [["AIDS", "DISEASE", 8, 12], ["AIDS", "DISEASE", 157, 161], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 149, 152], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 149, 152], ["HIV", "PROBLEM", 0, 3], ["AIDS incidence", "PROBLEM", 8, 22], ["a significant increasing trend", "PROBLEM", 30, 60], ["the HIV", "PROBLEM", 145, 152], ["AIDS incidence", "PROBLEM", 157, 171], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["increasing", "OBSERVATION_MODIFIER", 44, 54], ["trend", "OBSERVATION_MODIFIER", 55, 60]]], ["However, the major findings also highlight the unmet need for HIV and AIDS prevention efforts and call for a beforehand measure to prevent the emergency among certain provinces and elderly people.", [["HIV and", "DISEASE", 62, 69], ["AIDS", "DISEASE", 70, 74], ["people", "ORGANISM", 189, 195], ["people", "SPECIES", 189, 195], ["HIV", "SPECIES", 62, 65], ["HIV and AIDS prevention efforts", "TREATMENT", 62, 93]]]], "7dd2e6c02841a9825ce5fa560ddd0ba7296cec85": [["IntroductionClustered regularly interspaced short palindromic repeats (CRISPR) are segments of nucleic acid containing short, repetitive base sequences that play an important role in prokaryotic defense and form the basis of a genome editing technology that allows permanent modification of genes known as CRISPR-Cas9, as well as CRISPR-Cas12a and CRISPR-13 [1] [2] [3] .", [["nucleic acid", "CHEMICAL", 95, 107], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 306, 317], ["CRISPR-Cas12a", "GENE_OR_GENE_PRODUCT", 330, 343], ["Clustered regularly interspaced short palindromic repeats", "DNA", 12, 69], ["CRISPR", "DNA", 71, 77], ["short, repetitive base sequences", "DNA", 119, 151], ["CRISPR", "DNA", 306, 312], ["Cas9", "DNA", 313, 317], ["CRISPR", "DNA", 330, 336], ["Cas12a", "DNA", 337, 343], ["CRISPR", "DNA", 348, 354], ["IntroductionClustered regularly interspaced short palindromic repeats (CRISPR", "TREATMENT", 0, 77], ["nucleic acid containing short, repetitive base sequences", "PROBLEM", 95, 151], ["a genome editing technology", "TREATMENT", 225, 252], ["CRISPR", "TEST", 330, 336], ["CRISPR", "TEST", 348, 354]]], ["While much has been written about how this novel methodology will contribute to scientific inquiry, no literature yet exists on how these advances will affect hospitalistsspecialists in inpatient medicinewho care exclusively for hospitalized patients suffering from a variety of maladies [4] [5] [6] .", [["maladies", "DISEASE", 279, 287], ["patients", "ORGANISM", 242, 250], ["[4] [5", "SIMPLE_CHEMICAL", 288, 294], ["patients", "SPECIES", 242, 250]]], ["It concludes with a look at ethical issues and technical hurdles pertaining to the implementation of permanent gene modification in clinical practice.BackgroundThe CRISPR-Cas system evolved in microbes as an immune system in prokaryotes that confers resistance to foreign genetic elements such as those present within plasmids and phages [8, 9] .", [["immune system", "ANATOMY", 208, 221], ["plasmids", "ANATOMY", 318, 326], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 164, 174], ["Cas", "PROTEIN", 171, 174], ["foreign genetic elements", "DNA", 264, 288], ["plasmids", "DNA", 318, 326], ["permanent gene modification", "TREATMENT", 101, 128], ["foreign genetic elements", "PROBLEM", 264, 288]]], ["The Cas9 protein performs gene interrogation by unwinding foreign deoxyribonucleic acid (DNA) and determining whether the sequence is complementary to the 20-base pair spacer region of the guide ribonucleic acid (RNA) [10, 11] .BackgroundThe CRISPR-Cas9 system can be used to manipulate and excise stretches of DNA that have profound relevance for human health, ranging from aggressive malignancies to mitochondrial storage diseases, as well as potential applications in the prevention and treatment of infectious diseases such as human immunodeficiency virus, influenza virus, and malaria, among many others [12] [13] [14] [15] [16] .", [["malignancies", "ANATOMY", 386, 398], ["mitochondrial", "ANATOMY", 402, 415], ["deoxyribonucleic acid", "CHEMICAL", 66, 87], ["ribonucleic acid", "CHEMICAL", 195, 211], ["malignancies", "DISEASE", 386, 398], ["mitochondrial storage diseases", "DISEASE", 402, 432], ["infectious diseases", "DISEASE", 503, 522], ["human immunodeficiency virus", "DISEASE", 531, 559], ["influenza virus", "DISEASE", 561, 576], ["malaria", "DISEASE", 582, 589], ["Cas9", "GENE_OR_GENE_PRODUCT", 4, 8], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 242, 253], ["DNA", "CELLULAR_COMPONENT", 311, 314], ["human", "ORGANISM", 348, 353], ["malignancies", "CANCER", 386, 398], ["mitochondrial", "CELLULAR_COMPONENT", 402, 415], ["human immunodeficiency virus", "ORGANISM", 531, 559], ["influenza virus", "ORGANISM", 561, 576], ["[12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 609, 633], ["Cas9 protein", "PROTEIN", 4, 16], ["20-base pair spacer region", "DNA", 155, 181], ["guide ribonucleic acid", "RNA", 189, 211], ["CRISPR", "DNA", 242, 248], ["human", "SPECIES", 348, 353], ["human immunodeficiency virus", "SPECIES", 531, 559], ["influenza virus", "SPECIES", 561, 576], ["human", "SPECIES", 348, 353], ["human immunodeficiency virus", "SPECIES", 531, 559], ["The Cas9 protein", "TREATMENT", 0, 16], ["gene interrogation", "TEST", 26, 44], ["unwinding foreign deoxyribonucleic acid (DNA", "PROBLEM", 48, 92], ["the sequence", "TEST", 118, 130], ["The CRISPR-Cas9 system", "TREATMENT", 238, 260], ["DNA", "TREATMENT", 311, 314], ["aggressive malignancies", "PROBLEM", 375, 398], ["mitochondrial storage diseases", "PROBLEM", 402, 432], ["infectious diseases", "PROBLEM", 503, 522], ["human immunodeficiency virus", "PROBLEM", 531, 559], ["influenza virus", "PROBLEM", 561, 576], ["malaria", "PROBLEM", 582, 589], ["ribonucleic acid", "OBSERVATION", 195, 211], ["infectious", "OBSERVATION", 503, 513]]], ["Other genetic modification systems exist, such as CRISPR-12a and CRISPR-13, but they are outside of the scope of this manuscript, which will focus on CRISPR-Cas9.BackgroundInitial applications of gene modification have dealt primarily with conditions that are treated by subspecialty providers (oncologists, rheumatologists, infectious disease specialists), but the CRISPR-Cas9 platform also has profound relevance for primary providers, including pediatricians, obstetricians/ gynecologists, primary care physicians, and hospitalists, which will be the focus of this manuscript.BackgroundThe term 'hospitalist' was coined in 1996 by Watcher and Goldman and since that time, Hospital Medicine has emerged as the fastest growing subspecialty in the history of medicine [17] .", [["infectious disease", "DISEASE", 325, 343], ["CRISPR-12a", "GENE_OR_GENE_PRODUCT", 50, 60], ["CRISPR-13", "GENE_OR_GENE_PRODUCT", 65, 74], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 150, 161], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 366, 377], ["CRISPR", "DNA", 50, 56], ["CRISPR-13", "DNA", 65, 74], ["CRISPR", "DNA", 150, 156], ["Cas9", "DNA", 157, 161], ["CRISPR", "DNA", 366, 372], ["CRISPR", "TEST", 50, 56], ["CRISPR", "TEST", 65, 71], ["gene modification", "TREATMENT", 196, 213]]], ["Hospitalists care for a broad array of medical maladies, ranging from blood clots to pneumonia, and emerging research suggests that many of the medical conditions under the hospitalist's purview could be influenced by advances in the CRISPR-Cas9 [19, 20] .", [["blood clots", "ANATOMY", 70, 81], ["blood clots", "DISEASE", 70, 81], ["pneumonia", "DISEASE", 85, 94], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["clots", "ORGANISM_SUBSTANCE", 76, 81], ["CRISPR", "DNA", 234, 240], ["medical maladies", "PROBLEM", 39, 55], ["blood clots", "PROBLEM", 70, 81], ["pneumonia", "PROBLEM", 85, 94], ["pneumonia", "OBSERVATION", 85, 94]]], ["Given the rapid evolution of this technology and the widespread appreciation of its potential to alter the treatment of disease, it is necessary for hospitalists to be familiar with the relevance of CRISPR-Cas9.", [["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 199, 210], ["CRISPR", "DNA", 199, 205], ["Cas9", "DNA", 206, 210], ["disease", "PROBLEM", 120, 127], ["CRISPR-Cas9", "TREATMENT", 199, 210], ["disease", "OBSERVATION", 120, 127]]], ["An overview of the most common conditions cared for by hospitalists is provided below followed by an examination of how management of these diseases may change with advances in somatic and germline gene modification [21] .Infectious diseasesThe emergence of the hospitalist has altered the care of infectious diseases at many hospitals [22] [23] [24] .", [["Infectious diseases", "DISEASE", 222, 241], ["infectious diseases", "DISEASE", 298, 317], ["an examination", "TEST", 98, 112], ["these diseases", "PROBLEM", 134, 148], ["somatic and germline gene modification", "TREATMENT", 177, 215], ["Infectious diseases", "PROBLEM", 222, 241], ["diseases", "OBSERVATION", 140, 148]]], ["Patients requiring intravenous antimicrobial therapy are often cared for by hospitalists, with infectious disease specialists serving as consultant (when possible).", [["intravenous", "ANATOMY", 19, 30], ["Patients", "ORGANISM", 0, 8], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 30], ["Patients", "SPECIES", 0, 8], ["intravenous antimicrobial therapy", "TREATMENT", 19, 52]]], ["This means that hospitalists are the primary providers for patients with a wide variety of infectious diseases, which may be broadly divided into the following subgroups: viruses, bacteria, fungi, and parasites [25, 26] .", [["infectious diseases", "DISEASE", 91, 110], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["infectious diseases", "PROBLEM", 91, 110], ["viruses", "PROBLEM", 171, 178], ["bacteria", "PROBLEM", 180, 188], ["fungi", "PROBLEM", 190, 195], ["parasites", "PROBLEM", 201, 210], ["infectious", "OBSERVATION", 91, 101]]], ["Although these groupings have inherent limitations, they do serve to delineate how CRISPR might be utilized to improve the approach to both diagnosis and treatment.VirusesThe CRISPR-Cas9 systems evolved in microbes as a defense mechanism against viruses by cleaving nucleic acids from the invading bacteriophage [27, 28] .", [["nucleic acids", "CHEMICAL", 266, 279], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 175, 186], ["CRISPR", "DNA", 83, 89], ["CRISPR-Cas9 systems", "DNA", 175, 194], ["treatment", "TREATMENT", 154, 163], ["Cas9 systems", "PROBLEM", 182, 194], ["viruses", "PROBLEM", 246, 253], ["cleaving nucleic acids", "PROBLEM", 257, 279], ["the invading bacteriophage", "TREATMENT", 285, 311]]], ["For purposes of pathogen detection, cleavage of a labeled sing-strand RNA or DNA probe generates a signal that can provide a fluorescent readout in a number of portable formats, including the use of disposable paper strips, enabling rapid detection of pathogenic viruses [29] .", [["DNA", "CELLULAR_COMPONENT", 77, 80], ["labeled sing-strand RNA", "RNA", 50, 73], ["DNA probe", "DNA", 77, 86], ["pathogen detection", "TEST", 16, 34], ["a labeled sing-strand RNA", "TREATMENT", 48, 73], ["a fluorescent readout", "TEST", 123, 144], ["disposable paper strips", "TREATMENT", 199, 222], ["pathogenic viruses", "PROBLEM", 252, 270]]], ["CRISPR-based tests carry several advantages over traditional microbiological diagnostics such as polymerase chain reaction (PCR), which is generally considered to be the most sensitive and specific test available for viral detection.", [["CRISPR", "DNA", 0, 6], ["CRISPR-based tests", "TEST", 0, 18], ["traditional microbiological diagnostics", "TEST", 49, 88], ["polymerase chain reaction", "TEST", 97, 122], ["PCR", "TEST", 124, 127], ["specific test", "TEST", 189, 202], ["viral detection", "TEST", 217, 232]]], ["However, PCR require multiple steps to run the assay, including an upfront nucleic acid extraction and amplification steps, and require dedicated instrumentation [30] [31] [32] .", [["nucleic acid", "CHEMICAL", 75, 87], ["PCR", "TEST", 9, 12], ["the assay", "TEST", 43, 52], ["an upfront nucleic acid extraction", "TREATMENT", 64, 98], ["dedicated instrumentation", "TREATMENT", 136, 161]]], ["By contrast, CRISPR-Cas-based assays can be run directly on primary clinical samples as a single reaction and performed using minimal equipment [33] [34] [35] [36] .", [["samples", "ANATOMY", 77, 84], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 13, 23], ["CRISPR", "DNA", 13, 19], ["Cas", "PROTEIN", 20, 23]]], ["This is especially relevant for detection of SARS-CoV-2, where testing has been limited in many places due to a lack of testing materials and personal protective equipment [37] [38] [39] .VirusesAs front-line healthcare providers, hospitalists are often the clinicians who must coordinate the work-up of a patient with a suspected infection.", [["SARS", "DISEASE", 45, 49], ["infection", "DISEASE", 331, 340], ["patient", "ORGANISM", 306, 313], ["patient", "SPECIES", 306, 313], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53], ["testing", "TEST", 63, 70], ["personal protective equipment", "TREATMENT", 142, 171], ["a suspected infection", "PROBLEM", 319, 340], ["infection", "OBSERVATION", 331, 340]]], ["Determining the appropriate tests is essential to patient care but also to medical education [40, 41] .", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["the appropriate tests", "TEST", 12, 33]]], ["Hospitalists have emerged as the primary medical educators on the general medicine service at many academic medical centers and they must be familiar with emerging assays to ensure that patients receive proper treatment and that the next generation of clinicians is properly informed [42, 43] .", [["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["proper treatment", "TREATMENT", 203, 219]]], ["This includes diagnostic tests for common and emerging viral pathogens.VirusesThe SHERLOCK assay has been successfully used to detect both Zika virus and dengue virus directly from bodily fluids, including urine and respiratory samples, in less than two hours and enabled discrimination among viral serotypes [29, 44] .", [["bodily fluids", "ANATOMY", 181, 194], ["urine", "ANATOMY", 206, 211], ["respiratory samples", "ANATOMY", 216, 235], ["dengue", "DISEASE", 154, 160], ["Zika virus", "ORGANISM", 139, 149], ["dengue virus", "ORGANISM", 154, 166], ["urine", "ORGANISM_SUBSTANCE", 206, 211], ["Zika virus and dengue virus", "SPECIES", 139, 166], ["Zika virus", "SPECIES", 139, 149], ["dengue virus", "SPECIES", 154, 166], ["diagnostic tests", "TEST", 14, 30], ["emerging viral pathogens", "PROBLEM", 46, 70], ["The SHERLOCK assay", "TEST", 78, 96], ["Zika virus", "PROBLEM", 139, 149], ["dengue virus", "PROBLEM", 154, 166], ["bodily fluids", "TEST", 181, 194], ["urine and respiratory samples", "TEST", 206, 235], ["viral pathogens", "OBSERVATION", 55, 70], ["Zika virus", "OBSERVATION", 139, 149], ["respiratory", "ANATOMY", 216, 227]]], ["This approach may soon extend to serum samples, and has potential for the rapid diagnosis of human immunodeficiency virus (HIV) as well as hepatitis c virus (HCV) genotype in order to guide the choice of antiviral therapy, which may depend on the presence of single nucleotide polymorphisms [45] [46] [47] [48] .VirusesOthers have used the CRISPR-based DETECTR assay to detect human papillomavirus (HPV) types 16 and 18, which are associated with invasive genital tumors, and highlights the potential use of CRISPR-Cas technologies from infectious diseases to other fields, such as cancer (which will be discussed later in this manuscript) [49, 50] .", [["serum samples", "ANATOMY", 33, 46], ["invasive genital tumors", "ANATOMY", 447, 470], ["cancer", "ANATOMY", 582, 588], ["human immunodeficiency virus (HIV)", "DISEASE", 93, 127], ["hepatitis c", "DISEASE", 139, 150], ["nucleotide", "CHEMICAL", 266, 276], ["human papillomavirus (HPV) types", "DISEASE", 377, 409], ["genital tumors", "DISEASE", 456, 470], ["infectious diseases", "DISEASE", 537, 556], ["cancer", "DISEASE", 582, 588], ["nucleotide", "CHEMICAL", 266, 276], ["serum samples", "ORGANISM_SUBSTANCE", 33, 46], ["human immunodeficiency virus", "ORGANISM", 93, 121], ["hepatitis c virus", "ORGANISM", 139, 156], ["HCV", "ORGANISM", 158, 161], ["human papillomavirus (HPV", "ORGANISM", 377, 402], ["genital tumors", "CANCER", 456, 470], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 508, 518], ["cancer", "CANCER", 582, 588], ["CRISPR", "DNA", 340, 346], ["human immunodeficiency virus", "SPECIES", 93, 121], ["hepatitis c virus", "SPECIES", 139, 156], ["human", "SPECIES", 377, 382], ["human immunodeficiency virus", "SPECIES", 93, 121], ["HIV", "SPECIES", 123, 126], ["hepatitis c virus", "SPECIES", 139, 156], ["HCV", "SPECIES", 158, 161], ["human papillomavirus", "SPECIES", 377, 397], ["HPV", "SPECIES", 399, 402], ["serum samples", "TEST", 33, 46], ["human immunodeficiency virus", "PROBLEM", 93, 121], ["HIV", "PROBLEM", 123, 126], ["hepatitis c virus (HCV) genotype", "PROBLEM", 139, 171], ["antiviral therapy", "TREATMENT", 204, 221], ["single nucleotide polymorphisms", "PROBLEM", 259, 290], ["the CRISPR", "TEST", 336, 346], ["DETECTR assay", "TEST", 353, 366], ["human papillomavirus", "PROBLEM", 377, 397], ["invasive genital tumors", "PROBLEM", 447, 470], ["CRISPR-Cas technologies", "TREATMENT", 508, 531], ["infectious diseases", "PROBLEM", 537, 556], ["cancer", "PROBLEM", 582, 588], ["associated with", "UNCERTAINTY", 431, 446], ["invasive", "OBSERVATION_MODIFIER", 447, 455], ["genital", "ANATOMY", 456, 463], ["tumors", "OBSERVATION", 464, 470], ["infectious", "OBSERVATION", 537, 547], ["cancer", "OBSERVATION", 582, 588]]], ["Although more work is necessary to standardize and validate this approach to diagnosis, CRISPR-Cas-based assays show tremendous potential for point-of-care diagnostic because of its ease of implementation, short turnaround time, direct detection from human samples, and colorimetric fluorescent readout [51] [52] [53] .BacteriaCRISPR-based platforms also have the potential to detect and alter bacterial pathogens, including those that exist as external threats as well those that live within us and comprise the microbiome [54] .", [["samples", "ANATOMY", 257, 264], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 88, 98], ["human", "ORGANISM", 251, 256], ["CRISPR", "DNA", 88, 94], ["Cas", "PROTEIN", 95, 98], ["BacteriaCRISPR", "PROTEIN", 319, 333], ["human", "SPECIES", 251, 256], ["human", "SPECIES", 251, 256], ["CRISPR", "TEST", 88, 94], ["human samples", "TEST", 251, 264], ["BacteriaCRISPR", "TEST", 319, 333], ["alter bacterial pathogens", "PROBLEM", 388, 413]]], ["This platform also has tremendous potential to identify and eradicate bacterial resistance genes, which enable pathogens to evade or neutralize antibiotics [2] .", [["bacterial resistance genes", "DNA", 70, 96], ["bacterial resistance genes", "PROBLEM", 70, 96], ["neutralize antibiotics", "TREATMENT", 133, 155]]], ["One such approach, employed by Quan and colleagues, is FLASH (Finding Low Abundance Sequences by Hybridization), a nextgeneration CRISPR-based diagnostic method that leverages the flexibility and specificity of genetic modification [55] .", [["nextgeneration CRISPR", "DNA", 115, 136]]], ["This approach has been shown to antibiotic resistance genes in saliva and serum and may soon replace multiplex PCR [56] .", [["saliva", "ANATOMY", 63, 69], ["serum", "ANATOMY", 74, 79], ["saliva", "ORGANISM_SUBSTANCE", 63, 69], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["antibiotic resistance genes", "DNA", 32, 59], ["antibiotic resistance genes in saliva and serum", "PROBLEM", 32, 79], ["multiplex PCR", "TEST", 101, 114], ["antibiotic resistance", "OBSERVATION", 32, 53]]], ["However, significant hurdles remain.", [["significant", "OBSERVATION_MODIFIER", 9, 20], ["hurdles", "OBSERVATION", 21, 28]]], ["It is unclear how a CRISPR-based platform could remove all clinically-relevant resistance genes in a single bacterium or how this could be scaled up to remove these sequences from an entire population of pathogens.BacteriaCRISPR-based methods have also been used to treat drugresistant bacterial infections.", [["bacterial infections", "DISEASE", 286, 306], ["BacteriaCRISPR", "SIMPLE_CHEMICAL", 214, 228], ["CRISPR", "DNA", 20, 26], ["resistance genes", "DNA", 79, 95], ["relevant resistance genes", "PROBLEM", 70, 95], ["a single bacterium", "PROBLEM", 99, 117], ["these sequences", "TEST", 159, 174], ["pathogens", "PROBLEM", 204, 213], ["BacteriaCRISPR-based methods", "TREATMENT", 214, 242], ["drugresistant bacterial infections", "PROBLEM", 272, 306], ["pathogens", "OBSERVATION", 204, 213], ["bacterial", "OBSERVATION_MODIFIER", 286, 295], ["infections", "OBSERVATION", 296, 306]]], ["In one example, a fifteen-year-old girl with cystic fibrosis with a disseminated Mycobacterium abscessus infection (which included her skin) was treated Article highlights \u2022 Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of nucleic acid that play an important role in bacterial defense and form the basis of a genome editing technology known as CRISPR-Cas9. \u2022 CRISPR-Cas9 allows for the permanent modification of genetic material and may be harnessed to treat a variety of diseases in humans. \u2022 Many of the applications of CRISPR-Cas9 may ultimately affect hospitalists-specialists in inpatient medicine-who serve as the primary caregivers for patients with a wide variety of maladies, ranging from heart disease to cancer. \u2022 The CRISPR-Cas9 system has been employed to serve as a diagnostic tool for viral infections. \u2022 CRISPR-based human genome editing comes in two forms: heritable germline editing, and non-heritable somatic modifications. with a three-bacteriophage cocktail that had been manipulated using CRISPR [57] .", [["cystic", "ANATOMY", 45, 51], ["skin", "ANATOMY", 135, 139], ["heart", "ANATOMY", 732, 737], ["cancer", "ANATOMY", 749, 755], ["cystic fibrosis", "DISEASE", 45, 60], ["Mycobacterium abscessus infection", "DISEASE", 81, 114], ["nucleic acid", "CHEMICAL", 257, 269], ["heart disease", "DISEASE", 732, 745], ["cancer", "DISEASE", 749, 755], ["viral infections", "DISEASE", 834, 850], ["girl", "ORGANISM", 35, 39], ["Mycobacterium abscessus", "ORGANISM", 81, 104], ["skin", "ORGAN", 135, 139], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 378, 389], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 393, 404], ["humans", "ORGANISM", 518, 524], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 556, 567], ["patients", "ORGANISM", 677, 685], ["heart", "ORGAN", 732, 737], ["cancer", "CANCER", 749, 755], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 763, 774], ["human", "ORGANISM", 867, 872], ["Clustered regularly interspaced short palindromic repeats", "DNA", 174, 231], ["CRISPR", "DNA", 233, 239], ["CRISPR", "DNA", 378, 384], ["Cas9", "DNA", 385, 389], ["CRISPR-Cas9", "DNA", 393, 404], ["CRISPR", "DNA", 556, 562], ["Cas9", "DNA", 563, 567], ["CRISPR", "DNA", 763, 769], ["Cas9", "DNA", 770, 774], ["CRISPR", "DNA", 854, 860], ["germline", "DNA", 918, 926], ["girl", "SPECIES", 35, 39], ["Mycobacterium abscessus", "SPECIES", 81, 104], ["humans", "SPECIES", 518, 524], ["patients", "SPECIES", 677, 685], ["human", "SPECIES", 867, 872], ["Mycobacterium abscessus", "SPECIES", 81, 104], ["humans", "SPECIES", 518, 524], ["human", "SPECIES", 867, 872], ["cystic fibrosis", "PROBLEM", 45, 60], ["a disseminated Mycobacterium abscessus infection", "PROBLEM", 66, 114], ["Clustered regularly interspaced short palindromic repeats", "PROBLEM", 174, 231], ["segments of nucleic acid", "PROBLEM", 245, 269], ["CRISPR-Cas9", "TREATMENT", 393, 404], ["the permanent modification of genetic material", "TREATMENT", 416, 462], ["a variety of diseases in humans", "PROBLEM", 493, 524], ["CRISPR-Cas9", "TREATMENT", 556, 567], ["heart disease to cancer", "PROBLEM", 732, 755], ["The CRISPR-Cas9 system", "TREATMENT", 759, 781], ["viral infections", "PROBLEM", 834, 850], ["CRISPR-based human genome editing", "PROBLEM", 854, 887], ["heritable germline editing", "PROBLEM", 908, 934], ["non-heritable somatic modifications", "PROBLEM", 940, 975], ["a three-bacteriophage cocktail", "TREATMENT", 982, 1012], ["cystic", "OBSERVATION_MODIFIER", 45, 51], ["fibrosis", "OBSERVATION", 52, 60], ["disseminated", "OBSERVATION_MODIFIER", 68, 80], ["Mycobacterium", "OBSERVATION_MODIFIER", 81, 94], ["abscessus", "OBSERVATION_MODIFIER", 95, 104], ["infection", "OBSERVATION", 105, 114], ["skin", "ANATOMY", 135, 139], ["nucleic acid", "OBSERVATION", 257, 269], ["bacterial defense", "OBSERVATION", 301, 318], ["diseases", "OBSERVATION", 506, 514], ["maladies", "OBSERVATION", 709, 717], ["heart", "ANATOMY", 732, 737], ["disease", "OBSERVATION", 738, 745], ["cancer", "OBSERVATION", 749, 755], ["infections", "OBSERVATION", 840, 850], ["human genome", "OBSERVATION", 867, 879], ["germline editing", "OBSERVATION", 918, 934], ["somatic modifications", "OBSERVATION", 954, 975]]], ["Bacteriophage treatment was associated with marked clinical improvement in this patient who had undergone bilateral lung transplantation and had previously been unable to clear her infection, suggesting that phage therapy may prove to be a useful treatment for drugresistant bacterial infections for other patients, many of whom are now managed by hospitalists at medical centers around the world [12, 58] .FungiMycotic infections are broadly divided into those caused by yeasts, molds, and thermally-dimorphic fungi [59] .", [["lung", "ANATOMY", 116, 120], ["infection", "DISEASE", 181, 190], ["bacterial infections", "DISEASE", 275, 295], ["FungiMycotic infections", "DISEASE", 407, 430], ["patient", "ORGANISM", 80, 87], ["lung", "ORGAN", 116, 120], ["patients", "ORGANISM", 306, 314], ["patient", "SPECIES", 80, 87], ["patients", "SPECIES", 306, 314], ["Bacteriophage treatment", "TREATMENT", 0, 23], ["bilateral lung transplantation", "TREATMENT", 106, 136], ["her infection", "PROBLEM", 177, 190], ["phage therapy", "TREATMENT", 208, 221], ["a useful treatment", "TREATMENT", 238, 256], ["drugresistant bacterial infections", "PROBLEM", 261, 295], ["FungiMycotic infections", "PROBLEM", 407, 430], ["yeasts", "PROBLEM", 472, 478], ["molds", "PROBLEM", 480, 485], ["dimorphic fungi", "PROBLEM", 501, 516], ["marked", "OBSERVATION_MODIFIER", 44, 50], ["bilateral", "ANATOMY_MODIFIER", 106, 115], ["lung", "ANATOMY", 116, 120], ["transplantation", "OBSERVATION", 121, 136], ["infection", "OBSERVATION", 181, 190], ["infections", "OBSERVATION", 420, 430], ["yeasts", "OBSERVATION", 472, 478], ["dimorphic", "OBSERVATION_MODIFIER", 501, 510], ["fungi", "OBSERVATION", 511, 516]]], ["Many of these organisms are ubiquitous in our environment, and preferentially infect patients with immune impairment [60] .", [["immune impairment", "DISEASE", 99, 116], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["these organisms", "PROBLEM", 8, 23], ["immune impairment", "PROBLEM", 99, 116], ["organisms", "OBSERVATION", 14, 23]]], ["These opportunistic pathogens are on the rise, due to advances in the treatment of cancer and autoimmune conditions, which have produced a variety of new drugs that alter the human immune system [61] .", [["cancer", "ANATOMY", 83, 89], ["opportunistic pathogens", "DISEASE", 6, 29], ["cancer", "DISEASE", 83, 89], ["cancer", "CANCER", 83, 89], ["human", "ORGANISM", 175, 180], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["These opportunistic pathogens", "PROBLEM", 0, 29], ["cancer", "PROBLEM", 83, 89], ["autoimmune conditions", "PROBLEM", 94, 115], ["new drugs", "TREATMENT", 150, 159], ["opportunistic", "OBSERVATION_MODIFIER", 6, 19], ["pathogens", "OBSERVATION", 20, 29], ["cancer", "OBSERVATION", 83, 89]]], ["The arsenal of anti-fungal drugs is smallthere are only three major classes of antifungal drugsand novel treatment approaches are desperately needed.", [["anti-fungal drugs", "TREATMENT", 15, 32], ["antifungal drugsand novel treatment approaches", "TREATMENT", 79, 125], ["anti-fungal drugs", "OBSERVATION", 15, 32]]], ["One such approach involves CRISPR.", [["CRISPR", "DNA", 27, 33]]], ["Kwon and colleagues provided the first comprehensive analysis and evaluation of different CRISPR approaches for the modification of molds [62] .", [["the first comprehensive analysis", "TEST", 29, 61], ["evaluation", "TEST", 66, 76], ["different CRISPR approaches", "TREATMENT", 80, 107]]], ["Guide RNAs were created and CRISPR nucleases were delivered to the filamentous fungus Thermothelomyces thermophilus on plasmids.", [["plasmids", "ANATOMY", 119, 127], ["Thermothelomyces thermophilus", "ORGANISM", 86, 115], ["Guide RNAs", "RNA", 0, 10], ["CRISPR nucleases", "DNA", 28, 44], ["plasmids", "DNA", 119, 127], ["Thermothelomyces thermophilus", "SPECIES", 86, 115], ["Thermothelomyces thermophilus", "SPECIES", 86, 115], ["Guide RNAs", "TREATMENT", 0, 10], ["CRISPR nucleases", "PROBLEM", 28, 44], ["plasmids", "TREATMENT", 119, 127]]], ["The team was able to generated high numbers of positive transformants that could be useful for high-throughput assays to identify novel antifungal agents.", [["transformants", "ANATOMY", 56, 69], ["transformants", "CELL", 56, 69], ["positive transformants", "PROBLEM", 47, 69], ["novel antifungal agents", "TREATMENT", 130, 153]]], ["This approach will likely extend to other fungi, and may yield insights into drug resistance associated with mycotic infection, which have emerged as an important cause of morbidity and mortality in immunocompromised patients.ParasitesParasites encompass a variety of human pathogens [63] .", [["mycotic infection", "DISEASE", 109, 126], ["patients", "ORGANISM", 217, 225], ["human", "ORGANISM", 268, 273], ["patients", "SPECIES", 217, 225], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 268, 273], ["This approach", "TREATMENT", 0, 13], ["other fungi", "PROBLEM", 36, 47], ["drug resistance", "PROBLEM", 77, 92], ["mycotic infection", "PROBLEM", 109, 126], ["morbidity", "PROBLEM", 172, 181], ["ParasitesParasites", "PROBLEM", 226, 244], ["human pathogens", "PROBLEM", 268, 283], ["mycotic", "OBSERVATION_MODIFIER", 109, 116], ["infection", "OBSERVATION", 117, 126], ["morbidity", "OBSERVATION", 172, 181], ["variety", "OBSERVATION_MODIFIER", 257, 264]]], ["Parasitic worms, such as roundworms and flatworms, are amongst the most complex representing the sixth leading cause of morbidity worldwide and treatment options are limited [64] .", [["worms", "ANATOMY", 10, 15], ["roundworms", "ANATOMY", 25, 35], ["Parasitic worms", "DISEASE", 0, 15], ["worms", "SPECIES", 10, 15], ["Parasitic worms", "PROBLEM", 0, 15], ["flatworms", "PROBLEM", 40, 49], ["morbidity", "PROBLEM", 120, 129], ["treatment options", "TREATMENT", 144, 161], ["worms", "OBSERVATION", 10, 15], ["morbidity", "OBSERVATION", 120, 129]]], ["Several investigators have employed CRISPR to interrupt essential genes in parasitic worms.", [["CRISPR", "DNA", 36, 42], ["worms", "SPECIES", 85, 90], ["essential genes in parasitic worms", "PROBLEM", 56, 90], ["parasitic worms", "OBSERVATION", 75, 90]]], ["For example, in the flatworm Opisthorchis viverrini, CRISPR-induced mutations were introduced into the Ov-grn-1 transcript and protein levels were reduced within 48 h of transfection [65, 66] .", [["flatworm", "ORGANISM", 20, 28], ["Opisthorchis viverrini", "ORGANISM", 29, 51], ["CRISPR", "GENE_OR_GENE_PRODUCT", 53, 59], ["Ov-grn-1", "GENE_OR_GENE_PRODUCT", 103, 111], ["CRISPR", "DNA", 53, 59], ["Ov-grn", "PROTEIN", 103, 109], ["Opisthorchis viverrini", "SPECIES", 29, 51], ["Opisthorchis viverrini", "SPECIES", 29, 51], ["the flatworm Opisthorchis viverrini", "PROBLEM", 16, 51], ["CRISPR-induced mutations", "TREATMENT", 53, 77], ["protein levels", "TEST", 127, 141], ["transfection", "TEST", 170, 182], ["flatworm", "OBSERVATION_MODIFIER", 20, 28], ["Opisthorchis", "OBSERVATION", 29, 41]]], ["The livers of animals infected with modified worms were less swollen, and their biliary ducts had less scarring compared to the those of animals harboring unmodified worms, suggesting that this CRISPR-based method may serve as an approach to attenuate the pathogenicity of a devastating pathogen that affects humans around the world [67, 68] .CancerThe use of CRISPR holds tremendous promise for the treatment of infectious diseases, but many of those assays and therapies are years away.", [["livers", "ANATOMY", 4, 10], ["biliary ducts", "ANATOMY", 80, 93], ["worms", "ANATOMY", 166, 171], ["Cancer", "ANATOMY", 343, 349], ["scarring", "DISEASE", 103, 111], ["Cancer", "DISEASE", 343, 349], ["infectious diseases", "DISEASE", 413, 432], ["livers", "ORGAN", 4, 10], ["animals", "ORGANISM", 14, 21], ["worms", "ORGANISM", 45, 50], ["biliary ducts", "MULTI-TISSUE_STRUCTURE", 80, 93], ["humans", "ORGANISM", 309, 315], ["Cancer", "CANCER", 343, 349], ["CRISPR", "DNA", 194, 200], ["CRISPR", "DNA", 360, 366], ["worms", "SPECIES", 45, 50], ["worms", "SPECIES", 166, 171], ["humans", "SPECIES", 309, 315], ["humans", "SPECIES", 309, 315], ["Cancer", "SPECIES", 343, 349], ["modified worms", "PROBLEM", 36, 50], ["less swollen", "PROBLEM", 56, 68], ["less scarring", "PROBLEM", 98, 111], ["this CRISPR-based method", "TREATMENT", 189, 213], ["a devastating pathogen", "PROBLEM", 273, 295], ["Cancer", "PROBLEM", 343, 349], ["CRISPR", "TREATMENT", 360, 366], ["infectious diseases", "PROBLEM", 413, 432], ["livers", "ANATOMY", 4, 10], ["animals", "OBSERVATION_MODIFIER", 14, 21], ["infected", "OBSERVATION", 22, 30], ["less", "OBSERVATION_MODIFIER", 56, 60], ["swollen", "OBSERVATION", 61, 68], ["biliary ducts", "ANATOMY", 80, 93], ["less", "OBSERVATION_MODIFIER", 98, 102], ["scarring", "OBSERVATION", 103, 111], ["unmodified worms", "OBSERVATION", 155, 171], ["devastating", "OBSERVATION_MODIFIER", 275, 286], ["pathogen", "OBSERVATION", 287, 295], ["infectious", "OBSERVATION", 413, 423]]], ["For cancer treatment, CRISPR-based therapies have already arrived [47] .", [["cancer", "ANATOMY", 4, 10], ["cancer", "DISEASE", 4, 10], ["cancer", "CANCER", 4, 10], ["CRISPR", "DNA", 22, 28], ["cancer treatment", "TREATMENT", 4, 20], ["CRISPR-based therapies", "TREATMENT", 22, 44], ["cancer", "OBSERVATION", 4, 10]]], ["In fact, preliminary results of the first phase-one study using CRISPR to treat cancer were recently revealed.", [["cancer", "ANATOMY", 80, 86], ["cancer", "DISEASE", 80, 86], ["cancer", "CANCER", 80, 86], ["CRISPR", "DNA", 64, 70], ["one study", "TEST", 48, 57], ["CRISPR to treat cancer", "PROBLEM", 64, 86], ["cancer", "OBSERVATION", 80, 86]]], ["In that study, T-cells from the blood of three patients (two with multiple myeloma and one with sarcoma) and used CRISPR-Cas9 to remove three genes from the cells, including two T-cell receptors as well as programmed cell death-1 (PD-1) [69] .", [["T-cells", "ANATOMY", 15, 22], ["blood", "ANATOMY", 32, 37], ["myeloma", "ANATOMY", 75, 82], ["sarcoma", "ANATOMY", 96, 103], ["cells", "ANATOMY", 157, 162], ["T-cell", "ANATOMY", 178, 184], ["multiple myeloma", "DISEASE", 66, 82], ["sarcoma", "DISEASE", 96, 103], ["T-cells", "CELL", 15, 22], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["patients", "ORGANISM", 47, 55], ["myeloma", "CANCER", 75, 82], ["sarcoma", "CANCER", 96, 103], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 114, 125], ["cells", "CELL", 157, 162], ["T-cell receptors", "GENE_OR_GENE_PRODUCT", 178, 194], ["programmed cell death-1", "GENE_OR_GENE_PRODUCT", 206, 229], ["PD-1", "GENE_OR_GENE_PRODUCT", 231, 235], ["T-cells", "CELL_TYPE", 15, 22], ["CRISPR", "DNA", 114, 120], ["Cas9", "DNA", 121, 125], ["T-cell receptors", "PROTEIN", 178, 194], ["patients", "SPECIES", 47, 55], ["that study", "TEST", 3, 13], ["multiple myeloma", "PROBLEM", 66, 82], ["sarcoma", "PROBLEM", 96, 103], ["CRISPR-Cas9", "TREATMENT", 114, 125], ["two T-cell receptors", "TREATMENT", 174, 194], ["programmed cell death", "TEST", 206, 227], ["PD", "TEST", 231, 233], ["multiple", "OBSERVATION_MODIFIER", 66, 74], ["myeloma", "OBSERVATION", 75, 82], ["sarcoma", "OBSERVATION", 96, 103]]], ["The patients received modified cells after chemotherapy and the CRISPR-edited cells proliferated in all of the patients while no serious treatment-related adverse events were noted.", [["cells", "ANATOMY", 31, 36], ["cells", "ANATOMY", 78, 83], ["patients", "ORGANISM", 4, 12], ["cells", "CELL", 31, 36], ["cells", "CELL", 78, 83], ["patients", "ORGANISM", 111, 119], ["CRISPR-edited cells", "CELL_LINE", 64, 83], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 111, 119], ["modified cells", "TREATMENT", 22, 36], ["chemotherapy", "TREATMENT", 43, 55], ["the CRISPR", "TEST", 60, 70], ["serious treatment", "TREATMENT", 129, 146], ["adverse events", "PROBLEM", 155, 169]]], ["This proof-of-principle study shows that CRISPRbased treatments for cancer are both safe and feasible and will serve as the basis for phase two studies, which will likely begin in the near future [69] [70] [71] [72] .", [["cancer", "ANATOMY", 68, 74], ["cancer", "DISEASE", 68, 74], ["CRISPRbased", "SIMPLE_CHEMICAL", 41, 52], ["cancer", "CANCER", 68, 74], ["principle study", "TEST", 14, 29], ["CRISPRbased treatments", "TREATMENT", 41, 63], ["cancer", "PROBLEM", 68, 74], ["phase two studies", "TEST", 134, 151], ["cancer", "OBSERVATION", 68, 74]]], ["It is not yet known how these malignancies evade immune surveillance or how removal of these genes affected the efficacy of T-cells against cancer.CancerAnother CRISPR-based approach to the treatment of cancer is based on the production of next-generation chimeric antigen receptor (CAR) T-cells, which are created to express cancer-targeting receptors [73, 74] .", [["malignancies", "ANATOMY", 30, 42], ["T-cells", "ANATOMY", 124, 131], ["cancer", "ANATOMY", 140, 146], ["cancer", "ANATOMY", 203, 209], ["CAR) T-cells", "ANATOMY", 283, 295], ["cancer", "ANATOMY", 326, 332], ["malignancies", "DISEASE", 30, 42], ["cancer", "DISEASE", 140, 146], ["cancer", "DISEASE", 203, 209], ["cancer", "DISEASE", 326, 332], ["malignancies", "CANCER", 30, 42], ["T-cells", "CELL", 124, 131], ["cancer", "CANCER", 140, 146], ["cancer", "CANCER", 203, 209], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 256, 281], ["cancer", "CANCER", 326, 332], ["T-cells", "CELL_TYPE", 124, 131], ["chimeric antigen receptor (CAR) T-cells", "CELL_TYPE", 256, 295], ["cancer-targeting receptors", "PROTEIN", 326, 352], ["these malignancies", "PROBLEM", 24, 42], ["immune surveillance", "TREATMENT", 49, 68], ["cancer", "PROBLEM", 140, 146], ["CancerAnother CRISPR", "TREATMENT", 147, 167], ["cancer", "PROBLEM", 203, 209], ["not yet", "UNCERTAINTY", 6, 13], ["malignancies", "OBSERVATION", 30, 42], ["cancer", "OBSERVATION", 203, 209], ["cancer", "OBSERVATION", 326, 332]]], ["CAR T-cell therapy targeting the CD19 antigen has been the most studied and successful due to its specific expression in various forms of leukemia.", [["T-cell", "ANATOMY", 4, 10], ["leukemia", "ANATOMY", 138, 146], ["leukemia", "DISEASE", 138, 146], ["CAR", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD19 antigen", "GENE_OR_GENE_PRODUCT", 33, 45], ["leukemia", "CANCER", 138, 146], ["CD19 antigen", "PROTEIN", 33, 45], ["CAR T-cell therapy", "TREATMENT", 0, 18], ["the CD19 antigen", "TREATMENT", 29, 45], ["leukemia", "PROBLEM", 138, 146], ["leukemia", "OBSERVATION", 138, 146]]], ["Recently, investigators treated a patient with aggressive lung cancer with T-cells edited by CRISPR [75] .", [["lung cancer", "ANATOMY", 58, 69], ["T-cells", "ANATOMY", 75, 82], ["aggressive lung cancer", "DISEASE", 47, 69], ["patient", "ORGANISM", 34, 41], ["lung cancer", "CANCER", 58, 69], ["T-cells", "CELL", 75, 82], ["T-cells", "CELL_TYPE", 75, 82], ["patient", "SPECIES", 34, 41], ["aggressive lung cancer", "PROBLEM", 47, 69], ["aggressive", "OBSERVATION_MODIFIER", 47, 57], ["lung", "ANATOMY", 58, 62], ["cancer", "OBSERVATION", 63, 69]]], ["Clinical trials the safety and efficacy of CAR T-cell immunotherapy for leukemia and lymphoma are ongoing and may soon expand to solid organ malignancies [74, 76, 77] .Heart diseaseHeart disease comes in many forms [78, 79] .", [["T-cell", "ANATOMY", 47, 53], ["leukemia", "ANATOMY", 72, 80], ["lymphoma", "ANATOMY", 85, 93], ["solid organ malignancies", "ANATOMY", 129, 153], ["Heart", "ANATOMY", 168, 173], ["Heart", "ANATOMY", 181, 186], ["leukemia and lymphoma", "DISEASE", 72, 93], ["organ malignancies", "DISEASE", 135, 153], ["Heart disease", "DISEASE", 168, 181], ["Heart disease", "DISEASE", 181, 194], ["CAR T-cell", "CELL", 43, 53], ["leukemia", "CANCER", 72, 80], ["lymphoma", "CANCER", 85, 93], ["solid organ malignancies", "CANCER", 129, 153], ["Heart", "ORGAN", 168, 173], ["Heart", "ORGAN", 181, 186], ["CAR T-cell immunotherapy", "TREATMENT", 43, 67], ["leukemia", "PROBLEM", 72, 80], ["lymphoma", "PROBLEM", 85, 93], ["solid organ malignancies", "PROBLEM", 129, 153], ["Heart disease", "PROBLEM", 168, 181], ["Heart disease", "PROBLEM", 181, 194], ["lymphoma", "OBSERVATION", 85, 93], ["disease", "OBSERVATION", 174, 181], ["disease", "OBSERVATION", 187, 194]]], ["So too, do the treatment options.", [["the treatment options", "TREATMENT", 11, 32]]], ["Recently, CRISPR has been presented as a potential method to remove monogenic cardiovascular disorders from the offspring and subsequent generations of affected families [80] .", [["cardiovascular", "ANATOMY", 78, 92], ["monogenic cardiovascular disorders", "DISEASE", 68, 102], ["cardiovascular", "ANATOMICAL_SYSTEM", 78, 92], ["CRISPR", "DNA", 10, 16], ["monogenic cardiovascular disorders", "PROBLEM", 68, 102]]], ["Heritable cardiomyopathies, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, and Duchenne muscular dystrophy, vasculopathies such as Marfan's syndrome, and infiltrative diseases such as amyloidosis, serve potential candidates for clinical applications of CRISPR-based germline genome editing techniques [81, 82] .", [["Duchenne muscular dystrophy", "ANATOMY", 93, 120], ["cardiomyopathies", "DISEASE", 10, 26], ["dilated cardiomyopathy", "DISEASE", 36, 58], ["hypertrophic cardiomyopathy", "DISEASE", 60, 87], ["Duchenne muscular dystrophy", "DISEASE", 93, 120], ["vasculopathies", "DISEASE", 122, 136], ["Marfan's syndrome", "DISEASE", 145, 162], ["amyloidosis", "DISEASE", 198, 209], ["CRISPR", "DNA", 267, 273], ["germline genome", "DNA", 280, 295], ["Heritable cardiomyopathies", "PROBLEM", 0, 26], ["dilated cardiomyopathy", "PROBLEM", 36, 58], ["hypertrophic cardiomyopathy", "PROBLEM", 60, 87], ["Duchenne muscular dystrophy", "PROBLEM", 93, 120], ["vasculopathies", "PROBLEM", 122, 136], ["Marfan's syndrome", "PROBLEM", 145, 162], ["infiltrative diseases", "PROBLEM", 168, 189], ["amyloidosis", "PROBLEM", 198, 209], ["clinical applications of CRISPR", "TREATMENT", 242, 273], ["cardiomyopathies", "OBSERVATION", 10, 26], ["dilated", "OBSERVATION_MODIFIER", 36, 43], ["cardiomyopathy", "OBSERVATION", 44, 58], ["hypertrophic", "OBSERVATION_MODIFIER", 60, 72], ["cardiomyopathy", "OBSERVATION", 73, 87], ["Duchenne muscular dystrophy", "OBSERVATION", 93, 120], ["infiltrative", "OBSERVATION_MODIFIER", 168, 180], ["amyloidosis", "OBSERVATION", 198, 209], ["germline genome", "OBSERVATION", 280, 295]]], ["Permanently editing the germline will affect unborn children who are unable to consent to such a procedure and its use is currently prohibited [83] [84] [85] .", [["children", "ORGANISM", 52, 60], ["germline", "DNA", 24, 32], ["children", "SPECIES", 52, 60], ["a procedure", "TREATMENT", 95, 106]]], ["But that may soon change.Heart diseaseAs the technology advances, CRISPR-based treatments for heart disease may expand beyond heritable cardiomyopathies.", [["Heart", "ANATOMY", 25, 30], ["heart", "ANATOMY", 94, 99], ["Heart diseaseAs", "DISEASE", 25, 40], ["heart disease", "DISEASE", 94, 107], ["cardiomyopathies", "DISEASE", 136, 152], ["Heart", "ORGAN", 25, 30], ["heart", "ORGAN", 94, 99], ["Heart diseaseAs", "PROBLEM", 25, 40], ["CRISPR-based treatments", "TREATMENT", 66, 89], ["heart disease", "PROBLEM", 94, 107], ["heritable cardiomyopathies", "PROBLEM", 126, 152], ["diseaseAs", "OBSERVATION", 31, 40], ["heart", "ANATOMY", 94, 99], ["disease", "OBSERVATION", 100, 107], ["heritable", "OBSERVATION_MODIFIER", 126, 135], ["cardiomyopathies", "OBSERVATION", 136, 152]]], ["It is easy to foresee how gene-editing may be useful for polygenetic syndromes, including hypercholesterolemia, hypertension, and diabetes, among others [80, 86, 87] .", [["hypercholesterolemia", "DISEASE", 90, 110], ["hypertension", "DISEASE", 112, 124], ["diabetes", "DISEASE", 130, 138], ["polygenetic syndromes", "PROBLEM", 57, 78], ["hypercholesterolemia", "PROBLEM", 90, 110], ["hypertension", "PROBLEM", 112, 124], ["diabetes", "PROBLEM", 130, 138], ["hypercholesterolemia", "OBSERVATION", 90, 110], ["hypertension", "OBSERVATION", 112, 124], ["diabetes", "OBSERVATION", 130, 138]]], ["For example, one group used CRISPR-Cas9 genome editing to target genes linked to insulin production, SPRY2, and the functional consequences of SPRY2 knockout and overexpression subsequently assessed using glucose uptake and lipid assays [88] .", [["glucose", "CHEMICAL", 205, 212], ["glucose", "CHEMICAL", 205, 212], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 28, 39], ["insulin", "GENE_OR_GENE_PRODUCT", 81, 88], ["SPRY2", "GENE_OR_GENE_PRODUCT", 101, 106], ["SPRY2", "GENE_OR_GENE_PRODUCT", 143, 148], ["glucose", "SIMPLE_CHEMICAL", 205, 212], ["CRISPR", "DNA", 28, 34], ["SPRY2", "PROTEIN", 101, 106], ["SPRY2", "PROTEIN", 143, 148], ["SPRY2", "TREATMENT", 101, 106], ["SPRY2 knockout", "TEST", 143, 157], ["glucose uptake", "TEST", 205, 219], ["lipid assays", "TEST", 224, 236]]], ["This work implicates a novel mechanism in the development of glucose intolerance and has profound implications for the treatment of diabetes, which is known to be an important risk factor for heart disease.", [["heart", "ANATOMY", 192, 197], ["glucose intolerance", "DISEASE", 61, 80], ["diabetes", "DISEASE", 132, 140], ["heart disease", "DISEASE", 192, 205], ["glucose", "CHEMICAL", 61, 68], ["glucose", "SIMPLE_CHEMICAL", 61, 68], ["heart", "ORGAN", 192, 197], ["glucose intolerance", "PROBLEM", 61, 80], ["diabetes", "PROBLEM", 132, 140], ["heart disease", "PROBLEM", 192, 205], ["glucose intolerance", "OBSERVATION", 61, 80], ["diabetes", "OBSERVATION", 132, 140], ["heart", "ANATOMY", 192, 197], ["disease", "OBSERVATION", 198, 205]]], ["Research in this area is ongoing [82] .ConclusionsCRISPR-based platforms have been described as the greatest scientific discovery of the twentieth century.", [["ConclusionsCRISPR-based platforms", "TEST", 39, 72], ["greatest", "OBSERVATION_MODIFIER", 100, 108]]], ["It is incumbent upon clinicians to familiarize themselves with CRISPR to both understand how it may benefit patients and to help identify future areas of inquiry [89] .", [["patients", "ORGANISM", 108, 116], ["CRISPR", "DNA", 63, 69], ["patients", "SPECIES", 108, 116]]], ["As technical and ethical questions regarding the use of CRISPR in humans continue to mount, hospitalists must take a more active role in the discussions to ensure that relevant stakeholders have a say in determining how this technology is implemented.", [["humans", "ORGANISM", 66, 72], ["CRISPR", "DNA", 56, 62], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["CRISPR in humans", "TREATMENT", 56, 72]]], ["CRISPR provides tremendous potential but also comes with serious pitfalls, and the next decade will be an important period to determine how best to harness this platform to advance the field of hospital medicine.Expert opinionCRISPR-based platforms have profoundly altered molecular biology and are poised to redefine the practice of medicine [48, [90] [91] [92] .", [["CRISPR", "DNA", 0, 6], ["hospital medicine", "TREATMENT", 194, 211]]], ["This paper reviews some of the most promising developments in diagnostics and therapeutics that have pertinence to hospitalistsspecialists in inpatient medicinewho care for patients with a wide variety of maladies, ranging from infectious diseases to cancer to heart disease [93, 94] .", [["cancer", "ANATOMY", 251, 257], ["heart", "ANATOMY", 261, 266], ["infectious diseases", "DISEASE", 228, 247], ["cancer", "DISEASE", 251, 257], ["heart disease", "DISEASE", 261, 274], ["patients", "ORGANISM", 173, 181], ["cancer", "CANCER", 251, 257], ["heart", "ORGAN", 261, 266], ["patients", "SPECIES", 173, 181], ["infectious diseases", "PROBLEM", 228, 247], ["cancer to heart disease", "PROBLEM", 251, 274], ["maladies", "OBSERVATION", 205, 213], ["heart", "ANATOMY", 261, 266]]], ["It is important for hospitalists to understand this emerging new technology both to ensure that it is used properly and to identify areas where it might be further deployed.Expert opinionThis has become especially relevant with the emergence of the novel coronavirus, SARS-CoV-2.", [["coronavirus", "DISEASE", 255, 266], ["SARS", "DISEASE", 268, 272], ["coronavirus", "ORGANISM", 255, 266], ["SARS-CoV-2", "ORGANISM", 268, 278], ["SARS-CoV", "SPECIES", 268, 276]]], ["In many medical centers, hospitalists have been the primary physicians responsible for the care of patients with this infection.", [["infection", "DISEASE", 118, 127], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["this infection", "PROBLEM", 113, 127], ["infection", "OBSERVATION", 118, 127]]], ["Diagnostic and therapeutic options have been limited, and hospitalists on the front lines have been forced to make treatment decisions with little or no data.", [["front lines", "ANATOMY", 78, 89], ["front lines", "CELL", 78, 89]]], ["This experience has reinforced the crucial role of the hospitalist in the care of patients with novel infections and it further strengthens the argument that hospitalists must be a part of the future research involving emerging pathogens.", [["infections", "DISEASE", 102, 112], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["novel infections", "PROBLEM", 96, 112], ["emerging pathogens", "PROBLEM", 219, 237], ["infections", "OBSERVATION", 102, 112]]], ["Frontline clinicians have a better understanding of the questions pertinent to patient care and can help formulate research projects that will address knowledge gaps.", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86]]], ["One area that has not yet been full explored is the role of CRISPR-Cas9 in the battle against SARS-CoV-2.", [["SARS", "DISEASE", 94, 98], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 60, 71], ["SARS-CoV-2", "ORGANISM", 94, 104], ["CRISPR", "DNA", 60, 66], ["Cas9", "DNA", 67, 71], ["SARS-CoV", "SPECIES", 94, 102]]], ["Permanent nucleic acid modification may provide unique insights into a pandemic that has already infected more than two million people.Expert opinionBut this area of research comes with certain risks and important caveats [95] .", [["nucleic acid", "CHEMICAL", 10, 22], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["Permanent nucleic acid modification", "TREATMENT", 0, 35], ["a pandemic", "PROBLEM", 69, 79], ["nucleic acid", "OBSERVATION", 10, 22]]], ["CRISPR-based human genome editing comes in two forms: heritable germline editing, and nonheritable somatic modifications [36, 89] .", [["human", "ORGANISM", 13, 18], ["CRISPR", "DNA", 0, 6], ["germline", "DNA", 64, 72], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["heritable germline editing", "PROBLEM", 54, 80], ["genome editing", "OBSERVATION", 19, 33], ["germline editing", "OBSERVATION", 64, 80]]], ["The former results in genetic changes that are passed on to future generations and is currently prohibited to clinical researchers [21, 96] .", [["genetic changes", "PROBLEM", 22, 37]]], ["In 2019, the World Health Organization recommended against any clinical research on human germline editing until all technical and ethical considerations have been properly vetted and this policy is unlikely to change in the foreseeable future [97] [98] [99] .Expert opinionIn fact, some expert now believe that the most relevant hospital applications of CRISPR-Cas9 involve no editing of human DNA.", [["human", "ORGANISM", 84, 89], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 355, 366], ["human", "ORGANISM", 389, 394], ["DNA", "CELLULAR_COMPONENT", 395, 398], ["germline", "DNA", 90, 98], ["CRISPR", "DNA", 355, 361], ["Cas9", "DNA", 362, 366], ["human DNA", "DNA", 389, 398], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 389, 394], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 389, 394], ["human germline editing", "TREATMENT", 84, 106], ["CRISPR-Cas9", "TREATMENT", 355, 366], ["human DNA", "PROBLEM", 389, 398]]], ["Rather, they see the editing of the microbiota as a far more promising approach, as it would be non-heritable and non-somatic.", [["non-somatic", "PROBLEM", 114, 125]]], ["DNA manipulation may extend to a variety of human pathogens, and may include deletion of viral DNA and cancer DNA to hamper proliferation of malignant cells.", [["cancer", "ANATOMY", 103, 109], ["malignant cells", "ANATOMY", 141, 156], ["cancer", "DISEASE", 103, 109], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["human", "ORGANISM", 44, 49], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["cancer", "ORGANISM_SUBSTANCE", 103, 109], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["malignant cells", "CELL", 141, 156], ["viral DNA", "DNA", 89, 98], ["malignant cells", "CELL_TYPE", 141, 156], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["DNA manipulation", "TREATMENT", 0, 16], ["human pathogens", "PROBLEM", 44, 59], ["viral DNA", "PROBLEM", 89, 98], ["cancer DNA", "PROBLEM", 103, 113], ["malignant cells", "PROBLEM", 141, 156], ["pathogens", "OBSERVATION", 50, 59], ["viral DNA", "OBSERVATION", 89, 98], ["proliferation", "OBSERVATION_MODIFIER", 124, 137], ["malignant cells", "OBSERVATION", 141, 156]]], ["As mentioned above, CRISPR-based diagnosis may hasten detection of emerging viral pathogens, such as SARS-CoV-2.Expert opinionFor now, CRISPR-based clinical research will focus on the identification and alteration of infectious pathogens as well as novel treatment options for a variety of diseases ranging from infections to heart disease and cancer [45, [100] [101] [102] [103] .Expert opinionRecent research indicates that CRISPR has tremendous potential to improve the care of hematologic diseases, such as sickle cell disease and other heritable hemoglobinopathies, as well as autoimmune conditions, such as lupus [35, 47, [103] [104] [105] .", [["heart", "ANATOMY", 326, 331], ["cancer", "ANATOMY", 344, 350], ["hematologic", "ANATOMY", 481, 492], ["sickle cell", "ANATOMY", 511, 522], ["viral pathogens", "DISEASE", 76, 91], ["SARS", "DISEASE", 101, 105], ["infections", "DISEASE", 312, 322], ["heart disease", "DISEASE", 326, 339], ["cancer", "DISEASE", 344, 350], ["hematologic diseases", "DISEASE", 481, 501], ["sickle cell disease", "DISEASE", 511, 530], ["hemoglobinopathies", "DISEASE", 551, 569], ["lupus", "DISEASE", 613, 618], ["SARS-CoV-2", "ORGANISM", 101, 111], ["heart", "ORGAN", 326, 331], ["cancer", "CANCER", 344, 350], ["hematologic", "CANCER", 481, 492], ["sickle cell", "CELL", 511, 522], ["CRISPR", "DNA", 20, 26], ["CRISPR", "DNA", 426, 432], ["SARS-CoV", "SPECIES", 101, 109], ["emerging viral pathogens", "PROBLEM", 67, 91], ["the identification", "TEST", 180, 198], ["infectious pathogens", "PROBLEM", 217, 237], ["novel treatment options", "TREATMENT", 249, 272], ["diseases", "PROBLEM", 290, 298], ["infections", "PROBLEM", 312, 322], ["heart disease", "PROBLEM", 326, 339], ["cancer", "PROBLEM", 344, 350], ["hematologic diseases", "PROBLEM", 481, 501], ["sickle cell disease", "PROBLEM", 511, 530], ["other heritable hemoglobinopathies", "PROBLEM", 535, 569], ["autoimmune conditions", "PROBLEM", 582, 603], ["lupus", "TEST", 613, 618], ["infectious", "OBSERVATION", 217, 227], ["heart", "ANATOMY", 326, 331], ["disease", "OBSERVATION", 332, 339], ["sickle cell disease", "OBSERVATION", 511, 530], ["heritable", "OBSERVATION_MODIFIER", 541, 550], ["hemoglobinopathies", "OBSERVATION", 551, 569]]], ["CRISRP-based platforms have the potential to alter microbiota, which can be associated with adverse health events [106, 107] .", [["CRISRP", "PROTEIN", 0, 6]]], ["It will be crucial for hospitalists, who often care for these patients, to take a more involved role in this aspect of clinical research as CRISPR-based approaches will undoubtedly affect many of their patients in the years to come.FundingThis paper was not funded.Declaration of interestM McCarthy has served as a paid consultant to Allergan.", [["Allergan", "CHEMICAL", 334, 342], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 202, 210], ["Allergan", "TREATMENT", 334, 342]]], ["The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.", [["no other", "UNCERTAINTY", 15, 23]]]], "PMC6748269": [["IntroductionSocial media is an important platform for public health communication [1].", [["IntroductionSocial media", "TREATMENT", 0, 24]]], ["Topics of great relevance to global health, such as avian influenza, Ebola, HIV, malaria, Middle East respiratory syndrome, tuberculosis, and Zika, were discussed on Twitter and other social media platforms [23456789].", [["avian influenza", "DISEASE", 52, 67], ["Ebola, HIV, malaria", "DISEASE", 69, 88], ["Middle East respiratory syndrome", "DISEASE", 90, 122], ["tuberculosis", "DISEASE", 124, 136], ["Ebola", "ORGANISM", 69, 74], ["avian influenza", "SPECIES", 52, 67], ["Ebola", "SPECIES", 69, 74], ["HIV", "SPECIES", 76, 79], ["HIV", "SPECIES", 76, 79], ["Middle East respiratory syndrome, tuberculosis", "SPECIES", 90, 136], ["influenza", "PROBLEM", 58, 67], ["Ebola", "PROBLEM", 69, 74], ["HIV", "PROBLEM", 76, 79], ["malaria", "PROBLEM", 81, 88], ["Middle East respiratory syndrome", "PROBLEM", 90, 122], ["tuberculosis", "PROBLEM", 124, 136], ["Zika", "PROBLEM", 142, 146], ["great", "OBSERVATION_MODIFIER", 10, 15], ["Middle", "ANATOMY_MODIFIER", 90, 96], ["respiratory syndrome", "OBSERVATION", 102, 122], ["tuberculosis", "OBSERVATION", 124, 136]]], ["In particular, the Centers for Disease Control and Prevention (CDC) maintained a portfolio of social media communication efforts [13].", [["Disease Control", "TREATMENT", 31, 46]]], ["Prior research has studied user engagement of CDC Facebook communication during the Ebola emergency response [1415], as well as individual Twitter chats that CDC hosted during the Ebola and Zika outbreaks [1617].", [["Ebola", "DISEASE", 84, 89], ["Ebola", "DISEASE", 180, 185], ["Ebola", "ORGANISM", 84, 89], ["Ebola", "ORGANISM", 180, 185]]], ["In this case study, we are going to focus on CDC Public Health Grand Rounds and CDC Vital Signs and their related Twitter communication.IntroductionThe CDC hosts a monthly panel presentation coupled with a webcast titled \u2018Public Health Grand Rounds\u2019 that has been in circulation since September of 2009.", [["this case study", "TEST", 3, 18], ["Vital Signs", "TEST", 84, 95]]], ["The report includes an early release of the Morbidity and Mortality Weekly Report (MMWR), which is also a CDC publication, a graphic fact sheet and website, a media release, and social media tools.", [["a media release", "TREATMENT", 157, 172]]], ["The topics include alcohol, cancer, cardiovascular diseases, food safety, prescription drug overdoses, teen pregnancy, tobacco, healthcare-associated infections, HIV/AIDS, motor vehicle safety, obesity, and others [19].IntroductionTo promote Public Health Grand Rounds and Vital Signs, the CDC disseminates related information to their Twitter followers using the hashtags #CDCGrandRounds and #VitalSigns, respectively.", [["cancer", "ANATOMY", 28, 34], ["cardiovascular", "ANATOMY", 36, 50], ["alcohol", "CHEMICAL", 19, 26], ["cancer", "DISEASE", 28, 34], ["cardiovascular diseases", "DISEASE", 36, 59], ["drug overdoses", "DISEASE", 87, 101], ["infections", "DISEASE", 150, 160], ["HIV/AIDS", "DISEASE", 162, 170], ["obesity", "DISEASE", 194, 201], ["alcohol", "CHEMICAL", 19, 26], ["alcohol", "SIMPLE_CHEMICAL", 19, 26], ["cancer", "CANCER", 28, 34], ["cardiovascular", "ANATOMICAL_SYSTEM", 36, 50], ["tobacco", "ORGANISM", 119, 126], ["HIV", "SPECIES", 162, 165], ["tobacco", "SPECIES", 119, 126], ["HIV", "SPECIES", 162, 165], ["cancer", "PROBLEM", 28, 34], ["cardiovascular diseases", "PROBLEM", 36, 59], ["teen pregnancy", "PROBLEM", 103, 117], ["associated infections", "PROBLEM", 139, 160], ["HIV/AIDS", "PROBLEM", 162, 170], ["obesity", "PROBLEM", 194, 201], ["Vital Signs", "TEST", 273, 284], ["cancer", "OBSERVATION", 28, 34], ["cardiovascular", "ANATOMY", 36, 50], ["infections", "OBSERVATION", 150, 160]]], ["In this study, we analyzed two corpora of tweets, each with one of these two hashtags.IntroductionTo increase engagement with their followers, CDC health communication specialists often attach visual cues, such as images or videos, to their tweets.", [["this study", "TEST", 3, 13]]], ["In a recent study, it was found that attaching visual cues to posts posted by federal health agencies on their Facebook pages would generate more engagement with Facebook users [10].", [["a recent study", "TEST", 3, 17]]], ["In this study, we aimed to answer two research questions: (a) to quantify the effect of hashtag count, mention count, and URL link count on retweet frequency between the Twitter corpora of #CDCGrandRounds and #VitalSigns respectively; and (b) to quantify the effect of attaching visual cues on retweet frequency across cycles of #CDCGrandRounds and #VitalSigns Twitter health communication.MethodsData collection.", [["this study", "TEST", 3, 13], ["hashtag count", "TEST", 88, 101], ["count", "TEST", 111, 116], ["URL link count", "TEST", 122, 136], ["#CDCGrandRounds", "TREATMENT", 329, 344], ["MethodsData collection", "TEST", 390, 412]]], ["We retrieved tweets\u2019 IDs via web scraping and then used Twitter Search Application Programming Interface to download the tweet\u2019s meta-data to a server at Athens, Georgia, USA.", [["web scraping", "TREATMENT", 29, 41]]], ["In this corpus, four tweets were posted on April 21, 2011 and were excluded from further analysis.", [["corpus", "ANATOMY", 8, 14], ["corpus", "CANCER", 8, 14], ["further analysis", "TEST", 81, 97], ["corpus", "ANATOMY", 8, 14]]], ["The rest of the corpus (N = 6,962) began with August 18, 2011 and was the basis of subsequent analysis.", [["corpus", "ANATOMY", 16, 22], ["corpus", "ORGAN", 16, 22], ["subsequent analysis", "TEST", 83, 102], ["rest", "ANATOMY_MODIFIER", 4, 8], ["corpus", "ANATOMY", 16, 22]]], ["All original tweets containing the hashtag #VitalSigns dated from March 19, 2013 to October 31, 2016 were retrieved (N = 15,015).MethodsAnalysis of #CDCGrandRounds and #VitalSigns data sets.", [["hashtag #VitalSigns", "DNA", 35, 54], ["#CDCGrandRounds", "DNA", 148, 163], ["MethodsAnalysis", "TEST", 129, 144]]], ["Univariable and multivariable negative binomial regression models were applied to the two corpora to test if the three variables of interest (hashtag count, mention count, URL count) were associated with retweet frequency, after controlling for four confounders (users\u2019 followers count, friends\u2019 count, status count, and favorite count.)MethodsAnalysis by cycle.", [["hashtag count", "TEST", 142, 155], ["count", "TEST", 165, 170], ["URL count", "TEST", 172, 181], ["friends\u2019 count", "TEST", 287, 301], ["status count", "TEST", 303, 315], ["MethodsAnalysis", "TEST", 337, 352]]], ["Each corpus was sub-set into cycles (#CDCGrandRounds: n = 58, #VitalSigns: n = 42).", [["corpus", "ANATOMY", 5, 11], ["corpus", "ORGAN", 5, 11]]], ["Tweets that fell within a cycle corpus but were unrelated to the topic were excluded.", [["corpus", "ORGAN", 32, 38]]], ["The first cycle in the #CDCGrandRounds corpus was \u2018Newborn Screening: Improving Outcomes\u2019 in August 2011, and our data set ended with the cycle on \u2018Changes in Clinical Diagnostics and Tracking Infectious Diseases\u2019 in October 2016.MethodsFor the #VitalSigns corpus, a cycle was defined as the first day of the publication release, which was the first Tuesday of each month, until the day before the next publication was released.", [["Infectious Diseases\u2019", "DISEASE", 193, 213], ["our data", "TEST", 110, 118]]], ["Our #VitalSigns corpus began with the March 2013 cycle, \u2018Making Health Care Safer \u2013 Stop Infections from Lethal CRE Germs Now\u2019 and ended with the October 2016 cycle on \u2018Dental Sealants Prevent Cavities\u2019.MethodsManual coding was then performed on the top 30 most influential tweets, defined as the 30 tweets with the highest number of retweets for each cycle.", [["Infections", "DISEASE", 89, 99], ["Dental Sealants", "TREATMENT", 169, 184], ["Cavities", "OBSERVATION", 193, 201]]], ["Multivariable regression models were not applied because of the small sample size of 30 manually coded tweets of each cycle.MethodsStatistical language.", [["Multivariable regression models", "TEST", 0, 31], ["the small sample size", "PROBLEM", 60, 81], ["small", "OBSERVATION_MODIFIER", 64, 69], ["sample", "OBSERVATION_MODIFIER", 70, 76], ["size", "OBSERVATION_MODIFIER", 77, 81]]], ["R, version 3.3.1 [20], was used via RStudio, version 0.99.903 [21] to perform all analyses.MethodsEthics statement.", [["version", "TEST", 45, 52], ["all analyses", "TEST", 78, 90]]], ["In the #CDCGrandRounds corpus, the top 10 users were all CDC users and the top three URL domains were CDC, Twitter, and YouTube (Table 2).", [["corpus", "ANATOMY", 23, 29]]], ["In the #VitalSigns corpus, and ranked top number 3 and 5 users respectively and there were 2,058 (18.49% of 11,129) URL links directed to CDC\u2019s domain (www.cdc.gov).", [["#VitalSigns corpus", "ANATOMY", 7, 25], ["CDC\u2019s domain", "PROTEIN", 138, 150]]], ["For the #CDCGrandRounds corpus, after controlling for users\u2019 followers count, friends\u2019 count, status count, and favorite count, it was found that a unit increase in the number of hashtag will increase the retweet frequency by 8% (adjusted prevalence ratio, aPR = 1.0784, 95% CI, 1.0302, 1.1292, p < 0.001); increasing mention by one will reduce the retweet frequency of 14% (aPR = 0.8613, 95% CI, 0.8152, 0.9100; p < 0.001); and increasing URL link count by one will increase the retweet frequency by 78% (aPR = 1.7773, 95% CI, 1.6729, 1.8890; p < 0.001) (Table 3).", [["hashtag", "CHEMICAL", 179, 186], ["URL", "PROTEIN", 440, 443], ["followers count", "TEST", 61, 76], ["friends\u2019 count", "TEST", 78, 92], ["status count", "TEST", 94, 106], ["favorite count", "TEST", 112, 126], ["aPR", "TEST", 257, 260], ["CI", "TEST", 275, 277], ["aPR", "TEST", 375, 378], ["CI", "TEST", 393, 395], ["increasing URL link count", "PROBLEM", 429, 454], ["aPR", "TEST", 506, 509], ["CI", "TEST", 524, 526]]], ["For the #VitalSigns corpus, after controlling for users\u2019 followers count, friends\u2019 count, status count, and favorite count, it was found that adding one more hashtag would decrease retweet frequency by 3% (aPR = 0.9688, 95% CI, 0.9472, 0.9908, p < 0.001), while adding one more mention and one more URL link would increase retweet frequency by 17% (aPR = 1.1748, 95% CI, 1.1404, 1.2104, p < 0.001) and 22% (aPR = 1.2155, 95% CI, 1.1587, 1.2752, p < 0.001) respectively.ResultsTables S1 and S2 in the Online Supplementary Materials present the top retweet for each cycle of the #CDCGrandRounds and #VitalSigns corpora respectively, and whether they contain visual cues, as well as their retweet frequency.ResultsFigure 1 presents the per-cycle probability ratios of retweets for original tweets with images or videos as compared to those without.", [["#VitalSigns corpus", "ANATOMY", 8, 26], ["#VitalSigns corpus", "MULTI-TISSUE_STRUCTURE", 8, 26], ["corpora", "MULTI-TISSUE_STRUCTURE", 609, 616], ["followers count", "TEST", 57, 72], ["friends\u2019 count", "TEST", 74, 88], ["status count", "TEST", 90, 102], ["favorite count", "TEST", 108, 122], ["aPR", "TEST", 206, 209], ["CI", "TEST", 224, 226], ["aPR", "TEST", 349, 352], ["CI", "TEST", 367, 369], ["aPR", "TEST", 407, 410], ["CI", "TEST", 425, 427], ["the #CDCGrandRounds", "TREATMENT", 573, 592], ["images", "TEST", 799, 805], ["videos", "TEST", 809, 815], ["S2", "ANATOMY", 490, 492]]], ["Here we highlight a few important findings.ResultsOf the 58 #CDCGrandRounds cycles, 29 were found to have statistically significant difference between tweets with and without visual cues (Table S3).", [["few", "OBSERVATION_MODIFIER", 20, 23], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["difference", "OBSERVATION", 132, 142]]], ["Of these 29 cycles, one had a PR estimate < 1; twenty-four had PR between 1 and 3; and four had PR > 3.", [["PR", "PROTEIN", 30, 32], ["PR", "PROTEIN", 63, 65], ["PR", "PROTEIN", 96, 98], ["a PR estimate", "TEST", 28, 41], ["PR", "TEST", 63, 65], ["PR", "TEST", 96, 98], ["29 cycles", "OBSERVATION_MODIFIER", 9, 18]]], ["Two cycles were outliers: \u2018Preventing Suicide: A Comprehensive Public Health Approach\u2019 (September 2015) with PR = 36.353 (95% confidence intervals, CI, 4.869\u2013343.845, P < 0.001) and \u2018Understanding the Causes of Major Birth Defects: Steps to Prevention\u2019 (January 2015) with PR = 34.713 (95% CI, 7.662\u2013261.591, P < 0.001).ResultsOf the 42 #VitalSigns cycles, 19 were statistically significant (Table S4).", [["Suicide", "DISEASE", 38, 45], ["Birth Defects", "DISEASE", 217, 230], ["PR", "PROTEIN", 273, 275], ["PR", "TEST", 109, 111], ["CI", "TEST", 148, 150], ["Major Birth Defects", "PROBLEM", 211, 230], ["PR", "TEST", 273, 275], ["CI", "TEST", 290, 292], ["P", "TEST", 309, 310], ["Defects", "OBSERVATION", 223, 230]]], ["The PR estimates of six of these 19 cycles were between 1 and 3; and for 7 cycles, PR were between 3 and 5; for 6 cycles, PR was > 5.", [["PR", "PROTEIN", 4, 6], ["PR", "PROTEIN", 83, 85], ["PR", "PROTEIN", 122, 124], ["The PR estimates", "TEST", 0, 16], ["PR", "TEST", 83, 85], ["PR", "TEST", 122, 124]]], ["There were three outliers: \u2018Prescription Painkiller Overdoses\u2019 (July 2, 2013) with PR = 33.514 (95% CI, 8.715, 133.357, P < 0.001), \u2018Preventing Norovirus Outbreaks\u2019 (June 3, 2014) with PR = 29.536 (95% CI, 1.330, 326.283, P = 0.007), and \u2018Trucker Safety\u2019 (March 3, 2015), with PR = 10.270 (95% CI, 2.992, 37.010, P < 0.001).DiscussionIn this study, we quantified the strength of correlation between (a) hashtag count, mention count, and URL count, and (b) attaching visual cues to a CDC tweet and the retweet frequency.", [["Norovirus", "DISEASE", 144, 153], ["PR", "PROTEIN", 277, 279], ["PR", "TEST", 83, 85], ["PR", "TEST", 185, 187], ["CI", "TEST", 202, 204], ["P", "TEST", 222, 223], ["PR", "TEST", 277, 279], ["CI", "TEST", 294, 296], ["P", "TEST", 313, 314], ["this study", "TEST", 337, 347], ["a) hashtag count", "TEST", 400, 416], ["count", "TEST", 426, 431], ["URL count", "TEST", 437, 446], ["Norovirus", "OBSERVATION", 144, 153]]], ["We used tweets promoting CDC Public Health Grand Rounds and Vital Signs as a case study.DiscussionOur analysis of the entire corpora of #CDCGrandRounds and #VitalSigns found that the presence of URL links increased retweet frequency in both corpora.", [["corpora", "MULTI-TISSUE_STRUCTURE", 241, 248], ["URL", "PROTEIN", 195, 198], ["Vital Signs", "TEST", 60, 71], ["a case study", "TEST", 75, 87], ["DiscussionOur analysis", "TEST", 88, 110], ["URL links", "PROBLEM", 195, 204], ["URL", "OBSERVATION", 195, 198], ["increased", "OBSERVATION_MODIFIER", 205, 214], ["both", "ANATOMY_MODIFIER", 236, 240], ["corpora", "ANATOMY", 241, 248]]], ["Our results confirm that links to visual cues or additional information sources would attract more engagement from the users.DiscussionHowever, for the effect of hashtag count and mention count on retweet frequency, our results from the two corpora were found to be of opposite direction.", [["corpora", "MULTI-TISSUE_STRUCTURE", 241, 248], ["hashtag count", "TEST", 162, 175]]], ["Hashtag count was associated with more retweets among #CDCGrandRounds tweets and with fewer retweets among #VitalSigns tweets.", [["Hashtag count", "TEST", 0, 13]]], ["Mention count was associated with fewer retweets among #CDCGrandRounds tweets and with more retweets among #VitalSigns tweets.", [["count", "TEST", 8, 13]]], ["Our results suggest that the effect of hashtags and mentions on retweet frequency could be modified by contents or topics of the tweets.DiscussionIn our per-cycle analysis, it was found that for #CDCGrandRounds, the attachment of visual cues increased the probability of the tweets being retweeted in 28 of 58 cycles, of which for 24 cycles, the PR was between one and three; for one cycle, between three and five and for three cycles, above five.", [["PR", "PROTEIN", 346, 348], ["hashtags", "TREATMENT", 39, 47], ["our per-cycle analysis", "TEST", 149, 171], ["the PR", "TEST", 342, 348]]], ["For #VitalSigns, the attachment of a still image or video increased the probability of the tweets being retweeted in 19 of 42 cycles, of which for six cycles, the PR was between one and three; for seven cycles, between three and five; and for 6 cycles, above five.", [["PR", "PROTEIN", 163, 165], ["#VitalSigns", "PROBLEM", 4, 15], ["the PR", "TEST", 159, 165]]], ["Our research is in line with a study of federal health agencies\u2019 Facebook posts where the researchers found that visual cues increased Facebook posts engagement from users.", [["increased", "OBSERVATION_MODIFIER", 125, 134]]], ["In their study, photos and videos increase engagement by 6.253 and 2.833 folds respectively [10].DiscussionThe health communication policy implication is clear: attaching visual cues to tweets helps improve retweet frequency at large.", [["their study", "TEST", 3, 14]]], ["However, since the confidence intervals of most estimates overlap with each other, we chose not to perform a multivariable analysis, as it would not be informative.", [["a multivariable analysis", "TEST", 107, 131]]], ["This would require estimating many parameters and our sample size is not large enough for that.", [["our sample size", "TEST", 50, 65], ["size", "OBSERVATION_MODIFIER", 61, 65], ["large", "OBSERVATION_MODIFIER", 73, 78]]], ["In the future, control experiments could be performed to test the hypothesis that content might interact with visual cues to attract more retweets.DiscussionThere are several limitations in this study.", [["this study", "TEST", 190, 200]]], ["The hashtag #VitalSigns has been used by more than one organization to refer to different things.", [["The hashtag #VitalSigns", "TEST", 0, 23]]], ["This is not specific to the Vital Signs reports of the CDC.", [["the Vital Signs", "TEST", 24, 39]]], ["Results of the effect of visual cues reported here are univariable PRs.", [["visual cues", "TEST", 25, 36], ["univariable PRs", "PROBLEM", 55, 70]]], ["Given the limited sample size and the nature of our sample, we did not control for the effect of other variables.", [["size", "OBSERVATION_MODIFIER", 25, 29]]], ["Future studies can study other factors that can contribute towards increasing retweet frequency of tweets posted by health agencies.ConclusionsIn this paper, we studied the effect of hashtag count, mention count, URL count, and attaching visual cues to tweets pertinent to CDC Public Health Grand Rounds and Vital Signs.", [["Future studies", "TEST", 0, 14], ["hashtag count", "TEST", 183, 196], ["count", "TEST", 206, 211], ["URL count", "TEST", 213, 222], ["Vital Signs", "TEST", 308, 319]]], ["URL links were associated with higher retweet frequency for both corpora while the effect of hashtag count and mention count differed between corpora.", [["corpora", "MULTI-TISSUE_STRUCTURE", 65, 72], ["corpora", "MULTI-TISSUE_STRUCTURE", 142, 149], ["hashtag count", "TEST", 93, 106], ["mention count", "TEST", 111, 124]]], ["We found that there was an effect at large, of increasing retweets by attaching visual cues, but the effect varied depending on the cycles.", [["increasing retweets", "PROBLEM", 47, 66], ["effect", "OBSERVATION_MODIFIER", 27, 33], ["large", "OBSERVATION_MODIFIER", 37, 42], ["increasing", "OBSERVATION_MODIFIER", 47, 57]]]], "ae5006c43d3c5c9e46e8cc55da54b1b8bec8bca4": [["Introduction.The lack of knowledge for treating hospitalized SARS-CoV-2 infected patients is one of the pressing problems of the current COVID-19 pandemic.", [["SARS-CoV-2 infected", "DISEASE", 61, 80], ["SARS-CoV-2", "ORGANISM", 61, 71], ["patients", "ORGANISM", 81, 89], ["COVID-19", "ORGANISM", 137, 145], ["CoV-2", "SPECIES", 66, 71], ["patients", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 61, 69], ["the current COVID", "TEST", 125, 142], ["pandemic", "PROBLEM", 146, 154]]], ["The SARS-CoV-2 virus shows a close genetic similarity to the in April 2003 identified SARS virus (SARS-CoV-1) and to other SARS-related coronaviruses isolated from humans and bats.", [["SARS virus", "DISEASE", 86, 96], ["SARS", "DISEASE", 123, 127], ["SARS-CoV-2 virus", "ORGANISM", 4, 20], ["SARS virus", "ORGANISM", 86, 96], ["SARS-CoV-1", "ORGANISM", 98, 108], ["SARS-related coronaviruses", "ORGANISM", 123, 149], ["humans", "ORGANISM", 164, 170], ["CoV-2 virus", "SPECIES", 9, 20], ["CoV-1", "SPECIES", 103, 108], ["humans", "SPECIES", 164, 170], ["SARS-CoV-2 virus", "SPECIES", 4, 20], ["SARS virus", "SPECIES", 86, 96], ["SARS-CoV-1", "SPECIES", 98, 108], ["humans", "SPECIES", 164, 170], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["SARS virus", "PROBLEM", 86, 96], ["SARS-CoV", "TEST", 98, 106], ["other SARS", "PROBLEM", 117, 127], ["coronaviruses", "PROBLEM", 136, 149], ["coronaviruses", "OBSERVATION", 136, 149]]], ["SARS-CoV-2 induces clinical respiratory symptoms familiar to the 2003 virus, mostly in persons with underlying diseases like COPD, heart failure, diabetes and obesity (1: Wu et al. 2020) .", [["respiratory", "ANATOMY", 28, 39], ["heart", "ANATOMY", 131, 136], ["SARS", "DISEASE", 0, 4], ["respiratory symptoms", "DISEASE", 28, 48], ["COPD", "DISEASE", 125, 129], ["heart failure", "DISEASE", 131, 144], ["diabetes", "DISEASE", 146, 154], ["obesity", "DISEASE", 159, 166], ["SARS-CoV-2", "ORGANISM", 0, 10], ["heart", "ORGAN", 131, 136], ["persons", "SPECIES", 87, 94], ["SARS-CoV", "SPECIES", 0, 8], ["clinical respiratory symptoms", "PROBLEM", 19, 48], ["underlying diseases", "PROBLEM", 100, 119], ["COPD", "PROBLEM", 125, 129], ["heart failure", "PROBLEM", 131, 144], ["diabetes", "PROBLEM", 146, 154], ["obesity", "PROBLEM", 159, 166], ["diseases", "OBSERVATION", 111, 119], ["COPD", "OBSERVATION", 125, 129], ["heart", "ANATOMY", 131, 136], ["failure", "OBSERVATION", 137, 144], ["diabetes", "OBSERVATION", 146, 154], ["obesity", "OBSERVATION", 159, 166]]], ["Despite the 2003 SARS-CoV-1 virus has been extensively studied in the last two decades, there are no vaccines available yet, neither there are effective prophylactic and therapeutic treatment regimens with drugs that work equally well for each individual patient with SARS-induced respiratory problems.", [["respiratory", "ANATOMY", 281, 292], ["SARS", "DISEASE", 268, 272], ["respiratory problems", "DISEASE", 281, 301], ["SARS-CoV-1 virus", "ORGANISM", 17, 33], ["patient", "ORGANISM", 255, 262], ["CoV-1 virus", "SPECIES", 22, 33], ["patient", "SPECIES", 255, 262], ["SARS-CoV-1 virus", "SPECIES", 17, 33], ["vaccines", "TREATMENT", 101, 109], ["therapeutic treatment regimens", "TREATMENT", 170, 200], ["drugs", "TREATMENT", 206, 211], ["SARS", "PROBLEM", 268, 272], ["respiratory problems", "PROBLEM", 281, 301], ["no", "UNCERTAINTY", 98, 100], ["vaccines", "OBSERVATION", 101, 109], ["respiratory problems", "OBSERVATION", 281, 301]]], ["Such treatments might prevent development of severe disease patterns like \"acute respiratory distress syndrome\" (ARDS) and other, often fatal complications, and may decrease the case-fatality rate of SARS-CoV-2 infections.", [["respiratory", "ANATOMY", 81, 92], ["acute respiratory distress syndrome", "DISEASE", 75, 110], ["ARDS", "DISEASE", 113, 117], ["SARS", "DISEASE", 200, 204], ["infections", "DISEASE", 211, 221], ["SARS-CoV-2", "ORGANISM", 200, 210], ["SARS-CoV", "SPECIES", 200, 208], ["Such treatments", "TREATMENT", 0, 15], ["severe disease patterns", "PROBLEM", 45, 68], ["\"acute respiratory distress syndrome", "PROBLEM", 74, 110], ["ARDS", "PROBLEM", 113, 117], ["often fatal complications", "PROBLEM", 130, 155], ["SARS", "PROBLEM", 200, 204], ["CoV-2 infections", "PROBLEM", 205, 221], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["disease", "OBSERVATION", 52, 59], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory distress", "OBSERVATION", 81, 101], ["infections", "OBSERVATION", 211, 221]]], ["PEDV was first detected in pig herds in 1977 in Europe (2: Pensaert and de Bouck 1978) .", [["PEDV", "CHEMICAL", 0, 4], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["pig", "ORGANISM", 27, 30], ["pig", "SPECIES", 27, 30], ["PEDV", "SPECIES", 0, 4], ["pig", "SPECIES", 27, 30], ["PEDV", "PROBLEM", 0, 4]]], ["However, this virus reemerged in the spring of 2013 in North America causing a massive outbreak among pig herds, resulting in the death of about 30% of the suckling piglets due to severe diarrhea and dehydration ( Although several studies concluded that these clinical symptoms were caused by MRV itself, in concordance with the co-existence of MRV3 in PEDV infected piglets, also other MRV serotypes were isolated from hospitalized patients with airway problems diagnosed positive for SARS-CoV-1 (11: Cheng et al. 2009 , 12: Duan et al. 2003 , 13: Zuo et al. 2003 .", [["airway", "ANATOMY", 447, 453], ["death", "DISEASE", 130, 135], ["diarrhea", "DISEASE", 187, 195], ["dehydration", "DISEASE", 200, 211], ["MRV3", "CHEMICAL", 345, 349], ["airway problems", "DISEASE", 447, 462], ["SARS", "DISEASE", 486, 490], ["pig", "ORGANISM", 102, 105], ["piglets", "ORGANISM", 165, 172], ["MRV3", "GENE_OR_GENE_PRODUCT", 345, 349], ["PEDV", "ORGANISM", 353, 357], ["piglets", "ORGANISM", 367, 374], ["patients", "ORGANISM", 433, 441], ["airway", "MULTI-TISSUE_STRUCTURE", 447, 453], ["pig", "SPECIES", 102, 105], ["piglets", "SPECIES", 165, 172], ["piglets", "SPECIES", 367, 374], ["patients", "SPECIES", 433, 441], ["pig", "SPECIES", 102, 105], ["PEDV", "SPECIES", 353, 357], ["SARS-CoV-1", "SPECIES", 486, 496], ["this virus", "PROBLEM", 9, 19], ["the death", "PROBLEM", 126, 135], ["severe diarrhea", "PROBLEM", 180, 195], ["dehydration", "PROBLEM", 200, 211], ["several studies", "TEST", 223, 238], ["these clinical symptoms", "PROBLEM", 254, 277], ["MRV", "TEST", 293, 296], ["MRV3", "PROBLEM", 345, 349], ["PEDV infected piglets", "PROBLEM", 353, 374], ["other MRV serotypes", "PROBLEM", 381, 400], ["airway problems", "PROBLEM", 447, 462], ["SARS", "PROBLEM", 486, 490], ["massive", "OBSERVATION_MODIFIER", 79, 86], ["outbreak", "OBSERVATION_MODIFIER", 87, 95], ["pig herds", "OBSERVATION", 102, 111], ["severe", "OBSERVATION_MODIFIER", 180, 186], ["diarrhea", "OBSERVATION", 187, 195], ["dehydration", "OBSERVATION", 200, 211], ["airway", "ANATOMY", 447, 453]]], ["Recently, a cross-family recombinant coronavirus was isolated in China from bat faeces in which an RNA sequence originating from the S1 segment of MRV was inserted in the coronavirus genome between the N and Ns7a genes, indicating that both viruses were replicating simultaneously in a single cell in bats (14: Huang et al. 2016) .", [["cell", "ANATOMY", 293, 297], ["coronavirus", "ORGANISM", 37, 48], ["bat", "ORGANISM", 76, 79], ["faeces", "ORGANISM_SUBDIVISION", 80, 86], ["coronavirus", "ORGANISM", 171, 182], ["Ns7a", "GENE_OR_GENE_PRODUCT", 208, 212], ["cell", "CELL", 293, 297], ["S1 segment", "DNA", 133, 143], ["MRV", "DNA", 147, 150], ["coronavirus genome", "DNA", 171, 189], ["N and Ns7a genes", "DNA", 202, 218], ["coronavirus", "SPECIES", 37, 48], ["coronavirus", "SPECIES", 171, 182], ["a cross-family recombinant coronavirus", "PROBLEM", 10, 48], ["an RNA sequence", "TEST", 96, 111], ["MRV", "TEST", 147, 150], ["both viruses", "PROBLEM", 236, 248], ["S1", "ANATOMY", 133, 135], ["segment", "ANATOMY_MODIFIER", 136, 143], ["coronavirus genome", "OBSERVATION", 171, 189], ["viruses", "OBSERVATION", 241, 248]]], ["A prevalence study showed that this cross-family recombinant coronavirus circulated in an isolated bat colony in a cave in China (15: Obameso et al. 2017 ).", [["colony", "ANATOMY", 103, 109], ["coronavirus", "ORGANISM", 61, 72], ["coronavirus", "SPECIES", 61, 72], ["A prevalence study", "TEST", 0, 18], ["this cross-family recombinant coronavirus", "PROBLEM", 31, 72], ["an isolated bat colony", "PROBLEM", 87, 109], ["bat colony", "OBSERVATION", 99, 109]]], ["This cooccurrence of MRV with coronaviruses raised the questions whether a synergistic effect between both viruses exists and if such coexistence plays a role in viral pathogenesis.", [["MRV", "TEST", 21, 24], ["coronaviruses", "PROBLEM", 30, 43], ["a synergistic effect between both viruses", "PROBLEM", 73, 114], ["viral pathogenesis", "PROBLEM", 162, 180], ["viruses", "OBSERVATION", 107, 114]]], ["Therefore we studied the host response in cultured cells early (4 and 6 hours) after PEDV and MRV infection using RNAseq.", [["cells", "ANATOMY", 51, 56], ["PEDV", "CHEMICAL", 85, 89], ["MRV infection", "DISEASE", 94, 107], ["cells", "CELL", 51, 56], ["cultured cells", "CELL_LINE", 42, 56], ["PEDV", "SPECIES", 85, 89], ["MRV", "SPECIES", 94, 97], ["PEDV", "PROBLEM", 85, 89], ["MRV infection", "PROBLEM", 94, 107], ["RNAseq", "TREATMENT", 114, 120], ["infection", "OBSERVATION", 98, 107]]], ["Our original goal was to identify early factors and processes induced by PEDV or MRV that could stimulate or influence the replication and pathogenesis of the other virus.", [["PEDV", "CHEMICAL", 73, 77], ["PEDV", "GENE_OR_GENE_PRODUCT", 73, 77], ["PEDV", "SPECIES", 73, 77], ["PEDV", "PROBLEM", 73, 77], ["MRV", "TREATMENT", 81, 84], ["the replication", "PROBLEM", 119, 134], ["the other virus", "PROBLEM", 155, 170]]], ["The host, tissue and cell tropism of PEDV differs from SARS-CoV-1 and -2.", [["tissue", "ANATOMY", 10, 16], ["cell", "ANATOMY", 21, 25], ["tissue", "TISSUE", 10, 16], ["cell", "CELL", 21, 25], ["PEDV", "CELL", 37, 41], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 55, 65], ["-2", "GENE_OR_GENE_PRODUCT", 70, 72], ["PEDV", "SPECIES", 37, 41], ["SARS-CoV-1", "SPECIES", 55, 65], ["PEDV", "PROBLEM", 37, 41], ["SARS", "TEST", 55, 59], ["CoV", "TEST", 60, 63], ["tissue", "ANATOMY", 10, 16], ["cell tropism", "OBSERVATION", 21, 33]]], ["However, the genomic organization, replication strategy and function of a part of the viral nonstructural proteins share common features among all coronaviruses (16: Brian and Baric 2005) .", [["viral nonstructural proteins", "PROTEIN", 86, 114], ["replication strategy", "TREATMENT", 35, 55], ["the viral nonstructural proteins", "PROBLEM", 82, 114], ["genomic organization", "OBSERVATION", 13, 33], ["replication", "OBSERVATION_MODIFIER", 35, 46]]], ["This applies particularly for interactions in infected cells of nonstructural coronavirus proteins with specific host proteins.", [["cells", "ANATOMY", 55, 60], ["cells", "CELL", 55, 60], ["nonstructural coronavirus", "ORGANISM", 64, 89], ["infected cells", "CELL_TYPE", 46, 60], ["nonstructural coronavirus proteins", "PROTEIN", 64, 98], ["host proteins", "PROTEIN", 113, 126], ["nonstructural coronavirus", "SPECIES", 64, 89], ["nonstructural coronavirus proteins", "PROBLEM", 64, 98], ["infected cells", "OBSERVATION", 46, 60], ["nonstructural coronavirus", "OBSERVATION", 64, 89]]], ["Host proteins that are recruited or silenced to support virus replication, assembly and release.", [["Host proteins", "PROTEIN", 0, 13], ["Host proteins", "PROBLEM", 0, 13], ["support virus replication", "TREATMENT", 48, 73]]], ["In our experiment we used Vero cells (Cercopithecus aethiops epithelial kidney cell line; ATCC\u00ae CCL-81) because these cells support efficient infection and replication of both MRV and PEDV.", [["Vero cells", "ANATOMY", 26, 36], ["epithelial kidney cell line", "ANATOMY", 61, 88], ["ATCC\u00ae CCL-81", "ANATOMY", 90, 102], ["cells", "ANATOMY", 118, 123], ["infection", "DISEASE", 142, 151], ["Vero cells", "CELL", 26, 36], ["Cercopithecus", "ORGANISM", 38, 51], ["aethiops", "ORGANISM", 52, 60], ["epithelial kidney cell line", "CELL", 61, 88], ["ATCC\u00ae CCL-81", "CELL", 90, 102], ["cells", "CELL", 118, 123], ["Vero cells", "CELL_LINE", 26, 36], ["Cercopithecus aethiops epithelial kidney cell line", "CELL_LINE", 38, 88], ["ATCC\u00ae CCL-81", "CELL_LINE", 90, 102], ["Cercopithecus aethiops", "SPECIES", 38, 60], ["Cercopithecus aethiops", "SPECIES", 38, 60], ["ATCC\u00ae CCL-81", "SPECIES", 90, 102], ["PEDV", "SPECIES", 184, 188], ["Vero cells", "TREATMENT", 26, 36], ["Cercopithecus aethiops epithelial kidney cell line", "TREATMENT", 38, 88], ["ATCC", "TEST", 90, 94], ["CCL", "TEST", 96, 99], ["these cells", "PROBLEM", 112, 123], ["efficient infection", "PROBLEM", 132, 151], ["both MRV", "TREATMENT", 171, 179], ["PEDV", "PROBLEM", 184, 188], ["kidney", "ANATOMY", 72, 78], ["cell line", "OBSERVATION", 79, 88], ["infection", "OBSERVATION", 142, 151]]], ["Vero cells are susceptible for many coronaviruses, including SARS-CoV-1 and -2 (17: Chu et al. 2020).", [["Vero cells", "ANATOMY", 0, 10], ["Vero cells", "CELL", 0, 10], ["coronaviruses", "ORGANISM", 36, 49], ["SARS-CoV-1", "ORGANISM", 61, 71], ["Vero cells", "CELL_LINE", 0, 10], ["SARS-CoV-1", "SPECIES", 61, 71], ["Vero cells", "PROBLEM", 0, 10], ["many coronaviruses", "PROBLEM", 31, 49], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69]]], ["They originate from epithelial tissue, in part resembling nasal and bronchial epithelium cells, the prime target cells infected by SARS-CoV-2 in the airways of humans.", [["epithelial tissue", "ANATOMY", 20, 37], ["nasal", "ANATOMY", 58, 63], ["bronchial epithelium cells", "ANATOMY", 68, 94], ["cells", "ANATOMY", 113, 118], ["airways", "ANATOMY", 149, 156], ["epithelial tissue", "TISSUE", 20, 37], ["nasal", "ORGAN", 58, 63], ["bronchial epithelium cells", "CELL", 68, 94], ["cells", "CELL", 113, 118], ["SARS-CoV-2", "ORGANISM", 131, 141], ["airways", "MULTI-TISSUE_STRUCTURE", 149, 156], ["humans", "ORGANISM", 160, 166], ["nasal and bronchial epithelium cells", "CELL_TYPE", 58, 94], ["prime target cells", "CELL_TYPE", 100, 118], ["humans", "SPECIES", 160, 166], ["SARS-CoV", "SPECIES", 131, 139], ["humans", "SPECIES", 160, 166], ["epithelial tissue", "PROBLEM", 20, 37], ["nasal and bronchial epithelium cells", "PROBLEM", 58, 94], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139], ["epithelial tissue", "OBSERVATION", 20, 37], ["nasal", "ANATOMY", 58, 63], ["bronchial", "ANATOMY", 68, 77], ["epithelium cells", "OBSERVATION", 78, 94], ["target cells", "OBSERVATION", 106, 118], ["infected", "OBSERVATION_MODIFIER", 119, 127], ["airways", "ANATOMY", 149, 156], ["humans", "ANATOMY", 160, 166]]], ["Recent research showed that SARS-CoV-2 is also able to replicate in epithelial cells of human small intestinal organoids (18: Lamers et al. 2020) .", [["epithelial cells", "ANATOMY", 68, 84], ["small intestinal organoids", "ANATOMY", 94, 120], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["epithelial cells", "CELL", 68, 84], ["human", "ORGANISM", 88, 93], ["small intestinal organoids", "CELL", 94, 120], ["epithelial cells", "CELL_TYPE", 68, 84], ["human small intestinal organoids", "CELL_TYPE", 88, 120], ["human", "SPECIES", 88, 93], ["SARS-CoV", "SPECIES", 28, 36], ["human", "SPECIES", 88, 93], ["Recent research", "TEST", 0, 15], ["SARS", "PROBLEM", 28, 32], ["CoV", "TEST", 33, 36], ["human small intestinal organoids", "PROBLEM", 88, 120], ["SARS", "OBSERVATION", 28, 32], ["epithelial cells", "OBSERVATION", 68, 84], ["small", "OBSERVATION_MODIFIER", 94, 99], ["intestinal organoids", "ANATOMY", 100, 120]]], ["A disadvantage of Vero cells is a deletion in the type I interferon (IFN) gene cluster on chromosome 12 (19: Osada et al. 2014 ).", [["Vero cells", "ANATOMY", 18, 28], ["chromosome", "ANATOMY", 90, 100], ["Vero cells", "CELL", 18, 28], ["type I interferon", "GENE_OR_GENE_PRODUCT", 50, 67], ["IFN", "GENE_OR_GENE_PRODUCT", 69, 72], ["Vero cells", "CELL_LINE", 18, 28], ["type I interferon (IFN) gene cluster", "DNA", 50, 86], ["chromosome 12", "DNA", 90, 103], ["Vero cells", "PROBLEM", 18, 28], ["a deletion", "PROBLEM", 32, 42], ["the type I interferon (IFN", "TREATMENT", 46, 72], ["Vero cells", "OBSERVATION", 18, 28]]], ["Therefore, these cells lack expression of type I IFNs important for activation of antiviral defense mechanisms.", [["cells", "ANATOMY", 17, 22], ["cells", "CELL", 17, 22], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 42, 53], ["type I IFNs", "PROTEIN", 42, 53], ["type I IFNs", "TREATMENT", 42, 53], ["antiviral defense mechanisms", "TREATMENT", 82, 110], ["antiviral defense", "OBSERVATION", 82, 99]]], ["However, research has shown that Vero cells by-pass this IFNactivation route and could mount an antiviral response mediated by interferon regulatory factor 3 (20: Chew et al. 2009 ).Introduction.Single infections with PEDV or MRV3 alone and simultaneous (double) infections of Vero cells with both viruses were performed using a maximum multiplicity of infection (MOI) to achieve a synchronized infection of all cells.", [["Vero cells", "ANATOMY", 33, 43], ["Vero cells", "ANATOMY", 277, 287], ["cells", "ANATOMY", 412, 417], ["infections", "DISEASE", 202, 212], ["PEDV", "CHEMICAL", 218, 222], ["MRV3", "CHEMICAL", 226, 230], ["infections", "DISEASE", 263, 273], ["infection", "DISEASE", 353, 362], ["infection", "DISEASE", 395, 404], ["Vero cells", "CELL", 33, 43], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 127, 157], ["Vero cells", "CELL", 277, 287], ["cells", "CELL", 412, 417], ["Vero cells", "CELL_LINE", 33, 43], ["interferon regulatory factor 3", "PROTEIN", 127, 157], ["Vero cells", "CELL_LINE", 277, 287], ["PEDV", "SPECIES", 218, 222], ["Vero cells", "PROBLEM", 33, 43], ["this IFNactivation route", "TREATMENT", 52, 76], ["interferon regulatory factor", "TREATMENT", 127, 155], ["Single infections", "PROBLEM", 195, 212], ["PEDV", "PROBLEM", 218, 222], ["MRV3", "TREATMENT", 226, 230], ["simultaneous (double) infections of Vero cells", "PROBLEM", 241, 287], ["both viruses", "PROBLEM", 293, 305], ["infection", "PROBLEM", 353, 362], ["a synchronized infection of all cells", "PROBLEM", 380, 417], ["Vero cells", "OBSERVATION", 33, 43], ["infections", "OBSERVATION", 202, 212], ["PEDV", "OBSERVATION", 218, 222], ["Vero cells", "OBSERVATION", 277, 287], ["infection", "OBSERVATION", 353, 362], ["infection", "OBSERVATION", 395, 404], ["all cells", "OBSERVATION", 408, 417]]], ["By RNAseq measured expression levels of mRNA transcripts/genes in infected cells were compared to RNAseq profiles measured from similar treated mock-infected cells harvested at the same time point after infection.", [["cells", "ANATOMY", 75, 80], ["cells", "ANATOMY", 158, 163], ["infection", "DISEASE", 203, 212], ["cells", "CELL", 75, 80], ["cells", "CELL", 158, 163], ["mRNA transcripts", "RNA", 40, 56], ["infected cells", "CELL_TYPE", 66, 80], ["mock-infected cells", "CELL_TYPE", 144, 163], ["mRNA transcripts/genes in infected cells", "PROBLEM", 40, 80], ["RNAseq profiles", "TEST", 98, 113], ["infected cells", "PROBLEM", 149, 163], ["infection", "PROBLEM", 203, 212], ["infected cells", "OBSERVATION", 66, 80], ["infected cells harvested", "OBSERVATION", 149, 173], ["infection", "OBSERVATION", 203, 212]]], ["The detected sets of differential expressed genes (DEGs) for PEDV and MRV were analyzed by gene set enrichment analysis (GSEA) using functional bioinformatic programs to retrieve biological processes (pathways and Gene Ontology terms [GO-term]) and associations with chemical compounds, including drugs.", [["PEDV", "GENE_OR_GENE_PRODUCT", 61, 65], ["differential expressed genes", "DNA", 21, 49], ["DEGs", "DNA", 51, 55], ["PEDV", "DNA", 61, 65], ["MRV", "DNA", 70, 73], ["PEDV", "SPECIES", 61, 65], ["PEDV", "PROBLEM", 61, 65], ["MRV", "TEST", 70, 73], ["gene set enrichment analysis", "TEST", 91, 119], ["functional bioinformatic programs", "TREATMENT", 133, 166]]], ["In addition, we searched the literature for functional information of the PEDV-DEGs to find possible associations with SARS-CoV-2 pathogenesis.", [["SARS", "DISEASE", 119, 123], ["CoV-2", "ORGANISM", 124, 129], ["PEDV-DEGs", "DNA", 74, 83], ["SARS-CoV", "SPECIES", 119, 127], ["the PEDV", "TEST", 70, 78], ["SARS", "PROBLEM", 119, 123], ["CoV-2 pathogenesis", "PROBLEM", 124, 142]]], ["Because of the COVID-2 pandemic we gave priority to publish the results of this functional bioinformatical analysis and datamining for the single infected Vero cells with PEDV separate from the results of the double infections with MRV3.", [["Vero cells", "ANATOMY", 155, 165], ["infections", "DISEASE", 216, 226], ["MRV3", "CHEMICAL", 232, 236], ["Vero cells", "CELL", 155, 165], ["Vero cells", "CELL_LINE", 155, 165], ["this functional bioinformatical analysis", "TEST", 75, 115], ["datamining", "TREATMENT", 120, 130], ["the single infected Vero cells", "PROBLEM", 135, 165], ["PEDV", "PROBLEM", 171, 175], ["the double infections", "PROBLEM", 205, 226], ["MRV3", "TREATMENT", 232, 236], ["Vero cells", "OBSERVATION", 155, 165], ["double", "OBSERVATION_MODIFIER", 209, 215], ["infections", "OBSERVATION", 216, 226]]], ["In this report we focused on the \"very early\" host response of epithelial cells to an infection with the coronavirus PEDV and pay less attention to the role of specific viral proteins in this host response to PEDV.", [["epithelial cells", "ANATOMY", 63, 79], ["infection", "DISEASE", 86, 95], ["epithelial cells", "CELL", 63, 79], ["coronavirus PEDV", "ORGANISM", 105, 121], ["PEDV", "GENE_OR_GENE_PRODUCT", 209, 213], ["epithelial cells", "CELL_TYPE", 63, 79], ["viral proteins", "PROTEIN", 169, 183], ["coronavirus", "SPECIES", 105, 116], ["PEDV", "SPECIES", 209, 213], ["epithelial cells", "PROBLEM", 63, 79], ["an infection", "PROBLEM", 83, 95], ["the coronavirus PEDV", "TREATMENT", 101, 121], ["specific viral proteins", "PROBLEM", 160, 183], ["PEDV", "PROBLEM", 209, 213], ["epithelial cells", "OBSERVATION", 63, 79], ["infection", "OBSERVATION", 86, 95]]], ["In part our results were in agreement with results of a previous RNAseq study comparing SARS-CoV-2 and Influenza host responses by RNAseq (21: Blanco-Melo et al. 2020).", [["CoV-2", "ORGANISM", 93, 98], ["Influenza", "ORGANISM", 103, 112], ["SARS-CoV", "SPECIES", 88, 96], ["a previous RNAseq study", "TEST", 54, 77], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96]]], ["But we also found associations with biological processes, and pivotal genes/proteins acting in these processes, that had not been recognized before.", [["biological processes", "PROBLEM", 36, 56], ["pivotal genes/proteins", "PROBLEM", 62, 84]]], ["This information may contribute to the search for novel or alternative preventive or therapeutic drugs and treatment protocols for this devastating COVID-19 disease.RNA transcription profilingA time-dependent infection experiment was performed with cultured Vero cells.", [["Vero cells", "ANATOMY", 258, 268], ["COVID", "DISEASE", 148, 153], ["COVID-19", "CANCER", 148, 156], ["Vero cells", "CELL", 258, 268], ["cultured Vero cells", "CELL_LINE", 249, 268], ["therapeutic drugs", "TREATMENT", 85, 102], ["treatment protocols", "TREATMENT", 107, 126], ["this devastating COVID-19 disease", "PROBLEM", 131, 164], ["RNA transcription profiling", "TEST", 165, 192], ["A time-dependent infection experiment", "PROBLEM", 192, 229], ["infection", "OBSERVATION", 209, 218], ["Vero cells", "OBSERVATION", 258, 268]]], ["Briefly, overnight cultured Vero cells grown in 2 cm 2 wells were mock-infected, infected with MRV3 strain WBVR (7: Hulst et al. 2017) or PEDV strain CV777 (2: Pensaert and de Bouck 1978, 22: Rasmussen et al. 2018] ) with a multiplicity of infection of \u22651 for 30 min at 4\u00b0C. For PEDV and corresponding mockinfected cells, 10 \u00b5g/ml of trypsin in serum-free medium was used to facilitate infection of Vero cells during the whole experiment.", [["Vero cells", "ANATOMY", 28, 38], ["cells", "ANATOMY", 315, 320], ["serum", "ANATOMY", 345, 350], ["Vero cells", "ANATOMY", 399, 409], ["infection", "DISEASE", 240, 249], ["infection", "DISEASE", 386, 395], ["Vero cells", "CELL", 28, 38], ["cells", "CELL", 315, 320], ["trypsin", "GENE_OR_GENE_PRODUCT", 334, 341], ["serum", "ORGANISM_SUBSTANCE", 345, 350], ["Vero cells", "CELL", 399, 409], ["overnight cultured Vero cells", "CELL_LINE", 9, 38], ["mockinfected cells", "CELL_LINE", 302, 320], ["trypsin", "PROTEIN", 334, 341], ["Vero cells", "CELL_LINE", 399, 409], ["PEDV", "SPECIES", 279, 283], ["Vero cells", "TEST", 28, 38], ["mock", "TEST", 66, 70], ["infected", "PROBLEM", 71, 79], ["MRV3 strain WBVR", "PROBLEM", 95, 111], ["PEDV strain", "PROBLEM", 138, 149], ["infection", "PROBLEM", 240, 249], ["PEDV", "PROBLEM", 279, 283], ["corresponding mockinfected cells", "PROBLEM", 288, 320], ["trypsin in serum-free medium", "TREATMENT", 334, 362], ["infection of Vero cells", "PROBLEM", 386, 409], ["infection", "OBSERVATION", 240, 249], ["mockinfected cells", "OBSERVATION", 302, 320], ["infection", "OBSERVATION", 386, 395], ["Vero cells", "OBSERVATION", 399, 409]]], ["All virus and mock-infected timepoints were performed in quadruplicate.", [["All virus and mock-infected timepoints", "PROBLEM", 0, 38], ["virus", "OBSERVATION", 4, 9]]], ["After incubation for 30 min at 4\u00b0C, virus was discarded and cells were washed twice and supplied with fresh culture medium.", [["cells", "ANATOMY", 60, 65], ["cells", "CELL", 60, 65], ["virus", "PROBLEM", 36, 41], ["cells", "PROBLEM", 60, 65], ["fresh culture medium", "TREATMENT", 102, 122]]], ["Cells were incubated for 0, 2, 4, 6, and 16h at 37\u00b0C and 5% CO2.", [["Cells", "ANATOMY", 0, 5], ["CO2", "CHEMICAL", 60, 63], ["CO2", "CHEMICAL", 60, 63], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 60, 63], ["Cells", "TEST", 0, 5]]], ["After incubation for the indicated times, cells were placed on ice before total RNA was isolated from three of the quadruplicate wells.", [["cells", "ANATOMY", 42, 47], ["cells", "CELL", 42, 47], ["incubation", "TREATMENT", 6, 16], ["cells", "TREATMENT", 42, 47], ["ice", "TREATMENT", 63, 66], ["total RNA", "TREATMENT", 74, 83]]], ["The replication of both viruses in Vero cells was monitored using virus-specific RT-qPCR tests ( Fig.1 : methods and primers used for PCR are provided in supplementary file 1).", [["Vero cells", "ANATOMY", 35, 45], ["Vero cells", "CELL", 35, 45], ["Vero cells", "CELL_LINE", 35, 45], ["both viruses in Vero cells", "PROBLEM", 19, 45], ["virus", "TREATMENT", 66, 71], ["qPCR tests", "TEST", 84, 94], ["methods and primers", "TREATMENT", 105, 124], ["PCR", "TEST", 134, 137], ["both", "OBSERVATION_MODIFIER", 19, 23], ["viruses", "OBSERVATION", 24, 31]]], ["In addition, cells in one of the quadruplicate wells incubated for 16h were fixated and stained with antibodies directed against the S2 spike protein of PEDV and the S1 attachment protein (\u03b11) of MRV3.", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["PEDV", "GENE_OR_GENE_PRODUCT", 153, 157], ["\u03b11", "GENE_OR_GENE_PRODUCT", 189, 191], ["MRV3", "GENE_OR_GENE_PRODUCT", 196, 200], ["antibodies", "PROTEIN", 101, 111], ["S2 spike protein", "PROTEIN", 133, 149], ["PEDV", "PROTEIN", 153, 157], ["S1 attachment protein", "PROTEIN", 166, 187], ["\u03b11", "PROTEIN", 189, 191], ["MRV3", "PROTEIN", 196, 200], ["antibodies", "TREATMENT", 101, 111], ["PEDV", "PROBLEM", 153, 157], ["the S1 attachment protein", "TEST", 162, 187], ["MRV3", "TEST", 196, 200]]], ["A decrease in CT-values for PEDV was not observed before 6 h post inoculation (6 h.p.i), indicating that replication in PEDV infected cells started later than was observed for MRV (at 4 h.p.i).", [["cells", "ANATOMY", 134, 139], ["PEDV", "ORGANISM", 120, 124], ["cells", "CELL", 134, 139], ["CT", "PROTEIN", 14, 16], ["PEDV infected cells", "CELL_TYPE", 120, 139], ["PEDV", "SPECIES", 120, 124], ["A decrease", "PROBLEM", 0, 10], ["CT-values", "TEST", 14, 23], ["PEDV", "PROBLEM", 28, 32], ["PEDV infected cells", "PROBLEM", 120, 139], ["MRV", "TEST", 176, 179], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["infected cells", "OBSERVATION", 125, 139]]], ["Staining of the cells after 16h indicated that nearly all Vero cells were infected with MRV3 and more than 50% with PEDV.", [["cells", "ANATOMY", 16, 21], ["Vero cells", "ANATOMY", 58, 68], ["PEDV", "CHEMICAL", 116, 120], ["cells", "CELL", 16, 21], ["Vero cells", "CELL", 58, 68], ["Vero cells", "CELL_LINE", 58, 68], ["PEDV", "SPECIES", 116, 120], ["Staining of the cells", "PROBLEM", 0, 21], ["MRV3", "TEST", 88, 92], ["PEDV", "PROBLEM", 116, 120], ["Vero cells", "OBSERVATION", 58, 68]]], ["Also more than 50% of the cells in 16hwells appeared as fused cells (syncytia), confirming that more than 50% of the cells were infected with PEDV.", [["cells", "ANATOMY", 26, 31], ["16hwells", "ANATOMY", 35, 43], ["cells", "ANATOMY", 62, 67], ["syncytia", "ANATOMY", 69, 77], ["cells", "ANATOMY", 117, 122], ["cells", "CELL", 26, 31], ["16hwells", "CELL", 35, 43], ["cells", "CELL", 62, 67], ["syncytia", "CELL", 69, 77], ["cells", "CELL", 117, 122], ["fused cells", "CELL_TYPE", 56, 67], ["PEDV", "SPECIES", 142, 146], ["fused cells", "PROBLEM", 56, 67], ["PEDV", "PROBLEM", 142, 146], ["fused cells", "OBSERVATION", 56, 67]]], ["Quality control of the total RNA isolated from infected cells using an Agilent Bioanalyzer showed that RNAs isolated from PEDV infected wells at 16 h.p.i. were partially degraded (RIN values below 9), making them unsuitable for RNAseq analysis.", [["cells", "ANATOMY", 56, 61], ["cells", "CELL", 56, 61], ["infected cells", "CELL_TYPE", 47, 61], ["PEDV", "SPECIES", 122, 126], ["the total RNA", "PROBLEM", 19, 32], ["infected cells", "PROBLEM", 47, 61], ["an Agilent Bioanalyzer", "TEST", 68, 90], ["RNAs", "PROBLEM", 103, 107], ["PEDV infected wells", "PROBLEM", 122, 141], ["RIN values", "TEST", 180, 190], ["RNAseq analysis", "TEST", 228, 243], ["infected cells", "OBSERVATION", 47, 61]]], ["Therefore, only 0, 4 and 6h timepoints were analyzed using RNAseq. stained with a monoclonal antibody directed against the S2 spike protein.", [["S2", "GENE_OR_GENE_PRODUCT", 123, 125], ["monoclonal antibody", "PROTEIN", 82, 101], ["S2 spike protein", "PROTEIN", 123, 139], ["RNAseq", "TREATMENT", 59, 65], ["a monoclonal antibody", "TREATMENT", 80, 101], ["the S2 spike protein", "PROBLEM", 119, 139]]], ["MRV and mock infected cells were stained with a polyclonal rabbit serum raised against a peptide sequence of the S1-attachment protein of MRV serotype 3.", [["cells", "ANATOMY", 22, 27], ["serum", "ANATOMY", 66, 71], ["cells", "CELL", 22, 27], ["rabbit", "ORGANISM", 59, 65], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["mock infected cells", "CELL_TYPE", 8, 27], ["S1-attachment protein", "PROTEIN", 113, 134], ["rabbit", "SPECIES", 59, 65], ["rabbit", "SPECIES", 59, 65], ["MRV", "TEST", 0, 3], ["mock infected cells", "PROBLEM", 8, 27], ["a polyclonal rabbit serum", "TEST", 46, 71], ["a peptide sequence", "TEST", 87, 105], ["MRV serotype", "PROBLEM", 138, 150], ["infected cells", "OBSERVATION", 13, 27], ["S1", "ANATOMY", 113, 115]]], ["Nuclei were stained blue with the Hoechst, 4',6-diamidino-2-phenylindole dye.RNA transcription profilingEqual amounts of total RNA isolated from triplicate wells were pooled and subjected to RNAseq analysis by GenomeScan B.V.(Leiden, The Netherlands) using Next Generation Sequencing (NGS) (see supplementary file 2a for details).", [["Nuclei", "ANATOMY", 0, 6], ["Hoechst", "CHEMICAL", 34, 41], ["4',6-diamidino-2-phenylindole", "CHEMICAL", 43, 72], ["Hoechst, 4',6-diamidino-2-phenylindole", "CHEMICAL", 34, 72], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["Hoechst", "SIMPLE_CHEMICAL", 34, 41], ["4',6-diamidino-2-phenylindole dye", "SIMPLE_CHEMICAL", 43, 76], ["the Hoechst", "TEST", 30, 41], ["diamidino", "TEST", 48, 57], ["phenylindole dye", "TREATMENT", 60, 76], ["RNA transcription profiling", "TEST", 77, 104], ["total RNA", "PROBLEM", 121, 130], ["triplicate wells", "TEST", 145, 161], ["RNAseq analysis", "TEST", 191, 206], ["Equal", "OBSERVATION_MODIFIER", 104, 109], ["amounts", "OBSERVATION_MODIFIER", 110, 117]]], ["Mapping of NGS reads to the Cercopithecus aethiops reference genome and preparation of datafiles with calculated Fold Change (FC) of expression levels of mapped mRNAs, were performed for each comparison at 0, 4, and 6h by GenomeScan (see supplementary file 2b).", [["Cercopithecus", "ORGANISM", 28, 41], ["aethiops", "ORGANISM", 42, 50], ["NGS reads", "DNA", 11, 20], ["Cercopithecus aethiops reference genome", "DNA", 28, 67], ["mRNAs", "RNA", 161, 166], ["Cercopithecus aethiops", "SPECIES", 28, 50], ["Cercopithecus aethiops", "SPECIES", 28, 50], ["Mapping of NGS", "TEST", 0, 14], ["datafiles", "TREATMENT", 87, 96], ["calculated Fold Change (FC)", "TREATMENT", 102, 129], ["expression levels", "TEST", 133, 150], ["mapped mRNAs", "TEST", 154, 166]]], ["From these datafiles we extracted lists of DEGs with a FC>2 and p-value of <0.05.", [["a FC", "TEST", 53, 57], ["p-value", "TEST", 64, 71]]], ["After accessing the NCBI, Panther or KEGG databases for human orthologs, not annotated Cercopithecus aethiops DEGs were annotated with an HUGO official gene symbols (http://www.genenames.org).", [["human", "ORGANISM", 56, 61], ["Cercopithecus", "ORGANISM", 87, 100], ["aethiops", "ORGANISM", 101, 109], ["NCBI, Panther or KEGG databases", "DNA", 20, 51], ["human orthologs", "DNA", 56, 71], ["Cercopithecus aethiops DEGs", "DNA", 87, 114], ["HUGO official gene symbols", "DNA", 138, 164], ["human", "SPECIES", 56, 61], ["Cercopithecus aethiops", "SPECIES", 87, 109], ["human", "SPECIES", 56, 61], ["Cercopithecus aethiops", "SPECIES", 87, 109], ["Panther or KEGG databases", "TEST", 26, 51], ["human orthologs", "TEST", 56, 71]]], ["In supplementary file 3 sheet \"PEDV-MRV DEGs FC>2\", lists of all annotated PEDV and MRV DEGs are presented with their FC.", [["PEDV", "CANCER", 75, 79], ["PEDV and MRV DEGs", "DNA", 75, 92], ["PEDV", "TEST", 31, 35], ["FC", "TEST", 45, 47], ["MRV DEGs", "TREATMENT", 84, 92]]], ["In a separate sheet \"PEDV-DEGs functional info\" all 266 individual DEGs regulated by PEDV at 4 and 6 h.p.i. are presented with their FC, information about their function and the types of human cells in which expression of the gene is relatively high compared to other human cells (retrieved from the \"Primary Cell Atlas\" dataset of BioGPS: http://biogps.org/).", [["cells", "ANATOMY", 193, 198], ["cells", "ANATOMY", 274, 279], ["Cell", "ANATOMY", 309, 313], ["human", "ORGANISM", 187, 192], ["cells", "CELL", 193, 198], ["human", "ORGANISM", 268, 273], ["cells", "CELL", 274, 279], ["Cell", "CELL", 309, 313], ["PEDV", "DNA", 21, 25], ["DEGs", "DNA", 26, 30], ["DEGs", "DNA", 67, 71], ["PEDV", "PROTEIN", 85, 89], ["human cells", "CELL_TYPE", 187, 198], ["human cells", "CELL_TYPE", 268, 279], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 268, 273], ["human cells", "PROBLEM", 187, 198]]], ["In all results paragraphs beneath information about the biological function of DEGs was retrieved by consulting the \"GeneCards\" (Weizmann Institute of Science: https://www.genecards.org/) and NCBI Gene reports (Entrez Gene: https://www.ncbi.nlm.nih.gov/gene/), and literature linked to these reports (for references about these biological functions of genes/proteins we refer to publications cited in these reports: \"GeneCards\" weblinks are provided in supplementary file 3).RNA transcription profilingSets of PEDV and MRV DEGs were analyzed using the GSEA program GeneAnalytics (LifeMap Sciences, Inc.) and pathways (for MRV and PEDV), GO-terms (not for MRV), and associations with compounds/drugs (not for MRV) with a high or medium score (p-value <0.05) were retrieved and listed in 3 separate sheets in supplementary file 3 (sheets \"MRV-PEDV pathways\", \"PEDV G0-terms\" and \"PEDV Compounds\").", [["PEDV", "GENE_OR_GENE_PRODUCT", 510, 514], ["DEGs", "DNA", 79, 83], ["PEDV and MRV DEGs", "DNA", 510, 527], ["PEDV", "SPECIES", 510, 514], ["RNA transcription", "TEST", 475, 492], ["PEDV", "PROBLEM", 510, 514], ["MRV DEGs", "TEST", 519, 527], ["MRV", "TEST", 622, 625], ["PEDV", "PROBLEM", 630, 634], ["MRV", "TEST", 655, 658], ["drugs", "TREATMENT", 693, 698], ["MRV", "TEST", 708, 711], ["a high or medium score", "PROBLEM", 718, 740], ["p-value", "TEST", 742, 749]]], ["Similar and related pathways retrieved for both PEDV and MRV, and remarkable PEDV pathways, GO-terms and compound associations are summarized in Table 1 .", [["PEDV", "SPECIES", 48, 52], ["MRV", "TEST", 57, 60]]], ["For PEDV all DEGs within these pathways are provided with their regulation, up (green) or down (red).", [["PEDV", "SPECIES", 4, 8], ["PEDV", "PROBLEM", 4, 8]]], ["For MRV only DEGs in common with PEDV-DEGs were listed in Table 1 (see sheet \"MRV-PEDV pathways\" in supplementary file 3 for all MRV-DEGs acting in these pathways).", [["PEDV", "DNA", 33, 37], ["DEGs", "DNA", 38, 42], ["MRV", "DNA", 129, 132], ["DEGs", "DNA", 133, 137], ["MRV", "TEST", 4, 7], ["MRV", "TEST", 78, 81], ["all MRV", "TEST", 125, 132]]], ["Subsets of PEDV-DEGs were selected matching the terms \"chemokines-cytokines\", \"antiviral\" , and terms related to the pathogenesis of COVID-2 (explained below) using the genotyping program VarElect (LifeMap Sciences, Inc.) and displayed in supplementary file 3 in separate sheets: \"chemokines-cytokines\", \"(anti)-viral\", etc. Based on these selections we prepared a set of PEDV KEY-DEGs consisting of genes regulated with a FC of >10 (up) or <-10 (down) or playing an important role in biological processes induced by PEDV and related to COVID-19 pathology.", [["COVID-2", "CELL", 133, 140], ["PEDV", "DNA", 11, 15], ["chemokines", "PROTEIN", 55, 65], ["cytokines", "PROTEIN", 66, 75], ["chemokines", "PROTEIN", 281, 291], ["cytokines", "PROTEIN", 292, 301], ["anti", "PROTEIN", 306, 310], ["PEDV KEY-DEGs", "DNA", 372, 385], ["PEDV", "SPECIES", 372, 376], ["PEDV", "SPECIES", 517, 521], ["PEDV-DEGs", "TREATMENT", 11, 20], ["cytokines\"", "TREATMENT", 66, 76], ["antiviral\"", "TREATMENT", 79, 89], ["COVID", "TEST", 133, 138], ["a FC", "TEST", 421, 425], ["PEDV", "PROBLEM", 517, 521], ["COVID", "TEST", 537, 542]]], ["In beneath results sections we tried to give as much as possible meaningful information about the function of KEY-DEGs for which we found an association with SARS-CoV-2 infections.", [["sections", "ANATOMY", 19, 27], ["SARS-CoV-2 infections", "DISEASE", 158, 179], ["SARS-CoV-2", "ORGANISM", 158, 168], ["KEY", "PROTEIN", 110, 113], ["SARS-CoV", "SPECIES", 158, 166], ["SARS", "PROBLEM", 158, 162], ["CoV-2 infections", "PROBLEM", 163, 179]]], ["We emphasize that further dedicated experimental and in-silico research is necessary to confirm the involvement of the proteins encoded by these genes for pathogenesis of this viral disease.", [["viral disease", "DISEASE", 176, 189], ["the proteins", "PROBLEM", 115, 127], ["this viral disease", "PROBLEM", 171, 189], ["viral disease", "OBSERVATION", 176, 189]]], ["Enriched pathways, GO-terms and compound associations of PEDV-DEGs.RNA transcription profiling*PEDV enriched pathways (A), GO-terms (B), and associations with compounds and drugs (C) with a high and medium score and with at least 2 matching genes were retrieved from GeneAnalytics.", [["PEDV", "GENE_OR_GENE_PRODUCT", 57, 61], ["PEDV", "PROTEIN", 57, 61], ["DEGs", "DNA", 62, 66], ["PEDV", "PROBLEM", 57, 61], ["a high and medium score", "PROBLEM", 188, 211], ["PEDV", "OBSERVATION", 57, 61]]], ["Common pathways for MRV were included in Table 1A .", [["MRV", "PROTEIN", 20, 23], ["MRV", "TEST", 20, 23]]], ["A full list of pathways with DEGs, retrieved for MRV at 4 and 6h, is provided in supplementary file 3 (sheet MRV-PEDV pathways).", [["DEGs", "DNA", 29, 33], ["MRV", "TEST", 49, 52]]], ["A possible function or process related to specific DEGs, pathways, GO-term, or compounds/drugs is provided in blue text between brackets. $ Official Gene-symbols (HUGO abbreviations) are listed for DEGs.", [["Gene-symbols", "DNA", 149, 161], ["HUGO abbreviations", "DNA", 163, 181], ["DEGs", "DNA", 198, 202], ["process", "PROBLEM", 23, 30], ["drugs", "TREATMENT", 89, 94], ["possible", "UNCERTAINTY", 2, 10]]], ["Down-regulated DEGs were colored red and up-regulated DEGs were colored green.", [["DEGs", "DNA", 15, 19], ["colored red and up-regulated DEGs", "DNA", 25, 58]]], ["In section A the number of DEGs regulated by MRV in a pathway and the common DEGs are provided between brackets.", [["DEGs", "DNA", 27, 31], ["MRV", "PROTEIN", 45, 48], ["MRV", "TEST", 45, 48], ["common DEGs", "ANATOMY", 70, 81]]], ["DEGs regulated by both PEDV and MRV are underlined.Regulation of immune and antiviral genes.Compared to MRV, only a few genes involved in \"cytokine/chemokine signaling\" were regulated at 4 and 6h by PEDV.", [["PEDV", "GENE_OR_GENE_PRODUCT", 23, 27], ["chemokine", "GENE_OR_GENE_PRODUCT", 148, 157], ["PEDV", "SIMPLE_CHEMICAL", 199, 203], ["PEDV", "DNA", 23, 27], ["MRV", "DNA", 32, 35], ["immune and antiviral genes", "DNA", 65, 91], ["MRV", "DNA", 104, 107], ["cytokine", "PROTEIN", 139, 147], ["chemokine", "PROTEIN", 148, 157], ["MRV", "TEST", 32, 35], ["immune and antiviral genes", "TREATMENT", 65, 91], ["MRV", "TEST", 104, 107], ["cytokine/chemokine signaling", "TREATMENT", 139, 167], ["PEDV", "PROBLEM", 199, 203], ["antiviral genes", "OBSERVATION", 76, 91]]], ["In Fig. 2A the regulation of cytokines/chemokines in PEDV and MRV infected Vero cells are displayed.", [["Vero cells", "ANATOMY", 75, 85], ["PEDV", "CELL", 53, 57], ["Vero cells", "CELL", 75, 85], ["cytokines", "PROTEIN", 29, 38], ["chemokines", "PROTEIN", 39, 49], ["PEDV and MRV infected Vero cells", "CELL_LINE", 53, 85], ["PEDV", "SPECIES", 53, 57], ["cytokines/chemokines", "TREATMENT", 29, 49], ["PEDV", "PROBLEM", 53, 57], ["MRV infected Vero cells", "PROBLEM", 62, 85], ["infected", "OBSERVATION_MODIFIER", 66, 74], ["Vero cells", "OBSERVATION", 75, 85]]], ["This indicated that MRV increased the transcription of a broad set of cytokines/chemokines, including interferonmediated cytokines like CXCL10 and CXCL8 (alias IL8), already at 4 h.p.i., whereas PEDV did not, even not when replication of PEDV RNA was detected by RT-qPCR at 6 h.p.i..", [["CXCL10", "GENE_OR_GENE_PRODUCT", 136, 142], ["CXCL8", "GENE_OR_GENE_PRODUCT", 147, 152], ["IL8", "GENE_OR_GENE_PRODUCT", 160, 163], ["PEDV", "GENE_OR_GENE_PRODUCT", 238, 242], ["cytokines", "PROTEIN", 70, 79], ["chemokines", "PROTEIN", 80, 90], ["interferonmediated cytokines", "PROTEIN", 102, 130], ["CXCL10", "PROTEIN", 136, 142], ["CXCL8", "PROTEIN", 147, 152], ["alias IL8", "PROTEIN", 154, 163], ["PEDV RNA", "RNA", 238, 246], ["PEDV", "SPECIES", 195, 199], ["PEDV", "SPECIES", 238, 242], ["MRV", "TEST", 20, 23], ["cytokines/chemokines", "TREATMENT", 70, 90], ["interferonmediated cytokines", "TREATMENT", 102, 130], ["CXCL10", "TEST", 136, 142], ["CXCL8 (alias IL8)", "TREATMENT", 147, 164], ["PEDV", "PROBLEM", 195, 199], ["PEDV RNA", "PROBLEM", 238, 246], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["For MRV, this cytokine/chemokine response at 4 h.p.i. was followed by high up-regulation of \"hallmark\" antiviral genes at 6 h.p.i. (see Fig. 2B : e.g. interferoninduced genes [IFI] and OASL) and chemokines that attract T cells, monocytes, granulocytes, including basophils (e.g. CXCL8, CXCL11 and CCL2).", [["T cells", "ANATOMY", 219, 226], ["monocytes", "ANATOMY", 228, 237], ["granulocytes", "ANATOMY", 239, 251], ["basophils", "ANATOMY", 263, 272], ["interferoninduced", "GENE_OR_GENE_PRODUCT", 151, 168], ["OASL", "GENE_OR_GENE_PRODUCT", 185, 189], ["T cells", "CELL", 219, 226], ["monocytes", "CELL", 228, 237], ["granulocytes", "CELL", 239, 251], ["basophils", "CELL", 263, 272], ["CXCL8", "GENE_OR_GENE_PRODUCT", 279, 284], ["CXCL11", "GENE_OR_GENE_PRODUCT", 286, 292], ["CCL2", "GENE_OR_GENE_PRODUCT", 297, 301], ["cytokine", "PROTEIN", 14, 22], ["chemokine", "PROTEIN", 23, 32], ["antiviral genes", "DNA", 103, 118], ["interferoninduced genes", "DNA", 151, 174], ["IFI", "DNA", 176, 179], ["OASL", "DNA", 185, 189], ["chemokines", "PROTEIN", 195, 205], ["T cells", "CELL_TYPE", 219, 226], ["monocytes", "CELL_TYPE", 228, 237], ["granulocytes", "CELL_TYPE", 239, 251], ["basophils", "CELL_TYPE", 263, 272], ["CXCL8", "PROTEIN", 279, 284], ["CXCL11", "PROTEIN", 286, 292], ["CCL2", "PROTEIN", 297, 301], ["MRV", "TEST", 4, 7], ["this cytokine/chemokine response", "TREATMENT", 9, 41], ["\"hallmark\" antiviral genes", "TREATMENT", 92, 118], ["interferoninduced genes", "PROBLEM", 151, 174], ["chemokines", "TEST", 195, 205], ["monocytes", "TEST", 228, 237], ["granulocytes", "TEST", 239, 251], ["basophils", "TEST", 263, 272], ["CXCL8", "TEST", 279, 284], ["CXCL11", "TEST", 286, 292], ["CCL2", "TEST", 297, 301], ["granulocytes", "ANATOMY", 239, 251], ["basophils", "ANATOMY", 263, 272]]], ["PEDV infection up-regulated only a few genes coding for proteins with cytokine activity (CTF1 and EDN2), and also did not elevated gene expression of these \"hallmark\" antiviral genes.", [["PEDV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 5, 14], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["CTF1", "GENE_OR_GENE_PRODUCT", 89, 93], ["EDN2", "GENE_OR_GENE_PRODUCT", 98, 102], ["cytokine", "PROTEIN", 70, 78], ["CTF1", "PROTEIN", 89, 93], ["EDN2", "PROTEIN", 98, 102], ["antiviral genes", "DNA", 167, 182], ["PEDV", "SPECIES", 0, 4], ["PEDV infection", "PROBLEM", 0, 14], ["cytokine activity", "PROBLEM", 70, 87], ["infection", "OBSERVATION", 5, 14], ["antiviral genes", "OBSERVATION", 167, 182]]], ["In contrast, PEDV down-regulated expression of 6 genes (out of 9 in total) coding for Zinc Finger Proteins (out of 9 in total), all 6 with an antiviral activity towards Herpes simplex virus 1 ( Fig 2C) Binding of thrombin to F2RL2 reduces inflammation, activates platelets and increases vasodilation and permeability of the vascular wall (see also below in the section \"platelets activation\").", [["platelets", "ANATOMY", 263, 272], ["vascular wall", "ANATOMY", 324, 337], ["platelets", "ANATOMY", 370, 379], ["Herpes simplex", "DISEASE", 169, 183], ["inflammation", "DISEASE", 239, 251], ["Zinc", "CHEMICAL", 86, 90], ["PEDV", "GENE_OR_GENE_PRODUCT", 13, 17], ["Zinc Finger Proteins", "GENE_OR_GENE_PRODUCT", 86, 106], ["Herpes simplex virus 1", "ORGANISM", 169, 191], ["thrombin", "GENE_OR_GENE_PRODUCT", 213, 221], ["F2RL2", "GENE_OR_GENE_PRODUCT", 225, 230], ["platelets", "CELL", 263, 272], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 324, 337], ["platelets", "CELL", 370, 379], ["PEDV", "PROTEIN", 13, 17], ["6 genes", "DNA", 47, 54], ["Zinc Finger Proteins", "PROTEIN", 86, 106], ["thrombin", "PROTEIN", 213, 221], ["F2RL2", "PROTEIN", 225, 230], ["platelets", "CELL_TYPE", 263, 272], ["platelets", "CELL_TYPE", 370, 379], ["Herpes simplex virus", "SPECIES", 169, 189], ["Herpes simplex virus 1", "SPECIES", 169, 191], ["PEDV", "PROBLEM", 13, 17], ["Zinc Finger Proteins", "TEST", 86, 106], ["an antiviral activity", "TREATMENT", 139, 160], ["Herpes simplex virus", "PROBLEM", 169, 189], ["thrombin", "TREATMENT", 213, 221], ["inflammation", "PROBLEM", 239, 251], ["activates platelets", "PROBLEM", 253, 272], ["increases vasodilation", "PROBLEM", 277, 299], ["permeability of the vascular wall", "PROBLEM", 304, 337], ["inflammation", "OBSERVATION", 239, 251], ["vascular wall", "ANATOMY", 324, 337]]], ["CSF1R is a receptor for the cytokine colony stimulating factor 1, a cytokine that regulates differentiation and function of macrophages, and in the CNS, the density and distribution of microglia cells.", [["macrophages", "ANATOMY", 124, 135], ["CNS", "ANATOMY", 148, 151], ["microglia cells", "ANATOMY", 185, 200], ["CSF1R", "GENE_OR_GENE_PRODUCT", 0, 5], ["cytokine colony stimulating factor 1", "GENE_OR_GENE_PRODUCT", 28, 64], ["macrophages", "CELL", 124, 135], ["CNS", "ANATOMICAL_SYSTEM", 148, 151], ["microglia cells", "CELL", 185, 200], ["CSF1R", "PROTEIN", 0, 5], ["cytokine colony stimulating factor 1", "PROTEIN", 28, 64], ["cytokine", "PROTEIN", 68, 76], ["macrophages", "CELL_TYPE", 124, 135], ["microglia cells", "CELL_TYPE", 185, 200], ["the cytokine colony stimulating factor", "TEST", 24, 62], ["a cytokine", "TEST", 66, 76], ["microglia cells", "PROBLEM", 185, 200], ["macrophages", "OBSERVATION", 124, 135], ["CNS", "ANATOMY", 148, 151], ["density", "OBSERVATION", 157, 164], ["distribution", "OBSERVATION_MODIFIER", 169, 181], ["microglia cells", "OBSERVATION", 185, 200]]], ["The BLNK gene codes for a cytosolic protein that passes on B-cell receptor signals in the signaling cascade that activates B-cell development and function.", [["cytosolic", "ANATOMY", 26, 35], ["B-cell", "ANATOMY", 59, 65], ["B-cell", "ANATOMY", 123, 129], ["BLNK", "GENE_OR_GENE_PRODUCT", 4, 8], ["B-cell receptor", "GENE_OR_GENE_PRODUCT", 59, 74], ["B-cell", "CELL", 123, 129], ["BLNK gene", "DNA", 4, 13], ["cytosolic protein", "PROTEIN", 26, 43], ["a cytosolic protein", "TEST", 24, 43], ["B-cell receptor signals", "TREATMENT", 59, 82], ["cell", "OBSERVATION", 125, 129]]], ["Gene expression of genes coding for essential components of this B-cell signaling, like \"spleen associated tyrosine kinase\" (SYK) and \"LYN proto-oncogene\"(LYN) were not regulated by PEDV, nor by MRV.Regulation of immune and antiviral genes.Genes involved in amino acid, protein translation and metabolism of immuno-active compounds.Regulation of immune and antiviral genes.PEDV DEGs coding for enzymes involved in the metabolism of the non-essential amino acids histidine, phenylalanine, tryptophan and proline were found enriched in the PEDV dataset (see supplementary file 3, sheet PEDV-compounds).", [["B-cell", "ANATOMY", 65, 71], ["spleen", "ANATOMY", 89, 95], ["tyrosine", "CHEMICAL", 107, 115], ["amino acid", "CHEMICAL", 258, 268], ["amino acids", "CHEMICAL", 450, 461], ["histidine", "CHEMICAL", 462, 471], ["phenylalanine", "CHEMICAL", 473, 486], ["tryptophan", "CHEMICAL", 488, 498], ["proline", "CHEMICAL", 503, 510], ["tyrosine", "CHEMICAL", 107, 115], ["amino acid", "CHEMICAL", 258, 268], ["amino acids", "CHEMICAL", 450, 461], ["histidine", "CHEMICAL", 462, 471], ["phenylalanine", "CHEMICAL", 473, 486], ["tryptophan", "CHEMICAL", 488, 498], ["proline", "CHEMICAL", 503, 510], ["B-cell", "CELL", 65, 71], ["spleen", "ORGAN", 89, 95], ["associated tyrosine kinase", "GENE_OR_GENE_PRODUCT", 96, 122], ["SYK", "GENE_OR_GENE_PRODUCT", 125, 128], ["LYN proto-oncogene", "GENE_OR_GENE_PRODUCT", 135, 153], ["LYN", "GENE_OR_GENE_PRODUCT", 155, 158], ["PEDV", "GENE_OR_GENE_PRODUCT", 182, 186], ["amino acid", "AMINO_ACID", 258, 268], ["amino acids", "AMINO_ACID", 450, 461], ["histidine", "AMINO_ACID", 462, 471], ["phenylalanine", "AMINO_ACID", 473, 486], ["tryptophan", "AMINO_ACID", 488, 498], ["proline", "AMINO_ACID", 503, 510], ["spleen associated tyrosine kinase", "PROTEIN", 89, 122], ["SYK", "PROTEIN", 125, 128], ["LYN proto-oncogene", "DNA", 135, 153], ["LYN", "DNA", 155, 158], ["PEDV", "PROTEIN", 182, 186], ["immune and antiviral genes", "DNA", 213, 239], ["immune and antiviral genes", "DNA", 346, 372], ["PEDV DEGs", "DNA", 373, 382], ["PEDV", "SPECIES", 373, 377], ["this B-cell signaling", "PROBLEM", 60, 81], ["\"spleen associated tyrosine kinase\"", "PROBLEM", 88, 123], ["MRV", "TEST", 195, 198], ["immune and antiviral genes", "TREATMENT", 213, 239], ["amino acid", "TREATMENT", 258, 268], ["protein translation", "TREATMENT", 270, 289], ["immuno-active compounds", "PROBLEM", 308, 331], ["immune and antiviral genes", "TREATMENT", 346, 372], ["enzymes", "TEST", 394, 401], ["the non-essential amino acids histidine", "TREATMENT", 432, 471], ["phenylalanine", "TREATMENT", 473, 486], ["tryptophan", "TREATMENT", 488, 498], ["proline", "TREATMENT", 503, 510], ["spleen", "ANATOMY", 89, 95], ["antiviral genes", "OBSERVATION", 224, 239], ["immuno-active compounds", "OBSERVATION", 308, 331], ["antiviral genes", "OBSERVATION", 357, 372]]], ["Remarkable were the DEGs coding for amine oxidases involved in the catabolism of the biogenic amines histamine, tryptamine and phenylethylamine, their derivates and related substrates/products of these enzymes (Fig. 3, AOC1 , MAOA, IL4I1).", [["amine", "CHEMICAL", 36, 41], ["histamine", "CHEMICAL", 101, 110], ["tryptamine", "CHEMICAL", 112, 122], ["phenylethylamine", "CHEMICAL", 127, 143], ["amine", "CHEMICAL", 36, 41], ["amines", "CHEMICAL", 94, 100], ["histamine", "CHEMICAL", 101, 110], ["tryptamine", "CHEMICAL", 112, 122], ["phenylethylamine", "CHEMICAL", 127, 143], ["amine oxidases", "GENE_OR_GENE_PRODUCT", 36, 50], ["histamine", "SIMPLE_CHEMICAL", 101, 110], ["tryptamine", "SIMPLE_CHEMICAL", 112, 122], ["phenylethylamine", "SIMPLE_CHEMICAL", 127, 143], ["Fig. 3", "GENE_OR_GENE_PRODUCT", 211, 217], ["AOC1", "GENE_OR_GENE_PRODUCT", 219, 223], ["MAOA", "GENE_OR_GENE_PRODUCT", 226, 230], ["IL4I1", "GENE_OR_GENE_PRODUCT", 232, 237], ["DEGs", "DNA", 20, 24], ["amine oxidases", "PROTEIN", 36, 50], ["enzymes", "PROTEIN", 202, 209], ["Fig. 3", "PROTEIN", 211, 217], ["AOC1", "PROTEIN", 219, 223], ["MAOA", "PROTEIN", 226, 230], ["IL4I1", "PROTEIN", 232, 237], ["amine oxidases", "TREATMENT", 36, 50], ["the biogenic amines histamine", "TREATMENT", 81, 110], ["tryptamine", "TREATMENT", 112, 122], ["phenylethylamine", "TREATMENT", 127, 143], ["these enzymes", "TEST", 196, 209]]], ["None of these amino oxidase genes were regulated by MRV.", [["amino", "CHEMICAL", 14, 19], ["amino oxidase", "GENE_OR_GENE_PRODUCT", 14, 27], ["amino oxidase genes", "DNA", 14, 33], ["MRV", "PROTEIN", 52, 55], ["these amino oxidase genes", "TREATMENT", 8, 33], ["MRV", "TEST", 52, 55]]], ["Using the genotyping program VarElect, PEDV-DEGs with an association with these biogenic amines were retrieved (supplementary file 3, sheet \"Biogenic amines\").", [["amines", "CHEMICAL", 89, 95], ["amines", "CHEMICAL", 150, 156], ["amines", "CHEMICAL", 89, 95], ["Biogenic amines", "CHEMICAL", 141, 156], ["biogenic amines", "SIMPLE_CHEMICAL", 80, 95], ["PEDV-DEGs", "DNA", 39, 48], ["these biogenic amines", "TREATMENT", 74, 95]]], ["Three enzymes clustered in the \"Histidine metabolism\" pathway (https://www.kegg.jp/keggbin/show_pathway?hsa00340+4128) with histamine and reaction products generated from this biogenic amine (Fig. 3) .", [["Histidine", "CHEMICAL", 32, 41], ["histamine", "CHEMICAL", 124, 133], ["amine", "CHEMICAL", 185, 190], ["Histidine", "CHEMICAL", 32, 41], ["histamine", "CHEMICAL", 124, 133], ["biogenic amine", "CHEMICAL", 176, 190], ["Histidine", "SIMPLE_CHEMICAL", 32, 41], ["histamine", "SIMPLE_CHEMICAL", 124, 133], ["biogenic amine", "SIMPLE_CHEMICAL", 176, 190], ["Three enzymes", "TEST", 0, 13], ["histamine and reaction products", "TREATMENT", 124, 155]]], ["Also most association of PEDV-DEGs were found by VarElect for histamine.", [["histamine", "CHEMICAL", 62, 71], ["histamine", "CHEMICAL", 62, 71], ["PEDV", "GENE_OR_GENE_PRODUCT", 25, 29], ["VarElect", "SIMPLE_CHEMICAL", 49, 57], ["histamine", "SIMPLE_CHEMICAL", 62, 71], ["PEDV", "PROTEIN", 25, 29], ["PEDV", "PROBLEM", 25, 29], ["histamine", "TREATMENT", 62, 71], ["PEDV", "OBSERVATION", 25, 29]]], ["The gene coding for the amine oxidase \"Interleukin 4 Induced 1\" (IL4I1) was strongly down-regulated (30-fold) 4h after infection with PEDV.", [["amine", "CHEMICAL", 24, 29], ["infection", "DISEASE", 119, 128], ["PEDV", "CHEMICAL", 134, 138], ["amine", "CHEMICAL", 24, 29], ["amine oxidase", "GENE_OR_GENE_PRODUCT", 24, 37], ["Interleukin 4 Induced 1", "GENE_OR_GENE_PRODUCT", 39, 62], ["IL4I1", "GENE_OR_GENE_PRODUCT", 65, 70], ["amine oxidase", "PROTEIN", 24, 37], ["Interleukin 4", "PROTEIN", 39, 52], ["IL4I1", "PROTEIN", 65, 70], ["PEDV", "SPECIES", 134, 138], ["The gene coding", "TREATMENT", 0, 15], ["the amine oxidase \"Interleukin", "TREATMENT", 20, 50], ["infection", "PROBLEM", 119, 128], ["PEDV", "PROBLEM", 134, 138], ["infection", "OBSERVATION", 119, 128]]], ["Besides catalysis of L-Phenylaniline into Phenylpyruvate (Fig.3) , IL4I1 also fulfills an important role in signaling in \"synaptic clefts\" formed between antigen presenting cells (APC) and T cells (so-called \"immune cleft\": see also below) ( Expression of the Prostaglandin-Endoperoxide Synthase 2 (PTGS2) gene was upregulated by MRV at 6h p.i.", [["synaptic clefts", "ANATOMY", 122, 137], ["antigen presenting cells", "ANATOMY", 154, 178], ["APC", "ANATOMY", 180, 183], ["T cells", "ANATOMY", 189, 196], ["immune cleft", "ANATOMY", 209, 221], ["L-Phenylaniline", "CHEMICAL", 21, 36], ["Phenylpyruvate", "CHEMICAL", 42, 56], ["IL4I1", "CHEMICAL", 67, 72], ["L-Phenylaniline", "CHEMICAL", 21, 36], ["Phenylpyruvate", "CHEMICAL", 42, 56], ["Fig.3", "CHEMICAL", 58, 63], ["IL4I1", "CHEMICAL", 67, 72], ["Prostaglandin", "CHEMICAL", 260, 273], ["L-Phenylaniline", "SIMPLE_CHEMICAL", 21, 36], ["Phenylpyruvate", "SIMPLE_CHEMICAL", 42, 56], ["Fig.3", "SIMPLE_CHEMICAL", 58, 63], ["IL4I1", "GENE_OR_GENE_PRODUCT", 67, 72], ["synaptic clefts", "CELLULAR_COMPONENT", 122, 137], ["antigen presenting", "GENE_OR_GENE_PRODUCT", 154, 172], ["cells", "CELL", 173, 178], ["APC", "CELL", 180, 183], ["T cells", "CELL", 189, 196], ["Prostaglandin-Endoperoxide Synthase 2", "GENE_OR_GENE_PRODUCT", 260, 297], ["PTGS2", "GENE_OR_GENE_PRODUCT", 299, 304], ["IL4I1", "PROTEIN", 67, 72], ["antigen presenting cells", "CELL_TYPE", 154, 178], ["APC", "CELL_TYPE", 180, 183], ["T cells", "CELL_TYPE", 189, 196], ["Prostaglandin-Endoperoxide Synthase 2 (PTGS2) gene", "DNA", 260, 310], ["L-Phenylaniline into Phenylpyruvate", "TREATMENT", 21, 56], ["synaptic clefts", "PROBLEM", 122, 137], ["T cells", "PROBLEM", 189, 196], ["the Prostaglandin-Endoperoxide Synthase", "TREATMENT", 256, 295]]], ["PTGS2 synthesizes prostaglandin endoperoxide H2 (PGH2), an compound with a short half-life and the precursor of many biological active prostaglandins: e.g. Thromboxane-A2 (mediates activation of platelets), PGI2 and PGE2.", [["platelets", "ANATOMY", 195, 204], ["prostaglandin endoperoxide H2", "CHEMICAL", 18, 47], ["PGH2", "CHEMICAL", 49, 53], ["prostaglandins", "CHEMICAL", 135, 149], ["Thromboxane-A2", "CHEMICAL", 156, 170], ["PGI2", "CHEMICAL", 207, 211], ["PGE2", "CHEMICAL", 216, 220], ["prostaglandin endoperoxide H2", "CHEMICAL", 18, 47], ["PGH2", "CHEMICAL", 49, 53], ["prostaglandins", "CHEMICAL", 135, 149], ["Thromboxane-A2", "CHEMICAL", 156, 170], ["PGI2", "CHEMICAL", 207, 211], ["PGE2", "CHEMICAL", 216, 220], ["PTGS2", "GENE_OR_GENE_PRODUCT", 0, 5], ["prostaglandin endoperoxide H2", "SIMPLE_CHEMICAL", 18, 47], ["PGH2", "SIMPLE_CHEMICAL", 49, 53], ["prostaglandins", "SIMPLE_CHEMICAL", 135, 149], ["Thromboxane-A2", "GENE_OR_GENE_PRODUCT", 156, 170], ["platelets", "CELL", 195, 204], ["PGI2", "SIMPLE_CHEMICAL", 207, 211], ["PGE2", "SIMPLE_CHEMICAL", 216, 220], ["PTGS2", "PROTEIN", 0, 5], ["platelets", "CELL_TYPE", 195, 204], ["PTGS2 synthesizes prostaglandin endoperoxide H2 (PGH2", "TREATMENT", 0, 53], ["Thromboxane-A2 (mediates activation of platelets", "TREATMENT", 156, 204], ["PGI2", "TREATMENT", 207, 211], ["PGE2", "TREATMENT", 216, 220]]], ["In contrast, PEDV increased the expression of the gene coding for Prostaglandin E Synthase (PTGES) which converts PGH2 into PGE2.", [["PEDV", "CHEMICAL", 13, 17], ["Prostaglandin E", "CHEMICAL", 66, 81], ["PGH2", "CHEMICAL", 114, 118], ["PGE2", "CHEMICAL", 124, 128], ["PEDV", "CHEMICAL", 13, 17], ["Prostaglandin E", "CHEMICAL", 66, 81], ["PGH2", "CHEMICAL", 114, 118], ["PGE2", "CHEMICAL", 124, 128], ["PEDV", "SIMPLE_CHEMICAL", 13, 17], ["Prostaglandin E Synthase", "GENE_OR_GENE_PRODUCT", 66, 90], ["PTGES", "GENE_OR_GENE_PRODUCT", 92, 97], ["PGH2", "SIMPLE_CHEMICAL", 114, 118], ["PGE2", "SIMPLE_CHEMICAL", 124, 128], ["PEDV", "PROTEIN", 13, 17], ["Prostaglandin E Synthase", "PROTEIN", 66, 90], ["PTGES", "PROTEIN", 92, 97], ["PEDV", "PROBLEM", 13, 17], ["Prostaglandin E Synthase (PTGES)", "TREATMENT", 66, 98], ["PGH2 into PGE2", "TREATMENT", 114, 128]]], ["PGE2 is a direct vasodilator, but does not inhibit platelet aggregation.", [["platelet", "ANATOMY", 51, 59], ["PGE2", "CHEMICAL", 0, 4], ["platelet aggregation", "DISEASE", 51, 71], ["PGE2", "CHEMICAL", 0, 4], ["PGE2", "SIMPLE_CHEMICAL", 0, 4], ["platelet", "CELL", 51, 59], ["a direct vasodilator", "TREATMENT", 8, 28], ["platelet aggregation", "PROBLEM", 51, 71]]], ["PGE2 also suppresses T cell receptor signaling.", [["T cell", "ANATOMY", 21, 27], ["PGE2", "CHEMICAL", 0, 4], ["PGE2", "CHEMICAL", 0, 4], ["PGE2", "SIMPLE_CHEMICAL", 0, 4], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 21, 36], ["T cell receptor", "PROTEIN", 21, 36], ["PGE2", "TREATMENT", 0, 4]]], ["PEDV decreased expression of the Gamma-Glutamyltransferase 1 gene (GGT1) after 4h (2-fold), but increased expression of this gene 2 hours later to a 4-fold level compared to mock infected cells.", [["cells", "ANATOMY", 188, 193], ["PEDV", "CHEMICAL", 0, 4], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["Gamma-Glutamyltransferase 1", "GENE_OR_GENE_PRODUCT", 33, 60], ["GGT1", "GENE_OR_GENE_PRODUCT", 67, 71], ["cells", "CELL", 188, 193], ["Gamma-Glutamyltransferase 1 gene", "DNA", 33, 65], ["GGT1", "DNA", 67, 71], ["mock infected cells", "CELL_TYPE", 174, 193], ["PEDV", "PROBLEM", 0, 4], ["the Gamma", "TEST", 29, 38], ["Gamma", "ANATOMY", 33, 38], ["infected cells", "OBSERVATION", 179, 193]]], ["GGT synthesizes Leukotriene D4 (LTD4) from LTC4.", [["Leukotriene D4", "CHEMICAL", 16, 30], ["LTD4", "CHEMICAL", 32, 36], ["LTC4", "CHEMICAL", 43, 47], ["Leukotriene D4", "CHEMICAL", 16, 30], ["LTD4", "CHEMICAL", 32, 36], ["LTC4", "CHEMICAL", 43, 47], ["GGT", "SIMPLE_CHEMICAL", 0, 3], ["Leukotriene D4", "GENE_OR_GENE_PRODUCT", 16, 30], ["LTD4", "SIMPLE_CHEMICAL", 32, 36], ["LTC4", "SIMPLE_CHEMICAL", 43, 47], ["GGT", "PROTEIN", 0, 3], ["GGT synthesizes", "TREATMENT", 0, 15], ["Leukotriene D4 (LTD4)", "TREATMENT", 16, 37], ["LTC4", "TEST", 43, 47], ["Leukotriene D4", "OBSERVATION", 16, 30], ["LTC4", "ANATOMY", 43, 47]]], ["IgE-activated mast cells may secrete LTD4 and LTC4, together with histamine and platelets activating factor (PAF).", [["mast cells", "ANATOMY", 14, 24], ["LTD4", "CHEMICAL", 37, 41], ["LTC4", "CHEMICAL", 46, 50], ["histamine", "CHEMICAL", 66, 75], ["LTC4", "CHEMICAL", 46, 50], ["histamine", "CHEMICAL", 66, 75], ["IgE", "GENE_OR_GENE_PRODUCT", 0, 3], ["mast cells", "CELL", 14, 24], ["LTD4", "GENE_OR_GENE_PRODUCT", 37, 41], ["LTC4", "SIMPLE_CHEMICAL", 46, 50], ["histamine", "SIMPLE_CHEMICAL", 66, 75], ["platelets activating factor", "GENE_OR_GENE_PRODUCT", 80, 107], ["PAF", "GENE_OR_GENE_PRODUCT", 109, 112], ["IgE", "PROTEIN", 0, 3], ["activated mast cells", "CELL_TYPE", 4, 24], ["platelets activating factor", "PROTEIN", 80, 107], ["PAF", "PROTEIN", 109, 112], ["IgE", "TEST", 0, 3], ["activated mast cells", "TREATMENT", 4, 24], ["LTD4", "TEST", 37, 41], ["LTC4", "TEST", 46, 50], ["histamine", "TREATMENT", 66, 75], ["platelets activating factor", "PROBLEM", 80, 107], ["PAF", "PROBLEM", 109, 112], ["mast cells", "OBSERVATION", 14, 24]]], ["This vesicle mediated secretion by mast cells (degranulation) results in stimulation of mucus production, and similar to histamine, increases the permeability and smooth muscle contraction of the vascular wall.", [["vesicle", "ANATOMY", 5, 12], ["mast cells", "ANATOMY", 35, 45], ["mucus", "ANATOMY", 88, 93], ["smooth muscle", "ANATOMY", 163, 176], ["vascular wall", "ANATOMY", 196, 209], ["histamine", "CHEMICAL", 121, 130], ["histamine", "CHEMICAL", 121, 130], ["vesicle", "CELLULAR_COMPONENT", 5, 12], ["mast cells", "CELL", 35, 45], ["mucus", "ORGANISM_SUBSTANCE", 88, 93], ["histamine", "SIMPLE_CHEMICAL", 121, 130], ["smooth muscle", "TISSUE", 163, 176], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 196, 209], ["mast cells", "CELL_TYPE", 35, 45], ["This vesicle mediated secretion", "PROBLEM", 0, 31], ["mast cells", "PROBLEM", 35, 45], ["mucus production", "PROBLEM", 88, 104], ["histamine", "TEST", 121, 130], ["the permeability", "PROBLEM", 142, 158], ["mast cells", "OBSERVATION", 35, 45], ["mucus production", "OBSERVATION", 88, 104], ["permeability", "OBSERVATION_MODIFIER", 146, 158], ["smooth muscle contraction", "OBSERVATION", 163, 188], ["vascular wall", "ANATOMY", 196, 209]]], ["In persons suffering from asthma this degranulation leads to an immediate allergic response (bronchospasm, airflow obstruction and forming of edema).Regulation of immune and antiviral genes.Genes involved in \"Cilia and Synaptic cleft\" formation.Regulation of immune and antiviral genes.GSEA detected \"Axon Guidance\" as the GO-term with the highest score for PEDV (see Table 1 ).", [["edema", "ANATOMY", 142, 147], ["Cilia", "ANATOMY", 209, 214], ["Synaptic cleft", "ANATOMY", 219, 233], ["asthma", "DISEASE", 26, 32], ["allergic", "DISEASE", 74, 82], ["bronchospasm", "DISEASE", 93, 105], ["airflow obstruction", "DISEASE", 107, 126], ["edema", "DISEASE", 142, 147], ["persons", "ORGANISM", 3, 10], ["edema", "PATHOLOGICAL_FORMATION", 142, 147], ["Cilia", "MULTI-TISSUE_STRUCTURE", 209, 214], ["Synaptic cleft", "CELLULAR_COMPONENT", 219, 233], ["immune and antiviral genes", "DNA", 163, 189], ["immune and antiviral genes", "DNA", 259, 285], ["persons", "SPECIES", 3, 10], ["asthma this degranulation", "PROBLEM", 26, 51], ["an immediate allergic response", "PROBLEM", 61, 91], ["bronchospasm", "PROBLEM", 93, 105], ["airflow obstruction", "PROBLEM", 107, 126], ["edema", "PROBLEM", 142, 147], ["immune and antiviral genes", "TREATMENT", 163, 189], ["Synaptic cleft\" formation", "PROBLEM", 219, 244], ["immune and antiviral genes", "TREATMENT", 259, 285], ["PEDV", "PROBLEM", 358, 362], ["asthma", "OBSERVATION", 26, 32], ["allergic response", "OBSERVATION", 74, 91], ["airflow obstruction", "OBSERVATION", 107, 126], ["edema", "OBSERVATION", 142, 147], ["antiviral genes", "OBSERVATION", 174, 189], ["Synaptic cleft", "OBSERVATION", 219, 233], ["antiviral genes", "OBSERVATION", 270, 285]]], ["In addition, PEDV-DEGs were enriched coding for proteins involved in calcium ion-dependent exocytosis from vesicles into the \"synaptic clefts\" between two cells (e.g. between axons and dendrites), and DEGs coding for proteins involved in formation of cilia.", [["vesicles", "ANATOMY", 107, 115], ["synaptic clefts", "ANATOMY", 126, 141], ["cells", "ANATOMY", 155, 160], ["axons", "ANATOMY", 175, 180], ["dendrites", "ANATOMY", 185, 194], ["cilia", "ANATOMY", 251, 256], ["calcium", "CHEMICAL", 69, 76], ["calcium", "CHEMICAL", 69, 76], ["PEDV", "GENE_OR_GENE_PRODUCT", 13, 17], ["calcium", "SIMPLE_CHEMICAL", 69, 76], ["vesicles", "CELLULAR_COMPONENT", 107, 115], ["synaptic clefts", "CELLULAR_COMPONENT", 126, 141], ["cells", "CELL", 155, 160], ["axons", "CELLULAR_COMPONENT", 175, 180], ["dendrites", "CELLULAR_COMPONENT", 185, 194], ["cilia", "CELLULAR_COMPONENT", 251, 256], ["PEDV", "PROTEIN", 13, 17], ["DEGs", "DNA", 18, 22], ["DEGs", "PROTEIN", 201, 205], ["PEDV", "PROBLEM", 13, 17], ["proteins", "PROBLEM", 48, 56], ["calcium ion-dependent exocytosis", "PROBLEM", 69, 101], ["the \"synaptic clefts", "PROBLEM", 121, 141], ["proteins", "PROBLEM", 217, 225], ["ion-dependent exocytosis", "OBSERVATION", 77, 101], ["cilia", "ANATOMY_MODIFIER", 251, 256]]], ["Cilia protruding from cells are found in many forms.", [["Cilia", "ANATOMY", 0, 5], ["cells", "ANATOMY", 22, 27], ["Cilia", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 22, 27], ["Cilia protruding from cells", "PROBLEM", 0, 27]]], ["They can have a static (structural) function, e.g. in forming of clefts between two cells (see Fig. 4 ), or a motile function.", [["cells", "ANATOMY", 84, 89], ["cells", "CELL", 84, 89], ["a static (structural) function", "PROBLEM", 14, 44], ["clefts between two cells", "PROBLEM", 65, 89]]], ["Motile cilia on the surface of ciliated cells lining up the epithelial layers in the nose, trachea and bronchia sweep out superfluous mucus containing dirt from the airways.", [["cilia", "ANATOMY", 7, 12], ["surface", "ANATOMY", 20, 27], ["ciliated cells", "ANATOMY", 31, 45], ["epithelial layers", "ANATOMY", 60, 77], ["nose", "ANATOMY", 85, 89], ["trachea", "ANATOMY", 91, 98], ["bronchia", "ANATOMY", 103, 111], ["mucus", "ANATOMY", 134, 139], ["airways", "ANATOMY", 165, 172], ["cilia", "CELLULAR_COMPONENT", 7, 12], ["surface", "CELLULAR_COMPONENT", 20, 27], ["ciliated cells", "CELL", 31, 45], ["epithelial layers", "TISSUE", 60, 77], ["nose", "ORGAN", 85, 89], ["trachea", "MULTI-TISSUE_STRUCTURE", 91, 98], ["mucus", "ORGANISM_SUBSTANCE", 134, 139], ["airways", "MULTI-TISSUE_STRUCTURE", 165, 172], ["ciliated cells", "CELL_TYPE", 31, 45], ["Motile cilia", "PROBLEM", 0, 12], ["ciliated cells", "PROBLEM", 31, 45], ["superfluous mucus", "PROBLEM", 122, 139], ["cilia", "ANATOMY_MODIFIER", 7, 12], ["surface", "OBSERVATION_MODIFIER", 20, 27], ["ciliated cells", "OBSERVATION", 31, 45], ["lining", "OBSERVATION_MODIFIER", 46, 52], ["epithelial", "ANATOMY_MODIFIER", 60, 70], ["layers", "ANATOMY_MODIFIER", 71, 77], ["nose", "ANATOMY", 85, 89], ["trachea", "ANATOMY", 91, 98], ["bronchia", "ANATOMY", 103, 111], ["superfluous", "OBSERVATION_MODIFIER", 122, 133], ["mucus", "OBSERVATION", 134, 139], ["dirt", "OBSERVATION_MODIFIER", 151, 155], ["airways", "ANATOMY", 165, 172]]], ["PEDV DEGs matching the terms \"Cilia\" and \"Synaptic cleft\" retrieved form the genotyping program VarElect were further examined by consulting functional information in the NCBI Gene and GeneCards reports in order to evaluate their association with these processes (see supplementary file 3, sheet \"Cilia and Synaptic cleft\").", [["Cilia", "ANATOMY", 30, 35], ["Synaptic cleft", "ANATOMY", 42, 56], ["Cilia", "ANATOMY", 297, 302], ["Synaptic cleft", "ANATOMY", 307, 321], ["Cilia", "CELLULAR_COMPONENT", 30, 35], ["PEDV DEGs", "DNA", 0, 9], ["NCBI Gene", "DNA", 171, 180], ["PEDV", "SPECIES", 0, 4], ["PEDV DEGs", "TREATMENT", 0, 9]]], ["Based on this analysis we identified genes in the set of PEDV DEGs which can i) negatively regulate cell adhesion (RND1 and SEMA5A), ii) inhibit formation of cilia (kinases MAK1 and CDK20, highly up-regulated at 6h), and iii) regulate cytoskeleton rearrangements that facilitate axon growth and growth and stabilization of dendritic spines (F2RL2, Regulation of genes involved in histamine/biogenic amines (see above) and formation of cilia/clefts suggested that gene expression related to this intersynaptic signaling between immune cells could be affected in response to infection with PEDV (Fig 4) .", [["cell", "ANATOMY", 100, 104], ["cilia", "ANATOMY", 158, 163], ["cytoskeleton", "ANATOMY", 235, 247], ["axon", "ANATOMY", 279, 283], ["dendritic spines", "ANATOMY", 323, 339], ["cilia", "ANATOMY", 435, 440], ["immune cells", "ANATOMY", 527, 539], ["histamine", "CHEMICAL", 380, 389], ["amines", "CHEMICAL", 399, 405], ["infection", "DISEASE", 573, 582], ["histamine", "CHEMICAL", 380, 389], ["amines", "CHEMICAL", 399, 405], ["PEDV", "GENE_OR_GENE_PRODUCT", 57, 61], ["cell", "CELL", 100, 104], ["RND1", "GENE_OR_GENE_PRODUCT", 115, 119], ["SEMA5A", "GENE_OR_GENE_PRODUCT", 124, 130], ["cilia", "CELLULAR_COMPONENT", 158, 163], ["MAK1", "GENE_OR_GENE_PRODUCT", 173, 177], ["CDK20", "GENE_OR_GENE_PRODUCT", 182, 187], ["cytoskeleton", "CELLULAR_COMPONENT", 235, 247], ["axon", "MULTI-TISSUE_STRUCTURE", 279, 283], ["dendritic spines", "MULTI-TISSUE_STRUCTURE", 323, 339], ["F2RL2", "GENE_OR_GENE_PRODUCT", 341, 346], ["histamine", "SIMPLE_CHEMICAL", 380, 389], ["biogenic amines", "SIMPLE_CHEMICAL", 390, 405], ["cilia", "CELLULAR_COMPONENT", 435, 440], ["immune cells", "CELL", 527, 539], ["PEDV DEGs", "DNA", 57, 66], ["RND1", "PROTEIN", 115, 119], ["SEMA5A", "PROTEIN", 124, 130], ["kinases", "PROTEIN", 165, 172], ["MAK1", "PROTEIN", 173, 177], ["CDK20", "PROTEIN", 182, 187], ["dendritic spines", "CELL_TYPE", 323, 339], ["immune cells", "CELL_TYPE", 527, 539], ["PEDV", "SPECIES", 588, 592], ["this analysis", "TEST", 9, 22], ["cilia (kinases MAK1", "TEST", 158, 177], ["CDK20", "TEST", 182, 187], ["axon growth", "TEST", 279, 290], ["stabilization of dendritic spines (F2RL2", "TREATMENT", 306, 346], ["histamine/biogenic amines", "TREATMENT", 380, 405], ["cilia/clefts", "PROBLEM", 435, 447], ["gene expression", "PROBLEM", 463, 478], ["this intersynaptic signaling between immune cells", "PROBLEM", 490, 539], ["infection", "PROBLEM", 573, 582], ["PEDV (Fig", "TREATMENT", 588, 597], ["cell adhesion", "OBSERVATION", 100, 113], ["cilia", "ANATOMY_MODIFIER", 158, 163], ["cytoskeleton rearrangements", "OBSERVATION", 235, 262], ["dendritic spines", "OBSERVATION", 323, 339], ["infection", "OBSERVATION", 573, 582]]], ["In particular, the highly down-regulated gene IL4I1 (30-fold at 4h p.i.) is of interest (see also above).", [["IL4I1", "GENE_OR_GENE_PRODUCT", 46, 51], ["IL4I1", "DNA", 46, 51]]], ["IL4I1 is believed to be secreted from APC's (e.g. DC's) in the immune cleft formed with T cells (31: Molinier-Frenkel et al. 2019).", [["DC", "ANATOMY", 50, 52], ["immune cleft", "ANATOMY", 63, 75], ["T cells", "ANATOMY", 88, 95], ["IL4I1", "GENE_OR_GENE_PRODUCT", 0, 5], ["APC", "GENE_OR_GENE_PRODUCT", 38, 41], ["T cells", "CELL", 88, 95], ["IL4I1", "PROTEIN", 0, 5], ["APC", "CELL_TYPE", 38, 41], ["DC", "CELL_TYPE", 50, 52], ["T cells", "CELL_TYPE", 88, 95], ["APC's", "PROBLEM", 38, 43], ["T cells", "PROBLEM", 88, 95], ["believed to be", "UNCERTAINTY", 9, 23]]], ["The mechanism how IL4I1 transmits its signal to T cells is not completely understood.", [["T cells", "ANATOMY", 48, 55], ["IL4I1", "GENE_OR_GENE_PRODUCT", 18, 23], ["T cells", "CELL", 48, 55], ["IL4I1", "PROTEIN", 18, 23], ["T cells", "CELL_TYPE", 48, 55]]], ["It could bind to a receptor that concentrates this amino oxidase in the cleft, resulting in elevated H2O2 and ammonia production, phenylalanine depletion and phenylpyruvate production in the cleft space.", [["cleft space", "ANATOMY", 191, 202], ["H2O2", "CHEMICAL", 101, 105], ["ammonia", "CHEMICAL", 110, 117], ["phenylalanine", "CHEMICAL", 130, 143], ["phenylpyruvate", "CHEMICAL", 158, 172], ["amino", "CHEMICAL", 51, 56], ["H2O2", "CHEMICAL", 101, 105], ["ammonia", "CHEMICAL", 110, 117], ["phenylalanine", "CHEMICAL", 130, 143], ["phenylpyruvate", "CHEMICAL", 158, 172], ["amino oxidase", "GENE_OR_GENE_PRODUCT", 51, 64], ["cleft", "ORGAN", 72, 77], ["H2O2", "SIMPLE_CHEMICAL", 101, 105], ["ammonia", "SIMPLE_CHEMICAL", 110, 117], ["phenylalanine", "SIMPLE_CHEMICAL", 130, 143], ["phenylpyruvate", "SIMPLE_CHEMICAL", 158, 172], ["amino oxidase", "PROTEIN", 51, 64], ["this amino oxidase", "TREATMENT", 46, 64], ["elevated H2O2", "PROBLEM", 92, 105], ["ammonia production", "PROBLEM", 110, 128], ["phenylalanine depletion", "TREATMENT", 130, 153], ["phenylpyruvate production in the cleft space", "PROBLEM", 158, 202], ["cleft", "ANATOMY", 72, 77], ["elevated H2O2", "OBSERVATION", 92, 105], ["ammonia production", "OBSERVATION", 110, 128], ["phenylalanine depletion", "OBSERVATION", 130, 153], ["cleft space", "ANATOMY", 191, 202]]], ["These alteration in the concentration of these chemicals in the cleft are sensed by the T cell.", [["cleft", "ANATOMY", 64, 69], ["T cell", "ANATOMY", 88, 94], ["cleft", "ORGAN", 64, 69], ["T cell", "CELL", 88, 94], ["T cell", "CELL_TYPE", 88, 94], ["These alteration", "PROBLEM", 0, 16], ["these chemicals in the cleft", "PROBLEM", 41, 69], ["alteration", "OBSERVATION", 6, 16], ["concentration", "OBSERVATION_MODIFIER", 24, 37], ["chemicals", "OBSERVATION", 47, 56], ["cleft", "ANATOMY", 64, 69], ["T cell", "OBSERVATION", 88, 94]]], ["The paralog of IL4I1, amino oxidase MAOA (down-regulated 11-fold by PEDV) could also play a similar role in this signaling process.", [["amino", "CHEMICAL", 22, 27], ["IL4I1", "GENE_OR_GENE_PRODUCT", 15, 20], ["amino oxidase", "GENE_OR_GENE_PRODUCT", 22, 35], ["MAOA", "GENE_OR_GENE_PRODUCT", 36, 40], ["PEDV", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL4I1", "PROTEIN", 15, 20], ["amino oxidase MAOA", "PROTEIN", 22, 40], ["PEDV", "PROTEIN", 68, 72], ["amino oxidase MAOA", "TEST", 22, 40], ["PEDV", "PROBLEM", 68, 72]]], ["Remarkable was also the strong down-regulation of genes coding for the Olfactory Receptor Family 2 Subfamily A Member 14 (OR2A14; 17-fold at 4h) and Anoctamin 2 (ANO2, alias CaCC;14-fold at 4h).", [["Anoctamin 2", "CHEMICAL", 149, 160], ["Subfamily A Member 14", "GENE_OR_GENE_PRODUCT", 99, 120], ["OR2A14", "GENE_OR_GENE_PRODUCT", 122, 128], ["Anoctamin 2", "GENE_OR_GENE_PRODUCT", 149, 160], ["Olfactory Receptor Family 2 Subfamily A Member 14", "PROTEIN", 71, 120], ["OR2A14", "PROTEIN", 122, 128], ["Anoctamin 2", "PROTEIN", 149, 160], ["ANO2", "PROTEIN", 162, 166], ["Anoctamin 2 (ANO2, alias CaCC", "TREATMENT", 149, 178]]], ["ANO2 is a calcium-activated chloride channel imbedded in the basal membranes of neurons that harbor apical membrane receptors like OR2A14 that sense odorants.", [["basal membranes", "ANATOMY", 61, 76], ["neurons", "ANATOMY", 80, 87], ["apical membrane", "ANATOMY", 100, 115], ["calcium", "CHEMICAL", 10, 17], ["chloride", "CHEMICAL", 28, 36], ["calcium", "CHEMICAL", 10, 17], ["chloride", "CHEMICAL", 28, 36], ["ANO2", "GENE_OR_GENE_PRODUCT", 0, 4], ["calcium", "SIMPLE_CHEMICAL", 10, 17], ["chloride", "SIMPLE_CHEMICAL", 28, 36], ["basal membranes", "CELLULAR_COMPONENT", 61, 76], ["neurons", "CELL", 80, 87], ["apical membrane", "CELLULAR_COMPONENT", 100, 115], ["OR2A14", "GENE_OR_GENE_PRODUCT", 131, 137], ["ANO2", "PROTEIN", 0, 4], ["calcium-activated chloride channel", "PROTEIN", 10, 44], ["apical membrane receptors", "PROTEIN", 100, 125], ["OR2A14", "PROTEIN", 131, 137], ["a calcium", "TEST", 8, 17], ["activated chloride channel", "TREATMENT", 18, 44], ["apical membrane receptors", "PROBLEM", 100, 125], ["basal", "ANATOMY_MODIFIER", 61, 66], ["membranes", "ANATOMY_MODIFIER", 67, 76], ["apical", "ANATOMY_MODIFIER", 100, 106], ["membrane receptors", "OBSERVATION", 107, 125]]], ["By importing chloride ions into the cytosol ANO2 contributes to the depolarization of these neurons (https://www.kegg.jp/kegg-bin/show_pathway?hsa04740+57101).", [["cytosol", "ANATOMY", 36, 43], ["neurons", "ANATOMY", 92, 99], ["chloride", "CHEMICAL", 13, 21], ["chloride", "CHEMICAL", 13, 21], ["chloride ions", "SIMPLE_CHEMICAL", 13, 26], ["cytosol", "CELLULAR_COMPONENT", 36, 43], ["ANO2", "SIMPLE_CHEMICAL", 44, 48], ["neurons", "CELL", 92, 99], ["cytosol ANO2", "PROTEIN", 36, 48], ["importing chloride ions", "TREATMENT", 3, 26], ["neurons", "ANATOMY", 92, 99]]], ["Loss of smell and taste is one of the first noticeable symptoms of COVID-19.", [["Loss of smell", "DISEASE", 0, 13], ["COVID-19", "CHEMICAL", 67, 75], ["Loss of smell and taste", "PROBLEM", 0, 23], ["COVID", "TEST", 67, 72], ["smell", "OBSERVATION", 8, 13]]], ["Genetic defects in the ANO2 gene are associated with Von Willebrand disease, a bleeding disorder due to defective platelet aggregation ( .", [["platelet", "ANATOMY", 114, 122], ["Von Willebrand disease", "DISEASE", 53, 75], ["bleeding disorder", "DISEASE", 79, 96], ["platelet aggregation", "DISEASE", 114, 134], ["ANO2", "GENE_OR_GENE_PRODUCT", 23, 27], ["Willebrand", "GENE_OR_GENE_PRODUCT", 57, 67], ["platelet", "CELL", 114, 122], ["ANO2 gene", "DNA", 23, 32], ["Genetic defects", "PROBLEM", 0, 15], ["Von Willebrand disease", "PROBLEM", 53, 75], ["a bleeding disorder", "PROBLEM", 77, 96], ["defective platelet aggregation", "PROBLEM", 104, 134], ["defects", "OBSERVATION", 8, 15], ["associated with", "UNCERTAINTY", 37, 52], ["Von Willebrand disease", "OBSERVATION", 53, 75], ["bleeding", "OBSERVATION", 79, 87], ["defective platelet aggregation", "OBSERVATION", 104, 134]]], ["Also disease incidence in adult males is significantly higher than in females of the same age.Regulation of immune and antiviral genes.To assess whether PEDV-DEGs relate to these pathological symptoms, the genotyping program VarElect was used to identify genes matching the terms \"ARDS\", \"Cardiomyopathy\", \"Obesity (Diabetic)\", and \"Platelets activation\".", [["Platelets", "ANATOMY", 333, 342], ["ARDS", "DISEASE", 281, 285], ["Cardiomyopathy", "DISEASE", 289, 303], ["Obesity", "DISEASE", 307, 314], ["Diabetic", "DISEASE", 316, 324], ["PEDV", "GENE_OR_GENE_PRODUCT", 153, 157], ["Platelets", "CELL", 333, 342], ["immune and antiviral genes", "DNA", 108, 134], ["PEDV", "PROTEIN", 153, 157], ["immune and antiviral genes", "TREATMENT", 108, 134], ["PEDV", "PROBLEM", 153, 157], ["DEGs", "PROBLEM", 158, 162], ["these pathological symptoms", "PROBLEM", 173, 200], ["ARDS", "PROBLEM", 281, 285], ["Cardiomyopathy", "PROBLEM", 289, 303], ["Obesity (Diabetic)", "PROBLEM", 307, 325], ["Platelets activation\"", "PROBLEM", 333, 354], ["disease", "OBSERVATION", 5, 12], ["adult", "OBSERVATION_MODIFIER", 26, 31], ["males", "OBSERVATION", 32, 37], ["significantly", "OBSERVATION_MODIFIER", 41, 54], ["higher", "OBSERVATION_MODIFIER", 55, 61], ["antiviral genes", "OBSERVATION", 119, 134], ["ARDS", "OBSERVATION", 281, 285], ["Obesity", "OBSERVATION", 307, 314]]], ["Detailed information about all matching DEGs is provided in supplementary file 3 in separate sheets for all 4 queried terms.", [["DEGs", "DNA", 40, 44]]], ["DEGs matching to more than one query term are displayed in Fig. 5 .", [["DEGs matching", "TREATMENT", 0, 13]]], ["Remarkable associations of DEGs with these terms are mentioned in sections beneath. .", [["sections", "ANATOMY", 66, 74], ["DEGs", "DNA", 27, 31]]], ["EDN2 and AGT2 are vasoactive peptides and binding of EDN2 and AGT2 to their receptors on granular cells of the juxtaglomerular apparatus in the kidney raises free calcium levels in the cytosol, leading to inhibition of cAMP-mediated secretion of the aspartylprotease renin (REN), the key regulator of renin-angiotensin-aldosterone system (RAAS) (https://www.kegg.jp/kegg-bin/show_pathway?hsa04924+1907).", [["granular cells", "ANATOMY", 89, 103], ["juxtaglomerular apparatus", "ANATOMY", 111, 136], ["kidney", "ANATOMY", 144, 150], ["cytosol", "ANATOMY", 185, 192], ["calcium", "CHEMICAL", 163, 170], ["cAMP", "CHEMICAL", 219, 223], ["aldosterone", "CHEMICAL", 319, 330], ["calcium", "CHEMICAL", 163, 170], ["cAMP", "CHEMICAL", 219, 223], ["EDN2", "GENE_OR_GENE_PRODUCT", 0, 4], ["AGT2", "GENE_OR_GENE_PRODUCT", 9, 13], ["EDN2", "GENE_OR_GENE_PRODUCT", 53, 57], ["AGT2", "GENE_OR_GENE_PRODUCT", 62, 66], ["granular cells", "CELL", 89, 103], ["juxtaglomerular apparatus", "MULTI-TISSUE_STRUCTURE", 111, 136], ["kidney", "ORGAN", 144, 150], ["calcium", "SIMPLE_CHEMICAL", 163, 170], ["cytosol", "CELLULAR_COMPONENT", 185, 192], ["cAMP", "SIMPLE_CHEMICAL", 219, 223], ["aspartylprotease", "GENE_OR_GENE_PRODUCT", 250, 266], ["renin", "GENE_OR_GENE_PRODUCT", 267, 272], ["REN", "GENE_OR_GENE_PRODUCT", 274, 277], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 301, 330], ["EDN2", "PROTEIN", 0, 4], ["AGT2", "PROTEIN", 9, 13], ["EDN2", "PROTEIN", 53, 57], ["AGT2", "PROTEIN", 62, 66], ["granular cells", "CELL_TYPE", 89, 103], ["aspartylprotease renin", "PROTEIN", 250, 272], ["REN", "PROTEIN", 274, 277], ["renin", "PROTEIN", 301, 306], ["EDN2", "TEST", 0, 4], ["AGT2", "TREATMENT", 9, 13], ["vasoactive peptides", "TREATMENT", 18, 37], ["EDN2", "TEST", 53, 57], ["AGT2", "TREATMENT", 62, 66], ["free calcium levels", "TEST", 158, 177], ["cAMP", "TEST", 219, 223], ["the aspartylprotease renin", "TREATMENT", 246, 272], ["renin-angiotensin-aldosterone system", "TREATMENT", 301, 337], ["vasoactive peptides", "OBSERVATION", 18, 37], ["granular cells", "OBSERVATION", 89, 103], ["juxtaglomerular", "ANATOMY", 111, 126], ["apparatus", "ANATOMY_MODIFIER", 127, 136], ["kidney", "ANATOMY", 144, 150], ["free calcium levels", "OBSERVATION", 158, 177]]], ["REN converts pre-angiotensinogen (AGT) to the endocrine peptide-hormone AGT1Regulation of immune and antiviral genes.(https://www.kegg.jp/kegg-bin/show_pathway?hsa04614+5972).", [["REN", "GENE_OR_GENE_PRODUCT", 0, 3], ["pre-angiotensinogen", "GENE_OR_GENE_PRODUCT", 13, 32], ["AGT", "GENE_OR_GENE_PRODUCT", 34, 37], ["REN", "DNA", 0, 3], ["pre-angiotensinogen", "PROTEIN", 13, 32], ["AGT", "PROTEIN", 34, 37], ["immune and antiviral genes", "DNA", 90, 116], ["pre-angiotensinogen (AGT", "TREATMENT", 13, 37], ["the endocrine peptide", "TEST", 42, 63], ["hormone AGT1Regulation", "TREATMENT", 64, 86], ["immune and antiviral genes", "TREATMENT", 90, 116], ["antiviral genes", "OBSERVATION", 101, 116]]], ["AGT1 is further cleaved to variants with specific endocrine activity by Angiotensin I Converting Enzymes (e.g. ACE and ACE2: ).", [["endocrine", "ANATOMY", 50, 59], ["Angiotensin", "CHEMICAL", 72, 83], ["AGT1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Angiotensin I Converting Enzymes", "GENE_OR_GENE_PRODUCT", 72, 104], ["ACE", "GENE_OR_GENE_PRODUCT", 111, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 119, 123], ["AGT1", "PROTEIN", 0, 4], ["Angiotensin I Converting Enzymes", "PROTEIN", 72, 104], ["ACE", "PROTEIN", 111, 114], ["ACE2", "PROTEIN", 119, 123], ["Enzymes", "TEST", 97, 104], ["ACE", "TEST", 111, 114], ["ACE2", "TEST", 119, 123]]], ["On the surface of bronchial epithelial cells ACE2 was identified as entry receptor for SARS-CoV-1 and -2 (43: Hoffmann et al. 2020).", [["surface", "ANATOMY", 7, 14], ["bronchial epithelial cells", "ANATOMY", 18, 44], ["surface", "CELLULAR_COMPONENT", 7, 14], ["bronchial epithelial cells", "CELL", 18, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 87, 97], ["bronchial epithelial cells", "CELL_TYPE", 18, 44], ["ACE2", "PROTEIN", 45, 49], ["entry receptor", "TEST", 68, 82], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["bronchial", "ANATOMY", 18, 27], ["epithelial cells", "OBSERVATION", 28, 44]]], ["The octamer peptide AGT2 stimulates secretion of the mineralocorticoid hormone aldosterone by the adrenal glands.", [["adrenal glands", "ANATOMY", 98, 112], ["aldosterone", "CHEMICAL", 79, 90], ["aldosterone", "CHEMICAL", 79, 90], ["AGT2", "GENE_OR_GENE_PRODUCT", 20, 24], ["mineralocorticoid hormone aldosterone", "GENE_OR_GENE_PRODUCT", 53, 90], ["adrenal glands", "ORGAN", 98, 112], ["The octamer peptide AGT2", "TEST", 0, 24], ["the mineralocorticoid hormone aldosterone", "TEST", 49, 90], ["adrenal glands", "ANATOMY", 98, 112]]], ["Aldosterone, and the AGT and EDN peptide hormones regulate an array of physiological processes in the body, e.g. vascular smooth muscle contraction, blood pressure, fluid and electrolyte homeostasis (44: Agapitov et al. 2002) .", [["body", "ANATOMY", 102, 106], ["vascular smooth muscle", "ANATOMY", 113, 135], ["blood", "ANATOMY", 149, 154], ["fluid", "ANATOMY", 165, 170], ["Aldosterone", "CHEMICAL", 0, 11], ["Aldosterone", "CHEMICAL", 0, 11], ["Aldosterone", "SIMPLE_CHEMICAL", 0, 11], ["AGT", "GENE_OR_GENE_PRODUCT", 21, 24], ["EDN peptide hormones", "GENE_OR_GENE_PRODUCT", 29, 49], ["body", "ORGANISM_SUBDIVISION", 102, 106], ["vascular smooth muscle", "TISSUE", 113, 135], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["fluid", "ORGANISM_SUBSTANCE", 165, 170], ["AGT", "PROTEIN", 21, 24], ["Aldosterone", "TREATMENT", 0, 11], ["the AGT and EDN peptide hormones", "TREATMENT", 17, 49], ["blood pressure", "TEST", 149, 163], ["fluid and electrolyte homeostasis", "TEST", 165, 198], ["physiological processes", "OBSERVATION", 71, 94], ["body", "ANATOMY_MODIFIER", 102, 106], ["vascular", "ANATOMY", 113, 121], ["smooth muscle", "ANATOMY", 122, 135], ["pressure", "OBSERVATION_MODIFIER", 155, 163], ["fluid", "OBSERVATION", 165, 170]]], ["All processes that are important for proper functioning of the vascular system, heart muscles and kidneys.", [["vascular system", "ANATOMY", 63, 78], ["heart muscles", "ANATOMY", 80, 93], ["kidneys", "ANATOMY", 98, 105], ["vascular system", "MULTI-TISSUE_STRUCTURE", 63, 78], ["heart muscles", "MULTI-TISSUE_STRUCTURE", 80, 93], ["kidneys", "ORGAN", 98, 105], ["vascular system", "ANATOMY", 63, 78], ["heart muscles", "ANATOMY", 80, 93], ["kidneys", "ANATOMY", 98, 105]]], ["CTF1 is directly involved in the pathology of numerous cardiovascular diseases by promoting cardiac myocyte hypertrophy (41: Wollert et al. 1996) , which may lead to the onset of heart-diseases like \"hypertrophic cardiomyopathy\" or \"dilated cardiomyopathy\", and eventually, to (lethal) heart failure.", [["cardiovascular", "ANATOMY", 55, 69], ["cardiac myocyte", "ANATOMY", 92, 107], ["heart", "ANATOMY", 179, 184], ["heart", "ANATOMY", 286, 291], ["cardiovascular diseases", "DISEASE", 55, 78], ["cardiac myocyte hypertrophy", "DISEASE", 92, 119], ["heart-diseases", "DISEASE", 179, 193], ["hypertrophic cardiomyopathy", "DISEASE", 200, 227], ["dilated cardiomyopathy", "DISEASE", 233, 255], ["heart failure", "DISEASE", 286, 299], ["CTF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["cardiovascular", "ANATOMICAL_SYSTEM", 55, 69], ["cardiac myocyte", "CELL", 92, 107], ["heart", "ORGAN", 179, 184], ["heart", "ORGAN", 286, 291], ["CTF1", "PROTEIN", 0, 4], ["numerous cardiovascular diseases", "PROBLEM", 46, 78], ["promoting cardiac myocyte hypertrophy", "PROBLEM", 82, 119], ["heart-diseases", "PROBLEM", 179, 193], ["\"hypertrophic cardiomyopathy", "PROBLEM", 199, 227], ["\"dilated cardiomyopathy", "PROBLEM", 232, 255], ["heart failure", "PROBLEM", 286, 299], ["numerous", "OBSERVATION_MODIFIER", 46, 54], ["cardiovascular diseases", "OBSERVATION", 55, 78], ["cardiac myocyte", "ANATOMY", 92, 107], ["hypertrophy", "OBSERVATION", 108, 119], ["heart", "ANATOMY", 179, 184], ["diseases", "OBSERVATION", 185, 193], ["hypertrophic", "OBSERVATION_MODIFIER", 200, 212], ["cardiomyopathy", "OBSERVATION", 213, 227], ["dilated", "OBSERVATION_MODIFIER", 233, 240], ["cardiomyopathy", "OBSERVATION", 241, 255], ["heart", "ANATOMY", 286, 291], ["failure", "OBSERVATION", 292, 299]]], ["PEDV induced a strong down-or up-regulation of several other genes directly involved in the function of cardiomyocytes.", [["cardiomyocytes", "ANATOMY", 104, 118], ["PEDV", "CHEMICAL", 0, 4], ["PEDV", "CHEMICAL", 0, 4], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["cardiomyocytes", "CELL", 104, 118], ["cardiomyocytes", "CELL_TYPE", 104, 118], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["cardiomyocytes", "PROBLEM", 104, 118], ["strong", "OBSERVATION_MODIFIER", 15, 21], ["cardiomyocytes", "ANATOMY", 104, 118]]], ["Sodium voltage-gated channel subunit 4 (SCN4B) was strongly upregulated (15-fold) and MYLK2 (see above), Citrate Synthase (CS; down-regulation 24-fold) and Ankyrin Repeat Domain 1 (ANKRD1) were strongly down-regulated.", [["Sodium", "CHEMICAL", 0, 6], ["Citrate", "CHEMICAL", 105, 112], ["Sodium", "CHEMICAL", 0, 6], ["Citrate", "CHEMICAL", 105, 112], ["Sodium voltage-gated channel subunit 4", "GENE_OR_GENE_PRODUCT", 0, 38], ["SCN4B", "GENE_OR_GENE_PRODUCT", 40, 45], ["MYLK2", "GENE_OR_GENE_PRODUCT", 86, 91], ["Citrate Synthase", "GENE_OR_GENE_PRODUCT", 105, 121], ["CS", "GENE_OR_GENE_PRODUCT", 123, 125], ["Ankyrin Repeat Domain 1", "GENE_OR_GENE_PRODUCT", 156, 179], ["ANKRD1", "GENE_OR_GENE_PRODUCT", 181, 187], ["Sodium voltage-gated channel subunit 4", "PROTEIN", 0, 38], ["SCN4B", "PROTEIN", 40, 45], ["MYLK2", "PROTEIN", 86, 91], ["Citrate Synthase", "PROTEIN", 105, 121], ["CS", "PROTEIN", 123, 125], ["Ankyrin Repeat Domain 1", "PROTEIN", 156, 179], ["ANKRD1", "PROTEIN", 181, 187], ["Sodium voltage", "TEST", 0, 14], ["gated channel subunit", "TEST", 15, 36], ["MYLK2", "TEST", 86, 91], ["Citrate Synthase", "TREATMENT", 105, 121], ["CS", "TEST", 123, 125], ["Ankyrin Repeat Domain", "TREATMENT", 156, 177], ["ANKRD1", "TEST", 181, 187]]], ["Down-regulation of CS may reduce oxidative capacity in cardiomyocytes.", [["cardiomyocytes", "ANATOMY", 55, 69], ["CS", "SIMPLE_CHEMICAL", 19, 21], ["cardiomyocytes", "CELL", 55, 69], ["cardiomyocytes", "CELL_TYPE", 55, 69], ["CS", "PROBLEM", 19, 21], ["oxidative capacity in cardiomyocytes", "PROBLEM", 33, 69], ["oxidative capacity", "OBSERVATION", 33, 51], ["cardiomyocytes", "ANATOMY", 55, 69]]], ["Gene expression of ANKRD1 was down-regulated 12-fold in response to MRV infection at 4 h.p.i, but reverted to a 24-fold up-regulation 2h later.", [["infection", "DISEASE", 72, 81], ["ANKRD1", "GENE_OR_GENE_PRODUCT", 19, 25], ["ANKRD1", "PROTEIN", 19, 25], ["ANKRD1", "TEST", 19, 25], ["MRV infection", "PROBLEM", 68, 81], ["infection", "OBSERVATION", 72, 81]]], ["ANKRD1 is a putative transcription factor involved in regulation of gene expression in hypertrophic myocytes (https://www.wikipathways.org/index.php/Pathway:WP516) Regulation of cytosolic calcium levels in the cytosol of cardiomyocytes, e.g. by binding of COL1A1 and COL2A (up-regulated by PEDV, see above) to integrin subunit alpha on the surface of cardiomyocytes or after import of calcium ions mediated by calcium voltage-gated channels (e.g. by CACNA1H; down-regulated 5-fold at 4h by PEDV) may also trigger myocyte hypertrophy.", [["hypertrophic myocytes", "ANATOMY", 87, 108], ["cytosolic", "ANATOMY", 178, 187], ["cytosol", "ANATOMY", 210, 217], ["cardiomyocytes", "ANATOMY", 221, 235], ["surface", "ANATOMY", 340, 347], ["cardiomyocytes", "ANATOMY", 351, 365], ["myocyte", "ANATOMY", 513, 520], ["calcium", "CHEMICAL", 188, 195], ["calcium", "CHEMICAL", 385, 392], ["calcium", "CHEMICAL", 410, 417], ["hypertrophy", "DISEASE", 521, 532], ["calcium", "CHEMICAL", 188, 195], ["calcium", "CHEMICAL", 385, 392], ["calcium", "CHEMICAL", 410, 417], ["ANKRD1", "GENE_OR_GENE_PRODUCT", 0, 6], ["hypertrophic myocytes", "CELL", 87, 108], ["cytosolic", "ORGANISM_SUBSTANCE", 178, 187], ["calcium", "SIMPLE_CHEMICAL", 188, 195], ["cytosol", "CELLULAR_COMPONENT", 210, 217], ["cardiomyocytes", "CELL", 221, 235], ["COL1A1", "GENE_OR_GENE_PRODUCT", 256, 262], ["COL2A", "GENE_OR_GENE_PRODUCT", 267, 272], ["PEDV", "GENE_OR_GENE_PRODUCT", 290, 294], ["integrin subunit alpha", "GENE_OR_GENE_PRODUCT", 310, 332], ["surface", "CELLULAR_COMPONENT", 340, 347], ["cardiomyocytes", "CELL", 351, 365], ["calcium ions", "SIMPLE_CHEMICAL", 385, 397], ["calcium", "SIMPLE_CHEMICAL", 410, 417], ["CACNA1H", "GENE_OR_GENE_PRODUCT", 450, 457], ["myocyte", "CELL", 513, 520], ["ANKRD1", "PROTEIN", 0, 6], ["transcription factor", "PROTEIN", 21, 41], ["hypertrophic myocytes", "CELL_TYPE", 87, 108], ["cardiomyocytes", "CELL_TYPE", 221, 235], ["COL1A1", "PROTEIN", 256, 262], ["COL2A", "PROTEIN", 267, 272], ["PEDV", "PROTEIN", 290, 294], ["integrin subunit alpha", "PROTEIN", 310, 332], ["cardiomyocytes", "CELL_TYPE", 351, 365], ["calcium voltage-gated channels", "PROTEIN", 410, 440], ["CACNA1H", "PROTEIN", 450, 457], ["PEDV", "PROTEIN", 490, 494], ["a putative transcription factor", "PROBLEM", 10, 41], ["hypertrophic myocytes", "PROBLEM", 87, 108], ["cytosolic calcium levels", "TEST", 178, 202], ["COL1A1", "PROBLEM", 256, 262], ["COL2A", "TEST", 267, 272], ["PEDV", "PROBLEM", 290, 294], ["cardiomyocytes", "PROBLEM", 351, 365], ["calcium ions", "TREATMENT", 385, 397], ["calcium voltage", "TEST", 410, 425], ["CACNA1H", "TEST", 450, 457], ["PEDV", "PROBLEM", 490, 494], ["myocyte hypertrophy", "PROBLEM", 513, 532], ["hypertrophic myocytes", "OBSERVATION", 87, 108], ["cytosolic calcium levels", "OBSERVATION", 178, 202], ["cardiomyocytes", "ANATOMY", 221, 235], ["cardiomyocytes", "ANATOMY", 351, 365], ["myocyte", "ANATOMY", 513, 520], ["hypertrophy", "OBSERVATION", 521, 532]]], ["PEDV strongly down-regulated gene expression of a potassium voltage-gated channel (KCNQ4;16-fold).", [["PEDV", "CHEMICAL", 0, 4], ["potassium", "CHEMICAL", 50, 59], ["potassium", "CHEMICAL", 50, 59], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["potassium", "SIMPLE_CHEMICAL", 50, 59], ["PEDV", "PROTEIN", 0, 4], ["potassium voltage-gated channel", "PROTEIN", 50, 81], ["KCNQ4", "PROTEIN", 83, 88], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["a potassium voltage", "TEST", 48, 67], ["KCNQ4", "TEST", 83, 88]]], ["This in contrast to a strong up-regulation of the sodium symporter SCN4B.", [["sodium", "CHEMICAL", 50, 56], ["sodium", "CHEMICAL", 50, 56], ["sodium symporter SCN4B", "GENE_OR_GENE_PRODUCT", 50, 72], ["sodium symporter", "PROTEIN", 50, 66], ["SCN4B", "PROTEIN", 67, 72]]], ["For the potassium channel CACNA1H (alias Kv7.4) it was reported that this channel regulates the membrane potential and Ca 2+ permeability of mitochondria located in the vicinity the sarcoplasmic reticulum in rat cardiomyocytes (45: Testai et al. 2016).", [["membrane", "ANATOMY", 96, 104], ["mitochondria", "ANATOMY", 141, 153], ["sarcoplasmic reticulum", "ANATOMY", 182, 204], ["cardiomyocytes", "ANATOMY", 212, 226], ["potassium", "CHEMICAL", 8, 17], ["Ca", "CHEMICAL", 119, 121], ["potassium", "CHEMICAL", 8, 17], ["Ca 2+", "CHEMICAL", 119, 124], ["potassium", "SIMPLE_CHEMICAL", 8, 17], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["mitochondria", "CELLULAR_COMPONENT", 141, 153], ["sarcoplasmic reticulum", "CELLULAR_COMPONENT", 182, 204], ["rat", "ORGANISM", 208, 211], ["cardiomyocytes", "CELL", 212, 226], ["potassium channel CACNA1H", "PROTEIN", 8, 33], ["alias Kv7.4", "PROTEIN", 35, 46], ["rat cardiomyocytes", "CELL_TYPE", 208, 226], ["rat", "SPECIES", 208, 211], ["the potassium channel CACNA1H", "TREATMENT", 4, 33], ["Ca", "TEST", 119, 121], ["permeability of mitochondria", "PROBLEM", 125, 153], ["sarcoplasmic reticulum", "ANATOMY", 182, 204], ["rat cardiomyocytes", "ANATOMY", 208, 226]]], ["All three above mentioned ion channels are also involved in the process of excitation, contraction/relaxation and repolarization of cardiac myocytes.", [["cardiac myocytes", "ANATOMY", 132, 148], ["cardiac myocytes", "CELL", 132, 148], ["ion channels", "PROTEIN", 26, 38], ["cardiac myocytes", "CELL_TYPE", 132, 148], ["contraction/relaxation", "TREATMENT", 87, 109], ["repolarization of cardiac myocytes", "PROBLEM", 114, 148], ["cardiac myocytes", "ANATOMY", 132, 148]]], ["MRV also downregulated gene expression 3 to 4-fold for the potassium (KCNQ4) and calcium channel CACNA1H, but did not increased expression of the sodium symporter gene SCN4B or orthologs of this gene.Obesity/DiabeticChronic hypertension and heart disease/failure is a complication frequently observed in obese/diabetic patients.", [["heart", "ANATOMY", 241, 246], ["potassium", "CHEMICAL", 59, 68], ["calcium", "CHEMICAL", 81, 88], ["sodium", "CHEMICAL", 146, 152], ["Obesity", "DISEASE", 200, 207], ["DiabeticChronic hypertension", "DISEASE", 208, 236], ["heart disease", "DISEASE", 241, 254], ["diabetic", "DISEASE", 310, 318], ["potassium", "CHEMICAL", 59, 68], ["calcium", "CHEMICAL", 81, 88], ["sodium", "CHEMICAL", 146, 152], ["potassium", "SIMPLE_CHEMICAL", 59, 68], ["KCNQ4", "GENE_OR_GENE_PRODUCT", 70, 75], ["calcium", "SIMPLE_CHEMICAL", 81, 88], ["CACNA1H", "GENE_OR_GENE_PRODUCT", 97, 104], ["sodium symporter", "GENE_OR_GENE_PRODUCT", 146, 162], ["SCN4B", "GENE_OR_GENE_PRODUCT", 168, 173], ["heart", "ORGAN", 241, 246], ["patients", "ORGANISM", 319, 327], ["KCNQ4", "PROTEIN", 70, 75], ["calcium channel CACNA1H", "PROTEIN", 81, 104], ["sodium symporter gene", "DNA", 146, 167], ["SCN4B", "DNA", 168, 173], ["patients", "SPECIES", 319, 327], ["MRV", "TEST", 0, 3], ["the potassium", "TEST", 55, 68], ["calcium channel CACNA1H", "TEST", 81, 104], ["Obesity", "PROBLEM", 200, 207], ["DiabeticChronic hypertension", "PROBLEM", 208, 236], ["heart disease", "PROBLEM", 241, 254], ["failure", "PROBLEM", 255, 262], ["a complication", "PROBLEM", 266, 280], ["obese/diabetic patients", "PROBLEM", 304, 327], ["hypertension", "OBSERVATION", 224, 236], ["heart", "ANATOMY", 241, 246], ["disease", "OBSERVATION", 247, 254], ["failure", "OBSERVATION", 255, 262], ["diabetic", "OBSERVATION", 310, 318]]], ["In accordance with this, 16 out of the 65 PEDV DEGs matching the term \"Obesity\" also matched with the term \"Cardiomyopathy\" (see Additional remarkable PEDV-DEGs.Obesity/DiabeticHighly up-or down-regulated PEDV-DEGs not mentioned in the text, and to our opinion interesting with regard to coronavirus infection, are briefly described in Table 2 .", [["Obesity", "DISEASE", 71, 78], ["Cardiomyopathy", "DISEASE", 108, 122], ["Obesity", "DISEASE", 161, 168], ["coronavirus infection", "DISEASE", 288, 309], ["PEDV", "GENE_OR_GENE_PRODUCT", 205, 209], ["coronavirus", "ORGANISM", 288, 299], ["PEDV DEGs", "DNA", 42, 51], ["PEDV", "PROTEIN", 205, 209], ["DEGs", "DNA", 210, 214], ["Obesity", "PROBLEM", 71, 78], ["the term \"Cardiomyopathy", "PROBLEM", 98, 122], ["Obesity", "PROBLEM", 161, 168], ["DiabeticHighly", "PROBLEM", 169, 183], ["coronavirus infection", "PROBLEM", 288, 309], ["infection", "OBSERVATION", 300, 309]]], ["Among these DEGs several genes coding for transcription factors and genes transcribed in antisense RNA's that inhibit translation of their coding counterparts.Obesity/DiabeticFor more functional information about these DEGs we refer to the weblinks provided in supplementary file 3, sheet \"PEDV KEY DEGs\".", [["Obesity", "DISEASE", 159, 166], ["Diabetic", "DISEASE", 167, 175], ["DEGs", "DNA", 12, 16], ["transcription factors", "PROTEIN", 42, 63], ["antisense RNA", "RNA", 89, 102], ["transcription factors", "TREATMENT", 42, 63], ["antisense RNA's", "TREATMENT", 89, 104], ["Obesity", "PROBLEM", 159, 166], ["Diabetic", "PROBLEM", 167, 175], ["Diabetic", "OBSERVATION", 167, 175]]], ["Remarkable PEDV-DEGS not mentioned in the text.Discussion.In this report we measured the transcriptional response of Vero cells shortly after infection with the coronavirus PEDV.", [["Vero cells", "ANATOMY", 117, 127], ["infection", "DISEASE", 142, 151], ["Vero cells", "CELL", 117, 127], ["coronavirus", "ORGANISM", 161, 172], ["PEDV", "DNA", 11, 15], ["DEGS", "DNA", 16, 20], ["Vero cells", "CELL_LINE", 117, 127], ["coronavirus", "SPECIES", 161, 172], ["coronavirus PEDV", "SPECIES", 161, 177], ["Vero cells", "PROBLEM", 117, 127], ["infection", "PROBLEM", 142, 151], ["the coronavirus PEDV", "PROBLEM", 157, 177], ["PEDV", "OBSERVATION", 11, 15], ["Vero cells", "OBSERVATION", 117, 127], ["coronavirus PEDV", "OBSERVATION", 161, 177]]], ["The function of the responding host genes and the biological processes in which they act were studied in detail by us to find plausible relations to COVID-19 pathology.", [["responding host genes", "DNA", 20, 41], ["COVID", "TEST", 149, 154]]], ["Because of the differences in genomic organization and expression of viral proteins between SARS-CoV-2 and PEDV, we paid less attention to couple the response of specific host genes to the function of specific coronavirus proteins.", [["SARS-CoV-2", "ORGANISM", 92, 102], ["PEDV", "CELL", 107, 111], ["coronavirus", "ORGANISM", 210, 221], ["viral proteins", "PROTEIN", 69, 83], ["coronavirus proteins", "PROTEIN", 210, 230], ["SARS-CoV", "SPECIES", 92, 100], ["PEDV", "SPECIES", 107, 111], ["viral proteins", "PROBLEM", 69, 83], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["PEDV", "PROBLEM", 107, 111], ["specific coronavirus proteins", "PROBLEM", 201, 230], ["viral proteins", "OBSERVATION", 69, 83]]], ["We were able to infect the majority of Vero cells (>50%) with PEDV and MRV synchronically.", [["Vero cells", "ANATOMY", 39, 49], ["Vero cells", "CELL", 39, 49], ["Vero cells", "CELL_LINE", 39, 49], ["PEDV", "SPECIES", 62, 66], ["Vero cells", "TEST", 39, 49], ["PEDV", "PROBLEM", 62, 66], ["MRV", "TEST", 71, 74], ["Vero cells", "OBSERVATION", 39, 49]]], ["This resulted in a unique set of highly up-and down-regulated DEGs for PEDV.", [["PEDV", "GENE_OR_GENE_PRODUCT", 71, 75], ["DEGs", "DNA", 62, 66], ["PEDV", "PROTEIN", 71, 75], ["PEDV", "SPECIES", 71, 75], ["PEDV", "PROBLEM", 71, 75]]], ["Not more than 14% of the 266 PEDV-DEGs (n=37) were similar to MRV-DEGS (total of 727 MRV-DEGs).", [["MRV", "DNA", 62, 65], ["DEGS", "DNA", 66, 70], ["PEDV-DEGs", "TEST", 29, 38], ["MRV", "TEST", 62, 65], ["DEGS", "TEST", 66, 70], ["MRV", "TEST", 85, 88]]], ["In contrast to MRV, we observed no typical response of antiviral genes and related cytokine/chemokine genes in Vero cells within 6 h.p.i. for PEDV.", [["Vero cells", "ANATOMY", 111, 121], ["Vero cells", "CELL", 111, 121], ["antiviral genes", "DNA", 55, 70], ["cytokine/chemokine genes", "DNA", 83, 107], ["Vero cells", "CELL_LINE", 111, 121], ["PEDV", "SPECIES", 142, 146], ["MRV", "TEST", 15, 18], ["antiviral genes", "PROBLEM", 55, 70], ["cytokine/chemokine genes", "TREATMENT", 83, 107], ["Vero cells", "PROBLEM", 111, 121], ["PEDV", "PROBLEM", 142, 146], ["antiviral genes", "OBSERVATION", 55, 70]]], ["For MRV these processes started already before 4 h.p.i..", [["MRV", "TEST", 4, 7]]], ["We have to notice that PEDV replication started 2h later than MRV3 replication, which could in part be the reason for not detecting transcriptional regulation of specific cytokine, chemokine and antiviral genes for PEDV.", [["PEDV", "SIMPLE_CHEMICAL", 23, 27], ["PEDV", "GENE_OR_GENE_PRODUCT", 215, 219], ["cytokine", "PROTEIN", 171, 179], ["chemokine", "PROTEIN", 181, 190], ["antiviral genes", "DNA", 195, 210], ["PEDV", "PROTEIN", 215, 219], ["PEDV", "SPECIES", 23, 27], ["MRV3", "SPECIES", 62, 66], ["PEDV", "SPECIES", 215, 219], ["PEDV replication", "TREATMENT", 23, 39], ["MRV3 replication", "TREATMENT", 62, 78], ["specific cytokine", "TREATMENT", 162, 179], ["chemokine and antiviral genes", "TREATMENT", 181, 210], ["PEDV", "PROBLEM", 215, 219]]], ["Longer incubation times than 6h were not planned in the original design of our experiments and would have resulted in a set of PEDV-DEGs dominated by genes involved in syncytia forming and apoptotic/necrotic cell death.", [["syncytia", "ANATOMY", 168, 176], ["cell", "ANATOMY", 208, 212], ["necrotic", "DISEASE", 199, 207], ["death", "DISEASE", 213, 218], ["syncytia", "CELL", 168, 176], ["necrotic cell", "CELL", 199, 212], ["PEDV-DEGs", "DNA", 127, 136], ["PEDV", "PROBLEM", 127, 131], ["syncytia forming", "PROBLEM", 168, 184], ["apoptotic/necrotic cell death", "PROBLEM", 189, 218], ["necrotic cell death", "OBSERVATION", 199, 218]]], ["Nevertheless, at 6h replication of PEDV RNA was detected by RT-PCR, indicating that dsRNA was present in the cells and could have be sensed by cytosolic pattern recognition receptors of the RIG-I-like family to initiate an antiviral and related cytokine/chemokine response.", [["cells", "ANATOMY", 109, 114], ["cytosolic", "ANATOMY", 143, 152], ["PEDV", "GENE_OR_GENE_PRODUCT", 35, 39], ["cells", "CELL", 109, 114], ["RIG-I", "GENE_OR_GENE_PRODUCT", 190, 195], ["PEDV RNA", "RNA", 35, 43], ["cytosolic pattern recognition receptors", "PROTEIN", 143, 182], ["RIG-I-like family", "PROTEIN", 190, 207], ["cytokine", "PROTEIN", 245, 253], ["chemokine", "PROTEIN", 254, 263], ["PEDV", "SPECIES", 35, 39], ["PEDV RNA", "PROBLEM", 35, 43], ["RT-PCR", "TEST", 60, 66], ["dsRNA", "PROBLEM", 84, 89], ["an antiviral", "TREATMENT", 220, 232], ["related cytokine/chemokine response", "TREATMENT", 237, 272], ["dsRNA", "OBSERVATION", 84, 89]]], ["Similar as observed in another study with PEDV and Vero cells, and in analogy with SARS-CoV-1 and -2, we observed a high up-regulation of the transmembrane serine protease gene (TMPRSS13) that acts as a co-factor in the infection process of cells ( We observed a reduced expression of EEF1A1, as part of a transcription factor-complex that binds and activates the promotor of IFN\u03b3, and of the cytokine EDA and its receptor (EDARADD) involved in activation of canonical-NFKB transcription of antiviral cytokine-chemokine genes like CXCL8 (alias IL8) an CXCL10.", [["Vero cells", "ANATOMY", 51, 61], ["cells", "ANATOMY", 241, 246], ["infection", "DISEASE", 220, 229], ["serine", "CHEMICAL", 156, 162], ["PEDV", "CELL", 42, 46], ["Vero cells", "CELL", 51, 61], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 83, 93], ["-2", "GENE_OR_GENE_PRODUCT", 98, 100], ["transmembrane", "CELLULAR_COMPONENT", 142, 155], ["TMPRSS13", "GENE_OR_GENE_PRODUCT", 178, 186], ["cells", "CELL", 241, 246], ["EEF1A1", "GENE_OR_GENE_PRODUCT", 285, 291], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 376, 380], ["EDA", "GENE_OR_GENE_PRODUCT", 402, 405], ["EDARADD", "GENE_OR_GENE_PRODUCT", 424, 431], ["NFKB", "GENE_OR_GENE_PRODUCT", 469, 473], ["CXCL8", "GENE_OR_GENE_PRODUCT", 531, 536], ["IL8", "GENE_OR_GENE_PRODUCT", 544, 547], ["CXCL10", "GENE_OR_GENE_PRODUCT", 552, 558], ["PEDV and Vero cells", "CELL_LINE", 42, 61], ["transmembrane serine protease gene", "DNA", 142, 176], ["TMPRSS13", "DNA", 178, 186], ["EEF1A1", "PROTEIN", 285, 291], ["transcription factor", "PROTEIN", 306, 326], ["IFN\u03b3", "PROTEIN", 376, 380], ["cytokine", "PROTEIN", 393, 401], ["EDA", "PROTEIN", 402, 405], ["EDARADD", "PROTEIN", 424, 431], ["NFKB", "PROTEIN", 469, 473], ["antiviral cytokine-chemokine genes", "DNA", 491, 525], ["CXCL8", "PROTEIN", 531, 536], ["IL8", "DNA", 544, 547], ["CXCL10", "PROTEIN", 552, 558], ["PEDV", "SPECIES", 42, 46], ["SARS-CoV", "SPECIES", 83, 91], ["another study", "TEST", 23, 36], ["PEDV", "PROBLEM", 42, 46], ["Vero cells", "PROBLEM", 51, 61], ["SARS-CoV", "TEST", 83, 91], ["the transmembrane serine protease gene", "TREATMENT", 138, 176], ["a co-factor in the infection process of cells", "PROBLEM", 201, 246], ["a reduced expression of EEF1A1", "PROBLEM", 261, 291], ["the cytokine EDA", "TREATMENT", 389, 405], ["canonical-NFKB transcription", "TREATMENT", 459, 487], ["antiviral cytokine", "TREATMENT", 491, 509], ["chemokine genes", "TREATMENT", 510, 525], ["an CXCL10", "TEST", 549, 558], ["Vero cells", "OBSERVATION", 51, 61], ["infection", "OBSERVATION", 220, 229]]], ["This reduced expression of EEF1A1 and EDA and its receptor may play a crucial role in delaying or downgrading an IFN-mediated antiviral and cytokine/chemokine response in our Vero cell system.", [["Vero cell system", "ANATOMY", 175, 191], ["EEF1A1", "GENE_OR_GENE_PRODUCT", 27, 33], ["EDA", "GENE_OR_GENE_PRODUCT", 38, 41], ["IFN", "GENE_OR_GENE_PRODUCT", 113, 116], ["Vero cell", "CELL", 175, 184], ["EEF1A1", "PROTEIN", 27, 33], ["EDA", "PROTEIN", 38, 41], ["IFN", "PROTEIN", 113, 116], ["cytokine", "PROTEIN", 140, 148], ["chemokine", "PROTEIN", 149, 158], ["EEF1A1 and EDA", "TREATMENT", 27, 41], ["an IFN-mediated antiviral", "TREATMENT", 110, 135], ["cytokine/chemokine response", "TREATMENT", 140, 167], ["Vero cell", "OBSERVATION", 175, 184]]], ["The elevated transcription of many cytokine and chemokine genes in Vero cells by MRV suggests that replication of this RNA virus in epithelial cells induces secretion of these immune effectors (more information about the genes/processes that responded to MRV infection will be published elsewhere).", [["Vero cells", "ANATOMY", 67, 77], ["epithelial cells", "ANATOMY", 132, 148], ["MRV infection", "DISEASE", 255, 268], ["Vero cells", "CELL", 67, 77], ["epithelial cells", "CELL", 132, 148], ["cytokine and chemokine genes", "DNA", 35, 63], ["Vero cells", "CELL_LINE", 67, 77], ["epithelial cells", "CELL_TYPE", 132, 148], ["immune effectors", "PROTEIN", 176, 192], ["The elevated transcription", "PROBLEM", 0, 26], ["many cytokine and chemokine genes in Vero cells", "PROBLEM", 30, 77], ["MRV", "TEST", 81, 84], ["this RNA virus", "PROBLEM", 114, 128], ["epithelial cells", "PROBLEM", 132, 148], ["these immune effectors", "PROBLEM", 170, 192], ["the genes/processes", "PROBLEM", 217, 236], ["MRV infection", "PROBLEM", 255, 268], ["elevated", "OBSERVATION", 4, 12], ["epithelial cells", "OBSERVATION", 132, 148]]], ["PEDV, and also the MRV3 strain we used both replicate in enterocytes lined up in the intestinal mucosal layer.Discussion.In the intestinal and bronchial epithelial layer, microfold (M) cells are imbedded between these lined up epithelial cells.", [["enterocytes", "ANATOMY", 57, 68], ["intestinal mucosal layer", "ANATOMY", 85, 109], ["intestinal", "ANATOMY", 128, 138], ["bronchial epithelial layer", "ANATOMY", 143, 169], ["microfold (M) cells", "ANATOMY", 171, 190], ["epithelial cells", "ANATOMY", 227, 243], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["MRV3", "GENE_OR_GENE_PRODUCT", 19, 23], ["enterocytes", "CELL", 57, 68], ["intestinal mucosal layer", "CANCER", 85, 109], ["intestinal", "ORGAN", 128, 138], ["bronchial epithelial layer", "TISSUE", 143, 169], ["microfold (M) cells", "CELL", 171, 190], ["epithelial cells", "CELL", 227, 243], ["microfold (M) cells", "CELL_LINE", 171, 190], ["lined up epithelial cells", "CELL_TYPE", 218, 243], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["the MRV3 strain", "TREATMENT", 15, 30], ["enterocytes", "ANATOMY", 57, 68], ["intestinal mucosal", "ANATOMY", 85, 103], ["layer", "ANATOMY_MODIFIER", 104, 109], ["intestinal", "ANATOMY", 128, 138], ["bronchial epithelial", "ANATOMY", 143, 163], ["layer", "ANATOMY_MODIFIER", 164, 169], ["epithelial cells", "OBSERVATION", 227, 243]]], ["M-cells sense and engulf foreign pathogens/antigens from the lumen to present them to residing immune cells.Discussion.According to pathway analysis, most T cell related immune genes regulated in response to MRV infection were part of the pathways \"T-helper 17 (Th17) differentiation/activation\" and \"IL17 signaling\".", [["M-cells", "ANATOMY", 0, 7], ["lumen", "ANATOMY", 61, 66], ["immune cells", "ANATOMY", 95, 107], ["T cell", "ANATOMY", 155, 161], ["infection", "DISEASE", 212, 221], ["M-cells", "CELL", 0, 7], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 66], ["immune cells", "CELL", 95, 107], ["T cell", "CELL", 155, 161], ["T-helper 17", "GENE_OR_GENE_PRODUCT", 249, 260], ["Th17", "GENE_OR_GENE_PRODUCT", 262, 266], ["IL17", "GENE_OR_GENE_PRODUCT", 301, 305], ["M-cells", "CELL_LINE", 0, 7], ["antigens", "PROTEIN", 43, 51], ["immune cells", "CELL_TYPE", 95, 107], ["immune genes", "DNA", 170, 182], ["IL17", "PROTEIN", 301, 305], ["cells sense", "PROBLEM", 2, 13], ["engulf foreign pathogens/antigens", "PROBLEM", 18, 51], ["the lumen", "TREATMENT", 57, 66], ["pathway analysis", "TEST", 132, 148], ["most T cell related immune genes", "PROBLEM", 150, 182], ["MRV infection", "PROBLEM", 208, 221], ["engulf", "OBSERVATION_MODIFIER", 18, 24], ["foreign pathogens", "OBSERVATION", 25, 42], ["lumen", "ANATOMY", 61, 66], ["immune cells", "OBSERVATION", 95, 107], ["infection", "OBSERVATION", 212, 221]]], ["Antigen presentation by M cells to Th17 cells in the submucosal layers stimulate secretion of different types of IL17 cytokines (IL17A-D, IL25 and Il17F) resulting in activation of different types of innate immune cells and T cells, including Th1/Th2 cells.", [["M cells", "ANATOMY", 24, 31], ["Th17 cells", "ANATOMY", 35, 45], ["submucosal layers", "ANATOMY", 53, 70], ["immune cells", "ANATOMY", 207, 219], ["T cells", "ANATOMY", 224, 231], ["Th1/Th2 cells", "ANATOMY", 243, 256], ["M cells", "CELL", 24, 31], ["Th17 cells", "CELL", 35, 45], ["submucosal layers", "TISSUE", 53, 70], ["IL17", "GENE_OR_GENE_PRODUCT", 113, 117], ["IL17A-D", "GENE_OR_GENE_PRODUCT", 129, 136], ["IL25", "GENE_OR_GENE_PRODUCT", 138, 142], ["Il17F", "GENE_OR_GENE_PRODUCT", 147, 152], ["innate immune cells", "CELL", 200, 219], ["T cells", "CELL", 224, 231], ["Th2 cells", "CELL", 247, 256], ["M cells", "CELL_TYPE", 24, 31], ["Th17 cells", "CELL_TYPE", 35, 45], ["IL17 cytokines", "PROTEIN", 113, 127], ["IL17A", "PROTEIN", 129, 134], ["D", "PROTEIN", 135, 136], ["IL25", "PROTEIN", 138, 142], ["Il17F", "PROTEIN", 147, 152], ["innate immune cells", "CELL_TYPE", 200, 219], ["T cells", "CELL_TYPE", 224, 231], ["Th1/Th2 cells", "CELL_TYPE", 243, 256], ["Th17 cells", "PROBLEM", 35, 45], ["IL17 cytokines", "TREATMENT", 113, 127], ["IL17A", "TEST", 129, 134], ["IL25", "TEST", 138, 142], ["innate immune cells", "PROBLEM", 200, 219], ["T cells", "PROBLEM", 224, 231], ["Th1/Th2 cells", "PROBLEM", 243, 256], ["Th17 cells", "OBSERVATION", 35, 45], ["submucosal", "ANATOMY", 53, 63], ["layers", "ANATOMY_MODIFIER", 64, 70], ["different types", "OBSERVATION_MODIFIER", 94, 109], ["different types", "OBSERVATION_MODIFIER", 181, 196], ["innate immune cells", "OBSERVATION", 200, 219], ["Th2 cells", "OBSERVATION", 247, 256]]], ["Dysregulation of this pathogen-induced IL17 response may disturb the balance between Th1/Th2-cell mediated immune responses, resulting in excessive inflammation, damage to the epithelial layer and on the long term, to autoimmune reactions.", [["Th2-cell", "ANATOMY", 89, 97], ["epithelial layer", "ANATOMY", 176, 192], ["inflammation", "DISEASE", 148, 160], ["autoimmune reactions", "DISEASE", 218, 238], ["IL17", "GENE_OR_GENE_PRODUCT", 39, 43], ["Th1", "GENE_OR_GENE_PRODUCT", 85, 88], ["cell", "CELL", 93, 97], ["epithelial layer", "TISSUE", 176, 192], ["IL17", "PROTEIN", 39, 43], ["this pathogen", "PROBLEM", 17, 30], ["excessive inflammation", "PROBLEM", 138, 160], ["damage to the epithelial layer", "PROBLEM", 162, 192], ["autoimmune reactions", "PROBLEM", 218, 238], ["excessive", "OBSERVATION_MODIFIER", 138, 147], ["inflammation", "OBSERVATION", 148, 160], ["epithelial", "ANATOMY_MODIFIER", 176, 186], ["layer", "OBSERVATION_MODIFIER", 187, 192], ["long term", "OBSERVATION_MODIFIER", 204, 213]]], ["TF RORC (or specific isoforms of this TF, see above) plays a pivotal in controlling IL17 expression and secretion by Th17 cells.", [["Th17 cells", "ANATOMY", 117, 127], ["TF RORC", "GENE_OR_GENE_PRODUCT", 0, 7], ["TF", "GENE_OR_GENE_PRODUCT", 38, 40], ["IL17", "GENE_OR_GENE_PRODUCT", 84, 88], ["Th17 cells", "CELL", 117, 127], ["TF", "PROTEIN", 0, 2], ["RORC", "PROTEIN", 3, 7], ["TF", "PROTEIN", 38, 40], ["IL17", "PROTEIN", 84, 88], ["Th17 cells", "CELL_TYPE", 117, 127], ["this TF", "TREATMENT", 33, 40], ["RORC", "OBSERVATION", 3, 7], ["Th17 cells", "OBSERVATION", 117, 127]]], ["PEDV strongly up-regulated gene expression of RORC in Vero cells whereas MRV down-regulated expression of this TF.", [["Vero cells", "ANATOMY", 54, 64], ["PEDV", "CHEMICAL", 0, 4], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["RORC", "GENE_OR_GENE_PRODUCT", 46, 50], ["Vero cells", "CELL", 54, 64], ["TF", "GENE_OR_GENE_PRODUCT", 111, 113], ["PEDV", "PROTEIN", 0, 4], ["RORC", "PROTEIN", 46, 50], ["Vero cells", "CELL_LINE", 54, 64], ["TF", "PROTEIN", 111, 113], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["RORC in Vero cells", "PROBLEM", 46, 64], ["MRV", "TEST", 73, 76], ["this TF", "TREATMENT", 106, 113], ["RORC", "ANATOMY", 46, 50]]], ["This difference in regulation of TF RORC suggests that virus-induced activation or suppression of IL17 secretion by Th17 cells in submucosal layers of airway epithelium can be an important mechanism to dysregulate the activation of T cell responses.", [["Th17 cells", "ANATOMY", 116, 126], ["submucosal layers", "ANATOMY", 130, 147], ["airway epithelium", "ANATOMY", 151, 168], ["T cell", "ANATOMY", 232, 238], ["TF RORC", "GENE_OR_GENE_PRODUCT", 33, 40], ["IL17", "GENE_OR_GENE_PRODUCT", 98, 102], ["Th17 cells", "CELL", 116, 126], ["submucosal layers", "TISSUE", 130, 147], ["airway epithelium", "TISSUE", 151, 168], ["T cell", "CELL", 232, 238], ["TF RORC", "PROTEIN", 33, 40], ["IL17", "PROTEIN", 98, 102], ["Th17 cells", "CELL_TYPE", 116, 126], ["TF RORC", "TEST", 33, 40], ["virus", "PROBLEM", 55, 60], ["IL17 secretion", "PROBLEM", 98, 112], ["Th17 cells", "PROBLEM", 116, 126], ["submucosal layers of airway epithelium", "PROBLEM", 130, 168], ["TF RORC", "OBSERVATION", 33, 40], ["virus", "OBSERVATION", 55, 60], ["Th17 cells", "OBSERVATION", 116, 126], ["submucosal", "ANATOMY_MODIFIER", 130, 140], ["layers", "ANATOMY_MODIFIER", 141, 147], ["airway", "ANATOMY", 151, 157], ["epithelium", "ANATOMY_MODIFIER", 158, 168]]], ["Therefore, TF RORC might be a potential target for drug treatment/development.", [["TF RORC", "GENE_OR_GENE_PRODUCT", 11, 18], ["TF", "PROTEIN", 11, 13], ["RORC", "PROTEIN", 14, 18], ["TF RORC", "TREATMENT", 11, 18], ["drug treatment", "TREATMENT", 51, 65], ["TF RORC", "OBSERVATION", 11, 18]]], ["Drugs affecting expression of RORC, like the fluorinated steroid \"Dexamethasone\" and the synthetic tetracycline derivative \"Doxycycline\" (http://ctdbase.org/basicQuery.go?bqCat=gene&bq=RAR+related+orphan+receptor +C) are already under investigation in relation to SARS-CoV-2 pathogenesis.", [["steroid", "CHEMICAL", 57, 64], ["Dexamethasone", "CHEMICAL", 66, 79], ["tetracycline", "CHEMICAL", 99, 111], ["Doxycycline", "CHEMICAL", 124, 135], ["steroid", "CHEMICAL", 57, 64], ["Dexamethasone", "CHEMICAL", 66, 79], ["tetracycline", "CHEMICAL", 99, 111], ["Doxycycline", "CHEMICAL", 124, 135], ["RORC", "GENE_OR_GENE_PRODUCT", 30, 34], ["steroid", "SIMPLE_CHEMICAL", 57, 64], ["Dexamethasone", "SIMPLE_CHEMICAL", 66, 79], ["tetracycline derivative", "SIMPLE_CHEMICAL", 99, 122], ["Doxycycline", "SIMPLE_CHEMICAL", 124, 135], ["CoV-2", "ORGANISM", 269, 274], ["RORC", "PROTEIN", 30, 34], ["SARS-CoV", "SPECIES", 264, 272], ["RORC", "PROBLEM", 30, 34], ["the fluorinated steroid \"Dexamethasone", "TREATMENT", 41, 79], ["the synthetic tetracycline derivative", "TREATMENT", 85, 122], ["Doxycycline\" (http://ctdbase.org/basicQuery.go?bqCat=gene&bq=RAR+related+orphan+receptor +C", "TREATMENT", 124, 215], ["SARS", "PROBLEM", 264, 268], ["CoV-2 pathogenesis", "PROBLEM", 269, 287], ["RORC", "ANATOMY", 30, 34]]], ["Transcriptional regulation of a set of genes coding for enzymes involved in biogenic amine metabolism was unique for PEDV, and not observed for MRV.", [["amine", "CHEMICAL", 85, 90], ["amine", "CHEMICAL", 85, 90], ["biogenic amine", "SIMPLE_CHEMICAL", 76, 90], ["PEDV", "PROTEIN", 117, 121], ["MRV", "PROTEIN", 144, 147], ["enzymes", "TEST", 56, 63], ["PEDV", "PROBLEM", 117, 121], ["MRV", "TEST", 144, 147]]], ["Most associations of these PEDV-DEGs were found with histamine, a compound produced by mast cells and basophils, and released by these cells in response to allergens and pathogen-induced inflammation.", [["mast cells", "ANATOMY", 87, 97], ["basophils", "ANATOMY", 102, 111], ["cells", "ANATOMY", 135, 140], ["histamine", "CHEMICAL", 53, 62], ["inflammation", "DISEASE", 187, 199], ["histamine", "CHEMICAL", 53, 62], ["PEDV", "GENE_OR_GENE_PRODUCT", 27, 31], ["histamine", "SIMPLE_CHEMICAL", 53, 62], ["mast cells", "CELL", 87, 97], ["basophils", "CELL", 102, 111], ["cells", "CELL", 135, 140], ["PEDV", "DNA", 27, 31], ["mast cells", "CELL_TYPE", 87, 97], ["basophils", "CELL_TYPE", 102, 111], ["these PEDV-DEGs", "PROBLEM", 21, 36], ["histamine", "TREATMENT", 53, 62], ["mast cells", "PROBLEM", 87, 97], ["basophils", "TEST", 102, 111], ["allergens", "PROBLEM", 156, 165], ["pathogen", "PROBLEM", 170, 178], ["inflammation", "PROBLEM", 187, 199], ["mast cells", "OBSERVATION", 87, 97], ["inflammation", "OBSERVATION", 187, 199]]], ["The 10-fold up-regulation of the enzyme AOC1 suggests that histamine is converted to imidazole-acetaldehyde (see Fig. 3 ).Discussion.However, without data of intra-and extracellular concentrations of the chemicals this remains speculative.", [["extracellular", "ANATOMY", 168, 181], ["histamine", "CHEMICAL", 59, 68], ["imidazole-acetaldehyde", "CHEMICAL", 85, 107], ["histamine", "CHEMICAL", 59, 68], ["imidazole-acetaldehyde", "CHEMICAL", 85, 107], ["AOC1", "GENE_OR_GENE_PRODUCT", 40, 44], ["histamine", "SIMPLE_CHEMICAL", 59, 68], ["imidazole-acetaldehyde", "SIMPLE_CHEMICAL", 85, 107], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 181], ["enzyme AOC1", "PROTEIN", 33, 44], ["the enzyme AOC1", "TEST", 29, 44], ["histamine", "TREATMENT", 59, 68], ["imidazole-acetaldehyde", "TREATMENT", 85, 107], ["intra-and extracellular concentrations", "PROBLEM", 158, 196]]], ["Recent reports indicated that submucosal mast cells in the lungs were triggered by SARS-CoV-2 infection to release pro-inflammatory cytokines (IL1, IL6 and TNF-alpha) .", [["submucosal mast cells", "ANATOMY", 30, 51], ["lungs", "ANATOMY", 59, 64], ["submucosal mast cells", "CELL", 30, 51], ["lungs", "ORGAN", 59, 64], ["SARS-CoV-2", "ORGANISM", 83, 93], ["IL1", "GENE_OR_GENE_PRODUCT", 143, 146], ["IL6", "GENE_OR_GENE_PRODUCT", 148, 151], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 156, 165], ["submucosal mast cells", "CELL_TYPE", 30, 51], ["pro-inflammatory cytokines", "PROTEIN", 115, 141], ["IL1", "PROTEIN", 143, 146], ["IL6", "PROTEIN", 148, 151], ["TNF-alpha", "PROTEIN", 156, 165], ["submucosal mast cells in the lungs", "PROBLEM", 30, 64], ["SARS", "PROBLEM", 83, 87], ["CoV-2 infection", "PROBLEM", 88, 103], ["pro-inflammatory cytokines", "TEST", 115, 141], ["IL1", "TEST", 143, 146], ["IL6", "TEST", 148, 151], ["TNF", "TEST", 156, 159], ["submucosal", "ANATOMY", 30, 40], ["mast cells", "OBSERVATION", 41, 51], ["lungs", "ANATOMY", 59, 64]]], ["MDSCs infiltrate these tumors and inflamed tissues to suppress the local activity of specific immune cells.", [["MDSCs", "ANATOMY", 0, 5], ["tumors", "ANATOMY", 23, 29], ["tissues", "ANATOMY", 43, 50], ["immune cells", "ANATOMY", 94, 106], ["tumors", "DISEASE", 23, 29], ["MDSCs", "CELL", 0, 5], ["tumors", "CANCER", 23, 29], ["inflamed tissues", "TISSUE", 34, 50], ["immune cells", "CELL", 94, 106], ["MDSCs", "CELL_TYPE", 0, 5], ["immune cells", "CELL_TYPE", 94, 106], ["MDSCs infiltrate these tumors", "PROBLEM", 0, 29], ["inflamed tissues", "PROBLEM", 34, 50], ["tumors", "OBSERVATION", 23, 29], ["inflamed tissues", "OBSERVATION", 34, 50], ["immune cells", "OBSERVATION", 94, 106]]], ["Therefore, the role of infiltrating MDSCs at inflammatory sites in the lungs of COVID-19 patients, as part of an SARS-CoV-2 immune-evading strategy, and the role of IL4I1 in this process, is worthwhile to investigate in more detail.", [["MDSCs", "ANATOMY", 36, 41], ["inflammatory sites", "ANATOMY", 45, 63], ["lungs", "ANATOMY", 71, 76], ["MDSCs", "CELL", 36, 41], ["inflammatory sites", "MULTI-TISSUE_STRUCTURE", 45, 63], ["lungs", "ORGAN", 71, 76], ["patients", "ORGANISM", 89, 97], ["CoV-2", "ORGANISM", 118, 123], ["IL4I1", "GENE_OR_GENE_PRODUCT", 165, 170], ["infiltrating MDSCs", "CELL_TYPE", 23, 41], ["IL4I1", "PROTEIN", 165, 170], ["patients", "SPECIES", 89, 97], ["infiltrating MDSCs at inflammatory sites", "PROBLEM", 23, 63], ["COVID", "TEST", 80, 85], ["an SARS", "TEST", 110, 117], ["CoV", "TEST", 118, 121], ["infiltrating", "OBSERVATION_MODIFIER", 23, 35], ["MDSCs", "OBSERVATION", 36, 41], ["inflammatory", "OBSERVATION_MODIFIER", 45, 57], ["lungs", "ANATOMY", 71, 76]]], ["Expression of genes that promote or inhibit the formation and motility function of cilia were time-dependently regulated by PEDV.", [["cilia", "ANATOMY", 83, 88], ["PEDV", "CHEMICAL", 124, 128], ["cilia", "CELLULAR_COMPONENT", 83, 88], ["PEDV", "SIMPLE_CHEMICAL", 124, 128], ["PEDV", "PROTEIN", 124, 128], ["PEDV", "PROBLEM", 124, 128]]], ["The 20-fold up-regulation of FEZ1 gene expression at 4h (20-fold) descended within 2h to a moderate 6-fold upregulation.", [["FEZ1", "GENE_OR_GENE_PRODUCT", 29, 33], ["FEZ1 gene", "DNA", 29, 38], ["FEZ1 gene expression", "TREATMENT", 29, 49]]], ["This descend occurred simultaneously with elevation of gene expression of the kinases MAK and CDK20, both involved in inhibition of cilia formation.", [["cilia", "ANATOMY", 132, 137], ["MAK", "GENE_OR_GENE_PRODUCT", 86, 89], ["CDK20", "GENE_OR_GENE_PRODUCT", 94, 99], ["cilia", "CELLULAR_COMPONENT", 132, 137], ["kinases", "PROTEIN", 78, 85], ["MAK", "PROTEIN", 86, 89], ["CDK20", "PROTEIN", 94, 99], ["cilia formation", "PROBLEM", 132, 147], ["elevation", "OBSERVATION_MODIFIER", 42, 51], ["cilia formation", "OBSERVATION", 132, 147]]], ["Because PEDV efficiently replicates in enterocytes that carry ciliated membrane protrusions (microvilli) on their luminal surface, regulation of these genes could be related to structural changes in the cytoskeleton of cells imposed by virus replication (e.g. syncytia forming in PEDV infected Vero cultures).", [["enterocytes", "ANATOMY", 39, 50], ["membrane protrusions", "ANATOMY", 71, 91], ["microvilli", "ANATOMY", 93, 103], ["luminal surface", "ANATOMY", 114, 129], ["cytoskeleton", "ANATOMY", 203, 215], ["cells", "ANATOMY", 219, 224], ["syncytia", "ANATOMY", 260, 268], ["cultures", "ANATOMY", 299, 307], ["PEDV", "GENE_OR_GENE_PRODUCT", 8, 12], ["enterocytes", "CELL", 39, 50], ["ciliated membrane protrusions", "CELLULAR_COMPONENT", 62, 91], ["microvilli", "CELLULAR_COMPONENT", 93, 103], ["luminal surface", "CELLULAR_COMPONENT", 114, 129], ["cytoskeleton", "CELLULAR_COMPONENT", 203, 215], ["cells", "CELL", 219, 224], ["Vero cultures", "CELL", 294, 307], ["PEDV", "PROTEIN", 8, 12], ["PEDV infected Vero cultures", "CELL_LINE", 280, 307], ["PEDV", "SPECIES", 8, 12], ["PEDV", "SPECIES", 280, 284], ["PEDV", "PROBLEM", 8, 12], ["ciliated membrane protrusions", "PROBLEM", 62, 91], ["structural changes in the cytoskeleton of cells", "PROBLEM", 177, 224], ["virus replication", "TREATMENT", 236, 253], ["syncytia", "PROBLEM", 260, 268], ["PEDV infected Vero cultures", "PROBLEM", 280, 307], ["enterocytes", "ANATOMY", 39, 50], ["ciliated", "OBSERVATION_MODIFIER", 62, 70], ["membrane protrusions", "OBSERVATION", 71, 91], ["microvilli", "OBSERVATION_MODIFIER", 93, 103], ["luminal", "ANATOMY_MODIFIER", 114, 121], ["surface", "ANATOMY_MODIFIER", 122, 129], ["could be related to", "UNCERTAINTY", 157, 176], ["cytoskeleton of cells", "OBSERVATION", 203, 224]]], ["Likewise, SARS-CoV-2 replication could also impose structural changes in cilia protruding from the surface of upperairway epithelial cells (nose, trachea) and bronchi.", [["cilia", "ANATOMY", 73, 78], ["surface", "ANATOMY", 99, 106], ["upperairway epithelial cells", "ANATOMY", 110, 138], ["nose", "ANATOMY", 140, 144], ["trachea", "ANATOMY", 146, 153], ["bronchi", "ANATOMY", 159, 166], ["SARS", "DISEASE", 10, 14], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["cilia", "CELLULAR_COMPONENT", 73, 78], ["surface", "CELLULAR_COMPONENT", 99, 106], ["upperairway epithelial cells", "CELL", 110, 138], ["nose", "ORGAN", 140, 144], ["trachea", "ORGAN", 146, 153], ["bronchi", "MULTI-TISSUE_STRUCTURE", 159, 166], ["upperairway epithelial cells", "CELL_TYPE", 110, 138], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "PROBLEM", 10, 14], ["CoV-2 replication", "TREATMENT", 15, 32], ["structural changes in cilia protruding", "PROBLEM", 51, 89], ["epithelial cells (nose, trachea) and bronchi", "PROBLEM", 122, 166], ["cilia protruding", "OBSERVATION", 73, 89], ["surface", "ANATOMY_MODIFIER", 99, 106], ["upperairway", "ANATOMY_MODIFIER", 110, 121], ["epithelial cells", "OBSERVATION", 122, 138], ["nose", "ANATOMY", 140, 144], ["trachea", "ANATOMY", 146, 153], ["bronchi", "ANATOMY", 159, 166]]], ["Based on our results we cannot pinpoint a specific process in which these cilia-regulating genes act.", [["cilia-", "GENE_OR_GENE_PRODUCT", 74, 80], ["cilia-regulating genes", "DNA", 74, 96]]], ["Possible processes can either be formation of an immune cleft, a virological cleft to promote more effective infection of neighboring cells, or cytoskeleton rearrangements to support virus replication, morphogenesis and budding from cells.", [["cells", "ANATOMY", 134, 139], ["cytoskeleton", "ANATOMY", 144, 156], ["cells", "ANATOMY", 233, 238], ["infection", "DISEASE", 109, 118], ["cells", "CELL", 134, 139], ["cytoskeleton", "CELLULAR_COMPONENT", 144, 156], ["cells", "CELL", 233, 238], ["neighboring cells", "CELL_TYPE", 122, 139], ["an immune cleft", "PROBLEM", 46, 61], ["a virological cleft", "PROBLEM", 63, 82], ["neighboring cells", "PROBLEM", 122, 139], ["cytoskeleton rearrangements", "PROBLEM", 144, 171], ["virus replication", "TREATMENT", 183, 200]]], ["Interestingly, two recent studies revealed a high level of expression of the SARS-CoV-2 entry receptor ACE2 and its co-receptor TMPRSS2 in ciliated airway epithelial cells ( .", [["ciliated airway epithelial cells", "ANATOMY", 139, 171], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 77, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 103, 107], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 128, 135], ["ciliated airway epithelial cells", "CELL", 139, 171], ["SARS-CoV-2 entry receptor", "PROTEIN", 77, 102], ["ACE2", "PROTEIN", 103, 107], ["co-receptor TMPRSS2", "PROTEIN", 116, 135], ["ciliated airway epithelial cells", "CELL_TYPE", 139, 171], ["two recent studies", "TEST", 15, 33], ["the SARS", "TEST", 73, 81], ["CoV", "TEST", 82, 85], ["its co-receptor TMPRSS2", "TEST", 112, 135], ["ciliated airway epithelial cells", "PROBLEM", 139, 171], ["co-receptor TMPRSS2", "OBSERVATION", 116, 135], ["ciliated", "ANATOMY_MODIFIER", 139, 147], ["airway", "ANATOMY", 148, 154], ["epithelial cells", "OBSERVATION", 155, 171]]], ["These processes deserve more attention, and may also be considered as possible target-processes for interference with drugs.Discussion.Within our set of PEDV-DEGs, and the biological processes deduced from this set, we found associations with diverse aspects of COVID-19 pathogenesis, i.e.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 262, 270], ["PEDV", "DNA", 153, 157], ["DEGs", "DNA", 158, 162], ["drugs", "TREATMENT", 118, 123], ["COVID", "TEST", 262, 267]]], ["\"ARDS\", \"Cardiomyopathy\", \"Obesity (Diabetic)\", and \"Platelets activation\".", [["Platelets", "ANATOMY", 53, 62], ["ARDS", "DISEASE", 1, 5], ["Cardiomyopathy", "DISEASE", 9, 23], ["Obesity", "DISEASE", 27, 34], ["Diabetic", "DISEASE", 36, 44], ["Platelets", "CELL", 53, 62], ["ARDS", "PROBLEM", 1, 5], ["Cardiomyopathy", "PROBLEM", 9, 23], ["Obesity (Diabetic)", "PROBLEM", 27, 45], ["Platelets activation\"", "PROBLEM", 53, 74], ["ARDS", "OBSERVATION", 1, 5], ["Obesity", "OBSERVATION", 27, 34]]], ["However, it is unknown whether the proteins encoded by these PEDV-DEGS indeed play a role in the biological processes underlying the symptoms and complications observed in hospitalized persons infected with SARS-CoV-2.", [["SARS", "DISEASE", 207, 211], ["PEDV", "GENE_OR_GENE_PRODUCT", 61, 65], ["DEGS", "GENE_OR_GENE_PRODUCT", 66, 70], ["persons", "ORGANISM", 185, 192], ["SARS-CoV-2", "ORGANISM", 207, 217], ["PEDV", "PROTEIN", 61, 65], ["DEGS", "PROTEIN", 66, 70], ["persons", "SPECIES", 185, 192], ["SARS-CoV", "SPECIES", 207, 215], ["the symptoms", "PROBLEM", 129, 141], ["complications", "PROBLEM", 146, 159]]], ["Research to fine tune drug treatment protocols that are already applied for COVID-19 patients, or research that provides new insights for treatments with alternative prophylactic and therapeutic approved drugs.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["fine tune drug treatment protocols", "TREATMENT", 12, 46], ["treatments", "TREATMENT", 138, 148], ["alternative prophylactic", "TREATMENT", 154, 178], ["therapeutic approved drugs", "TREATMENT", 183, 209]]], ["In Table 3 . we summarized the PEDV-DEGs that are, to our opinion, of interest for modulation of the biological processes underlying the pathogenesis of COVID-19.", [["COVID-19", "CHEMICAL", 153, 161], ["COVID-19", "CELL", 153, 161], ["PEDV", "DNA", 31, 35], ["COVID", "TEST", 153, 158]]], ["Possible target genes for COVID-19 therapy.Discussion.Colophon.Discussion.The overwhelming amount of data published recently made it impossible for us to oversee all (novel) facts about the SARS-CoV-2 virus and pathology of the COVID-19 disease.", [["COVID-19", "CHEMICAL", 26, 34], ["Colophon", "CHEMICAL", 54, 62], ["SARS", "DISEASE", 190, 194], ["COVID-19", "CHEMICAL", 26, 34], ["COVID-19", "GENE_OR_GENE_PRODUCT", 26, 34], ["SARS-CoV-2 virus", "ORGANISM", 190, 206], ["COVID-19", "CANCER", 228, 236], ["target genes", "DNA", 9, 21], ["SARS-CoV-2 virus", "SPECIES", 190, 206], ["COVID-19 therapy", "TREATMENT", 26, 42], ["Colophon", "TREATMENT", 54, 62], ["the SARS", "TEST", 186, 194], ["CoV", "TEST", 195, 198], ["the COVID-19 disease", "PROBLEM", 224, 244], ["overwhelming", "OBSERVATION_MODIFIER", 78, 90], ["amount", "OBSERVATION_MODIFIER", 91, 97]]], ["Some important genes and related processes imbedded in our set of PEDV-DEGs may have been overlooked by us.", [["PEDV", "GENE_OR_GENE_PRODUCT", 66, 70], ["PEDV", "DNA", 66, 70], ["Some important genes and related processes", "PROBLEM", 0, 42], ["PEDV", "PROBLEM", 66, 70]]], ["By publishing these PEDV data ahead of our complete study, we hope that some of the gene targets and cognate processes we have identified for the coronavirus PEDV will contribute to a better understanding how hospitalized COVID-19 patients can be treated and cured.", [["coronavirus PEDV", "ORGANISM", 146, 162], ["patients", "ORGANISM", 231, 239], ["coronavirus", "SPECIES", 146, 157], ["patients", "SPECIES", 231, 239], ["our complete study", "TEST", 39, 57], ["the coronavirus PEDV", "PROBLEM", 142, 162]]], ["A more condensed version of this manuscript, focusing on the original goal of our study, will be submitted to a peer-reviewed virological journal soon.", [["our study", "TEST", 78, 87]]]], "dc45028785e8308de18df3a42fe11fe571da2cdc": [["IntroductionLeukotriene cascade is associated with the biosynthesis of variety of leukotrienes (LT) from the phospholipids of the nuclear membrane of the leukocytes [1] .", [["nuclear membrane", "ANATOMY", 130, 146], ["leukocytes", "ANATOMY", 154, 164], ["IntroductionLeukotriene", "CHEMICAL", 0, 23], ["leukotrienes", "CHEMICAL", 82, 94], ["IntroductionLeukotriene", "CHEMICAL", 0, 23], ["IntroductionLeukotriene", "SIMPLE_CHEMICAL", 0, 23], ["leukotrienes", "SIMPLE_CHEMICAL", 82, 94], ["LT", "SIMPLE_CHEMICAL", 96, 98], ["nuclear membrane", "CELLULAR_COMPONENT", 130, 146], ["leukocytes", "CELL", 154, 164], ["LT", "PROTEIN", 96, 98], ["leukocytes", "CELL_TYPE", 154, 164], ["IntroductionLeukotriene cascade", "TREATMENT", 0, 31], ["leukotrienes (LT", "TREATMENT", 82, 98], ["nuclear membrane", "ANATOMY", 130, 146], ["leukocytes", "ANATOMY", 154, 164]]], ["The LTs are a group of lipid mediators associated with acute and chronic inflammatory diseases such as asthma, rhinitis, psoriasis, chronic obstructive pulmonary disease, and atherosclerosis [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .", [["pulmonary", "ANATOMY", 152, 161], ["asthma", "DISEASE", 103, 109], ["rhinitis", "DISEASE", 111, 119], ["psoriasis", "DISEASE", 121, 130], ["chronic obstructive pulmonary disease", "DISEASE", 132, 169], ["atherosclerosis", "DISEASE", 175, 190], ["pulmonary", "ORGAN", 152, 161], ["[2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 191, 242], ["acute and chronic inflammatory diseases", "PROBLEM", 55, 94], ["asthma", "PROBLEM", 103, 109], ["rhinitis", "PROBLEM", 111, 119], ["psoriasis", "PROBLEM", 121, 130], ["chronic obstructive pulmonary disease", "PROBLEM", 132, 169], ["atherosclerosis", "PROBLEM", 175, 190], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["inflammatory", "OBSERVATION", 73, 85], ["asthma", "OBSERVATION", 103, 109], ["rhinitis", "OBSERVATION", 111, 119], ["psoriasis", "OBSERVATION", 121, 130], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["obstructive", "OBSERVATION_MODIFIER", 140, 151], ["pulmonary", "ANATOMY", 152, 161], ["disease", "OBSERVATION", 162, 169], ["atherosclerosis", "OBSERVATION", 175, 190]]], ["Cytosolic phospholipase A2 (cPLA2) hydrolyzes the ester bond present in sn-2 position of phospholipids and yields lysophospholipids and free fatty acid, arachidonic acid (AA) [1, 14] .", [["ester", "CHEMICAL", 50, 55], ["sn-2 position of phospholipids", "CHEMICAL", 72, 102], ["lysophospholipids", "CHEMICAL", 114, 131], ["fatty acid", "CHEMICAL", 141, 151], ["arachidonic acid", "CHEMICAL", 153, 169], ["AA", "CHEMICAL", 171, 173], ["ester", "CHEMICAL", 50, 55], ["lysophospholipids", "CHEMICAL", 114, 131], ["fatty acid", "CHEMICAL", 141, 151], ["arachidonic acid", "CHEMICAL", 153, 169], ["Cytosolic phospholipase A2", "GENE_OR_GENE_PRODUCT", 0, 26], ["cPLA2", "GENE_OR_GENE_PRODUCT", 28, 33], ["ester", "SIMPLE_CHEMICAL", 50, 55], ["phospholipids", "SIMPLE_CHEMICAL", 89, 102], ["lysophospholipids", "SIMPLE_CHEMICAL", 114, 131], ["free fatty acid", "SIMPLE_CHEMICAL", 136, 151], ["arachidonic acid", "SIMPLE_CHEMICAL", 153, 169], ["AA", "SIMPLE_CHEMICAL", 171, 173], ["Cytosolic phospholipase A2", "PROTEIN", 0, 26], ["cPLA2", "PROTEIN", 28, 33], ["Cytosolic phospholipase A2 (cPLA2", "TEST", 0, 33], ["hydrolyzes the ester bond", "TREATMENT", 35, 60], ["phospholipids", "TREATMENT", 89, 102], ["lysophospholipids", "TEST", 114, 131], ["free fatty acid", "TEST", 136, 151], ["arachidonic acid (AA)", "TEST", 153, 174]]], ["This increases the level of free AA available for the synthesis of inflammatory leukotrienes upon the action of more enzymes.", [["AA", "CHEMICAL", 33, 35], ["leukotrienes", "CHEMICAL", 80, 92], ["AA", "SIMPLE_CHEMICAL", 33, 35], ["enzymes", "PROTEIN", 117, 124], ["inflammatory leukotrienes", "PROBLEM", 67, 92], ["more enzymes", "TEST", 112, 124], ["inflammatory", "OBSERVATION", 67, 79]]], ["The enzyme 5-lipoxygenase (5-LO) assisted by file-lipoxygenase-activating protein (FLAP) converts the AA into the highly unstable allylic epoxide, leukotriene A4 (LTA4) [15] [16] [17] [18] [19] [20] [21] .", [["5-lipoxygenase", "CHEMICAL", 11, 25], ["5-LO", "CHEMICAL", 27, 31], ["AA", "CHEMICAL", 102, 104], ["leukotriene A4", "CHEMICAL", 147, 161], ["LTA4", "CHEMICAL", 163, 167], ["allylic epoxide", "CHEMICAL", 130, 145], ["leukotriene A4", "CHEMICAL", 147, 161], ["LTA4", "CHEMICAL", 163, 167], ["5-lipoxygenase", "SIMPLE_CHEMICAL", 11, 25], ["5-LO", "SIMPLE_CHEMICAL", 27, 31], ["file-lipoxygenase-activating protein", "GENE_OR_GENE_PRODUCT", 45, 81], ["FLAP", "GENE_OR_GENE_PRODUCT", 83, 87], ["AA", "SIMPLE_CHEMICAL", 102, 104], ["allylic epoxide", "SIMPLE_CHEMICAL", 130, 145], ["leukotriene A4", "SIMPLE_CHEMICAL", 147, 161], ["LTA4) [15] [16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 163, 203], ["enzyme 5-lipoxygenase", "PROTEIN", 4, 25], ["LO", "PROTEIN", 29, 31], ["lipoxygenase", "PROTEIN", 50, 62], ["activating protein", "PROTEIN", 63, 81], ["FLAP", "PROTEIN", 83, 87], ["The enzyme", "TEST", 0, 10], ["lipoxygenase", "TEST", 13, 25], ["lipoxygenase", "TEST", 50, 62], ["activating protein (FLAP", "TREATMENT", 63, 87], ["leukotriene A4 (LTA4)", "TREATMENT", 147, 168], ["allylic epoxide", "OBSERVATION", 130, 145]]], ["This unstable intermediate is converted into two different products LTB4 and LTC4 by the action of two different enzymes LTA4 hydrolase (LTA4H) and LTC4 synthase (LTC4S), respectively [1, [22] [23] [24] [25] .", [["LTB4", "CHEMICAL", 68, 72], ["LTC4", "CHEMICAL", 77, 81], ["LTC4", "CHEMICAL", 148, 152], ["LTB4", "CHEMICAL", 68, 72], ["LTC4", "CHEMICAL", 77, 81], ["LTB4", "SIMPLE_CHEMICAL", 68, 72], ["LTC4", "SIMPLE_CHEMICAL", 77, 81], ["LTA4 hydrolase", "GENE_OR_GENE_PRODUCT", 121, 135], ["LTA4H", "GENE_OR_GENE_PRODUCT", 137, 142], ["LTC4 synthase", "GENE_OR_GENE_PRODUCT", 148, 161], ["LTC4S", "SIMPLE_CHEMICAL", 163, 168], ["[22] [23] [24] [25]", "SIMPLE_CHEMICAL", 188, 207], ["enzymes", "PROTEIN", 113, 120], ["LTA4 hydrolase", "PROTEIN", 121, 135], ["LTA4H", "PROTEIN", 137, 142], ["LTC4 synthase", "PROTEIN", 148, 161], ["LTC4S", "PROTEIN", 163, 168], ["LTB4", "TEST", 68, 72], ["LTC4", "TEST", 77, 81], ["two different enzymes LTA4 hydrolase", "TEST", 99, 135], ["LTA4H", "TEST", 137, 142], ["LTC4 synthase (LTC4S)", "TEST", 148, 169], ["LTB4", "OBSERVATION_MODIFIER", 68, 72]]], ["The LTC4 is subsequently converted to LTD4 and LTE4 substances by the action of different enzymes.", [["LTC4", "CHEMICAL", 4, 8], ["LTD4", "CHEMICAL", 38, 42], ["LTE4", "CHEMICAL", 47, 51], ["LTD4", "CHEMICAL", 38, 42], ["LTE4", "CHEMICAL", 47, 51], ["LTC4", "SIMPLE_CHEMICAL", 4, 8], ["LTD4", "SIMPLE_CHEMICAL", 38, 42], ["LTE4", "SIMPLE_CHEMICAL", 47, 51], ["enzymes", "PROTEIN", 90, 97], ["The LTC4", "TEST", 0, 8], ["LTD4", "TEST", 38, 42], ["LTE4 substances", "TREATMENT", 47, 62], ["different enzymes", "TEST", 80, 97], ["LTC4", "ANATOMY", 4, 8]]], ["All of these LTB4, LTC4, LTD4, and LTE4 are powerful proinflammatory mediators [1, 26] .", [["LTB4", "CHEMICAL", 13, 17], ["LTC4", "CHEMICAL", 19, 23], ["LTD4", "CHEMICAL", 25, 29], ["LTE4", "CHEMICAL", 35, 39], ["LTE4", "CHEMICAL", 35, 39], ["LTB4", "GENE_OR_GENE_PRODUCT", 13, 17], ["LTC4", "GENE_OR_GENE_PRODUCT", 19, 23], ["LTD4", "GENE_OR_GENE_PRODUCT", 25, 29], ["LTE4", "GENE_OR_GENE_PRODUCT", 35, 39], ["proinflammatory mediators", "PROTEIN", 53, 78], ["these LTB4", "TEST", 7, 17], ["LTC4", "TEST", 19, 23], ["LTD4", "TEST", 25, 29], ["LTE4", "TEST", 35, 39], ["LTB4", "ANATOMY", 13, 17], ["LTC4", "ANATOMY", 19, 23], ["LTD4", "OBSERVATION_MODIFIER", 25, 29], ["LTE4", "ANATOMY", 35, 39]]], ["The LTA4H, which catalyzes the conversion of LTA4 to the chemotactic agent LTB4, was identified as a bi-functional enzyme capable of processing two highly diverse substrates such as LTA4 (a fatty acid) and peptide through its epoxide hydrolase and aminopeptidase activities [27, 28] .", [["LTA4H", "CHEMICAL", 4, 9], ["LTA4", "CHEMICAL", 45, 49], ["LTB4", "CHEMICAL", 75, 79], ["LTA4", "CHEMICAL", 182, 186], ["fatty acid", "CHEMICAL", 190, 200], ["LTA4", "CHEMICAL", 45, 49], ["LTA4", "CHEMICAL", 182, 186], ["fatty acid", "CHEMICAL", 190, 200], ["epoxide", "CHEMICAL", 226, 233], ["LTA4H", "GENE_OR_GENE_PRODUCT", 4, 9], ["LTA4", "GENE_OR_GENE_PRODUCT", 45, 49], ["LTB4", "SIMPLE_CHEMICAL", 75, 79], ["LTA4", "SIMPLE_CHEMICAL", 182, 186], ["fatty acid", "SIMPLE_CHEMICAL", 190, 200], ["epoxide hydrolase", "GENE_OR_GENE_PRODUCT", 226, 243], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 248, 262], ["LTA4H", "PROTEIN", 4, 9], ["LTA4", "PROTEIN", 45, 49], ["epoxide hydrolase", "PROTEIN", 226, 243], ["aminopeptidase", "PROTEIN", 248, 262], ["LTA4", "TREATMENT", 45, 49], ["the chemotactic agent LTB4", "TEST", 53, 79], ["a bi-functional enzyme", "TEST", 99, 121], ["LTA4", "TEST", 182, 186], ["a fatty acid)", "TREATMENT", 188, 201], ["its epoxide hydrolase", "TREATMENT", 222, 243], ["aminopeptidase activities", "TEST", 248, 273]]], ["This enzyme was first discovered for its epoxide hydrolase activity and later for its aminopeptidase activity based on the presence of consensus Zn binding motif (HEXXH-X 18 -E), which was found in M1 family of Zn containing aminopeptidases [29] [30] [31] [32] .", [["Zn", "CHEMICAL", 145, 147], ["Zn", "CHEMICAL", 211, 213], ["epoxide", "CHEMICAL", 41, 48], ["Zn", "CHEMICAL", 145, 147], ["Zn", "CHEMICAL", 211, 213], ["epoxide hydrolase", "GENE_OR_GENE_PRODUCT", 41, 58], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 86, 100], ["Zn containing aminopeptidases [29] [30] [31] [32]", "SIMPLE_CHEMICAL", 211, 260], ["epoxide hydrolase", "PROTEIN", 41, 58], ["aminopeptidase", "PROTEIN", 86, 100], ["consensus Zn binding motif", "PROTEIN", 135, 161], ["HEXXH", "PROTEIN", 163, 168], ["M1 family", "PROTEIN", 198, 207], ["Zn", "PROTEIN", 211, 213], ["This enzyme", "TEST", 0, 11], ["its epoxide hydrolase activity", "TREATMENT", 37, 67], ["its aminopeptidase activity", "PROBLEM", 82, 109], ["HEXXH", "TEST", 163, 168]]], ["The natural peptide substrate for this enzyme is still not known but preference is shown over arginyl di-and tripeptide and can selectively be blocked by the mutation of either E296 or Y383 residues [33] [34] [35] [36] .", [["arginyl di-and tripeptide", "CHEMICAL", 94, 119], ["arginyl di-and tripeptide", "CHEMICAL", 94, 119], ["Y383", "CHEMICAL", 185, 189], ["arginyl di-and tripeptide", "SIMPLE_CHEMICAL", 94, 119], ["this enzyme", "TEST", 34, 45], ["arginyl di-and tripeptide", "TREATMENT", 94, 119]]], ["Upon the determination of LTA4H crystal structures it was revealed that this enzyme is composed of three domains, a fully beta N-terminal domain, a mixed alpha/beta catalytic domain, and a fully alpha-helical C-terminal domain ( Figure 1 ) [37] [38] [39] [40] [41] [42] .", [["LTA4H", "CHEMICAL", 26, 31], ["N", "CHEMICAL", 127, 128], ["C", "CHEMICAL", 209, 210], ["LTA4H", "GENE_OR_GENE_PRODUCT", 26, 31], ["[37] [38] [39] [40] [41] [42]", "SIMPLE_CHEMICAL", 240, 269], ["LTA4H", "PROTEIN", 26, 31], ["beta N-terminal domain", "PROTEIN", 122, 144], ["mixed alpha/beta catalytic domain", "PROTEIN", 148, 181], ["alpha-helical C-terminal domain", "PROTEIN", 195, 226], ["this enzyme", "TEST", 72, 83], ["a mixed alpha/beta catalytic domain", "PROBLEM", 146, 181]]], ["In terms of the hydrolase activity of the enzyme, D375 from a narrow hydrophobic pocket is specifically required as it is involved in the nucleophilic attack targeting C12 atom of LTA4 [43] .", [["D375", "CHEMICAL", 50, 54], ["C12 atom", "CHEMICAL", 168, 176], ["LTA4", "CHEMICAL", 180, 184], ["D375", "CHEMICAL", 50, 54], ["C12", "CHEMICAL", 168, 171], ["LTA4", "CHEMICAL", 180, 184], ["D375", "SIMPLE_CHEMICAL", 50, 54], ["C12 atom", "SIMPLE_CHEMICAL", 168, 176], ["LTA4 [43]", "SIMPLE_CHEMICAL", 180, 189], ["hydrolase", "PROTEIN", 16, 25], ["enzyme", "PROTEIN", 42, 48], ["D375", "PROTEIN", 50, 54], ["the enzyme", "TEST", 38, 48], ["a narrow hydrophobic pocket", "TREATMENT", 60, 87], ["LTA4", "TEST", 180, 184]]], ["In addition, this residue belongs to the peptide K21 (L365-K385) segment identified by Lys-specific peptide mapping of suicide inactivated LTA4H.", [["LTA4H", "GENE_OR_GENE_PRODUCT", 139, 144], ["peptide K21 (L365-K385) segment", "DNA", 41, 72], ["suicide inactivated LTA4H", "PROTEIN", 119, 144], ["the peptide K21", "TEST", 37, 52], ["Lys-specific peptide mapping", "TREATMENT", 87, 115], ["suicide inactivated LTA4H", "TREATMENT", 119, 144]]], ["The carboxylate moiety of LTA4 was observed to form direct electrostatic interactions with the two positively charged conserved R563 and K565 residues present at the entrance of the active center [28, 44] .", [["carboxylate", "CHEMICAL", 4, 15], ["LTA4", "CHEMICAL", 26, 30], ["carboxylate", "CHEMICAL", 4, 15], ["LTA4", "CHEMICAL", 26, 30], ["R563", "CHEMICAL", 128, 132], ["K565", "CHEMICAL", 137, 141], ["LTA4", "SIMPLE_CHEMICAL", 26, 30], ["R563 and K565 residues", "PROTEIN", 128, 150], ["The carboxylate moiety of LTA4", "TREATMENT", 0, 30], ["active", "OBSERVATION_MODIFIER", 182, 188]]], ["These interactions are very much essential in aligning LTA4 along with the catalytic elements of the active site.", [["LTA4", "GENE_OR_GENE_PRODUCT", 55, 59], ["LTA4", "PROTEIN", 55, 59], ["catalytic elements", "DNA", 75, 93], ["active site", "DNA", 101, 112], ["active site", "OBSERVATION", 101, 112]]], ["Based on the mutagenic experiments, E271 residue from another conserved GXMEN motif in the family of zinc peptidases was found to be important for both the functions of the enzyme [14] as the mutagenic replacements abrogated both the activities.", [["E271", "CHEMICAL", 36, 40], ["zinc", "CHEMICAL", 101, 105], ["E271", "CHEMICAL", 36, 40], ["zinc", "CHEMICAL", 101, 105], ["E271", "SIMPLE_CHEMICAL", 36, 40], ["GXMEN", "GENE_OR_GENE_PRODUCT", 72, 77], ["zinc peptidases", "GENE_OR_GENE_PRODUCT", 101, 116], ["GXMEN motif", "PROTEIN", 72, 83], ["zinc peptidases", "PROTEIN", 101, 116], ["the mutagenic experiments", "TEST", 9, 34], ["E271 residue", "PROBLEM", 36, 48], ["zinc peptidases", "TREATMENT", 101, 116], ["the enzyme", "TEST", 169, 179], ["the mutagenic replacements", "TREATMENT", 188, 214]]], ["A crystal structure of LTA4H with E271Q mutation has revealed only minimal conformational changes and did not explain the loss of enzyme function [14] .", [["LTA4H", "GENE_OR_GENE_PRODUCT", 23, 28], ["E271Q", "AMINO_ACID", 34, 39], ["LTA4H", "PROTEIN", 23, 28], ["E271Q", "PROTEIN", 34, 39], ["E271Q mutation", "TEST", 34, 48], ["minimal conformational changes", "PROBLEM", 67, 97], ["the loss of enzyme function", "PROBLEM", 118, 145], ["crystal", "OBSERVATION_MODIFIER", 2, 9], ["minimal", "OBSERVATION_MODIFIER", 67, 74], ["conformational", "OBSERVATION", 75, 89]]], ["It was also suggested that the carboxylate of E271 participates in an acid-induced opening of the epoxide moiety of LTA4 and as N-terminal recognition site in terms of peptide substrates [14, 26, 45] .", [["carboxylate", "CHEMICAL", 31, 42], ["E271", "CHEMICAL", 46, 50], ["LTA4", "CHEMICAL", 116, 120], ["carboxylate", "CHEMICAL", 31, 42], ["E271", "CHEMICAL", 46, 50], ["epoxide", "CHEMICAL", 98, 105], ["LTA4", "CHEMICAL", 116, 120], ["N", "CHEMICAL", 128, 129], ["E271", "SIMPLE_CHEMICAL", 46, 50], ["epoxide", "SIMPLE_CHEMICAL", 98, 105], ["LTA4", "SIMPLE_CHEMICAL", 116, 120], ["N-terminal recognition site", "PROTEIN", 128, 155], ["the carboxylate of E271", "TREATMENT", 27, 50], ["the epoxide moiety of LTA4", "TREATMENT", 94, 120]]], ["Some mutagenic experiments have also reported the critical role of R563 residue in epoxide hydrolase reaction by positioning the carboxylate tail along the catalytic elements of the active site [28, 34] .", [["R563", "CHEMICAL", 67, 71], ["epoxide", "CHEMICAL", 83, 90], ["carboxylate", "CHEMICAL", 129, 140], ["R563", "SIMPLE_CHEMICAL", 67, 71], ["epoxide hydrolase", "GENE_OR_GENE_PRODUCT", 83, 100], ["epoxide hydrolase", "PROTEIN", 83, 100], ["carboxylate tail", "PROTEIN", 129, 145], ["catalytic elements", "PROTEIN", 156, 174], ["epoxide hydrolase reaction", "TREATMENT", 83, 109], ["the carboxylate tail", "TREATMENT", 125, 145], ["active", "OBSERVATION_MODIFIER", 182, 188], ["site", "OBSERVATION_MODIFIER", 189, 193]]], ["In aminopeptidase reaction, both R563 and K565 residues co-operate each other to ensure the necessary binding strength and productive alignment of the substrate.", [["R563", "CHEMICAL", 33, 37], ["K565", "CHEMICAL", 42, 46], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 3, 17], ["R563", "SIMPLE_CHEMICAL", 33, 37], ["aminopeptidase", "PROTEIN", 3, 17], ["aminopeptidase reaction", "TEST", 3, 26], ["productive alignment", "OBSERVATION", 123, 143]]], ["Altogether, R563 plays important roles in both the functions of the enzyme whereas K565 residue assists R563 in catalyzing the peptide substrate but not in hydrolase reaction, which catalyzes the fatty acid substrate [27] .", [["R563", "CHEMICAL", 12, 16], ["R563", "CHEMICAL", 104, 108], ["fatty acid", "CHEMICAL", 196, 206], ["fatty acid", "CHEMICAL", 196, 206], ["R563", "GENE_OR_GENE_PRODUCT", 12, 16], ["K565", "GENE_OR_GENE_PRODUCT", 83, 87], ["R563", "AMINO_ACID", 104, 108], ["fatty acid", "SIMPLE_CHEMICAL", 196, 206], ["R563", "PROTEIN", 12, 16], ["R563", "PROTEIN", 104, 108], ["hydrolase", "PROTEIN", 156, 165], ["the enzyme", "TEST", 64, 74], ["hydrolase reaction", "PROBLEM", 156, 174], ["the fatty acid substrate", "TEST", 192, 216]]], ["These residues were reported to be the common carboxylate recognition site for both lipid and peptide substrates in the active site of LTA4H [27] .IntroductionMutations of R563 to any other amino acid including a conservative replacement of R by K preserving the positive charge abolished the enzyme function but exhibited a significant residual aminopeptidase activity [27] .", [["R563", "CHEMICAL", 172, 176], ["amino acid", "CHEMICAL", 190, 200], ["K", "CHEMICAL", 246, 247], ["carboxylate", "CHEMICAL", 46, 57], ["amino acid", "CHEMICAL", 190, 200], ["lipid", "SIMPLE_CHEMICAL", 84, 89], ["amino acid", "AMINO_ACID", 190, 200], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 346, 360], ["carboxylate recognition site", "PROTEIN", 46, 74], ["aminopeptidase", "PROTEIN", 346, 360], ["both lipid and peptide substrates", "TREATMENT", 79, 112], ["IntroductionMutations", "TEST", 147, 168], ["amino acid", "TREATMENT", 190, 200], ["a conservative replacement", "TREATMENT", 211, 237], ["the enzyme function", "TEST", 289, 308], ["a significant residual aminopeptidase activity", "PROBLEM", 323, 369], ["active", "OBSERVATION_MODIFIER", 120, 126], ["site", "OBSERVATION_MODIFIER", 127, 131], ["significant", "OBSERVATION_MODIFIER", 325, 336], ["residual", "OBSERVATION_MODIFIER", 337, 345], ["aminopeptidase activity", "OBSERVATION", 346, 369]]], ["Crystal structure with R563A mutant could not reveal any structural changes explaining the complete loss of catalytic activity.", [["R563A", "AMINO_ACID", 23, 28], ["R563A mutant", "PROTEIN", 23, 35], ["Crystal structure", "TEST", 0, 17], ["any structural changes", "PROBLEM", 53, 75], ["the complete loss of catalytic activity", "PROBLEM", 87, 126], ["catalytic activity", "OBSERVATION", 108, 126]]], ["It was also reported that esterified LTA4 cannot be the substrate of the enzyme and this phenomenon was explained with the steric hindrance [46] , which also proved that a free carboxylate group of LTA4 is critical for the hydrolase function.", [["LTA4", "CHEMICAL", 37, 41], ["carboxylate", "CHEMICAL", 177, 188], ["LTA4", "CHEMICAL", 198, 202], ["LTA4", "CHEMICAL", 37, 41], ["carboxylate", "CHEMICAL", 177, 188], ["LTA4", "CHEMICAL", 198, 202], ["LTA4", "SIMPLE_CHEMICAL", 37, 41], ["LTA4", "SIMPLE_CHEMICAL", 198, 202], ["hydrolase", "PROTEIN", 223, 232], ["esterified LTA4", "PROBLEM", 26, 41], ["the enzyme", "TEST", 69, 79], ["a free carboxylate group of LTA4", "TREATMENT", 170, 202], ["the hydrolase function", "TEST", 219, 241]]], ["The other carboxylate recognition residue K565 located in a way that it can also involve in carboxylate recognition but its mutagenic replacements have not decreased the epoxide hydrolase activity [27] .", [["carboxylate", "CHEMICAL", 10, 21], ["carboxylate", "CHEMICAL", 92, 103], ["carboxylate", "CHEMICAL", 10, 21], ["carboxylate", "CHEMICAL", 92, 103], ["epoxide", "CHEMICAL", 170, 177], ["K565", "AMINO_ACID", 42, 46], ["carboxylate", "SIMPLE_CHEMICAL", 92, 103], ["epoxide hydrolase", "GENE_OR_GENE_PRODUCT", 170, 187], ["epoxide hydrolase", "PROTEIN", 170, 187], ["The other carboxylate recognition residue", "PROBLEM", 0, 41], ["carboxylate recognition", "TREATMENT", 92, 115], ["its mutagenic replacements", "TREATMENT", 120, 146]]], ["The difference in observed aminopeptidase activities between the wild type and K565 mutants have suggested that K565 is a carboxylate binding site for peptide substrates also [27] .", [["K565", "CHEMICAL", 112, 116], ["carboxylate", "CHEMICAL", 122, 133], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 27, 41], ["K565", "GENE_OR_GENE_PRODUCT", 79, 83], ["K565", "SIMPLE_CHEMICAL", 112, 116], ["aminopeptidase", "PROTEIN", 27, 41], ["K565 mutants", "PROTEIN", 79, 91], ["K565", "PROTEIN", 112, 116], ["carboxylate binding site", "PROTEIN", 122, 146], ["observed aminopeptidase activities", "PROBLEM", 18, 52], ["a carboxylate binding site", "TREATMENT", 120, 146], ["peptide substrates", "TEST", 151, 169]]], ["The information of a binding pocket for its ligand is very important for drug design, particularly for conducting mutagenesis studies [47] .", [["a binding pocket", "PROBLEM", 19, 35], ["conducting mutagenesis studies", "TEST", 103, 133]]], ["In the literature, the binding pocket of a protein receptor to a ligand is usually defined by those residues that have at least one heavy atom (i.e., an atom other than hydrogen) with a distance from a heavy atom of the ligand.", [["hydrogen", "CHEMICAL", 169, 177], ["hydrogen", "CHEMICAL", 169, 177], ["hydrogen", "SIMPLE_CHEMICAL", 169, 177], ["protein receptor", "PROTEIN", 43, 59], ["a protein receptor", "TREATMENT", 41, 59], ["pocket", "OBSERVATION_MODIFIER", 31, 37], ["ligand", "ANATOMY", 220, 226]]], ["Such a criterion was originally used to define the binding pocket of ATP in the Cdk5-Nck5a* complex [48] that has later proved quite useful in identifying functional domains and stimulating the relevant truncation experiments [49] .", [["ATP", "CHEMICAL", 69, 72], ["ATP", "CHEMICAL", 69, 72], ["ATP", "SIMPLE_CHEMICAL", 69, 72], ["Cdk5", "GENE_OR_GENE_PRODUCT", 80, 84], ["Cdk5", "PROTEIN", 80, 84], ["Nck5a", "PROTEIN", 85, 90]]], ["The similar approach has also been used to define the binding pockets of many other receptor-ligand interactions important for drug design [50] [51] [52] [53] [54] .IntroductionThis study has focused on structural changes and binding mode differences between wild types and mutant forms of hLTA4H-fatty acid and -tripeptide substrate complexes.", [["fatty acid", "CHEMICAL", 297, 307], ["fatty acid", "CHEMICAL", 297, 307], ["tripeptide", "CHEMICAL", 313, 323], ["[50] [51] [52] [53] [54]", "SIMPLE_CHEMICAL", 139, 163], ["hLTA4H-fatty acid", "SIMPLE_CHEMICAL", 290, 307], ["hLTA4H", "PROTEIN", 290, 296], ["fatty acid and -tripeptide substrate complexes", "PROTEIN", 297, 343], ["the binding pockets", "PROBLEM", 50, 69], ["This study", "TEST", 177, 187], ["binding mode differences", "PROBLEM", 226, 250], ["hLTA4H", "TEST", 290, 296], ["fatty acid", "TEST", 297, 307], ["tripeptide substrate complexes", "TREATMENT", 313, 343]]], ["Molecular dynamics (MD) simulations of two wild types of the enzyme-substrate complexes and three mutations including E272Q, R563A, and K565A were studied with LTA4 (fatty acid) and Arg-Ala-Arg (RAR, tripeptide) substrate ( Figure 2 ).", [["LTA4", "CHEMICAL", 160, 164], ["fatty acid", "CHEMICAL", 166, 176], ["Arg-Ala-Arg", "CHEMICAL", 182, 193], ["fatty acid", "CHEMICAL", 166, 176], ["Arg-Ala-Arg", "CHEMICAL", 182, 193], ["tripeptide", "CHEMICAL", 200, 210], ["LTA4", "SIMPLE_CHEMICAL", 160, 164], ["fatty acid", "SIMPLE_CHEMICAL", 166, 176], ["Arg-Ala-Arg", "SIMPLE_CHEMICAL", 182, 193], ["RAR", "GENE_OR_GENE_PRODUCT", 195, 198], ["enzyme-substrate complexes", "PROTEIN", 61, 87], ["LTA4", "PROTEIN", 160, 164], ["RAR", "PROTEIN", 195, 198], ["the enzyme", "TEST", 57, 67], ["K565A", "TEST", 136, 141], ["LTA4", "TEST", 160, 164], ["fatty acid", "TEST", 166, 176], ["Arg", "TEST", 182, 185], ["Ala", "TEST", 186, 189], ["Arg (RAR, tripeptide) substrate", "TREATMENT", 190, 221]]], ["The binding mode comparison of enzyme-substrate complexes revealed essential structural differences, which were not shown in X-ray structures, explaining the loss of catalytic functions of the enzyme.", [["enzyme-substrate complexes", "PROTEIN", 31, 57], ["enzyme", "PROTEIN", 193, 199], ["enzyme-substrate complexes", "TEST", 31, 57], ["essential structural differences", "PROBLEM", 67, 99], ["the loss of catalytic functions of the enzyme", "PROBLEM", 154, 199], ["essential", "OBSERVATION_MODIFIER", 67, 76], ["structural differences", "OBSERVATION", 77, 99]]], ["The overlay of binding modes of LTA4 and RAR substrates has proved the previous assumption of similar but overlapped active site is used in both the functions of the enzyme.", [["LTA4", "GENE_OR_GENE_PRODUCT", 32, 36], ["RAR", "GENE_OR_GENE_PRODUCT", 41, 44], ["LTA4", "PROTEIN", 32, 36], ["RAR substrates", "PROTEIN", 41, 55], ["enzyme", "PROTEIN", 166, 172], ["LTA4 and RAR substrates", "TREATMENT", 32, 55], ["the enzyme", "TEST", 162, 172], ["binding modes", "OBSERVATION", 15, 28], ["overlapped", "OBSERVATION_MODIFIER", 106, 116], ["active", "OBSERVATION", 117, 123]]], ["The results from this study provide valuable information over the way the two functions of the enzyme are exerted over two substrates of diverse nature.", [["enzyme", "PROTEIN", 95, 101], ["this study", "TEST", 17, 27], ["the enzyme", "TEST", 91, 101], ["diverse", "OBSERVATION_MODIFIER", 137, 144]]], ["In addition, the structural information obtained from this study can be utilized in structure-based hLTA4H inhibitor design as inhibition of the hydrolase and aminopeptidase functions will lead to the development of anticancer and anti-inflammatory drugs, respectively.Preparation of complex structuresAs this study was aimed at investigating the binding of fatty acid and peptide substrates of the enzyme, independent hLTA4H-LTA4 (L-LTA4) and hLTA4H-RAR (L-RAR) complexes were prepared.", [["anticancer", "ANATOMY", 216, 226], ["fatty acid", "CHEMICAL", 358, 368], ["fatty acid", "CHEMICAL", 358, 368], ["hLTA4H", "SIMPLE_CHEMICAL", 100, 106], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 159, 173], ["anticancer", "CANCER", 216, 226], ["fatty acid", "SIMPLE_CHEMICAL", 358, 368], ["hLTA4H-LTA4", "GENE_OR_GENE_PRODUCT", 419, 430], ["L-LTA4", "SIMPLE_CHEMICAL", 432, 438], ["hLTA4H-RAR", "GENE_OR_GENE_PRODUCT", 444, 454], ["L-RAR", "GENE_OR_GENE_PRODUCT", 456, 461], ["hydrolase", "PROTEIN", 145, 154], ["aminopeptidase", "PROTEIN", 159, 173], ["hLTA4H", "PROTEIN", 419, 425], ["LTA4", "PROTEIN", 426, 430], ["L-LTA4", "PROTEIN", 432, 438], ["hLTA4H", "PROTEIN", 444, 450], ["RAR (L-RAR) complexes", "PROTEIN", 451, 472], ["this study", "TEST", 54, 64], ["structure-based hLTA4H inhibitor", "TREATMENT", 84, 116], ["the hydrolase", "TREATMENT", 141, 154], ["aminopeptidase functions", "TREATMENT", 159, 183], ["anticancer", "TREATMENT", 216, 226], ["anti-inflammatory drugs", "TREATMENT", 231, 254], ["this study", "TEST", 305, 315], ["the enzyme", "TEST", 395, 405], ["hLTA4H", "TEST", 444, 450]]], ["The LTA4 of AA cascade is the natural substrate of the enzyme but no 3D structural information was available for its binding from X-ray studies.", [["LTA4", "CHEMICAL", 4, 8], ["AA", "CHEMICAL", 12, 14], ["LTA4", "GENE_OR_GENE_PRODUCT", 4, 8], ["AA", "SIMPLE_CHEMICAL", 12, 14], ["enzyme", "PROTEIN", 55, 61], ["AA cascade", "TREATMENT", 12, 22], ["the enzyme", "TEST", 51, 61], ["its binding", "PROBLEM", 113, 124], ["X-ray studies", "TEST", 130, 143]]], ["Some previous studies have reported the proposed binding of this fatty acid substrate at the active site of the enzyme.", [["fatty acid", "CHEMICAL", 65, 75], ["fatty acid", "CHEMICAL", 65, 75], ["fatty acid", "SIMPLE_CHEMICAL", 65, 75], ["enzyme", "PROTEIN", 112, 118], ["Some previous studies", "TEST", 0, 21], ["this fatty acid substrate", "PROBLEM", 60, 85], ["the enzyme", "TEST", 108, 118]]], ["In this study, molecular docking methodology using GOLD 5.0.1 program was employed to obtain the reliable binding mode of LTA4.", [["LTA4", "CHEMICAL", 122, 126], ["LTA4", "CHEMICAL", 122, 126], ["LTA4", "SIMPLE_CHEMICAL", 122, 126], ["LTA4", "PROTEIN", 122, 126], ["this study", "TEST", 3, 13]]], ["The GOLD program from Cambridge Crystallographic Data Centre, UK uses a genetic algorithm to dock the small molecules into the protein active site [46, 55] .", [["protein active site", "PROTEIN", 127, 146], ["a genetic algorithm", "TREATMENT", 70, 89], ["small", "OBSERVATION_MODIFIER", 102, 107]]], ["The GOLD allows for a full range of flexibility of the ligands and partial flexibility of the protein.", [["GOLD", "PROTEIN", 4, 8]]], ["One of the crystal structures of hLTA4H bound with most active inhibitor (PDB ID: 3FUN) solved at high resolution was used in molecular docking.", [["hLTA4H", "CHEMICAL", 33, 39], ["hLTA4H", "CHEMICAL", 33, 39], ["hLTA4H", "SIMPLE_CHEMICAL", 33, 39], ["hLTA4H", "PROTEIN", 33, 39], ["3FUN", "PROTEIN", 82, 86], ["hLTA4H bound", "PROBLEM", 33, 45], ["most active inhibitor", "TREATMENT", 51, 72]]], ["The bound inhibitor of this crystal structure was removed and the apoform of this enzyme was subjected to MD simulations with the parameters discussed below.", [["The bound inhibitor", "TREATMENT", 0, 19], ["this enzyme", "TEST", 77, 88]]], ["The representative structure with a RMSD value close to the average structure of last 3 ns of the 5 ns MD simulations was selected and utilized in molecular docking experiments.", [["a RMSD value", "PROBLEM", 34, 46], ["the 5 ns MD simulations", "TREATMENT", 94, 117], ["RMSD", "OBSERVATION_MODIFIER", 36, 40], ["average", "OBSERVATION_MODIFIER", 60, 67], ["structure", "OBSERVATION_MODIFIER", 68, 77]]], ["The active site was defined with a 10 \u00c5 radius around the bound inhibitor.", [["The active site", "PROBLEM", 0, 15], ["a 10 \u00c5 radius around the bound inhibitor", "TREATMENT", 33, 73], ["active", "OBSERVATION_MODIFIER", 4, 10], ["site", "OBSERVATION_MODIFIER", 11, 15]]], ["Early termination option was used to skip the genetic optimization calculation when any five conformations of a particular compound were predicted within an RMS deviation value of 1.5 \u00c5 .", [["Early termination option", "TREATMENT", 0, 24], ["the genetic optimization calculation", "TEST", 42, 78], ["an RMS deviation value", "TEST", 154, 176]]], ["The GOLD fitness score is calculated from the contributions of hydrogen bond and van der Waals interactions between the protein and ligand, intramolecular hydrogen bonds and strains of the ligand [56] .", [["hydrogen", "CHEMICAL", 63, 71], ["hydrogen", "CHEMICAL", 155, 163], ["The GOLD fitness score", "PROBLEM", 0, 22], ["hydrogen bond", "OBSERVATION", 63, 76]]], ["Protein-ligand interactions were analyzed using DS and Molegro Molecule Viewer [57] .", [["Protein", "TEST", 0, 7], ["DS", "TEST", 48, 50]]], ["The best pose was selected based on the molecular interactions and the distance between epoxy group of LTA4 and metal ion (Zn 2+ ) present in the active site as well as the location of its carboxylate group which interacts with the carboxylate recognition residues R563 and K565.", [["LTA4", "CHEMICAL", 103, 107], ["Zn", "CHEMICAL", 123, 125], ["epoxy", "CHEMICAL", 88, 93], ["LTA4", "CHEMICAL", 103, 107], ["Zn 2+ )", "CHEMICAL", 123, 130], ["carboxylate", "CHEMICAL", 189, 200], ["carboxylate", "CHEMICAL", 232, 243], ["R563", "CHEMICAL", 265, 269], ["K565", "CHEMICAL", 274, 278], ["LTA4", "SIMPLE_CHEMICAL", 103, 107], ["metal ion", "SIMPLE_CHEMICAL", 112, 121], ["Zn 2+", "SIMPLE_CHEMICAL", 123, 128], ["K565", "SIMPLE_CHEMICAL", 274, 278], ["epoxy group of LTA4", "TREATMENT", 88, 107], ["metal ion (Zn 2+ )", "TREATMENT", 112, 130], ["the carboxylate recognition residues", "TREATMENT", 228, 264], ["active site", "OBSERVATION", 146, 157]]], ["Finally, the enzyme-LTA4 complex was prepared to be used in further steps in this study.Preparation of complex structuresIn terms of preparing the enzyme-peptide complex to investigate the aminopeptidase function of LTA4H enzyme, 3D coordinates of the bound tripeptide Arg-Ala-Arg (RAR) in a solved X-ray structure of hLTA4H with a mutation E271Q (PDB ID: 3B7T) was utilized.", [["Arg-Ala-Arg", "CHEMICAL", 269, 280], ["Arg-Ala-Arg", "CHEMICAL", 269, 280], ["enzyme-LTA4", "GENE_OR_GENE_PRODUCT", 13, 24], ["LTA4H", "GENE_OR_GENE_PRODUCT", 216, 221], ["Arg", "AMINO_ACID", 277, 280], ["RAR", "GENE_OR_GENE_PRODUCT", 282, 285], ["hLTA4H", "GENE_OR_GENE_PRODUCT", 318, 324], ["enzyme-LTA4 complex", "PROTEIN", 13, 32], ["enzyme", "PROTEIN", 147, 153], ["aminopeptidase", "PROTEIN", 189, 203], ["LTA4H enzyme", "PROTEIN", 216, 228], ["RAR", "PROTEIN", 282, 285], ["X-ray structure", "PROTEIN", 299, 314], ["hLTA4H", "PROTEIN", 318, 324], ["the enzyme-LTA4 complex", "TREATMENT", 9, 32], ["this study", "TEST", 77, 87], ["the enzyme", "TEST", 143, 153], ["the aminopeptidase function", "TEST", 185, 212], ["LTA4H enzyme", "TEST", 216, 228], ["the bound tripeptide Arg", "TEST", 248, 272]]], ["The Superimpose Structures protocol as available in Accelrys Discovery Studio 3.0 (DS) was employed to copy the 3D coordinates of this tripeptide into the representative structure of LTA4H picked from the 5 ns MD simulation by superimposition.", [["tripeptide", "CHEMICAL", 135, 145], ["LTA4H", "PROTEIN", 183, 188], ["this tripeptide", "TREATMENT", 130, 145]]], ["This complex was subjected to energy minimization using Energy Minimization protocol of DS before considered further in this study.Molecular dynamics simulationsMany marvelous biological functions in proteins and DNA and their profound dynamic mechanisms, such as switch between active and inactive states [58, 59] , cooperative effects [60] , allosteric transition [61, 62] , intercalation of drugs into DNA [63] , and assembly of microtubules [64] , can be revealed by studying their internal motions [65] .", [["microtubules", "ANATOMY", 432, 444], ["DNA", "CELLULAR_COMPONENT", 213, 216], ["DNA", "CELLULAR_COMPONENT", 405, 408], ["microtubules", "PROTEIN", 432, 444], ["Energy Minimization protocol of DS", "TREATMENT", 56, 90], ["this study", "TEST", 120, 130], ["DNA", "PROBLEM", 213, 216], ["intercalation of drugs", "TREATMENT", 377, 399]]], ["Initial coordinates for the protein atoms were taken from the wild type (WT) and mutant forms of both L-LTA4, L-RAR complex structures.", [["wild type (WT)", "ORGANISM", 62, 76], ["L-LTA4", "GENE_OR_GENE_PRODUCT", 102, 108], ["L-RAR", "GENE_OR_GENE_PRODUCT", 110, 115], ["protein atoms", "PROTEIN", 28, 41], ["LTA4", "PROTEIN", 104, 108], ["RAR complex", "PROTEIN", 112, 123], ["the protein atoms", "TREATMENT", 24, 41], ["both", "ANATOMY_MODIFIER", 97, 101], ["L", "ANATOMY_MODIFIER", 102, 103], ["LTA4", "ANATOMY", 104, 108], ["L", "ANATOMY_MODIFIER", 110, 111], ["RAR", "ANATOMY", 112, 115]]], ["Mutations were introduced at E271Q, R563A, and K565A of the enzyme based on the previous experimental reports to investigate the single active site that catalyzes two different functions upon diverse substrates [14, 45] .", [["the enzyme", "TEST", 56, 66], ["the single active site", "PROBLEM", 125, 147], ["diverse substrates", "TEST", 192, 210]]], ["The protonation states of all ionizable residues were set to their normal states at pH 7.", [["all ionizable residues", "PROBLEM", 26, 48], ["protonation", "OBSERVATION", 4, 15], ["ionizable residues", "OBSERVATION", 30, 48]]], ["Eight MD simulations were performed for systems including WT and mutant forms of L-LTA4 and L-RAR complexes ( Table 1 ).", [["L-LTA4", "GENE_OR_GENE_PRODUCT", 81, 87], ["L-RAR", "GENE_OR_GENE_PRODUCT", 92, 97], ["LTA4", "PROTEIN", 83, 87], ["L", "PROTEIN", 92, 93], ["RAR complexes", "PROTEIN", 94, 107], ["Table 1", "PROTEIN", 110, 117], ["Eight MD simulations", "TEST", 0, 20], ["WT", "TEST", 58, 60], ["L-LTA4", "TEST", 81, 87], ["RAR", "ANATOMY", 94, 97]]], ["During the MD simulations, all the protein atoms including divalent metal ion (Zn 2+ ) were surrounded by a cubic water box of SPC3 water molecules that extended 10 \u00c5 from the protein and periodic boundary conditions were applied in all directions.", [["Zn", "CHEMICAL", 79, 81], ["Zn 2+ )", "CHEMICAL", 79, 86], ["SPC3", "CHEMICAL", 127, 131], ["divalent metal ion", "SIMPLE_CHEMICAL", 59, 77], ["Zn 2+", "SIMPLE_CHEMICAL", 79, 84], ["SPC3 water molecules", "SIMPLE_CHEMICAL", 127, 147], ["cubic water box", "PROTEIN", 108, 123], ["SPC3 water molecules", "PROTEIN", 127, 147], ["all the protein atoms", "TREATMENT", 27, 48], ["divalent metal ion (Zn 2+ )", "TREATMENT", 59, 86], ["a cubic water box of SPC3 water molecules", "TREATMENT", 106, 147], ["periodic boundary conditions", "TREATMENT", 188, 216], ["boundary conditions", "OBSERVATION", 197, 216]]], ["The systems were neutralized with Na + and Cl 2 counter ions replacing the water molecules and energy minimization was performed using steepest descent algorithm for 10,000 steps.", [["Na", "CHEMICAL", 34, 36], ["Cl", "CHEMICAL", 43, 45], ["Na +", "CHEMICAL", 34, 38], ["Cl", "CHEMICAL", 43, 45], ["Na +", "SIMPLE_CHEMICAL", 34, 38], ["Cl 2 counter ions", "SIMPLE_CHEMICAL", 43, 60], ["Na", "TEST", 34, 36], ["Cl 2 counter ions", "TREATMENT", 43, 60], ["the water molecules", "TREATMENT", 71, 90], ["energy minimization", "TREATMENT", 95, 114], ["steepest descent algorithm", "TREATMENT", 135, 161]]], ["A 100 ps position restrained MD simulations were performed for every system followed by 5 ns production MD simulations with a time step of 2 fs at constant pressure (1 atm), temperature (300 K).", [["A 100 ps position restrained", "TREATMENT", 0, 28], ["temperature", "TEST", 174, 185]]], ["The electrostatic interactions were calculated by the PME algorithm and all bonds were constrained using LINCS algorithm.", [["the PME algorithm", "TEST", 50, 67], ["LINCS algorithm", "TEST", 105, 120], ["electrostatic interactions", "OBSERVATION", 4, 30]]], ["A twin range cutoff was used for long-range interactions including 0.9 nm for van der Waals and 1.4 nm for electrostatic interactions.", [["A twin range cutoff", "TEST", 0, 19], ["van der Waals", "TREATMENT", 78, 91], ["electrostatic interactions", "PROBLEM", 107, 133]]], ["The system stability and behavior of the catalytic structural components present in every system were analyzed using the tools available with GROMACS 4.0.5 and PyMol programs.Molecular mechanisms and enzyme-substrate complexesSurprisingly, the LTA4H enzyme catalyzes both hydrolase and aminopeptidase functions over fatty acid and peptide substrates utilizing the same active site.", [["fatty acid", "CHEMICAL", 316, 326], ["fatty acid", "CHEMICAL", 316, 326], ["LTA4H", "GENE_OR_GENE_PRODUCT", 244, 249], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 286, 300], ["fatty acid", "SIMPLE_CHEMICAL", 316, 326], ["enzyme", "PROTEIN", 200, 206], ["LTA4H enzyme", "PROTEIN", 244, 256], ["hydrolase", "PROTEIN", 272, 281], ["aminopeptidase", "PROTEIN", 286, 300], ["the tools", "TEST", 117, 126], ["GROMACS", "TREATMENT", 142, 149], ["PyMol programs", "TREATMENT", 160, 174], ["Molecular mechanisms", "TEST", 175, 195], ["enzyme", "TEST", 200, 206], ["the LTA4H enzyme catalyzes", "TEST", 240, 266], ["hydrolase", "TEST", 272, 281], ["aminopeptidase functions", "TEST", 286, 310], ["fatty acid and peptide substrates", "TREATMENT", 316, 349], ["stability", "OBSERVATION_MODIFIER", 11, 20], ["active site", "OBSERVATION", 369, 380]]], ["In order to obtain deeper insight upon this unique characteristic of the enzyme, a set of MD simulations were performed with WT and mutated enzymesubstrate complex structures.", [["enzyme", "PROTEIN", 73, 79], ["the enzyme", "TEST", 69, 79], ["MD simulations", "TEST", 90, 104], ["WT", "TEST", 125, 127]]], ["The natural epoxy substrate LTA4 of arachidonic acid pathway, which is converted to LTB4 upon the action of the enzyme, was selected as fatty acid substrate to investigate the hydrolase function of the enzyme.", [["LTA4", "CHEMICAL", 28, 32], ["arachidonic acid", "CHEMICAL", 36, 52], ["LTB4", "CHEMICAL", 84, 88], ["epoxy", "CHEMICAL", 12, 17], ["LTA4", "CHEMICAL", 28, 32], ["arachidonic acid", "CHEMICAL", 36, 52], ["LTB4", "CHEMICAL", 84, 88], ["fatty acid", "CHEMICAL", 136, 146], ["LTA4", "SIMPLE_CHEMICAL", 28, 32], ["arachidonic acid", "SIMPLE_CHEMICAL", 36, 52], ["LTB4", "SIMPLE_CHEMICAL", 84, 88], ["fatty acid", "SIMPLE_CHEMICAL", 136, 146], ["enzyme", "PROTEIN", 112, 118], ["hydrolase", "PROTEIN", 176, 185], ["enzyme", "PROTEIN", 202, 208], ["The natural epoxy substrate LTA4 of arachidonic acid pathway", "TREATMENT", 0, 60], ["LTB4", "TREATMENT", 84, 88], ["the enzyme", "TEST", 108, 118], ["fatty acid substrate", "PROBLEM", 136, 156], ["the enzyme", "TEST", 198, 208]]], ["In the other hand, RAR tripeptide that is reported to be the preferred peptide substrate of the enzyme [14] was selected to investigate the aminopeptidase function of the enzyme.", [["tripeptide", "CHEMICAL", 23, 33], ["RAR tripeptide", "GENE_OR_GENE_PRODUCT", 19, 33], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 140, 154], ["RAR tripeptide", "PROTEIN", 19, 33], ["aminopeptidase", "PROTEIN", 140, 154], ["enzyme", "PROTEIN", 171, 177], ["the enzyme", "TEST", 92, 102], ["the enzyme", "TEST", 167, 177]]], ["The L-LTA4 complex was prepared through the molecular docking methodology whereas L-RAR complex was prepared by copying the 3D coordinates of RAR from the X-ray crystal structure of LTA4 ( Figure 3 ).", [["L-LTA4", "GENE_OR_GENE_PRODUCT", 4, 10], ["L-RAR", "GENE_OR_GENE_PRODUCT", 82, 87], ["RAR", "GENE_OR_GENE_PRODUCT", 142, 145], ["LTA4", "SIMPLE_CHEMICAL", 182, 186], ["L-LTA4 complex", "PROTEIN", 4, 18], ["RAR complex", "PROTEIN", 84, 95], ["RAR", "PROTEIN", 142, 145], ["LTA4", "PROTEIN", 182, 186], ["LTA4", "ANATOMY", 182, 186]]], ["The representative structure obtained from the MD simulation of LTA4H-apoform was used in preparing both the complex structures to compare the structural changes effectively with no artifacts.", [["LTA4H", "CHEMICAL", 64, 69], ["LTA4H", "SIMPLE_CHEMICAL", 64, 69], ["LTA4H", "PROTEIN", 64, 69], ["LTA4H-apoform", "TREATMENT", 64, 77], ["artifacts", "PROBLEM", 182, 191], ["no", "UNCERTAINTY", 179, 181], ["artifacts", "OBSERVATION", 182, 191]]], ["From the reported site-directed mutagenesis experiments, three amino acid residues from the catalytic active site of the enzyme were predicted to be very important for the enzymatic activities of the enzyme.", [["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["amino acid", "AMINO_ACID", 63, 73], ["catalytic active site", "PROTEIN", 92, 113], ["enzyme", "PROTEIN", 121, 127], ["enzyme", "PROTEIN", 200, 206], ["directed mutagenesis experiments", "TREATMENT", 23, 55], ["three amino acid residues", "TREATMENT", 57, 82], ["the enzyme", "TEST", 117, 127], ["the enzyme", "TEST", 196, 206]]], ["These residues include one negatively charged E271 residue from the central catalytic domain and two positively charged R563 and K565 residues from the Cterminal domain.", [["E271", "CHEMICAL", 46, 50], ["R563", "CHEMICAL", 120, 124], ["K565", "CHEMICAL", 129, 133], ["central catalytic domain", "PROTEIN", 68, 92], ["R563", "PROTEIN", 120, 124], ["K565 residues", "PROTEIN", 129, 142], ["Cterminal domain", "PROTEIN", 152, 168]]], ["Studies mentioned that mutation of this negatively charged residue to a neutral glutamine (E271Q) has completely abrogated both the catalytic activities of the enzyme.", [["glutamine", "CHEMICAL", 80, 89], ["E271Q", "CHEMICAL", 91, 96], ["glutamine", "CHEMICAL", 80, 89], ["glutamine", "AMINO_ACID", 80, 89], ["E271Q", "AMINO_ACID", 91, 96], ["enzyme", "PROTEIN", 160, 166], ["this negatively charged residue", "PROBLEM", 35, 66], ["a neutral glutamine", "TREATMENT", 70, 89], ["the enzyme", "TEST", 156, 166]]], ["But the crystal structure solved with this mutation (PDB ID: 1H19) could not report any structural or conformational changes causing this drastic change in the catalytic activity [14] .", [["this mutation", "PROBLEM", 38, 51], ["any structural or conformational changes", "PROBLEM", 84, 124], ["this drastic change", "PROBLEM", 133, 152]]], ["It was also proposed that metal (Zn 2+ ) ion present close to the epoxide moiety of LTA4 acts as a weak Lewis acid to activate and open the epoxide ring.", [["Zn", "CHEMICAL", 33, 35], ["LTA4", "CHEMICAL", 84, 88], ["Zn 2+ )", "CHEMICAL", 33, 40], ["epoxide", "CHEMICAL", 66, 73], ["LTA4", "CHEMICAL", 84, 88], ["Lewis acid", "CHEMICAL", 104, 114], ["epoxide", "CHEMICAL", 140, 147], ["Zn 2+ )", "SIMPLE_CHEMICAL", 33, 40], ["epoxide", "SIMPLE_CHEMICAL", 66, 73], ["LTA4", "SIMPLE_CHEMICAL", 84, 88], ["Lewis acid", "SIMPLE_CHEMICAL", 104, 114], ["metal (Zn 2+ ) ion", "TREATMENT", 26, 44], ["the epoxide moiety of LTA4 acts", "TREATMENT", 62, 93], ["a weak Lewis acid", "TREATMENT", 97, 114], ["open the epoxide ring", "TREATMENT", 131, 152], ["epoxide ring", "OBSERVATION", 140, 152]]], ["It continued to explain that the E271 located in proximity to Zn 2+ also participates in this acid-induced opening of the epoxide ring of LTA4.", [["E271", "CHEMICAL", 33, 37], ["Zn", "CHEMICAL", 62, 64], ["LTA4", "CHEMICAL", 138, 142], ["Zn 2+", "CHEMICAL", 62, 67], ["epoxide", "CHEMICAL", 122, 129], ["LTA4", "CHEMICAL", 138, 142], ["Zn 2+", "SIMPLE_CHEMICAL", 62, 67], ["epoxide", "SIMPLE_CHEMICAL", 122, 129], ["LTA4", "SIMPLE_CHEMICAL", 138, 142], ["E271", "DNA", 33, 37], ["LTA4", "PROTEIN", 138, 142], ["the epoxide ring of LTA4", "TREATMENT", 118, 142]]], ["It was also reported that E271 acts as the N-terminal recognition point in stabilizing the peptide substrates in terms of aminopeptidase reaction of the enzyme.", [["E271", "CHEMICAL", 26, 30], ["E271", "CHEMICAL", 26, 30], ["N", "CHEMICAL", 43, 44], ["E271", "SIMPLE_CHEMICAL", 26, 30], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 122, 136], ["N-terminal recognition point", "PROTEIN", 43, 71], ["aminopeptidase", "PROTEIN", 122, 136], ["enzyme", "PROTEIN", 153, 159], ["aminopeptidase reaction", "PROBLEM", 122, 145], ["the enzyme", "TEST", 149, 159]]], ["The positively charged residues R563 and K565 were predicted as the carboxylate recognition sites for both the substrates of the enzyme.", [["R563", "CHEMICAL", 32, 36], ["K565", "CHEMICAL", 41, 45], ["carboxylate", "CHEMICAL", 68, 79], ["K565", "SIMPLE_CHEMICAL", 41, 45], ["carboxylate recognition sites", "PROTEIN", 68, 97], ["enzyme", "PROTEIN", 129, 135], ["the carboxylate recognition sites", "PROBLEM", 64, 97], ["the enzyme", "TEST", 125, 135], ["charged residues", "OBSERVATION", 15, 31]]], ["All mutations of R563 including R563K, which preserved the positive charge, have resulted in complete loss of catalytic functions of the enzyme.", [["R563K", "AMINO_ACID", 32, 37], ["enzyme", "PROTEIN", 137, 143], ["All mutations", "TEST", 0, 13], ["complete loss of catalytic functions of the enzyme", "PROBLEM", 93, 143], ["positive charge", "OBSERVATION", 59, 74]]], ["The R563K mutant has shown a significant aminopeptidase activity.", [["R563K", "GENE_OR_GENE_PRODUCT", 4, 9], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 41, 55], ["R563K mutant", "PROTEIN", 4, 16], ["aminopeptidase", "PROTEIN", 41, 55], ["a significant aminopeptidase activity", "PROBLEM", 27, 64], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["aminopeptidase activity", "OBSERVATION", 41, 64]]], ["All these mutations of R563 leading to tremendous change in enzyme functions did not reveal any structural changes explaining the loss of activities.", [["R563", "CHEMICAL", 23, 27], ["R563", "DNA", 23, 27], ["All these mutations", "TEST", 0, 19], ["tremendous change in enzyme functions", "PROBLEM", 39, 76], ["any structural changes", "PROBLEM", 92, 114], ["the loss of activities", "PROBLEM", 126, 148]]], ["Especially in epoxide hydrolase reaction, the role of R563 was presumed to position the carboxylate tail of the substrates along the catalytic components of the active site [45] .", [["R563", "CHEMICAL", 54, 58], ["epoxide", "CHEMICAL", 14, 21], ["carboxylate", "CHEMICAL", 88, 99], ["epoxide hydrolase", "GENE_OR_GENE_PRODUCT", 14, 31], ["R563", "GENE_OR_GENE_PRODUCT", 54, 58], ["epoxide hydrolase", "PROTEIN", 14, 31], ["R563", "PROTEIN", 54, 58], ["carboxylate tail", "PROTEIN", 88, 104], ["catalytic components", "PROTEIN", 133, 153], ["epoxide hydrolase reaction", "TREATMENT", 14, 40], ["carboxylate tail", "OBSERVATION", 88, 104], ["active", "OBSERVATION_MODIFIER", 161, 167], ["site", "OBSERVATION_MODIFIER", 168, 172]]], ["In terms of aminopeptidase reaction, both the positively charged (R563 and K565) residues help each other in aligning the substrate with the catalytic elements and maintaining the binding strength.", [["R563", "CHEMICAL", 66, 70], ["K565", "CHEMICAL", 75, 79], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 12, 26], ["aminopeptidase", "PROTEIN", 12, 26], ["catalytic elements", "PROTEIN", 141, 159], ["aminopeptidase reaction", "PROBLEM", 12, 35], ["aminopeptidase reaction", "OBSERVATION", 12, 35], ["binding strength", "OBSERVATION", 180, 196]]], ["The mutations K565A and K565M lacking the positive charge have reduced the aminopeptidase and revealed that this positively charged residue assists R563 in carboxylate recognition in aminopeptidase reaction [27] .", [["R563", "CHEMICAL", 148, 152], ["carboxylate", "CHEMICAL", 156, 167], ["R563", "CHEMICAL", 148, 152], ["carboxylate", "CHEMICAL", 156, 167], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 75, 89], ["R563", "SIMPLE_CHEMICAL", 148, 152], ["carboxylate", "SIMPLE_CHEMICAL", 156, 167], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 183, 197], ["aminopeptidase", "PROTEIN", 75, 89], ["aminopeptidase", "PROTEIN", 183, 197], ["The mutations K565A", "TEST", 0, 19], ["the aminopeptidase", "TEST", 71, 89], ["aminopeptidase reaction", "TEST", 183, 206]]], ["Despite of this information over the importance of E271, R563, and R565, the structural changes explaining the catalytic activities of the enzyme are lacking.", [["E271", "GENE_OR_GENE_PRODUCT", 51, 55], ["enzyme", "PROTEIN", 139, 145], ["the structural changes", "PROBLEM", 73, 95], ["the enzyme", "TEST", 135, 145]]], ["The results of MD simulations of WT and mutant enzyme-substrate complexes discussed in this study will provide a deeper insight from the structural perspective.Molecular mechanisms and enzyme-substrate complexesOverall structural stability of the systems The overall stability analyses are considered important to note that the systems did not undergo any unusual changes during the time scale of simulation because of erratic system preparation.", [["mutant enzyme", "PROTEIN", 40, 53], ["substrate complexes", "PROTEIN", 54, 73], ["enzyme-substrate complexes", "PROTEIN", 185, 211], ["WT", "TEST", 33, 35], ["mutant enzyme-substrate complexes", "PROBLEM", 40, 73], ["this study", "TEST", 87, 97], ["Molecular mechanisms", "PROBLEM", 160, 180], ["enzyme", "TEST", 185, 191], ["any unusual changes", "PROBLEM", 352, 371], ["erratic system preparation", "TREATMENT", 419, 445], ["structural stability", "OBSERVATION", 219, 239], ["stability", "OBSERVATION", 267, 276]]], ["In this study, root mean square deviation (rmsd), root mean square fluctuation (rmsf), and intra-molecular hydrogen bonds were used in analyzing and comparing the stability of the systems under study (Figure 4) .Molecular mechanisms and enzyme-substrate complexesIn terms of L-LTA4 systems, the calculated average rmsd value of K565A system was 0.158 nm which is lower than the rmsd values of WT (0.189 nm), E272Q (0.186 nm), and R563A (0.202 nm) systems ( Figure 4A ).", [["root", "ANATOMY", 15, 19], ["hydrogen", "CHEMICAL", 107, 115], ["enzyme-substrate complexes", "PROTEIN", 237, 263], ["L-LTA4", "PROTEIN", 275, 281], ["K565A", "PROTEIN", 328, 333], ["R563A", "PROTEIN", 430, 435], ["this study", "TEST", 3, 13], ["root mean square deviation (rmsd)", "PROBLEM", 15, 48], ["root mean square fluctuation (rmsf)", "PROBLEM", 50, 85], ["intra-molecular hydrogen bonds", "PROBLEM", 91, 121], ["Molecular mechanisms", "PROBLEM", 212, 232], ["enzyme", "TEST", 237, 243], ["the calculated average rmsd value", "TEST", 291, 324], ["K565A system", "TEST", 328, 340], ["WT", "TEST", 393, 395], ["root", "OBSERVATION_MODIFIER", 15, 19], ["root", "OBSERVATION_MODIFIER", 50, 54], ["hydrogen bonds", "OBSERVATION", 107, 121], ["lower", "OBSERVATION_MODIFIER", 363, 368]]], ["The R563A system has shown the higher rmsd value and thereby indicating the additional effect of this particular mutation.", [["R563A", "PROTEIN", 4, 9], ["The R563A system", "TEST", 0, 16], ["this particular mutation", "PROBLEM", 97, 121], ["higher rmsd", "OBSERVATION", 31, 42]]], ["Despite of these small differences in the rmsd values between the L-LTA4 systems, the systems were stabilized well throughout the timescale of simulation.", [["these small differences", "PROBLEM", 11, 34], ["the rmsd values", "TEST", 38, 53], ["small", "OBSERVATION_MODIFIER", 17, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34], ["stabilized", "OBSERVATION", 99, 109]]], ["As another method to investigate the stability of the systems, rmsf values of all systems were calculated during the simulation and plotted.", [["rmsf", "GENE_OR_GENE_PRODUCT", 63, 67], ["rmsf", "PROTEIN", 63, 67], ["rmsf values", "TEST", 63, 74], ["the simulation", "TEST", 113, 127], ["rmsf", "OBSERVATION", 63, 67]]], ["From the plot, it was observed that none of the active site residues were fluctuating higher than 0.2 nm and explained the stable nature of the systems over the time scale of simulation.", [["the active site residues", "PROBLEM", 44, 68], ["active", "OBSERVATION_MODIFIER", 48, 54], ["site residues", "OBSERVATION", 55, 68], ["stable", "OBSERVATION_MODIFIER", 123, 129]]], ["In addition, the number of intramolecular hydrogen bonds were calculated for all the systems and plotted.", [["hydrogen", "CHEMICAL", 42, 50], ["intramolecular hydrogen bonds", "PROBLEM", 27, 56], ["intramolecular", "OBSERVATION", 27, 41], ["hydrogen bonds", "OBSERVATION", 42, 56]]], ["The average number of hydrogen bonds revealed that R563A system has formed more number of hydrogen bonds (466.9) compared to WT (452.8), E272Q (451.7) and R565A (450.6) systems which displayed the reduced number of hydrogen bonds.", [["R563A", "CHEMICAL", 51, 56], ["hydrogen", "CHEMICAL", 22, 30], ["hydrogen", "CHEMICAL", 90, 98], ["hydrogen", "CHEMICAL", 215, 223], ["R563A", "PROTEIN", 51, 56], ["hydrogen bonds", "TEST", 22, 36], ["hydrogen bonds", "TEST", 90, 104], ["WT", "TEST", 125, 127], ["hydrogen bonds", "OBSERVATION", 22, 36], ["more", "OBSERVATION_MODIFIER", 75, 79], ["number", "OBSERVATION_MODIFIER", 80, 86], ["hydrogen bonds", "OBSERVATION", 90, 104], ["reduced", "OBSERVATION_MODIFIER", 197, 204], ["number", "OBSERVATION_MODIFIER", 205, 211], ["hydrogen bonds", "OBSERVATION", 215, 229]]], ["This result also has confirmed the stability of the systems despite of small differences between systems ( Figure 4A ).Molecular mechanisms and enzyme-substrate complexesIn L-RAR systems, the average rmsd value of K565A (0.212 nm) was higher than other systems, which is completely contrasted to the rmsd value of equivalent L-LTA4 system whereas the R563A system has shown the average lower rmsd value (0.168 nm).", [["L-RAR", "GENE_OR_GENE_PRODUCT", 173, 178], ["enzyme", "PROTEIN", 144, 150], ["RAR", "PROTEIN", 175, 178], ["-LTA4", "PROTEIN", 326, 331], ["R563A", "PROTEIN", 351, 356], ["small differences between systems", "PROBLEM", 71, 104], ["Molecular mechanisms", "TEST", 119, 139], ["enzyme", "TEST", 144, 150], ["K565A", "TEST", 214, 219], ["stability", "OBSERVATION_MODIFIER", 35, 44], ["small", "OBSERVATION_MODIFIER", 71, 76], ["RAR", "ANATOMY", 175, 178], ["average", "OBSERVATION_MODIFIER", 192, 199], ["rmsd", "OBSERVATION_MODIFIER", 200, 204], ["average", "OBSERVATION_MODIFIER", 378, 385], ["lower", "OBSERVATION_MODIFIER", 386, 391], ["rmsd", "OBSERVATION_MODIFIER", 392, 396]]], ["The other two systems, WT and E272Q, have shown the same average rmsd value of 0.189 nm from last 3 ns of the simulation time ( Figure 4B ).", [["WT", "TEST", 23, 25]]], ["In terms of rmsf calculations, the rmsf plot has shown that except D375 and Y378 residues of the active site all other important active site components were stable throughout the simulation.", [["D375", "CHEMICAL", 67, 71], ["Y378", "CHEMICAL", 76, 80], ["D375", "GENE_OR_GENE_PRODUCT", 67, 71], ["rmsf", "PROTEIN", 12, 16], ["rmsf calculations", "TEST", 12, 29], ["the rmsf plot", "TEST", 31, 44], ["the active site", "PROBLEM", 93, 108], ["rmsf", "OBSERVATION", 12, 16], ["active", "OBSERVATION_MODIFIER", 97, 103], ["site", "OBSERVATION_MODIFIER", 104, 108], ["active", "OBSERVATION_MODIFIER", 129, 135], ["stable", "OBSERVATION_MODIFIER", 157, 163]]], ["This high fluctuation of these two residues was mainly observed in K565A system.", [["K565A", "PROTEIN", 67, 72], ["This high fluctuation of these two residues", "PROBLEM", 0, 43], ["two residues", "OBSERVATION", 31, 43]]], ["The average number of intramolecular hydrogen bonds during last 3 ns of the simulation was very similar in all the systems.", [["hydrogen", "CHEMICAL", 37, 45], ["intramolecular hydrogen bonds", "PROBLEM", 22, 51], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["intramolecular hydrogen bonds", "OBSERVATION", 22, 51]]], ["At the end of the simulation time, the R563A and K565A systems started losing their hydrogen bonds and thereby became less intact compared to other systems.", [["hydrogen", "CHEMICAL", 84, 92], ["hydrogen bonds", "OBSERVATION", 84, 98], ["less", "OBSERVATION_MODIFIER", 118, 122], ["intact", "OBSERVATION", 123, 129]]], ["All the systems were investigated for the stability and found to be well stabilized during the simulation.", [["stabilized", "OBSERVATION", 73, 83]]], ["Thus the representative structures close to the least rmsd value of each system was obtained and used in structural comparison.Distance and hydrogen bond analysesThe distance between the most important metal (Zn 2+ ) ion and oxygen atom of the epoxy ring in case of L-LTA4 systems is very important for the hydrolase function of the enzyme.", [["Zn", "CHEMICAL", 209, 211], ["oxygen", "CHEMICAL", 225, 231], ["hydrogen", "CHEMICAL", 140, 148], ["Zn 2+ )", "CHEMICAL", 209, 216], ["oxygen", "CHEMICAL", 225, 231], ["epoxy", "CHEMICAL", 244, 249], ["Zn 2+ )", "SIMPLE_CHEMICAL", 209, 216], ["oxygen atom", "SIMPLE_CHEMICAL", 225, 236], ["L-LTA4", "SIMPLE_CHEMICAL", 266, 272], ["L-LTA4", "PROTEIN", 266, 272], ["hydrolase", "PROTEIN", 307, 316], ["enzyme", "PROTEIN", 333, 339], ["Distance and hydrogen bond analyses", "TEST", 127, 162], ["metal (Zn 2+ ) ion and oxygen atom", "TREATMENT", 202, 236], ["the epoxy ring", "TREATMENT", 240, 254], ["L-LTA4 systems", "PROBLEM", 266, 280], ["the enzyme", "TEST", 329, 339], ["hydrogen bond", "OBSERVATION", 140, 153], ["distance", "OBSERVATION_MODIFIER", 166, 174], ["epoxy ring", "OBSERVATION", 244, 254]]], ["The average distance value observed in WT system (0.56 nm) was lower compared to the mutant systems.", [["The average distance value", "TEST", 0, 26], ["average", "OBSERVATION_MODIFIER", 4, 11], ["distance", "OBSERVATION_MODIFIER", 12, 20]]], ["Among mutant systems R563A system has shown the higher average distance value of 0.78 nm whereas E271Q and K565A systems have shown similar average distance value of 0.69 nm and 0.63 nm, respectively.", [["K565A systems", "TEST", 107, 120], ["higher", "OBSERVATION_MODIFIER", 48, 54], ["average", "OBSERVATION_MODIFIER", 55, 62]]], ["During the end of the simulations, this distance in E271Q and K565A systems has reduced close to the distance of WT but R563A has maintained higher distance until the end ( Figure 5A ).", [["E271Q and K565A systems", "DNA", 52, 75], ["R563A", "PROTEIN", 120, 125]]], ["In terms of L-RAR systems, the distance between the same metal ion and carbonyl oxygen atom of N-terminal peptide bond was measured and compared between the L-RAR WT and mutant systems.", [["carbonyl", "CHEMICAL", 71, 79], ["oxygen", "CHEMICAL", 80, 86], ["N-terminal peptide", "CHEMICAL", 95, 113], ["carbonyl", "CHEMICAL", 71, 79], ["oxygen", "CHEMICAL", 80, 86], ["N", "CHEMICAL", 95, 96], ["L-RAR", "GENE_OR_GENE_PRODUCT", 12, 17], ["carbonyl oxygen atom", "SIMPLE_CHEMICAL", 71, 91], ["L-RAR", "GENE_OR_GENE_PRODUCT", 157, 162], ["RAR", "PROTEIN", 14, 17], ["RAR WT", "PROTEIN", 159, 165], ["the same metal ion and carbonyl oxygen atom", "TREATMENT", 48, 91], ["terminal peptide bond", "TEST", 97, 118], ["L", "ANATOMY_MODIFIER", 12, 13], ["RAR systems", "ANATOMY", 14, 25], ["carbonyl oxygen", "OBSERVATION", 71, 86]]], ["As observed in L-LTA4 systems, WT of L-RAR systems has maintained the lower average distance value of 0.59 nm whereas Figure 5B ).", [["L-LTA4", "CHEMICAL", 15, 21], ["L-LTA4", "GENE_OR_GENE_PRODUCT", 15, 21], ["L-RAR", "GENE_OR_GENE_PRODUCT", 37, 42], ["L-LTA4 systems", "CELL_LINE", 15, 29], ["RAR", "PROTEIN", 39, 42], ["L-LTA4 systems", "TEST", 15, 29], ["WT", "TEST", 31, 33], ["L-RAR systems", "TEST", 37, 50]]], ["The hydrogen bonds formed between the protein and bound ligands were also calculated for all the systems under study to investigate the molecular interactions that are lost during the mutations.", [["hydrogen", "CHEMICAL", 4, 12], ["hydrogen bonds", "OBSERVATION", 4, 18], ["bound ligands", "OBSERVATION", 50, 63]]], ["In L-LTA4 systems, WT system has formed high number of average hydrogen bonds (5.7) compared to the mutant systems.", [["hydrogen", "CHEMICAL", 63, 71], ["L-LTA4", "GENE_OR_GENE_PRODUCT", 3, 9], ["L-LTA4 systems", "TEST", 3, 17], ["WT system", "TEST", 19, 28], ["LTA4", "ANATOMY_MODIFIER", 5, 9], ["high", "OBSERVATION_MODIFIER", 40, 44], ["number", "OBSERVATION_MODIFIER", 45, 51], ["hydrogen bonds", "OBSERVATION", 63, 77]]], ["The K565A system has shown an average number of hydrogen bonds of 5.0 whereas E271Q and R563A systems have formed only 1.7 and 1.8 average number of hydrogen bonds with the bound ligand ( Figure 6A ).", [["hydrogen", "CHEMICAL", 48, 56], ["hydrogen", "CHEMICAL", 149, 157], ["The K565A system", "TEST", 0, 16], ["hydrogen bonds", "TEST", 48, 62], ["R563A systems", "TEST", 88, 101], ["average", "OBSERVATION_MODIFIER", 30, 37], ["number", "OBSERVATION_MODIFIER", 38, 44], ["hydrogen bonds", "OBSERVATION", 48, 62], ["hydrogen bonds", "OBSERVATION", 149, 163]]], ["This reduced number of hydrogen bonds correlate well with previously reported loss of hydrolase activity of the enzyme in E271Q and R563A mutated systems [14, 45] .", [["hydrogen", "CHEMICAL", 23, 31], ["hydrolase", "PROTEIN", 86, 95], ["R563A", "PROTEIN", 132, 137], ["loss of hydrolase activity", "PROBLEM", 78, 104], ["the enzyme", "TEST", 108, 118], ["hydrogen bonds", "OBSERVATION", 23, 37]]], ["In terms of L-RAR systems, the E271Q system has formed more number of average hydrogen bonds (8.7) with the bound RAR.", [["hydrogen", "CHEMICAL", 78, 86], ["L-RAR", "GENE_OR_GENE_PRODUCT", 12, 17], ["RAR", "GENE_OR_GENE_PRODUCT", 114, 117], ["RAR", "PROTEIN", 14, 17], ["RAR", "PROTEIN", 114, 117], ["the bound RAR", "PROBLEM", 104, 117], ["L", "ANATOMY_MODIFIER", 12, 13], ["RAR systems", "ANATOMY", 14, 25], ["more", "OBSERVATION_MODIFIER", 55, 59], ["number", "OBSERVATION_MODIFIER", 60, 66], ["hydrogen bonds", "OBSERVATION", 78, 92]]], ["Whereas the WT system has shown an average hydrogen bond value of 8.0, the other mutant systems R563A and K565A have shown the average hydrogen bond values of 4.3 and 3.9, respectively ( Figure 6B ).", [["hydrogen", "CHEMICAL", 43, 51], ["hydrogen", "CHEMICAL", 135, 143], ["the WT system", "TEST", 8, 21], ["an average hydrogen bond value", "TEST", 32, 62], ["K565A", "TEST", 106, 111], ["the average hydrogen bond values", "TEST", 123, 155], ["average", "OBSERVATION_MODIFIER", 35, 42], ["hydrogen bond", "OBSERVATION", 43, 56]]], ["This result of number of hydrogen bond values observed between protein and RAR has proved the importance of both R564 and K565 to maintain the substrate alignment in the active site and the binding strength of the substrate.", [["hydrogen", "CHEMICAL", 25, 33], ["hydrogen", "CHEMICAL", 25, 33], ["RAR", "GENE_OR_GENE_PRODUCT", 75, 78], ["RAR", "PROTEIN", 75, 78], ["K565", "PROTEIN", 122, 126], ["hydrogen bond values", "TEST", 25, 45], ["K565", "TREATMENT", 122, 126], ["hydrogen bond", "OBSERVATION", 25, 38], ["active site", "OBSERVATION", 170, 181]]], ["But the high number of observed hydrogen bonds in E271Q system does not correlate with the observed loss of catalytic activity due to the mutation of E271.", [["hydrogen", "CHEMICAL", 32, 40], ["E271", "CHEMICAL", 150, 154], ["hydrogen", "CHEMICAL", 32, 40], ["E271", "CHEMICAL", 150, 154], ["E271Q", "PROTEIN", 50, 55], ["E271", "PROTEIN", 150, 154], ["observed hydrogen bonds in E271Q system", "PROBLEM", 23, 62], ["the observed loss of catalytic activity", "PROBLEM", 87, 126], ["the mutation of E271", "PROBLEM", 134, 154], ["high", "OBSERVATION_MODIFIER", 8, 12], ["number", "OBSERVATION_MODIFIER", 13, 19], ["hydrogen bonds", "OBSERVATION", 32, 46]]], ["This indicated that other structural disturbances script the loss of catalytic function of the enzyme.Binding mode analysesL-LTA4 systems.", [["enzyme", "PROTEIN", 95, 101], ["other structural disturbances", "PROBLEM", 20, 49], ["the enzyme", "TEST", 91, 101], ["Binding mode analysesL", "TEST", 102, 124]]], ["In L-LTA4 systems, the binding mode of LTA4 in WT system has formed hydrogen bonds with Y383 through the oxygen atom of epoxy ring and the distance between this oxygen atom and the metal ion was maintained in a closer distance compared to that of mutant systems.", [["LTA4", "CHEMICAL", 39, 43], ["Y383", "CHEMICAL", 88, 92], ["oxygen", "CHEMICAL", 105, 111], ["oxygen", "CHEMICAL", 161, 167], ["LTA4", "CHEMICAL", 39, 43], ["hydrogen", "CHEMICAL", 68, 76], ["Y383", "CHEMICAL", 88, 92], ["oxygen", "CHEMICAL", 105, 111], ["epoxy", "CHEMICAL", 120, 125], ["oxygen", "CHEMICAL", 161, 167], ["LTA4", "GENE_OR_GENE_PRODUCT", 39, 43], ["Y383", "SIMPLE_CHEMICAL", 88, 92], ["oxygen", "SIMPLE_CHEMICAL", 105, 111], ["epoxy ring", "SIMPLE_CHEMICAL", 120, 130], ["oxygen atom", "SIMPLE_CHEMICAL", 161, 172], ["LTA4", "PROTEIN", 39, 43], ["LTA4 in WT system", "TREATMENT", 39, 56], ["the oxygen atom of epoxy ring", "TREATMENT", 101, 130], ["this oxygen atom", "TREATMENT", 156, 172], ["the metal ion", "TREATMENT", 177, 190], ["hydrogen bonds", "OBSERVATION", 68, 82], ["epoxy ring", "OBSERVATION", 120, 130], ["oxygen atom", "OBSERVATION", 161, 172]]], ["The carboxylate group of LTA4 in WT system was well recognized by both the positively charged residues R563 and K565 which are reported to be the carboxylate recognition sites.", [["carboxylate", "CHEMICAL", 4, 15], ["LTA4", "CHEMICAL", 25, 29], ["carboxylate", "CHEMICAL", 4, 15], ["LTA4", "CHEMICAL", 25, 29], ["R563", "CHEMICAL", 103, 107], ["K565", "CHEMICAL", 112, 116], ["carboxylate", "CHEMICAL", 146, 157], ["LTA4", "SIMPLE_CHEMICAL", 25, 29], ["K565", "AMINO_ACID", 112, 116], ["carboxylate recognition sites", "PROTEIN", 146, 175], ["The carboxylate group of LTA4 in WT system", "TREATMENT", 0, 42]]], ["Because of this recognition the carboxylate group has formed strong hydrogen bond interactions with R563 and K565.", [["carboxylate", "CHEMICAL", 32, 43], ["carboxylate", "CHEMICAL", 32, 43], ["hydrogen", "CHEMICAL", 68, 76], ["R563", "CHEMICAL", 100, 104], ["K565", "CHEMICAL", 109, 113], ["R563", "SIMPLE_CHEMICAL", 100, 104], ["K565", "SIMPLE_CHEMICAL", 109, 113], ["strong hydrogen bond interactions", "PROBLEM", 61, 94], ["strong", "OBSERVATION_MODIFIER", 61, 67], ["hydrogen bond", "OBSERVATION", 68, 81]]], ["The distance between the carboxylate of E271 and metal (Zn 2+ ) ion was maintained in close vicinity for the reported acid-induced catalytic reaction.", [["carboxylate", "CHEMICAL", 25, 36], ["E271", "CHEMICAL", 40, 44], ["metal", "CHEMICAL", 49, 54], ["Zn", "CHEMICAL", 56, 58], ["carboxylate", "CHEMICAL", 25, 36], ["E271", "CHEMICAL", 40, 44], ["Zn 2+ )", "CHEMICAL", 56, 63], ["E271", "SIMPLE_CHEMICAL", 40, 44], ["metal (Zn 2+ )", "SIMPLE_CHEMICAL", 49, 63], ["metal (Zn 2+ ) ion", "TREATMENT", 49, 67], ["the reported acid-induced catalytic reaction", "PROBLEM", 105, 149], ["acid-induced catalytic reaction", "OBSERVATION", 118, 149]]], ["The other residue Y378 has also formed a hydrogen bond interaction with the carboxylate group of LTA4 ( Figure 7A ).", [["Y378", "CHEMICAL", 18, 22], ["Y378", "CHEMICAL", 18, 22], ["hydrogen", "CHEMICAL", 41, 49], ["carboxylate", "CHEMICAL", 76, 87], ["LTA4", "CHEMICAL", 97, 101], ["Y378", "AMINO_ACID", 18, 22], ["LTA4", "SIMPLE_CHEMICAL", 97, 101], ["LTA4", "PROTEIN", 97, 101], ["a hydrogen bond interaction", "PROBLEM", 39, 66], ["the carboxylate group of LTA4", "TREATMENT", 72, 101], ["hydrogen bond", "OBSERVATION", 41, 54]]], ["In E271Q system, the binding mode of LTA4 is so different from that of WT system.", [["LTA4", "CHEMICAL", 37, 41], ["LTA4", "GENE_OR_GENE_PRODUCT", 37, 41], ["E271Q", "PROTEIN", 3, 8], ["LTA4", "PROTEIN", 37, 41]]], ["Because of the uncharged nature of the mutation (E271Q) the metal ion has slightly moved towards the carboxylate group of LTA4, which has also mutually moved towards the metal ion.", [["LTA4", "CHEMICAL", 122, 126], ["carboxylate", "CHEMICAL", 101, 112], ["LTA4", "CHEMICAL", 122, 126], ["LTA4", "SIMPLE_CHEMICAL", 122, 126], ["metal ion", "SIMPLE_CHEMICAL", 170, 179], ["the mutation", "PROBLEM", 35, 47], ["the metal ion", "TREATMENT", 56, 69], ["slightly", "OBSERVATION_MODIFIER", 74, 82], ["LTA4", "ANATOMY", 122, 126]]], ["This movement of carboxylate group of LTA4 has moved the central epoxy group of LTA4 further down and made it inaccessible by the catalytic metal ion ( Figure 7B ).", [["carboxylate", "CHEMICAL", 17, 28], ["LTA4", "CHEMICAL", 38, 42], ["LTA4", "CHEMICAL", 80, 84], ["carboxylate", "CHEMICAL", 17, 28], ["LTA4", "CHEMICAL", 38, 42], ["epoxy", "CHEMICAL", 65, 70], ["LTA4", "CHEMICAL", 80, 84], ["LTA4", "SIMPLE_CHEMICAL", 38, 42], ["LTA4", "SIMPLE_CHEMICAL", 80, 84], ["LTA4", "PROTEIN", 80, 84], ["carboxylate group of LTA4", "TREATMENT", 17, 42], ["the central epoxy group of LTA4", "TREATMENT", 53, 84], ["central", "OBSERVATION_MODIFIER", 57, 64], ["epoxy", "OBSERVATION_MODIFIER", 65, 70]]], ["This change in the E271 and distance between Zn 2+ and epoxy group (0.69 nm) can be directly correlated with the loss of activity ( Figure 5A ).", [["Zn", "CHEMICAL", 45, 47], ["Zn 2+", "CHEMICAL", 45, 50], ["epoxy", "CHEMICAL", 55, 60], ["Zn 2+", "SIMPLE_CHEMICAL", 45, 50], ["E271", "DNA", 19, 23], ["Zn 2+ and epoxy group", "TREATMENT", 45, 66]]], ["The hydrogen bonds formed with R563 and K565 residues were completely lost because of this mutation.", [["hydrogen", "CHEMICAL", 4, 12], ["R563", "CHEMICAL", 31, 35], ["K565", "CHEMICAL", 40, 44], ["R563", "SIMPLE_CHEMICAL", 31, 35], ["K565", "AMINO_ACID", 40, 44], ["K565 residues", "TREATMENT", 40, 53], ["this mutation", "PROBLEM", 86, 99], ["hydrogen bonds", "OBSERVATION", 4, 18]]], ["In R563A system, though E271 residue has maintained its hold on the metal ion because of the absence of R563, the important carboxylate recognition site, the LTA4 has moved backwards into the hydrophobic cavity formed by hydrophobic residues such as W311, F362, K364, L365, V366, V367, and V381 ( Figure 7C ).", [["E271", "CHEMICAL", 24, 28], ["LTA4", "CHEMICAL", 158, 162], ["E271", "CHEMICAL", 24, 28], ["R563", "CHEMICAL", 104, 108], ["carboxylate", "CHEMICAL", 124, 135], ["LTA4", "CHEMICAL", 158, 162], ["W311", "CHEMICAL", 250, 254], ["F362", "CHEMICAL", 256, 260], ["K364", "CHEMICAL", 262, 266], ["L365, V366, V367, and V381", "CHEMICAL", 268, 294], ["R563", "SIMPLE_CHEMICAL", 104, 108], ["LTA4", "SIMPLE_CHEMICAL", 158, 162], ["R563A", "PROTEIN", 3, 8], ["R563", "PROTEIN", 104, 108], ["carboxylate recognition site", "PROTEIN", 124, 152], ["LTA4", "PROTEIN", 158, 162], ["K364", "TEST", 262, 266], ["hydrophobic cavity", "ANATOMY", 192, 210], ["hydrophobic residues", "OBSERVATION", 221, 241]]], ["This change has not only brought the distance between Zn 2+ and the epoxy ring of LTA4 higher (0.78 nm) compared to any other L-LTA4 systems but also made hydrogen bonding with K565 impossible.", [["Zn", "CHEMICAL", 54, 56], ["LTA4", "CHEMICAL", 82, 86], ["Zn 2+", "CHEMICAL", 54, 59], ["epoxy", "CHEMICAL", 68, 73], ["LTA4", "CHEMICAL", 82, 86], ["hydrogen", "CHEMICAL", 155, 163], ["K565", "CHEMICAL", 177, 181], ["Zn 2+", "SIMPLE_CHEMICAL", 54, 59], ["LTA4", "SIMPLE_CHEMICAL", 82, 86], ["L-LTA4", "SIMPLE_CHEMICAL", 126, 132], ["hydrogen", "SIMPLE_CHEMICAL", 155, 163], ["K565", "SIMPLE_CHEMICAL", 177, 181], ["the epoxy ring of LTA4", "TREATMENT", 64, 86], ["hydrogen bonding", "TREATMENT", 155, 171], ["epoxy ring", "OBSERVATION", 68, 78], ["LTA4", "OBSERVATION_MODIFIER", 82, 86], ["higher", "OBSERVATION_MODIFIER", 87, 93]]], ["In terms of K565A system, the binding mode of LTA4 was similar to that of WT system.", [["LTA4", "CHEMICAL", 46, 50], ["LTA4", "CHEMICAL", 46, 50], ["K565A", "GENE_OR_GENE_PRODUCT", 12, 17], ["LTA4", "GENE_OR_GENE_PRODUCT", 46, 50], ["K565A", "PROTEIN", 12, 17], ["LTA4", "PROTEIN", 46, 50]]], ["Regardless of mutated K565 the hydrogen bonds were maintained with R563 but still the distance between Zn 2+ and epoxy ring of LTA4 was higher (0.68 nm) in this mutant system as well.", [["R563", "CHEMICAL", 67, 71], ["Zn", "CHEMICAL", 103, 105], ["LTA4", "CHEMICAL", 127, 131], ["hydrogen", "CHEMICAL", 31, 39], ["R563", "CHEMICAL", 67, 71], ["Zn 2+", "CHEMICAL", 103, 108], ["epoxy", "CHEMICAL", 113, 118], ["LTA4", "CHEMICAL", 127, 131], ["K565", "AMINO_ACID", 22, 26], ["Zn 2+", "SIMPLE_CHEMICAL", 103, 108], ["LTA4", "SIMPLE_CHEMICAL", 127, 131], ["mutated K565", "PROTEIN", 14, 26], ["the hydrogen bonds", "TEST", 27, 45], ["Zn", "TEST", 103, 105], ["epoxy ring of LTA4", "TEST", 113, 131], ["LTA4", "ANATOMY_MODIFIER", 127, 131], ["higher", "OBSERVATION_MODIFIER", 136, 142]]], ["The hydrogen bond between LTA4 and Y378 was also maintained as observed in WT system ( Figure 7D ).", [["LTA4", "CHEMICAL", 26, 30], ["hydrogen", "CHEMICAL", 4, 12], ["LTA4", "CHEMICAL", 26, 30], ["Y378", "CHEMICAL", 35, 39], ["LTA4", "SIMPLE_CHEMICAL", 26, 30], ["Y378", "SIMPLE_CHEMICAL", 35, 39], ["The hydrogen bond between LTA4 and Y378", "TREATMENT", 0, 39], ["hydrogen bond", "OBSERVATION", 4, 17]]], ["This observation also correlated the experimental observation that K565A mutation reduces the activity but does not abolish it.Binding mode analysesL-RAR systems.", [["K565A", "GENE_OR_GENE_PRODUCT", 67, 72], ["analysesL-RAR", "GENE_OR_GENE_PRODUCT", 140, 153], ["RAR", "PROTEIN", 150, 153], ["K565A mutation", "PROBLEM", 67, 81], ["Binding mode analysesL", "TEST", 127, 149], ["RAR", "ANATOMY", 150, 153]]], ["The binding modes of the tripeptide RAR in all systems were observed and compared to investigate the changes due to the mutated residues.", [["tripeptide RAR", "GENE_OR_GENE_PRODUCT", 25, 39], ["tripeptide RAR", "PROTEIN", 25, 39], ["the tripeptide RAR", "TREATMENT", 21, 39], ["the mutated residues", "PROBLEM", 116, 136], ["binding modes", "OBSERVATION", 4, 17], ["tripeptide RAR", "OBSERVATION", 25, 39]]], ["More number of hydrogen bonds was observed between the protein and bound substrate compared to the L-LTA4 systems because of the high number of polar hydrogen in the peptide substrate.", [["hydrogen", "CHEMICAL", 150, 158], ["hydrogen", "CHEMICAL", 15, 23], ["hydrogen", "CHEMICAL", 150, 158], ["hydrogen bonds", "SIMPLE_CHEMICAL", 15, 29], ["hydrogen", "SIMPLE_CHEMICAL", 150, 158], ["hydrogen bonds", "PROBLEM", 15, 29], ["the protein and bound substrate", "PROBLEM", 51, 82], ["hydrogen bonds", "OBSERVATION", 15, 29], ["high", "OBSERVATION_MODIFIER", 129, 133], ["polar hydrogen", "OBSERVATION", 144, 158]]], ["In the WT system, strong molecular interactions were observed through the hydrogen bonds and p-cation interactions formed between protein and substrate ( Figure 8A ).", [["hydrogen", "CHEMICAL", 74, 82], ["p-cation", "SIMPLE_CHEMICAL", 93, 101], ["the hydrogen bonds", "TREATMENT", 70, 88]]], ["The C-terminal carboxylate which is equivalent to the carboxylate of LTA4 has formed strong hydrogen bond interactions with both positively charged residues R563 and K565, the carboxylate recognition sites.", [["C-terminal carboxylate", "CHEMICAL", 4, 26], ["LTA4", "CHEMICAL", 69, 73], ["C-terminal carboxylate", "CHEMICAL", 4, 26], ["carboxylate", "CHEMICAL", 54, 65], ["LTA4", "CHEMICAL", 69, 73], ["hydrogen", "CHEMICAL", 92, 100], ["R563", "CHEMICAL", 157, 161], ["K565", "CHEMICAL", 166, 170], ["carboxylate", "CHEMICAL", 176, 187], ["C-terminal carboxylate", "SIMPLE_CHEMICAL", 4, 26], ["LTA4", "SIMPLE_CHEMICAL", 69, 73], ["K565", "SIMPLE_CHEMICAL", 166, 170], ["carboxylate recognition sites", "PROTEIN", 176, 205], ["The C-terminal carboxylate", "TREATMENT", 0, 26], ["the carboxylate of LTA4", "TREATMENT", 50, 73], ["strong hydrogen bond interactions", "PROBLEM", 85, 118], ["the carboxylate recognition sites", "TREATMENT", 172, 205], ["strong", "OBSERVATION_MODIFIER", 85, 91], ["hydrogen bond", "OBSERVATION", 92, 105]]], ["These interactions mainly hold the RAR at the active site and improve its binding strength.", [["RAR", "GENE_OR_GENE_PRODUCT", 35, 38], ["RAR", "PROTEIN", 35, 38]]], ["As reported, the N-terminal amino group interacted with the E271 which is the N-terminal recognition site for the peptide substrates.Binding mode analysesThese interactions altogether brings the carbonyl oxygen atom of N-terminal peptide bond close to the catalytic metal ion.", [["N-terminal amino", "CHEMICAL", 17, 33], ["E271", "CHEMICAL", 60, 64], ["oxygen", "CHEMICAL", 204, 210], ["N", "CHEMICAL", 17, 18], ["amino", "CHEMICAL", 28, 33], ["N", "CHEMICAL", 78, 79], ["carbonyl", "CHEMICAL", 195, 203], ["oxygen", "CHEMICAL", 204, 210], ["N", "CHEMICAL", 219, 220], ["E271", "SIMPLE_CHEMICAL", 60, 64], ["carbonyl oxygen", "SIMPLE_CHEMICAL", 195, 210], ["N-terminal amino group", "PROTEIN", 17, 39], ["E271", "PROTEIN", 60, 64], ["N-terminal recognition site", "PROTEIN", 78, 105], ["the peptide substrates", "TREATMENT", 110, 132], ["Binding mode analyses", "TEST", 133, 154], ["the carbonyl oxygen atom", "TREATMENT", 191, 215], ["N-terminal peptide bond", "TREATMENT", 219, 242], ["the catalytic metal ion", "TREATMENT", 252, 275]]], ["A pcation interaction was formed between the side chain of Cterminal Arg residue and Y378, which was found highly fluctuating in rmsf analysis.", [["Cterminal Arg", "CHEMICAL", 59, 72], ["Arg", "CHEMICAL", 69, 72], ["Y378", "CHEMICAL", 85, 89], ["Cterminal Arg residue", "SIMPLE_CHEMICAL", 59, 80], ["Y378", "AMINO_ACID", 85, 89], ["rmsf", "PROTEIN", 129, 133], ["A pcation interaction", "PROBLEM", 0, 21], ["Cterminal Arg residue", "TEST", 59, 80], ["rmsf analysis", "TEST", 129, 142], ["Arg residue", "OBSERVATION", 69, 80]]], ["This p-cation interaction between the same atoms was observed in R563A and K565A systems as well whereas it was between Y383 and C-terminal Arg residue in E271Q system (Figure 8 ).", [["Arg", "CHEMICAL", 140, 143], ["p-cation", "SIMPLE_CHEMICAL", 5, 13], ["Y383", "SIMPLE_CHEMICAL", 120, 124], ["Arg residue", "AMINO_ACID", 140, 151], ["R563A", "PROTEIN", 65, 70], ["C-terminal Arg residue in E271Q system", "PROBLEM", 129, 167]]], ["The binding mode of the substrate in E271Q system was different to that of WT system.", [["E271Q", "PROTEIN", 37, 42]]], ["The strength of the hydrogen bonds with R563 and K565 has become weak in this system because of the conformational changes of both carboxylate of substrate and R565 residue ( Figure 8B ).", [["R563", "CHEMICAL", 40, 44], ["K565", "CHEMICAL", 49, 53], ["hydrogen", "CHEMICAL", 20, 28], ["R563", "CHEMICAL", 40, 44], ["K565", "CHEMICAL", 49, 53], ["carboxylate", "CHEMICAL", 131, 142], ["R565", "CHEMICAL", 160, 164], ["R563", "SIMPLE_CHEMICAL", 40, 44], ["K565", "SIMPLE_CHEMICAL", 49, 53], ["the hydrogen bonds", "TEST", 16, 34], ["weak in this system", "PROBLEM", 65, 84], ["both carboxylate of substrate", "TREATMENT", 126, 155], ["hydrogen bonds", "OBSERVATION", 20, 34], ["weak", "OBSERVATION", 65, 69]]], ["The metal ion located in the active center was thrown away from its initial position because of the absence of negatively charged E271.", [["E271", "CHEMICAL", 130, 134], ["E271", "CHEMICAL", 130, 134], ["E271", "SIMPLE_CHEMICAL", 130, 134], ["E271", "PROTEIN", 130, 134], ["The metal ion", "TREATMENT", 0, 13], ["metal", "OBSERVATION_MODIFIER", 4, 9], ["active", "OBSERVATION_MODIFIER", 29, 35], ["center", "OBSERVATION_MODIFIER", 36, 42]]], ["This behavior observed in this system clearly reveals that E271 acts as a hook to hold the Zn 2+ ion in the active site.", [["E271", "CHEMICAL", 59, 63], ["Zn", "CHEMICAL", 91, 93], ["E271", "CHEMICAL", 59, 63], ["Zn 2+", "CHEMICAL", 91, 96], ["E271", "SIMPLE_CHEMICAL", 59, 63], ["Zn 2+", "SIMPLE_CHEMICAL", 91, 96], ["E271", "PROTEIN", 59, 63], ["the Zn", "TREATMENT", 87, 93], ["active site", "OBSERVATION", 108, 119]]], ["In terms of R563A system, the observed binding mode of this system is similar to that of E271Q system ( Figure 8C ).", [["R563A", "PROTEIN", 12, 17], ["E271Q", "PROTEIN", 89, 94]]], ["The metal ion was hooked by the presence of E271 residue but still the distance between Zn 2+ and the carbonyl oxygen atom of N-terminal peptide bond was high compared to that of WT.", [["E271", "CHEMICAL", 44, 48], ["Zn", "CHEMICAL", 88, 90], ["oxygen", "CHEMICAL", 111, 117], ["N-terminal peptide", "CHEMICAL", 126, 144], ["E271", "CHEMICAL", 44, 48], ["Zn 2+", "CHEMICAL", 88, 93], ["carbonyl", "CHEMICAL", 102, 110], ["oxygen", "CHEMICAL", 111, 117], ["N", "CHEMICAL", 126, 127], ["metal ion", "SIMPLE_CHEMICAL", 4, 13], ["E271", "AMINO_ACID", 44, 48], ["Zn 2+", "SIMPLE_CHEMICAL", 88, 93], ["carbonyl oxygen atom", "SIMPLE_CHEMICAL", 102, 122], ["The metal ion", "TREATMENT", 0, 13], ["E271 residue", "PROBLEM", 44, 56], ["Zn", "TREATMENT", 88, 90], ["the carbonyl oxygen atom", "TREATMENT", 98, 122], ["terminal peptide bond", "TREATMENT", 128, 149]]], ["The hydrogen bonds were formed between Y378, Y383, and G269 residues.", [["hydrogen", "CHEMICAL", 4, 12], ["Y378", "CHEMICAL", 39, 43], ["Y383", "CHEMICAL", 45, 49], ["G269", "CHEMICAL", 55, 59], ["hydrogen bonds", "SIMPLE_CHEMICAL", 4, 18], ["Y378", "SIMPLE_CHEMICAL", 39, 43], ["Y383", "AMINO_ACID", 45, 49], ["G269", "AMINO_ACID", 55, 59], ["The hydrogen bonds", "TEST", 0, 18], ["hydrogen bonds", "OBSERVATION", 4, 18]]], ["Surprisingly, two hydrogen bonds were formed with K565 residue in absence of R563.", [["hydrogen", "CHEMICAL", 18, 26], ["K565", "CHEMICAL", 50, 54], ["R563", "CHEMICAL", 77, 81], ["R563", "PROTEIN", 77, 81], ["two hydrogen bonds", "PROBLEM", 14, 32], ["hydrogen bonds", "OBSERVATION", 18, 32]]], ["This is different compared to that of the equivalent L-LTA4 system where the hydrogen bonds with both the positively charge residues were completely lost.", [["L-LTA4", "CHEMICAL", 53, 59], ["hydrogen", "CHEMICAL", 77, 85], ["L-LTA4", "PROTEIN", 53, 59], ["different", "OBSERVATION_MODIFIER", 8, 17], ["hydrogen bonds", "OBSERVATION", 77, 91], ["positively", "OBSERVATION_MODIFIER", 106, 116], ["charge residues", "OBSERVATION", 117, 132]]], ["This observation indicates the importance of K565 in assisting R563 in carboxylate recognition during peptide binding.", [["carboxylate", "CHEMICAL", 71, 82], ["K565", "SIMPLE_CHEMICAL", 45, 49], ["R563", "SIMPLE_CHEMICAL", 63, 67], ["carboxylate", "SIMPLE_CHEMICAL", 71, 82], ["K565", "PROTEIN", 45, 49], ["R563", "PROTEIN", 63, 67]]], ["In K565A system, the binding mode of the substrate is folded and completely different to the other systems.", [["folded", "OBSERVATION", 54, 60]]], ["The hydrogen bonds were observed only with Y383 and A565 residues along with an additional p-s interaction between Y378 and C- terminal Arg residue ( Figure 8D ).", [["hydrogen", "CHEMICAL", 4, 12], ["Y383", "CHEMICAL", 43, 47], ["A565", "CHEMICAL", 52, 56], ["Y378", "CHEMICAL", 115, 119], ["C", "CHEMICAL", 124, 125], ["Arg", "CHEMICAL", 136, 139], ["Y383", "SIMPLE_CHEMICAL", 43, 47], ["Y378", "SIMPLE_CHEMICAL", 115, 119], ["The hydrogen bonds", "PROBLEM", 0, 18], ["hydrogen bonds", "OBSERVATION", 4, 18]]], ["No hydrogen bonds were formed with R563 residue, which is one of the positively charged carboxylate recognition site residues.", [["hydrogen", "CHEMICAL", 3, 11], ["R563", "CHEMICAL", 35, 39], ["carboxylate", "CHEMICAL", 88, 99], ["R563 residue", "SIMPLE_CHEMICAL", 35, 47], ["hydrogen bonds", "PROBLEM", 3, 17], ["R563 residue", "PROBLEM", 35, 47], ["hydrogen bonds", "OBSERVATION", 3, 17]]], ["The molecular interactions observed in R563A and K565A systems revealed that both the residues are important for recognizing the carboxylate group and aligning the peptide substrate along the catalytic elements as reported.Binding mode analysesActive site structural changes L-LTA4 system.", [["carboxylate", "CHEMICAL", 129, 140], ["carboxylate", "CHEMICAL", 129, 140], ["L-LTA4", "GENE_OR_GENE_PRODUCT", 275, 281], ["R563A", "PROTEIN", 39, 44], ["catalytic elements", "PROTEIN", 192, 210], ["the carboxylate group", "TREATMENT", 125, 146], ["Binding mode analysesActive site structural changes L-LTA4 system", "PROBLEM", 223, 288], ["catalytic elements", "OBSERVATION", 192, 210], ["LTA4 system", "OBSERVATION", 277, 288]]], ["The overlay of each mutant system with the WT system has allowed observing the structural changes occurred because of the mutations (Figure 9 ).", [["the WT system", "TREATMENT", 39, 52], ["the structural changes", "PROBLEM", 75, 97], ["the mutations", "PROBLEM", 118, 131]]], ["In E271Q system, the loop of G269 was fluctuating and moved into the active site when compared to other systems.", [["G269", "GENE_OR_GENE_PRODUCT", 29, 33], ["E271Q", "PROTEIN", 3, 8], ["G269", "PROTEIN", 29, 33], ["the loop of G269", "TREATMENT", 17, 33], ["loop", "OBSERVATION_MODIFIER", 21, 25], ["active", "OBSERVATION_MODIFIER", 69, 75], ["site", "OBSERVATION_MODIFIER", 76, 80]]], ["This change observed in this loop could be because of the newly formed hydrogen bond between G269 and the tilted carboxylate group of LTA4, which was found to be a response to the metal ion that lost the interaction with mutated E271.", [["G269", "CHEMICAL", 93, 97], ["LTA4", "CHEMICAL", 134, 138], ["hydrogen", "CHEMICAL", 71, 79], ["G269", "CHEMICAL", 93, 97], ["carboxylate", "CHEMICAL", 113, 124], ["LTA4", "CHEMICAL", 134, 138], ["G269", "SIMPLE_CHEMICAL", 93, 97], ["LTA4", "SIMPLE_CHEMICAL", 134, 138], ["mutated E271", "PROTEIN", 221, 233], ["This change", "PROBLEM", 0, 11], ["the newly formed hydrogen bond between G269", "PROBLEM", 54, 97], ["the tilted carboxylate group of LTA4", "TREATMENT", 102, 138], ["the metal ion", "TREATMENT", 176, 189], ["hydrogen bond", "OBSERVATION", 71, 84]]], ["The carboxylate group of LTA4 and terminal NH 2 of R563 moved away from each other (2.7 to 8.4 \u00c5 ) because of the missing E271.", [["carboxylate", "CHEMICAL", 4, 15], ["LTA4", "CHEMICAL", 25, 29], ["NH 2 of R563", "CHEMICAL", 43, 55], ["carboxylate", "CHEMICAL", 4, 15], ["LTA4", "CHEMICAL", 25, 29], ["NH", "CHEMICAL", 43, 45], ["R563", "CHEMICAL", 51, 55], ["LTA4", "SIMPLE_CHEMICAL", 25, 29], ["R563", "PROTEIN", 51, 55], ["E271", "PROTEIN", 122, 126], ["The carboxylate group of LTA4", "TREATMENT", 0, 29], ["terminal NH", "TREATMENT", 34, 45]]], ["A short beta sheet formed by the residues V306-N308 of HEXXH-(X) 18 -E motif that possess two catalytically conserved histidine residues coordinating with Zn 2+ ion disappeared in E271Q system.", [["histidine", "CHEMICAL", 118, 127], ["Zn", "CHEMICAL", 155, 157], ["histidine", "CHEMICAL", 118, 127], ["Zn 2+", "CHEMICAL", 155, 160], ["histidine", "AMINO_ACID", 118, 127], ["Zn 2+ ion", "SIMPLE_CHEMICAL", 155, 164], ["HEXXH-(X) 18 -E motif", "DNA", 55, 76], ["E271Q", "PROTEIN", 180, 185], ["A short beta sheet", "TREATMENT", 0, 18], ["HEXXH", "TEST", 55, 60], ["18 -E motif", "TREATMENT", 65, 76], ["histidine residues", "OBSERVATION", 118, 136]]], ["Another helix followed by this short beta sheet was extended by four amino acids W311-F314 making the important F314 slightly backward from the active center ( Figure 9A ).", [["amino acids", "CHEMICAL", 69, 80], ["W311-F314", "CHEMICAL", 81, 90], ["amino acids", "CHEMICAL", 69, 80], ["W311-F314", "CHEMICAL", 81, 90], ["amino acids", "AMINO_ACID", 69, 80], ["W311-F314", "SIMPLE_CHEMICAL", 81, 90], ["this short beta sheet", "TREATMENT", 26, 47], ["four amino acids", "TEST", 64, 80]]], ["Two tyrosine residues Y378 and Y383 located opposite to each other in the active site were highly fluctuating in this system to adjust the binding of the LTA4.", [["tyrosine", "CHEMICAL", 4, 12], ["tyrosine", "CHEMICAL", 4, 12], ["tyrosine", "AMINO_ACID", 4, 12], ["Y378", "AMINO_ACID", 22, 26], ["Y383", "AMINO_ACID", 31, 35], ["LTA4", "GENE_OR_GENE_PRODUCT", 154, 158], ["LTA4", "PROTEIN", 154, 158], ["Two tyrosine residues", "TEST", 0, 21], ["tyrosine residues", "OBSERVATION", 4, 21], ["active", "OBSERVATION", 74, 80], ["LTA4", "ANATOMY", 154, 158]]], ["The K565 residue present in the loop has become a part of the long helix originally formed by T567-A575 residues during the simulation of E271Q system.", [["T567-A575", "CHEMICAL", 94, 103], ["K565", "GENE_OR_GENE_PRODUCT", 4, 8], ["long helix", "CELLULAR_COMPONENT", 62, 72], ["T567", "PROTEIN", 94, 98], ["E271Q", "PROTEIN", 138, 143], ["The K565 residue", "TREATMENT", 0, 16], ["the simulation of E271Q system", "TREATMENT", 120, 150], ["loop", "OBSERVATION_MODIFIER", 32, 36]]], ["This change slightly drew back the K565 residue from the active site.", [["K565", "CHEMICAL", 35, 39], ["active site", "OBSERVATION", 57, 68]]], ["The other important positively charged residue did not show any structural changes during the simulation.", [["any structural changes", "PROBLEM", 60, 82]]], ["The R563A system has shown different structural changes compared to E271Q system.", [["R563A", "PROTEIN", 4, 9], ["E271Q", "PROTEIN", 68, 73], ["different structural changes", "PROBLEM", 27, 55], ["different", "OBSERVATION_MODIFIER", 27, 36], ["structural", "OBSERVATION", 37, 47]]], ["The loop containing G269 has shown slight fluctuation only at the location of G269 because of the hydrogen bonds formed between the carboxylate of LTA4 and G269 but the lower part of the loop was stable unlike E271Q system ( Figure 9B ).", [["G269", "CHEMICAL", 20, 24], ["LTA4", "CHEMICAL", 147, 151], ["G269", "CHEMICAL", 156, 160], ["G269", "CHEMICAL", 20, 24], ["hydrogen", "CHEMICAL", 98, 106], ["carboxylate", "CHEMICAL", 132, 143], ["LTA4", "CHEMICAL", 147, 151], ["G269", "CHEMICAL", 156, 160], ["LTA4", "SIMPLE_CHEMICAL", 147, 151], ["G269", "AMINO_ACID", 156, 160], ["E271Q", "PROTEIN", 210, 215], ["slight fluctuation", "PROBLEM", 35, 53], ["the hydrogen bonds", "PROBLEM", 94, 112], ["the carboxylate of LTA4", "TREATMENT", 128, 151], ["loop", "OBSERVATION", 4, 8], ["slight", "OBSERVATION_MODIFIER", 35, 41], ["fluctuation", "OBSERVATION", 42, 53], ["hydrogen bonds", "OBSERVATION", 98, 112], ["lower", "ANATOMY_MODIFIER", 169, 174], ["loop", "OBSERVATION", 187, 191], ["stable", "OBSERVATION_MODIFIER", 196, 202]]], ["The short helix formed by V306-N308 residues was maintained in this system and the helix containing F314 was extended but kept for the same length during the simulation.", [["V306-N308", "CHEMICAL", 26, 35], ["V306-N308", "CHEMICAL", 26, 35], ["V306", "PROTEIN", 26, 30], ["F314", "PROTEIN", 100, 104], ["the helix containing F314", "TREATMENT", 79, 104], ["short helix", "OBSERVATION_MODIFIER", 4, 15]]], ["The region (W311-F314) that turned an extended helix was highly fluctuating in this system because of the moving alkyl part of LTA4.", [["alkyl", "CHEMICAL", 113, 118], ["LTA4", "CHEMICAL", 127, 131], ["LTA4", "CHEMICAL", 127, 131], ["LTA4", "SIMPLE_CHEMICAL", 127, 131], ["W311", "DNA", 12, 16], ["LTA4", "PROTEIN", 127, 131], ["an extended helix", "PROBLEM", 35, 52], ["region", "ANATOMY_MODIFIER", 4, 10]]], ["This backward movement buried the alkyl part into the hydrophobic pocket, formed by a mixture of aliphatic and aromatic hydrophobic residues (W311, F362, K364, L365, V366, V367, and V381), was observed because of the missing interactions with R563 residue (not shown in figure).", [["alkyl", "CHEMICAL", 34, 39], ["W311", "CHEMICAL", 142, 146], ["K364", "CHEMICAL", 154, 158], ["L365", "CHEMICAL", 160, 164], ["V366", "CHEMICAL", 166, 170], ["V367", "CHEMICAL", 172, 176], ["V381", "CHEMICAL", 182, 186], ["R563", "CHEMICAL", 243, 247], ["aliphatic and aromatic hydrophobic residues", "PROBLEM", 97, 140], ["K364", "TEST", 154, 158], ["R563 residue", "PROBLEM", 243, 255], ["alkyl", "OBSERVATION_MODIFIER", 34, 39], ["hydrophobic pocket", "OBSERVATION", 54, 72], ["aliphatic", "OBSERVATION_MODIFIER", 97, 106], ["aromatic hydrophobic residues", "OBSERVATION", 111, 140]]], ["Unlike E271Q system, Y378 residue has shown only slight side chain movement as a response to the moving LTA4 whereas Y383 did not show any fluctuations from its initial position.", [["Y378", "CHEMICAL", 21, 25], ["Y378", "CHEMICAL", 21, 25], ["LTA4", "CHEMICAL", 104, 108], ["Y383", "CHEMICAL", 117, 121], ["Y378", "AMINO_ACID", 21, 25], ["LTA4", "SIMPLE_CHEMICAL", 104, 108], ["E271Q", "PROTEIN", 7, 12], ["slight side chain movement", "PROBLEM", 49, 75], ["the moving LTA4", "TEST", 93, 108], ["slight", "OBSERVATION_MODIFIER", 49, 55], ["side chain", "OBSERVATION_MODIFIER", 56, 66]]], ["The same helix extension was observed as in E271Q system and thus K565 was included in helix formed by T567-A575 residues.", [["K565", "GENE_OR_GENE_PRODUCT", 66, 70], ["E271Q", "PROTEIN", 44, 49], ["K565", "PROTEIN", 66, 70], ["T567", "PROTEIN", 103, 107], ["helix", "OBSERVATION_MODIFIER", 9, 14]]], ["The missing R563 led to the loss of correct alignment of LTA4 along the catalytic elements and severe instability of the binding mode of LTA4.", [["R563", "CHEMICAL", 12, 16], ["LTA4", "CHEMICAL", 57, 61], ["LTA4", "CHEMICAL", 137, 141], ["LTA4", "GENE_OR_GENE_PRODUCT", 57, 61], ["LTA4", "GENE_OR_GENE_PRODUCT", 137, 141], ["R563", "DNA", 12, 16], ["LTA4", "PROTEIN", 57, 61], ["catalytic elements", "DNA", 72, 90], ["LTA4", "PROTEIN", 137, 141], ["severe instability of the binding mode of LTA4", "PROBLEM", 95, 141], ["alignment", "OBSERVATION_MODIFIER", 44, 53], ["LTA4", "OBSERVATION_MODIFIER", 57, 61], ["catalytic elements", "OBSERVATION", 72, 90], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["instability", "OBSERVATION", 102, 113]]], ["In the final mutant (K565A) system, the G269 loop was completely stable and no hydrogen bond interaction was observed between LTA4 and G269 residue.", [["LTA4", "CHEMICAL", 126, 130], ["hydrogen", "CHEMICAL", 79, 87], ["LTA4", "CHEMICAL", 126, 130], ["G269", "CHEMICAL", 135, 139], ["hydrogen", "SIMPLE_CHEMICAL", 79, 87], ["LTA4", "SIMPLE_CHEMICAL", 126, 130], ["G269", "AMINO_ACID", 135, 139], ["K565A", "PROTEIN", 21, 26], ["G269 loop", "PROTEIN", 40, 49], ["LTA4", "PROTEIN", 126, 130], ["the G269 loop", "TREATMENT", 36, 49], ["hydrogen bond interaction", "PROBLEM", 79, 104], ["LTA4", "TEST", 126, 130], ["stable", "OBSERVATION_MODIFIER", 65, 71], ["hydrogen bond", "OBSERVATION", 79, 92]]], ["The short helix of V306-N308 disappeared during the simulation of K565A system as observed in E271Q system ( Figure 9C ).", [["V306-N308", "CHEMICAL", 19, 28], ["V306", "PROTEIN", 19, 23], ["N308", "PROTEIN", 24, 28], ["K565A", "PROTEIN", 66, 71], ["The short helix of V306", "TEST", 0, 23]]], ["The helix of F314 was extended as seen in R563A system and thus has shown the mixed characteristics of E271Q and R563A systems.", [["F314", "GENE_OR_GENE_PRODUCT", 13, 17], ["E271Q", "GENE_OR_GENE_PRODUCT", 103, 108], ["F314", "PROTEIN", 13, 17], ["R563A", "PROTEIN", 42, 47], ["helix", "ANATOMY_MODIFIER", 4, 9]]], ["The Y378, one of the oppositely located pair of tyrosine residues, has fluctuated highly in this system.", [["Y378", "CHEMICAL", 4, 8], ["tyrosine", "CHEMICAL", 48, 56], ["tyrosine", "CHEMICAL", 48, 56], ["Y378", "GENE_OR_GENE_PRODUCT", 4, 8], ["tyrosine", "AMINO_ACID", 48, 56], ["tyrosine residues", "PROBLEM", 48, 65], ["tyrosine residues", "OBSERVATION", 48, 65], ["fluctuated", "OBSERVATION_MODIFIER", 71, 81], ["highly", "OBSERVATION_MODIFIER", 82, 88]]], ["The binding mode of LTA4 was quite similar to that of WT except its carboxylate group, which moved back because of the missing hydrogen bonds from K565 residue.", [["LTA4", "CHEMICAL", 20, 24], ["carboxylate", "CHEMICAL", 68, 79], ["LTA4", "CHEMICAL", 20, 24], ["carboxylate", "CHEMICAL", 68, 79], ["hydrogen", "CHEMICAL", 127, 135], ["K565", "CHEMICAL", 147, 151], ["LTA4", "SIMPLE_CHEMICAL", 20, 24], ["K565", "SIMPLE_CHEMICAL", 147, 151], ["its carboxylate group", "TREATMENT", 64, 85], ["the missing hydrogen bonds", "PROBLEM", 115, 141], ["K565 residue", "PROBLEM", 147, 159], ["hydrogen bonds", "OBSERVATION", 127, 141]]], ["But the hydrogen bonds with R563 were maintained and thus kept the alignment of LTA4 along with the catalytic elements.", [["R563", "CHEMICAL", 28, 32], ["LTA4", "CHEMICAL", 80, 84], ["hydrogen", "CHEMICAL", 8, 16], ["R563", "CHEMICAL", 28, 32], ["LTA4", "CHEMICAL", 80, 84], ["R563", "SIMPLE_CHEMICAL", 28, 32], ["LTA4", "GENE_OR_GENE_PRODUCT", 80, 84], ["LTA4", "PROTEIN", 80, 84], ["catalytic elements", "DNA", 100, 118], ["the hydrogen bonds", "TEST", 4, 22], ["hydrogen bonds", "OBSERVATION", 8, 22]]], ["The overlay of active sites of all the systems have made clear about the structural changes where Y378 was observed to be fluctuating differently in each system maintaining a close distance with the substrate ( Figure 9D ).", [["Y378", "CHEMICAL", 98, 102], ["Y378", "CHEMICAL", 98, 102], ["Y378", "SIMPLE_CHEMICAL", 98, 102], ["active", "OBSERVATION_MODIFIER", 15, 21], ["sites", "OBSERVATION_MODIFIER", 22, 27], ["clear", "OBSERVATION", 57, 62]]], ["Thus Y378 residue, along with the carboxylate recognition site residues R563 and K565, can play a key role in aligning the substrate at the active site.Binding mode analysesL-RAR systems.", [["carboxylate", "CHEMICAL", 34, 45], ["carboxylate", "CHEMICAL", 34, 45], ["Y378", "GENE_OR_GENE_PRODUCT", 5, 9], ["K565", "AMINO_ACID", 81, 85], ["analysesL-RAR", "GENE_OR_GENE_PRODUCT", 165, 178], ["carboxylate recognition site", "PROTEIN", 34, 62], ["RAR", "PROTEIN", 175, 178], ["Y378 residue", "PROBLEM", 5, 17], ["the carboxylate recognition", "TREATMENT", 30, 57], ["Binding mode analysesL", "TEST", 152, 174], ["active site", "OBSERVATION", 140, 151], ["RAR", "ANATOMY", 175, 178]]], ["Comparison of active site residues of WT and E271Q systems using the representative structures obtained from the simulations revealed the structural changes led to the differences in the catalytic activity of the enzyme ( Figure 10 ).", [["enzyme", "PROTEIN", 213, 219], ["the simulations", "TEST", 109, 124], ["the structural changes", "PROBLEM", 134, 156], ["active", "OBSERVATION_MODIFIER", 14, 20]]], ["The overlaid WT and E271Q structures have shown the difference in the locations of catalytically important Zn 2+ ion in the catalytic center ( Figure 10A ).", [["Zn", "CHEMICAL", 107, 109], ["Zn 2+", "CHEMICAL", 107, 112], ["Zn 2+", "SIMPLE_CHEMICAL", 107, 112], ["The overlaid WT", "TEST", 0, 15]]], ["The uncharged nature of the mutant residue Q271 the metal ion has lost the important interaction and moved far away from its original location.", [["Q271", "CHEMICAL", 43, 47], ["Q271", "CHEMICAL", 43, 47], ["Q271", "AMINO_ACID", 43, 47], ["the mutant residue", "PROBLEM", 24, 42], ["uncharged nature", "OBSERVATION_MODIFIER", 4, 20]]], ["The distance between the Zn 2+ ion and the oxygen atom of the N-terminal peptide bond was so high compared to the WT system.", [["Zn", "CHEMICAL", 25, 27], ["oxygen", "CHEMICAL", 43, 49], ["Zn 2+", "CHEMICAL", 25, 30], ["oxygen", "CHEMICAL", 43, 49], ["N", "CHEMICAL", 62, 63], ["Zn 2+ ion", "SIMPLE_CHEMICAL", 25, 34], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["the Zn", "TREATMENT", 21, 27], ["the oxygen atom", "TREATMENT", 39, 54], ["the N-terminal peptide bond", "TREATMENT", 58, 85], ["oxygen atom", "OBSERVATION", 43, 54]]], ["Thus the catalytic aminopeptidase reaction becomes impossible in E271Q system.", [["catalytic aminopeptidase", "PROTEIN", 9, 33], ["E271Q", "PROTEIN", 65, 70], ["the catalytic aminopeptidase reaction", "PROBLEM", 5, 42]]], ["The helix containing Y383 was extended during the simulation E271Q system moving Y383 backward from the active site.", [["Y383", "AMINO_ACID", 21, 25], ["E271Q", "PROTEIN", 61, 66], ["helix", "ANATOMY_MODIFIER", 4, 9], ["active site", "OBSERVATION", 104, 115]]], ["This movement of Y383 has formed p-cation and a hydrogen bond interactions with the C-terminal part of RAR whereas in WT system this residue has formed a hydrogen bond interaction with the N-terminal amino group.", [["Y383", "CHEMICAL", 17, 21], ["N-terminal amino", "CHEMICAL", 189, 205], ["Y383", "CHEMICAL", 17, 21], ["hydrogen", "CHEMICAL", 48, 56], ["C", "CHEMICAL", 84, 85], ["hydrogen", "CHEMICAL", 154, 162], ["N", "CHEMICAL", 189, 190], ["amino", "CHEMICAL", 200, 205], ["Y383", "GENE_OR_GENE_PRODUCT", 17, 21], ["p-cation", "SIMPLE_CHEMICAL", 33, 41], ["RAR", "GENE_OR_GENE_PRODUCT", 103, 106], ["C-terminal part", "PROTEIN", 84, 99], ["RAR", "PROTEIN", 103, 106], ["N-terminal amino group", "PROTEIN", 189, 211], ["a hydrogen bond interactions", "PROBLEM", 46, 74], ["a hydrogen bond interaction", "PROBLEM", 152, 179], ["the N-terminal amino group", "TREATMENT", 185, 211], ["RAR", "ANATOMY", 103, 106], ["hydrogen bond", "OBSERVATION", 154, 167]]], ["The other tyrosine residue Y378, which was found to be guiding the substrate along with the carboxylate recognition site residues, has formed hydrogen bond with the carboxylate of RAR.", [["tyrosine", "CHEMICAL", 10, 18], ["Y378", "CHEMICAL", 27, 31], ["carboxylate", "CHEMICAL", 92, 103], ["tyrosine", "CHEMICAL", 10, 18], ["carboxylate", "CHEMICAL", 92, 103], ["hydrogen", "CHEMICAL", 142, 150], ["carboxylate", "CHEMICAL", 165, 176], ["tyrosine", "AMINO_ACID", 10, 18], ["Y378", "AMINO_ACID", 27, 31], ["RAR", "GENE_OR_GENE_PRODUCT", 180, 183], ["RAR", "PROTEIN", 180, 183], ["The other tyrosine residue", "TEST", 0, 26], ["the carboxylate recognition", "TREATMENT", 88, 115], ["the carboxylate of RAR", "TREATMENT", 161, 183], ["hydrogen bond", "OBSERVATION", 142, 155]]], ["The binding mode of RAR observed in E271Q system has shown only weak hydrogen bonding interactions with R563 as it was moving away from it.", [["R563", "CHEMICAL", 104, 108], ["hydrogen", "CHEMICAL", 69, 77], ["R563", "CHEMICAL", 104, 108], ["RAR", "GENE_OR_GENE_PRODUCT", 20, 23], ["hydrogen", "SIMPLE_CHEMICAL", 69, 77], ["R563", "SIMPLE_CHEMICAL", 104, 108], ["RAR", "PROTEIN", 20, 23], ["E271Q", "PROTEIN", 36, 41], ["weak hydrogen bonding interactions", "PROBLEM", 64, 98], ["weak", "OBSERVATION_MODIFIER", 64, 68], ["hydrogen bonding", "OBSERVATION", 69, 85]]], ["The helix formed by K565-A575 residues was shortened slightly leaving K565, one of the carboxylate recognition residues, as a part of loop making it more flexible.", [["K565-A575", "CHEMICAL", 20, 29], ["K565", "CHEMICAL", 70, 74], ["carboxylate", "CHEMICAL", 87, 98], ["K565", "SIMPLE_CHEMICAL", 70, 74], ["K565", "PROTEIN", 20, 24], ["K565", "PROTEIN", 70, 74], ["the carboxylate recognition residues", "TREATMENT", 83, 119]]], ["But this residue has maintained hydrogen bond interactions with the peptide substrate through its carboxylate group.", [["carboxylate", "CHEMICAL", 98, 109], ["hydrogen", "CHEMICAL", 32, 40], ["carboxylate", "CHEMICAL", 98, 109], ["carboxylate", "SIMPLE_CHEMICAL", 98, 109], ["this residue", "PROBLEM", 4, 16], ["hydrogen bond interactions", "PROBLEM", 32, 58], ["the peptide substrate through its carboxylate group", "TREATMENT", 64, 115], ["hydrogen bond", "OBSERVATION", 32, 45]]], ["This change observed in helix containing K565 is different from that of L-LTA4 systems.", [["K565", "AMINO_ACID", 41, 45], ["L-LTA4", "GENE_OR_GENE_PRODUCT", 72, 78], ["K565", "PROTEIN", 41, 45], ["L-LTA4", "PROTEIN", 72, 78]]], ["The K565 is the key residue that assists the other positively charged residue R563 to maintain the proper alignment of RAR in the active site whereas in LTA4 binding K565 is not required to assist R563 residue [27] .", [["LTA4", "CHEMICAL", 153, 157], ["K565", "GENE_OR_GENE_PRODUCT", 4, 8], ["R563", "AMINO_ACID", 78, 82], ["RAR", "GENE_OR_GENE_PRODUCT", 119, 122], ["LTA4 binding K565", "GENE_OR_GENE_PRODUCT", 153, 170], ["K565", "DNA", 4, 8], ["R563", "PROTEIN", 78, 82], ["RAR", "PROTEIN", 119, 122], ["LTA4 binding K565", "PROTEIN", 153, 170], ["LTA4 binding K565", "TREATMENT", 153, 170]]], ["Moreover, the absence of negatively charged E271 residue also played a major role in observed loss of catalytic activity.", [["E271", "CHEMICAL", 44, 48], ["E271", "CHEMICAL", 44, 48], ["E271", "AMINO_ACID", 44, 48], ["negatively charged E271 residue", "PROBLEM", 25, 56], ["catalytic activity", "OBSERVATION", 102, 120]]], ["The R563A mutation has caused a high fluctuation of E271 that moved far from the N-terminal amino group of RAR and makes it impossible to act as N-terminal recognition site ( Figure 10B ).", [["N", "CHEMICAL", 81, 82], ["amino", "CHEMICAL", 92, 97], ["N-", "CHEMICAL", 145, 147], ["R563A", "GENE_OR_GENE_PRODUCT", 4, 9], ["RAR", "GENE_OR_GENE_PRODUCT", 107, 110], ["E271", "PROTEIN", 52, 56], ["N-terminal amino group", "PROTEIN", 81, 103], ["RAR", "PROTEIN", 107, 110], ["N-terminal recognition site", "PROTEIN", 145, 172], ["a high fluctuation of E271", "PROBLEM", 30, 56], ["high", "OBSERVATION_MODIFIER", 32, 36]]], ["The interacting distance between Zn 2+ and E271 was maintained in this mutation.", [["Zn", "CHEMICAL", 33, 35], ["Zn 2+", "CHEMICAL", 33, 38], ["E271", "CHEMICAL", 43, 47], ["Zn 2+", "SIMPLE_CHEMICAL", 33, 38], ["E271", "AMINO_ACID", 43, 47], ["E271", "PROTEIN", 43, 47], ["E271", "TREATMENT", 43, 47]]], ["The helix extension was observed near Y383 as displayed in E271Q system and this changed the flexibility of Y383 in the active site.", [["Y383", "CHEMICAL", 108, 112], ["Y383", "AMINO_ACID", 38, 42], ["Y383", "GENE_OR_GENE_PRODUCT", 108, 112], ["E271Q", "PROTEIN", 59, 64], ["Y383", "PROTEIN", 108, 112], ["helix", "ANATOMY_MODIFIER", 4, 9], ["active site", "OBSERVATION", 120, 131]]], ["The other tyrosine residue Y378 was highly fluctuating in this mutant system compared to any other systems and formed strong p-cation interaction than it is in WT system.", [["tyrosine", "CHEMICAL", 10, 18], ["tyrosine", "CHEMICAL", 10, 18], ["tyrosine", "AMINO_ACID", 10, 18], ["Y378", "AMINO_ACID", 27, 31], ["The other tyrosine residue Y378", "TEST", 0, 31], ["this mutant system", "PROBLEM", 58, 76], ["strong", "OBSERVATION_MODIFIER", 118, 124], ["p-cation", "OBSERVATION", 125, 133]]], ["The C-terminal part of RAR substrate has slightly went back as it missed the strong interactions from R563 but the alignment was almost maintained as observed in WT system except the side Cterminal side chain of RAR.", [["RAR", "GENE_OR_GENE_PRODUCT", 23, 26], ["RAR", "GENE_OR_GENE_PRODUCT", 212, 215], ["C-terminal part", "PROTEIN", 4, 19], ["RAR substrate", "PROTEIN", 23, 36], ["R563", "PROTEIN", 102, 106], ["side Cterminal side chain", "PROTEIN", 183, 208], ["RAR", "PROTEIN", 212, 215], ["The C-terminal part of RAR substrate", "PROBLEM", 0, 36], ["slightly", "OBSERVATION_MODIFIER", 41, 49], ["strong", "OBSERVATION_MODIFIER", 77, 83], ["RAR", "ANATOMY", 212, 215]]], ["Interestingly, K565 has taken the location of R563 in this mutant system to maintain the hydrogen bonds with the carboxylate of RAR and there was no change observed in the K565-A575 helix as observed in E271Q system.", [["K565", "CHEMICAL", 15, 19], ["hydrogen", "CHEMICAL", 89, 97], ["carboxylate", "CHEMICAL", 113, 124], ["R563", "GENE_OR_GENE_PRODUCT", 46, 50], ["RAR", "GENE_OR_GENE_PRODUCT", 128, 131], ["K565", "PROTEIN", 15, 19], ["R563", "PROTEIN", 46, 50], ["RAR", "PROTEIN", 128, 131], ["K565", "PROTEIN", 172, 176], ["A575 helix", "PROTEIN", 177, 187], ["E271Q", "PROTEIN", 203, 208], ["the carboxylate of RAR", "TEST", 109, 131], ["hydrogen bonds", "OBSERVATION", 89, 103], ["no", "UNCERTAINTY", 146, 148], ["change", "OBSERVATION", 149, 155]]], ["The K565A system also has shown some structural changes that were not observed in other L-RAR systems ( Figure 10C ).", [["L-RAR", "GENE_OR_GENE_PRODUCT", 88, 93], ["RAR", "PROTEIN", 90, 93], ["The K565A system", "TEST", 0, 16], ["some structural changes", "PROBLEM", 32, 55]]], ["The short helix (V306-N308) that has shown structural changes in L-LTA4 system disappeared in K565A system and the F314 helix was extended including W311-F314 residues.", [["L-LTA4", "CHEMICAL", 65, 71], ["L-LTA4", "GENE_OR_GENE_PRODUCT", 65, 71], ["LTA4", "PROTEIN", 67, 71], ["K565A", "PROTEIN", 94, 99], ["F314 helix", "PROTEIN", 115, 125], ["W311", "PROTEIN", 149, 153], ["structural changes in L-LTA4 system", "PROBLEM", 43, 78], ["L", "ANATOMY_MODIFIER", 65, 66]]], ["These changes were observed in other L-RAR systems.", [["L-RAR", "GENE_OR_GENE_PRODUCT", 37, 42], ["RAR", "PROTEIN", 39, 42], ["RAR", "ANATOMY", 39, 42]]], ["The extension of helix has drawn F314 residue back from the active site center.", [["F314", "PROTEIN", 33, 37], ["The extension of helix", "PROBLEM", 0, 22], ["helix", "ANATOMY", 17, 22], ["active", "OBSERVATION_MODIFIER", 60, 66], ["site", "OBSERVATION_MODIFIER", 67, 71]]], ["A folded binding mode of RAR was observed in K565 system much different from that of WT and other mutant L-RAR systems.", [["K565 system", "ANATOMY", 45, 56], ["RAR", "GENE_OR_GENE_PRODUCT", 25, 28], ["L-RAR", "GENE_OR_GENE_PRODUCT", 105, 110], ["RAR", "PROTEIN", 25, 28], ["K565 system", "CELL_LINE", 45, 56], ["RAR", "PROTEIN", 107, 110], ["A folded binding mode of RAR", "PROBLEM", 0, 28], ["WT", "TEST", 85, 87], ["folded", "OBSERVATION", 2, 8], ["RAR", "ANATOMY", 107, 110]]], ["Though R563 is present, the carboxylate group of RAR has moved back from its original position and formed p-interactions with Y378 and completely lost interactions with R563.", [["R563", "CHEMICAL", 7, 11], ["carboxylate", "CHEMICAL", 28, 39], ["carboxylate", "CHEMICAL", 28, 39], ["Y378", "CHEMICAL", 126, 130], ["R563", "CHEMICAL", 169, 173], ["RAR", "GENE_OR_GENE_PRODUCT", 49, 52], ["Y378", "SIMPLE_CHEMICAL", 126, 130], ["R563", "SIMPLE_CHEMICAL", 169, 173], ["R563", "PROTEIN", 7, 11], ["RAR", "PROTEIN", 49, 52], ["Y378", "PROTEIN", 126, 130], ["R563", "PROTEIN", 169, 173]]], ["This observation completely correlates with the observed activity and the reported statement that K565 assists R563 to act as carboxylate recognition site in aligning the substrate along the catalytic elements of the enzyme.", [["carboxylate", "CHEMICAL", 126, 137], ["K565", "SIMPLE_CHEMICAL", 98, 102], ["R563", "GENE_OR_GENE_PRODUCT", 111, 115], ["R563", "PROTEIN", 111, 115], ["carboxylate recognition site", "PROTEIN", 126, 154], ["catalytic elements", "PROTEIN", 191, 209], ["enzyme", "PROTEIN", 217, 223], ["carboxylate recognition site", "PROBLEM", 126, 154], ["the enzyme", "TEST", 213, 223]]], ["The overlay of all L-RAR systems revealed that along with E271, R563, K565 residues, Y378 and Y383 were also important in keeping the peptide substrate aligned within the active site ( Figure 10D ).", [["E271", "CHEMICAL", 58, 62], ["R563", "CHEMICAL", 64, 68], ["K565", "CHEMICAL", 70, 74], ["L-RAR", "GENE_OR_GENE_PRODUCT", 19, 24], ["E271", "GENE_OR_GENE_PRODUCT", 58, 62], ["Y383", "AMINO_ACID", 94, 98], ["RAR", "PROTEIN", 21, 24], ["all L-RAR systems", "TEST", 15, 32], ["E271", "TEST", 58, 62], ["the peptide substrate", "TREATMENT", 130, 151], ["active", "OBSERVATION_MODIFIER", 171, 177], ["site", "OBSERVATION_MODIFIER", 178, 182]]], ["As observed in L-LTA4 systems, Y378 residue has acted as a baffle to control the binding modes of the substrates.", [["Y378", "CHEMICAL", 31, 35], ["Y378", "CHEMICAL", 31, 35], ["Y378", "AMINO_ACID", 31, 35], ["L-LTA4", "PROTEIN", 15, 21], ["a baffle", "TREATMENT", 57, 65]]], ["This part of the study has documented various structural changes explaining the differences in activities between WT and mutated forms of the enzyme bound to its two different substrates which were not determined by the X-ray crystallography so far (Table S1 ).Binding modes of LTA4 and RAR substratesThe binding modes of fatty acid and peptide substrates that are catalyzed by hydrolase and aminopeptidase functions of the enzyme using same active site were compared.", [["fatty acid", "CHEMICAL", 322, 332], ["fatty acid", "CHEMICAL", 322, 332], ["LTA4", "GENE_OR_GENE_PRODUCT", 278, 282], ["RAR", "GENE_OR_GENE_PRODUCT", 287, 290], ["fatty acid", "SIMPLE_CHEMICAL", 322, 332], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 392, 406], ["enzyme", "PROTEIN", 142, 148], ["LTA4", "PROTEIN", 278, 282], ["RAR substrates", "PROTEIN", 287, 301], ["hydrolase", "PROTEIN", 378, 387], ["aminopeptidase", "PROTEIN", 392, 406], ["enzyme", "PROTEIN", 424, 430], ["the study", "TEST", 13, 22], ["various structural changes", "PROBLEM", 38, 64], ["WT", "TEST", 114, 116], ["the enzyme bound", "PROBLEM", 138, 154], ["the X-ray crystallography", "TEST", 216, 241], ["Binding modes of LTA4 and RAR substrates", "PROBLEM", 261, 301], ["fatty acid and peptide substrates", "TREATMENT", 322, 355], ["aminopeptidase functions", "TEST", 392, 416], ["the enzyme", "TEST", 420, 430]]], ["The overlay of two WT systems has given the overview of which parts of the active site were occupied by these two highly diverse substrates.", [["two WT systems", "TREATMENT", 15, 29], ["active", "OBSERVATION_MODIFIER", 75, 81]]], ["Both the substrates bind perpendicular to each other occupying majorly the different portion of the active site and sharing the carboxylate recognition sites in common ( Figure 11A ).", [["carboxylate", "CHEMICAL", 128, 139], ["carboxylate recognition sites", "PROTEIN", 128, 157], ["perpendicular", "OBSERVATION_MODIFIER", 25, 38], ["different", "OBSERVATION_MODIFIER", 75, 84], ["portion", "OBSERVATION_MODIFIER", 85, 92], ["active site", "OBSERVATION", 100, 111]]], ["The long alkyl part of LTA4 was snuggly bound into the hydrophobic pocket formed by a mixture of aliphatic and aromatic residues including W311, F314, K364, L365, V367, Y378, and V381.", [["alkyl", "CHEMICAL", 9, 14], ["LTA4", "CHEMICAL", 23, 27], ["LTA4", "CHEMICAL", 23, 27], ["W311", "CHEMICAL", 139, 143], ["F314", "CHEMICAL", 145, 149], ["K364", "CHEMICAL", 151, 155], ["L365", "CHEMICAL", 157, 161], ["V367", "CHEMICAL", 163, 167], ["Y378", "CHEMICAL", 169, 173], ["V381", "CHEMICAL", 179, 183], ["LTA4", "SIMPLE_CHEMICAL", 23, 27], ["W311", "SIMPLE_CHEMICAL", 139, 143], ["The long alkyl part of LTA4", "PROBLEM", 0, 27], ["aliphatic and aromatic residues", "PROBLEM", 97, 128], ["K364", "TEST", 151, 155], ["long", "OBSERVATION_MODIFIER", 4, 8], ["alkyl", "OBSERVATION_MODIFIER", 9, 14], ["hydrophobic pocket", "OBSERVATION", 55, 73], ["aromatic residues", "OBSERVATION", 111, 128]]], ["The side chain of Cterminal Arg residue of RAR was fit into the small cavity formed by F356, Y378, S379, M564, K565, and R568 residues.", [["Cterminal Arg", "CHEMICAL", 18, 31], ["Arg", "CHEMICAL", 28, 31], ["F356", "CHEMICAL", 87, 91], ["Y378", "CHEMICAL", 93, 97], ["S379", "CHEMICAL", 99, 103], ["M564", "CHEMICAL", 105, 109], ["K565", "CHEMICAL", 111, 115], ["R568", "CHEMICAL", 121, 125], ["Cterminal", "SIMPLE_CHEMICAL", 18, 27], ["Arg", "AMINO_ACID", 28, 31], ["RAR", "GENE_OR_GENE_PRODUCT", 43, 46], ["F356", "GENE_OR_GENE_PRODUCT", 87, 91], ["M564", "GENE_OR_GENE_PRODUCT", 105, 109], ["R568", "AMINO_ACID", 121, 125], ["RAR", "PROTEIN", 43, 46], ["Cterminal Arg residue of RAR", "PROBLEM", 18, 46], ["Arg residue", "OBSERVATION", 28, 39], ["RAR", "ANATOMY", 43, 46], ["small", "OBSERVATION_MODIFIER", 64, 69], ["cavity", "OBSERVATION", 70, 76]]], ["The overlay of active site residues has shown very few structural changes between the WT systems of L-LTA4 and L-RAR systems including the side chain movements of Y378, Y383, and K565 residues ( Figure 11B ).", [["Y378", "CHEMICAL", 163, 167], ["K565", "CHEMICAL", 179, 183], ["L-LTA4", "GENE_OR_GENE_PRODUCT", 100, 106], ["L-RAR", "GENE_OR_GENE_PRODUCT", 111, 116], ["Y378", "GENE_OR_GENE_PRODUCT", 163, 167], ["L-LTA4", "PROTEIN", 100, 106], ["L", "PROTEIN", 111, 112], ["RAR", "PROTEIN", 113, 116], ["active site residues", "PROBLEM", 15, 35], ["L-LTA4", "TEST", 100, 106], ["the side chain movements", "TEST", 135, 159], ["active", "OBSERVATION_MODIFIER", 15, 21], ["site residues", "OBSERVATION", 22, 35], ["very", "OBSERVATION_MODIFIER", 46, 50], ["few", "OBSERVATION_MODIFIER", 51, 54], ["structural", "OBSERVATION_MODIFIER", 55, 65], ["changes", "OBSERVATION", 66, 73], ["L", "ANATOMY_MODIFIER", 111, 112], ["RAR", "ANATOMY", 113, 116]]], ["The K565 residue was present in the loop in WT of L-LTA4 system and in the extended helix in WT of L-RAR system and thereby changing the flexibility and interacting behavior of K565.", [["K565", "GENE_OR_GENE_PRODUCT", 4, 8], ["L-LTA4", "GENE_OR_GENE_PRODUCT", 50, 56], ["L-RAR", "GENE_OR_GENE_PRODUCT", 99, 104], ["K565", "SIMPLE_CHEMICAL", 177, 181], ["L-LTA4", "PROTEIN", 50, 56], ["RAR", "PROTEIN", 101, 104], ["K565", "PROTEIN", 177, 181], ["The K565 residue", "PROBLEM", 0, 16], ["loop", "OBSERVATION_MODIFIER", 36, 40]]], ["This adds explanation to the importance of K565 residue in assisting R563 residue in aligning the peptide substrate whereas this residue is not required in aligning fatty acid substrate.ConclusionIn this study MD simulation methodology was used to simulate hLTA4H enzyme complexed with its two diverse substrates along with mutated key residues.", [["fatty acid", "CHEMICAL", 165, 175], ["fatty acid", "CHEMICAL", 165, 175], ["K565", "GENE_OR_GENE_PRODUCT", 43, 47], ["fatty acid", "SIMPLE_CHEMICAL", 165, 175], ["hLTA4H enzyme", "GENE_OR_GENE_PRODUCT", 257, 270], ["hLTA4H enzyme", "PROTEIN", 257, 270], ["K565 residue", "PROBLEM", 43, 55], ["this residue", "PROBLEM", 124, 136], ["this study", "TEST", 199, 209], ["hLTA4H enzyme", "TEST", 257, 270], ["mutated key residues", "PROBLEM", 324, 344]]], ["The aim of this study was to investigate the structural and conformational changes in the bi-functional active site of the enzyme reflecting on the catalytic activity.", [["bi-functional active site", "PROTEIN", 90, 115], ["enzyme", "PROTEIN", 123, 129], ["this study", "TEST", 11, 21], ["the structural and conformational changes in the bi-functional active site", "PROBLEM", 41, 115], ["the enzyme", "TEST", 119, 129]]], ["This was considered very important and necessary to script the reasons for the observed loss of activity due to particular mutations as the solved X-ray structures failed to show the structural changes.", [["X-ray structures", "DNA", 147, 163], ["the observed loss of activity", "PROBLEM", 75, 104], ["particular mutations", "PROBLEM", 112, 132], ["the solved X-ray structures", "PROBLEM", 136, 163], ["the structural changes", "PROBLEM", 179, 201]]], ["Eight systems including two WT, enzyme-LTA4 and enzyme-RAR complexes along with three independent mutations (E271Q, R563A, and K565A) in each complex were simulated in this study.", [["enzyme-LTA4", "GENE_OR_GENE_PRODUCT", 32, 43], ["enzyme-RAR", "GENE_OR_GENE_PRODUCT", 48, 58], ["enzyme-LTA4", "PROTEIN", 32, 43], ["enzyme", "PROTEIN", 48, 54], ["RAR complexes", "PROTEIN", 55, 68], ["Eight systems", "TEST", 0, 13], ["two WT", "TEST", 24, 30], ["enzyme-LTA4", "TEST", 32, 43], ["enzyme", "TEST", 48, 54], ["this study", "TEST", 168, 178]]], ["The observed hydrogen bond interaction network and distance between the catalytically important atoms have correlated well with the experimental results.", [["hydrogen", "CHEMICAL", 13, 21], ["hydrogen", "CHEMICAL", 13, 21], ["hydrogen bond", "OBSERVATION", 13, 26]]], ["The E271 residue which is considered very important for both functions of the enzyme and E271Q systems have revealed from our study that this residue acts as a hook to hold the catalytic metal ion at its location and also plays a role of N-terminal recognition point for the aminopeptidase function.", [["N", "CHEMICAL", 238, 239], ["E271Q", "GENE_OR_GENE_PRODUCT", 89, 94], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 275, 289], ["enzyme", "PROTEIN", 78, 84], ["E271Q", "PROTEIN", 89, 94], ["N-terminal recognition point", "PROTEIN", 238, 266], ["aminopeptidase", "PROTEIN", 275, 289], ["The E271 residue", "PROBLEM", 0, 16], ["the enzyme and E271Q systems", "TEST", 74, 102], ["our study", "TEST", 122, 131], ["the catalytic metal ion", "TREATMENT", 173, 196], ["the aminopeptidase function", "TEST", 271, 298]]], ["Both the E271Q systems have lost the expected binding mode of the substrates for the successful catalysis.", [["the successful catalysis", "TREATMENT", 81, 105]]], ["The other mutant R563A and K565A systems have also revealed the structural changes and binding mode differences explaining the loss of activity in mutant systems.", [["the structural changes", "PROBLEM", 60, 82], ["binding mode differences", "PROBLEM", 87, 111], ["the loss of activity in mutant systems", "PROBLEM", 123, 161]]], ["In L-LTA4 systems, the substrate binding mode in R563A system has changed completely that the long alkyl chain of LTA4 was completely buried into the hydrophobic pocket.", [["alkyl", "CHEMICAL", 99, 104], ["LTA4", "CHEMICAL", 114, 118], ["LTA4", "CHEMICAL", 114, 118], ["R563A", "AMINO_ACID", 49, 54], ["LTA4", "SIMPLE_CHEMICAL", 114, 118], ["the long alkyl chain of LTA4", "TREATMENT", 90, 118], ["hydrophobic pocket", "OBSERVATION", 150, 168]]], ["This difference in binding mode of LTA4 was completely because of the loss of hydrogen bond interaction with R563 residue.", [["LTA4", "CHEMICAL", 35, 39], ["LTA4", "CHEMICAL", 35, 39], ["hydrogen", "CHEMICAL", 78, 86], ["R563", "CHEMICAL", 109, 113], ["LTA4", "SIMPLE_CHEMICAL", 35, 39], ["R563", "SIMPLE_CHEMICAL", 109, 113], ["the loss of hydrogen bond interaction", "PROBLEM", 66, 103], ["R563 residue", "PROBLEM", 109, 121], ["hydrogen bond", "OBSERVATION", 78, 91]]], ["In terms of L-RAR systems, the same mutation R563A has affected the binding mode of RAR and N-terminal recognition through E271 residue in peptide binding.", [["N", "CHEMICAL", 92, 93], ["L-RAR", "GENE_OR_GENE_PRODUCT", 12, 17], ["RAR", "GENE_OR_GENE_PRODUCT", 84, 87], ["E271", "AMINO_ACID", 123, 127], ["RAR", "PROTEIN", 14, 17], ["RAR", "PROTEIN", 84, 87], ["E271 residue in peptide binding", "PROBLEM", 123, 154], ["L", "ANATOMY_MODIFIER", 12, 13], ["RAR systems", "ANATOMY", 14, 25]]], ["Because of this missing N-terminal recognition the catalytic distance between the metal ion and the carbonyl group of the N-terminal peptide bond was high in this system.", [["carbonyl", "CHEMICAL", 100, 108], ["N", "CHEMICAL", 24, 25], ["carbonyl", "CHEMICAL", 100, 108], ["N", "CHEMICAL", 122, 123], ["carbonyl", "SIMPLE_CHEMICAL", 100, 108], ["this missing N-terminal recognition", "PROBLEM", 11, 46], ["the metal ion", "TREATMENT", 78, 91], ["high", "OBSERVATION_MODIFIER", 150, 154]]], ["The K565A systems in both the substrate complexes have shown different structural changes.", [["substrate complexes", "PROTEIN", 30, 49], ["The K565A systems", "TEST", 0, 17], ["different structural changes", "PROBLEM", 61, 89], ["different", "OBSERVATION_MODIFIER", 61, 70], ["structural changes", "OBSERVATION", 71, 89]]], ["In L-LTA4 system the binding mode of the substrate was very much similar to the WT explaining the less importance of K565 in LTA4 binding whereas in L-RAR system the binding mode has lost both the N-terminal and C-terminal recognitions leading to the loss of activity.", [["LTA4", "CHEMICAL", 125, 129], ["C", "CHEMICAL", 212, 213], ["L-LTA4", "GENE_OR_GENE_PRODUCT", 3, 9], ["K565", "SIMPLE_CHEMICAL", 117, 121], ["LTA4", "SIMPLE_CHEMICAL", 125, 129], ["L-RAR", "GENE_OR_GENE_PRODUCT", 149, 154], ["L-LTA4", "PROTEIN", 3, 9], ["K565", "PROTEIN", 117, 121], ["LTA4", "PROTEIN", 125, 129], ["RAR", "PROTEIN", 151, 154], ["LTA4 binding", "PROBLEM", 125, 137], ["the N-terminal and C-terminal recognitions", "PROBLEM", 193, 235], ["the loss of activity", "PROBLEM", 247, 267]]], ["These results obtained from this study can be effectively used in designing future hLTA4H inhibitors as anti-inflammatory and anti-cancer therapeutics.", [["hLTA4H", "SIMPLE_CHEMICAL", 83, 89], ["anti-cancer", "CANCER", 126, 137], ["this study", "TEST", 28, 38], ["hLTA4H inhibitors", "TREATMENT", 83, 100], ["anti-inflammatory and anti-cancer therapeutics", "TREATMENT", 104, 150]]], ["Table S1 The structural changes which were not seen in experimental studies observed through the MD simulation studies.", [["experimental studies", "TEST", 55, 75], ["the MD simulation studies", "TEST", 93, 118], ["not seen", "UNCERTAINTY", 43, 51]]]], "90721a309e43efcef2948951f02eab0deda75701": [["Introductionthose with smaller economies that cannot afford social support for their citizens, as found with the stimulus and bailout packages in Europe and North America (5,6).IntroductionIn an April 2020 study, J\u00fcni et al. (7) use a prospective cohort study approach over a 14day period as the pandemic was beginning to unfold in most countries (March 7 to March 21, 2020) to explore the association between COVID-19 growth in 144 countries and territories and income and latitude.", [["a prospective cohort study approach", "TREATMENT", 233, 268], ["COVID", "TEST", 410, 415], ["smaller", "OBSERVATION_MODIFIER", 23, 30], ["economies", "OBSERVATION", 31, 40]]], ["They conclude that neither income nor latitude is statistically significant in its association with COVID-19 growth.", [["COVID", "TEST", 100, 105]]], ["They concluded that both income and latitude are strongly associated with COVID-19 incidence and deaths.", [["deaths", "DISEASE", 97, 103]]], ["They go on to say that low community infections in countries with high temperature and high relative humidity may be explained by their locations.", [["infections", "DISEASE", 37, 47], ["low community infections", "PROBLEM", 23, 47], ["high temperature", "PROBLEM", 66, 82], ["infections", "OBSERVATION", 37, 47]]], ["Livadiotis (9) confirmed a negative relationship between environmental temperature and infection growth rates in Italy and the United States, lending support to the latitude (as proxy for temperature) hypothesis.", [["Livadiotis", "CHEMICAL", 0, 10], ["infection", "DISEASE", 87, 96], ["infection growth rates", "PROBLEM", 87, 109], ["hypothesis", "PROBLEM", 201, 211], ["infection", "OBSERVATION", 87, 96]]], ["Another study suggested that the low mortality from COVID-19 in countries south of Latitude 35\u00b0N may be a result of Vitamin D's role in mitigating disease severity (10) , which further contribute to temperature's role in the unfolding story.", [["Vitamin D", "CHEMICAL", 116, 125], ["Vitamin D", "CHEMICAL", 116, 125], ["Vitamin D", "SIMPLE_CHEMICAL", 116, 125], ["Another study", "TEST", 0, 13], ["the low mortality", "PROBLEM", 29, 46], ["COVID", "TEST", 52, 57], ["Vitamin D's role", "TREATMENT", 116, 132], ["mitigating disease severity", "PROBLEM", 136, 163]]], ["Despite the foregoing, there is still some debate about the location characteristics and the infection numbers because of the changing environment (11, 12) .", [["infection", "DISEASE", 93, 102], ["the infection numbers", "PROBLEM", 89, 110], ["infection", "OBSERVATION", 93, 102]]], ["Apart from these climatic characteristics, there has also been suggestions of the association of the disease with age (13, 14) .", [["the disease", "PROBLEM", 97, 108], ["climatic", "OBSERVATION_MODIFIER", 17, 25], ["disease", "OBSERVATION", 101, 108]]], ["A recent Pew Research Center study (15) confirmed a correlation between the incidence of COVID-19 and the proportion of the population who are 60 years or older.IntroductionBecause longitude does not directly affect temperature and relative humidity, it has so far been ignored in COVID- 19 studies.", [["COVID", "TEST", 89, 94]]], ["Yet, the distribution of COVID-19 infections shows that there .", [["infections", "DISEASE", 34, 44], ["COVID-19", "ORGANISM", 25, 33], ["COVID", "TEST", 25, 30], ["19 infections", "PROBLEM", 31, 44], ["distribution", "OBSERVATION_MODIFIER", 9, 21], ["infections", "OBSERVATION", 34, 44]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint are differences as one moves away from the prime meridian.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 325, 341], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Understanding the extent to which it is associated with the prevalence of the disease could open up different exploration avenues and produce alternative insights.", [["the disease", "PROBLEM", 74, 85], ["disease", "OBSERVATION", 78, 85]]], ["To this end, this study seeks to contribute to resolving some of the outstanding issues surrounding the distribution of COVID-19 using all relevant and available data on infections from the beginning of the outbreak in China to date.", [["infections", "DISEASE", 170, 180], ["this study", "TEST", 13, 23], ["COVID", "TEST", 120, 125], ["infections", "PROBLEM", 170, 180]]], ["It hopes to provide policymakers with insights into how they might deal with the pandemic in their jurisdictions as seasons shift, with the north moving into summer and the south moving into winter (16) .DataThe study uses cross-sectional data for 211 countries and territories to explore the association between the explained variable of interest, total confirmed COVID-19 cases for each jurisdiction between December 31, 2019 and June 15, 2020, and a number of explanatory variables in line with the literature.", [["The study", "TEST", 208, 217], ["cross-sectional data", "TEST", 223, 243], ["COVID", "TEST", 365, 370]]], ["They included income, location (specified as latitude and longitude of the country's capital city), average temperature between December and March, and trade intensity.DataUsing the cumulative number of cases between the onset of the pandemic and a particular end date makes this study similar to Heneghan and Jefferson (8) .", [["this study", "TEST", 275, 285]]], ["This approach, instead of taking only a part of the data, ensures that all adjustments made by reporting agencies to address apparent reporting irregularities at the beginning of the pandemic are captured (17, 18) .", [["apparent reporting irregularities", "PROBLEM", 125, 158], ["irregularities", "OBSERVATION", 144, 158]]], ["The case data, along with population data, were obtained from the COVID-19 web pages of the European Centre for Disease Prevention and Control (1) .", [["population data", "TEST", 26, 41], ["Disease Prevention", "TREATMENT", 112, 130]]], ["From these two variables, the total number of cases per one million population was developed and used as the explained variable in the study.Data.", [["the study", "TEST", 131, 140]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)DataThe copyright holder for this preprint this version posted July 7, 2020.MethodsImported COVID-19 spread, in contrast to community spread, is through travel to specific locations and/or in transit, and from travel to countries by carriers of the virus.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["MethodsImported COVID", "TEST", 278, 299], ["the virus", "PROBLEM", 447, 456], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)MethodsThe copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint increased (24).", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 333, 340], ["med", "ANATOMY", 105, 108]]], ["Eder et al. (25) report that more than 430,000 people arrived in the United States, mainly in New York, San Francisco and Los Angeles from China between January 2020 and middle of March 2020.", [["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53]]], ["These cities became centers of the pandemic in the early days of the disease.", [["the pandemic", "PROBLEM", 31, 43], ["the disease", "PROBLEM", 65, 76], ["pandemic", "OBSERVATION_MODIFIER", 35, 43], ["disease", "OBSERVATION", 69, 76]]], ["Pullano et al. (26) observe that the first 41 infections of COVID-19 outside of China were all traceable to people who arrived from Wuhan to Europe, North America, Oceania and Asia.MethodsSimilarly, early infections in Africa were traced to travelers coming from Europe, Asia, and South America (27) .", [["infections", "DISEASE", 46, 56], ["infections", "DISEASE", 205, 215], ["people", "ORGANISM", 108, 114], ["people", "SPECIES", 108, 114], ["COVID", "TEST", 60, 65], ["early infections in Africa", "PROBLEM", 199, 225], ["early", "OBSERVATION_MODIFIER", 199, 204], ["infections", "OBSERVATION", 205, 215]]], ["Given the foregoing, it is hypothesized that the income elasticity of confirmed infections is positive, holding all other influencing variables constant.", [["infections", "DISEASE", 80, 90], ["infections", "PROBLEM", 80, 90], ["infections", "OBSERVATION", 80, 90]]], ["If there is an infection risk in the target country, then the risk of importing the infection increases.", [["infection", "DISEASE", 15, 24], ["infection", "DISEASE", 84, 93], ["an infection risk", "PROBLEM", 12, 29], ["the infection", "PROBLEM", 80, 93], ["infection", "OBSERVATION", 15, 24], ["infection", "OBSERVATION", 84, 93]]], ["Trade intensity is, therefore, hypothesized to have a positive association with confirmed cases, holding all other influencing variables constant.MethodsBecause there seems to be a negative association between the virus and ambient temperature (28) , it is hypothesized that the temperature elasticity of confirmed infections is negative, holding all other things constant.", [["infections", "DISEASE", 315, 325], ["the virus", "PROBLEM", 210, 219], ["ambient temperature", "TEST", 224, 243], ["the temperature elasticity", "TEST", 275, 301], ["infections", "PROBLEM", 315, 325], ["negative", "OBSERVATION", 181, 189], ["infections", "OBSERVATION", 315, 325], ["negative", "OBSERVATION", 329, 337]]], ["If this holds, then it is to be expected that the infection rates in the higher latitudes should decline as those regions enter their summer months, and they should increase as the countries in the lower latitudes enter their winter months.", [["infection", "DISEASE", 50, 59], ["the infection rates", "PROBLEM", 46, 65], ["infection", "OBSERVATION", 50, 59]]], ["While most studies exploring the effect of location on COVID-19 cases have used latitude as an associative variable, none has paid attention to the other location variable, i.e., longitude.", [["COVID", "TEST", 55, 60]]], ["Yet, the incidence map (29) shows that there seem to be differences in the cumulative cases as one moves from east to west.", [["the incidence map", "TEST", 5, 22]]], ["It is, therefore, included in this study as an explanatory variable for cumulative confirmed cases of COVID-19.", [["this study", "TEST", 30, 40], ["COVID", "TEST", 102, 107]]], ["It is hypothesized, on the basis of the incidence maps, that moving east decreases the incidence of COVID-19.Methods.", [["COVID-19", "CHEMICAL", 100, 108], ["the incidence maps", "PROBLEM", 36, 54], ["COVID", "TEST", 100, 105]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint(which was not certified by peer review)The foregoing suggests that the number of confirmed cases on June 15, 2020 in each country, , i C was influenced by a vector of explanatory variables defined to encompass the following: (i) the average income per person for each country; (ii) the location of the country (latitude and longitude); (iii) the country's average temperature between December and March;(which was not certified by peer review)and (iv) its trade intensity with China.", [["CC", "CHEMICAL", 0, 2], ["person", "SPECIES", 594, 600], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint Table 1 presents the summary statistics for the variables used in the analyses.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["It shows that the average and median of total confirmed COVID-19 cases on April 16, 2020 were, respectively, about 619 and about 93 per million people.", [["people", "ORGANISM", 144, 150], ["people", "SPECIES", 144, 150], ["COVID", "TEST", 56, 61]]], ["The average increased by about 70.1% a month later and by almost 165% two months later.", [["average", "OBSERVATION_MODIFIER", 4, 11], ["increased", "OBSERVATION_MODIFIER", 12, 21]]], ["The median, on the other hand, increased by 136% between April and May, and by more than 315% between April and June, indicating the number of cases is increasing in many countries instead of in a few countries.", [["median", "OBSERVATION_MODIFIER", 4, 10], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["increasing", "OBSERVATION_MODIFIER", 152, 162]]], ["For example, the differences in the average temperature between 15\u00b0N to 15\u00b0S and Above 15\u00b0N category are about 17.8\u00b0C (p < 0.000) and between Below 15\u00b0S and Above 15\u00b0N was approximately 14\u00b0C (p < 0.000).", [["the average temperature", "TEST", 32, 55], ["N category", "TEST", 90, 100], ["C", "TEST", 116, 117]]], ["However, the temperature difference between Below 15\u00b0S and the 15\u00b0N to 15\u00b0S categories was about 3.9\u00b0C (p < 0.000).", [["the temperature difference", "PROBLEM", 9, 35]]], ["Despite the statistically significant difference in their temperatures, there was no statistical difference between their average number of cases (123.5 cases/million, p < 0.755).(which was not certified by peer review).", [["their temperatures", "TEST", 52, 70], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION_MODIFIER", 38, 48], ["no", "UNCERTAINTY", 82, 84]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprintRegression Results and DiscussionThe OLS model specified in Equation (1) .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint Model 3 produced the best regression results based on adjusted R 2 for all three months.(which was not certified by peer review)The results, presented in Table 3 , show that the adjusted R 2 for April as higher than for May, which was higher than for June.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The decreasing coefficient of determination may be attributed to the decreasing variability in the number of COVID-19 cases per million over time, confirmed by the coefficient of variation statistics discussed above.", [["the decreasing variability", "PROBLEM", 65, 91], ["COVID", "TEST", 109, 114], ["decreasing", "OBSERVATION_MODIFIER", 4, 14], ["may be attributed to", "UNCERTAINTY", 44, 64], ["decreasing", "OBSERVATION_MODIFIER", 69, 79], ["variability", "OBSERVATION_MODIFIER", 80, 91]]], ["The results show that the log of confirmed number of COVID-19 cases per million people is increasing in the GNI per capita at a decreasing rate, with both the linear and quadratic forms of GNI per capita being statistically significant (p < 0.000).", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["COVID", "TEST", 53, 58], ["increasing", "OBSERVATION_MODIFIER", 90, 100], ["linear", "OBSERVATION_MODIFIER", 159, 165]]], ["Furthermore, coefficients on the linear and quadratic forms of GNI per capita both decreased in absolute terms over time.", [["decreased", "OBSERVATION_MODIFIER", 83, 92], ["absolute terms", "OBSERVATION_MODIFIER", 96, 110]]], ["The GNI/capita elasticities of case numbers per million for April, May and June were, respectively, 0.37 (p < 0.000), 0.25 (p < 0.000), and 0.75 (p < 0.000) at the mean.", [["GNI", "PROTEIN", 4, 7]]], ["The income elasticity for the three latitude categories -15\u00b0N to 15\u00b0S, Above 15\u00b0N, and Below 15\u00b0Sfor June were 0.17 (p < 0.000), 0.14 (p < 0.000), and 0.18 (p < 0.000), respectively.", [["the three latitude categories", "TEST", 26, 55]]], ["For May, the elasticities were 0.42 (p < 0.000), 0.32 (p < 0.000), and 0.31 (p < 0.000).", [["the elasticities", "TEST", 9, 25]]], ["And for April, the estimated elasticities were 0.27 (p < 0.000), 0.22 (p < 0.000), and 0.43 (p < 0.000).", [["the estimated elasticities", "TEST", 15, 41]]], ["The results also suggest that being in the Above Latitude 15\u00b0N instead of in the 15\u00b0N to 15\u00b0S category is associated with an increase of 1.2% in the number of confirmed cases (p < 0.000) for May and June and about 1.3% (p < 0.000) for April.", [["increase", "OBSERVATION_MODIFIER", 125, 133]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint numbers in May and June, but was in April (p < 0.026) and it exhibited the wrong sign.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["That is, a percentage point increase in the China trade intensity in April was associated with about 2.3% decline in the total number of cases per million.", [["a percentage point increase", "PROBLEM", 9, 36], ["percentage", "OBSERVATION_MODIFIER", 11, 21], ["point", "OBSERVATION_MODIFIER", 22, 27], ["increase", "OBSERVATION_MODIFIER", 28, 36]]], ["The lockdown and banned travel policies that started in March in most jurisdictions may explain why the trade intensity elasticity of COVID-19 cases per million on April 16, 2020 of -0.18 was not statistically significant p < 0.499). variables constant, the coefficient for latitude was less than half of that for temperature, but both .", [["The lockdown and banned travel policies", "TREATMENT", 0, 39], ["COVID", "TEST", 134, 139]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint were statistically significant (p < 0.000).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Additionally, the two variables exhibited their expected signs.(which was not certified by peer review)As indicated in the data and methods section, previous studies have ignored longitude, may be because it had nothing to do directly with temperature and humidity as latitude does.", [["methods section", "TEST", 132, 147], ["previous studies", "TEST", 149, 165]]], ["However, there was a clear trend in incidence maps showing that longitude was a factor.", [["incidence maps", "TEST", 36, 50], ["clear", "OBSERVATION_MODIFIER", 21, 26], ["trend", "OBSERVATION_MODIFIER", 27, 32]]], ["The results from all the estimated models indicate a statistically significant negative coefficient for longitude.", [["all the estimated models", "TEST", 17, 41]]], ["It has shown both longitude and latitude are statistically significant covariates for the log of total number of COVID-19 cases between December 31, 2019 and June 15, 2020.", [["COVID", "TEST", 113, 118], ["both", "OBSERVATION_MODIFIER", 13, 17], ["longitude", "OBSERVATION_MODIFIER", 18, 27], ["significant", "OBSERVATION_MODIFIER", 59, 70]]], ["It also showed a significant correlation between latitude and temperature, supporting the speculations that COVID-19 cases might be following the seasons.", [["COVID", "TEST", 108, 113], ["significant", "OBSERVATION_MODIFIER", 17, 28]]], ["Using GNI/capita as a proxy for travel, the results showed that while remaining statistically significant, the impact of this variable waned over time.", [["GNI", "PROTEIN", 6, 9], ["significant", "OBSERVATION_MODIFIER", 94, 105]]], ["This is expected because of the intervention policies that virtually stopped global travel by April.", [["the intervention policies", "TREATMENT", 28, 53]]], ["This is confirmed by the fact that while latitude (Model 1) and temperature (Model 5) both exhibited their hypothesized relationships with the number of confirmed cases of COVID-19, neither provided as strong a model as using latitude categories in place of both variables.", [["COVID", "TEST", 172, 177], ["latitude categories", "TREATMENT", 226, 245]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint expected that higher temperatures in the north would reduce its case numbers (9, 31) .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 325, 332], ["higher temperatures", "PROBLEM", 356, 375], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["higher", "OBSERVATION_MODIFIER", 356, 362], ["temperatures", "OBSERVATION_MODIFIER", 363, 375]]], ["However, as is already unfolding in the United States (32) and in Germany (33) , lifting the lockdown has probably increased local spread of the infection across local communities as susceptible (unexposed) people exiting their sheltersin-place encounter infected people.", [["infection", "DISEASE", 145, 154], ["people", "ORGANISM", 207, 213], ["people", "ORGANISM", 264, 270], ["people", "SPECIES", 207, 213], ["people", "SPECIES", 264, 270], ["the infection", "PROBLEM", 141, 154], ["probably", "UNCERTAINTY", 106, 114], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["local", "OBSERVATION_MODIFIER", 125, 130], ["spread", "OBSERVATION_MODIFIER", 131, 137], ["infection", "OBSERVATION", 145, 154], ["infected", "OBSERVATION", 255, 263]]], ["A few countries in the Below Latitude 15\u00b0S -Brazil, Peru, and Chilehave already started seeing spikes in their numbers.", [["few", "OBSERVATION_MODIFIER", 2, 5]]], ["It is still too early to confirm that it is due mainly to the changing seasons, and not to changing government policies about shelterin-place and people's commitment to social distancing guidelines.(which was not certified by peer review)The countries and jurisdictions lying between Latitude 15\u00b0N and 15\u00b0S do not experience the seasonal changes the others experience, and may therefore, not see major changes in their COVID-19 numbers in the second half of the year, as long as they effectively control imported infections, and continue to manage their current infected judiciously.", [["infections", "DISEASE", 513, 523], ["people", "ORGANISM", 146, 152], ["people", "SPECIES", 146, 152], ["infections", "OBSERVATION", 513, 523], ["infected", "OBSERVATION", 562, 570]]], ["If they succeed at this, then they can avoid the extensive lockdowns and their attendant adverse effects on national and local economies.", [["the extensive lockdowns", "TREATMENT", 45, 68], ["national and local economies", "TREATMENT", 108, 136]]], ["Yet, it is important for public health officials everywhere to remain vigilant because of the inherent possibilities for mutations of the virus (34), and the uncertainty about the effects of these mutations on infectivity (35,36).", [["mutations of the virus", "PROBLEM", 121, 143], ["these mutations on infectivity", "PROBLEM", 191, 221]]], ["Finally, the specific implications of the negative association with the longitude variable is unclear, yet its role in defining location, and its strong statistical significance suggests that it may not be ignored.", [["may not be", "UNCERTAINTY", 195, 205]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv preprint", "TREATMENT", 366, 382], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.07.20148007 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["medRxiv", "TREATMENT", 366, 373], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "PMC7269518": [["In March 2020, the epidemic caused by the novel coronavirus (or SARS-CoV-2) turned into a global pandemic, with Italy leading the tally with regard to the number of COVID-19 cases as well as fatalities.", [["coronavirus", "DISEASE", 48, 59], ["coronavirus", "ORGANISM", 48, 59], ["SARS-CoV-2", "ORGANISM", 64, 74], ["coronavirus", "SPECIES", 48, 59], ["SARS-CoV-2", "SPECIES", 64, 74], ["the novel coronavirus", "PROBLEM", 38, 59], ["SARS", "PROBLEM", 64, 68], ["COVID", "TEST", 165, 170]]]], "PMC7227567": [["IntroductionIn December 2019, a series of viral pneumonia cases appeared in Wuhan, Hubei, China [6].", [["viral pneumonia", "DISEASE", 42, 57], ["viral pneumonia cases", "PROBLEM", 42, 63], ["pneumonia", "OBSERVATION", 48, 57]]], ["Deep clinical trials indicated a novel coronavirus (COVID-19), which was named 2019 novel coronavirus (2019-nCoV).", [["coronavirus", "ORGANISM", 39, 50], ["COVID-19", "ORGANISM", 52, 60], ["coronavirus", "ORGANISM", 90, 101], ["coronavirus", "SPECIES", 90, 101], ["Deep clinical trials", "TEST", 0, 20], ["a novel coronavirus", "PROBLEM", 31, 50], ["COVID", "TEST", 52, 57], ["novel coronavirus", "PROBLEM", 84, 101]]], ["This infection is characterized by lung failure, which leads to respiratory distress.", [["lung", "ANATOMY", 35, 39], ["respiratory", "ANATOMY", 64, 75], ["infection", "DISEASE", 5, 14], ["lung failure", "DISEASE", 35, 47], ["respiratory distress", "DISEASE", 64, 84], ["lung", "ORGAN", 35, 39], ["This infection", "PROBLEM", 0, 14], ["lung failure", "PROBLEM", 35, 47], ["respiratory distress", "PROBLEM", 64, 84], ["infection", "OBSERVATION", 5, 14], ["lung", "ANATOMY", 35, 39], ["failure", "OBSERVATION", 40, 47], ["respiratory distress", "OBSERVATION", 64, 84]]], ["Countries have taken strict measures, including the use of protective measures such as wearing face masks and gloves, encouraging people to work from home to avoid contact with other people, and limiting the travel between provinces.", [["people", "ORGANISM", 130, 136], ["people", "ORGANISM", 183, 189], ["people", "SPECIES", 130, 136], ["people", "SPECIES", 183, 189], ["strict measures", "TREATMENT", 21, 36], ["protective measures", "TREATMENT", 59, 78], ["face masks", "TREATMENT", 95, 105], ["gloves", "TREATMENT", 110, 116]]], ["Due to geopolitical distrust, cooperation between countries, in this case, becomes very difficult.", [["geopolitical distrust", "PROBLEM", 7, 28]]], ["According to the World Health Organization (WHO), this pandemic has now infected more than 2 million people and 193825 cases confirmed deaths across the world [8].", [["deaths", "DISEASE", 135, 141], ["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107]]], ["The WHO has stated that the spread of coronavirus may be interrupted by quarantine.", [["coronavirus", "DISEASE", 38, 49], ["coronavirus", "ORGANISM", 38, 49], ["coronavirus", "PROBLEM", 38, 49]]], ["This strategy is defined as the separation of individuals who may have been exposed to an infectious disease like methicillin-resistant Staphylococcus aureus (MRSA), severe acute respiratory syndrome (SARS) or the influenza A (H1N1) virus from the rest of the population to reduce their risk of infecting others [5].", [["infectious disease", "DISEASE", 90, 108], ["methicillin", "CHEMICAL", 114, 125], ["Staphylococcus aureus", "DISEASE", 136, 157], ["MRSA", "DISEASE", 159, 163], ["acute respiratory syndrome", "DISEASE", 173, 199], ["SARS", "DISEASE", 201, 205], ["influenza A (H1N1) virus", "DISEASE", 214, 238], ["methicillin", "CHEMICAL", 114, 125], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 114, 157], ["MRSA", "CANCER", 159, 163], ["influenza A (H1N1) virus", "ORGANISM", 214, 238], ["Staphylococcus aureus", "SPECIES", 136, 157], ["MRSA", "SPECIES", 159, 163], ["influenza A (H1N1", "SPECIES", 214, 231], ["Staphylococcus aureus", "SPECIES", 136, 157], ["MRSA", "SPECIES", 159, 163], ["influenza A (H1N1) virus", "SPECIES", 214, 238], ["an infectious disease", "PROBLEM", 87, 108], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 114, 157], ["MRSA", "PROBLEM", 159, 163], ["severe acute respiratory syndrome", "PROBLEM", 166, 199], ["SARS", "PROBLEM", 201, 205], ["the influenza A (H1N1) virus", "PROBLEM", 210, 238], ["infectious", "OBSERVATION", 90, 100], ["Staphylococcus aureus", "OBSERVATION", 136, 157], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["respiratory syndrome", "OBSERVATION", 179, 199]]], ["During the coronavirus epidemic (COVID-19), quarantine was used as a public health fstrategy to reduce the transmission of disease.", [["coronavirus", "DISEASE", 11, 22], ["the coronavirus epidemic", "PROBLEM", 7, 31], ["COVID", "TEST", 33, 38], ["quarantine", "TREATMENT", 44, 54], ["a public health fstrategy", "TREATMENT", 67, 92], ["disease", "PROBLEM", 123, 130], ["disease", "OBSERVATION", 123, 130]]], ["The measures differ from one country to another (see Table 1).From Quarantine to DepreobesityThe Frustration related to the quarantine involves the loss of our daily routine (for example the regular activities at home and work, the purchases of necessities), social contacts and physical limitations with others [9].", [["The Frustration", "PROBLEM", 93, 108]]], ["Zandifar et al discussed that quarantine during Covid-19 can increase the psychological problems [10].", [["Covid-19", "CHEMICAL", 48, 56]]], ["This condition can show elevated rates of depression, anxiety, and post-traumatic stress disorder.", [["depression", "DISEASE", 42, 52], ["anxiety", "DISEASE", 54, 61], ["post-traumatic stress disorder", "DISEASE", 67, 97], ["elevated rates", "PROBLEM", 24, 38], ["depression", "PROBLEM", 42, 52], ["anxiety", "PROBLEM", 54, 61], ["post-traumatic stress disorder", "PROBLEM", 67, 97], ["elevated", "OBSERVATION_MODIFIER", 24, 32], ["depression", "OBSERVATION", 42, 52], ["post-traumatic stress disorder", "OBSERVATION", 67, 97]]], ["Like other pandemics, the fear of death can develop depression among people who are quarantined [11].", [["death", "DISEASE", 34, 39], ["depression", "DISEASE", 52, 62], ["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75], ["death", "PROBLEM", 34, 39], ["depression", "PROBLEM", 52, 62], ["pandemics", "OBSERVATION", 11, 20]]], ["On the one hand, the absence of financial sources, costs of healthcare can lead to socioeconomic distress, especially among people with low incomes.", [["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130], ["socioeconomic distress", "PROBLEM", 83, 105]]], ["On the other hand, fear or suspicion, avoidance or exclusion from leisure, work, or school activities and perceived stigma, are some of the important factors causing depression.", [["depression", "DISEASE", 166, 176], ["perceived stigma", "PROBLEM", 106, 122], ["depression", "PROBLEM", 166, 176]]], ["When the quarantine ends, returning to work and social routines can take several weeks, or even months, thus increasing even more worry, anxiety, and frustration.", [["anxiety", "DISEASE", 137, 144], ["anxiety", "PROBLEM", 137, 144]]], ["Specifically, media exposure should be monitored because unreliable sources can increase stress.", [["media exposure", "TREATMENT", 14, 28]]], ["Consequently, stress and depression push people to consume specifically high sugar food like chocolate and soft drinks, and choose to eat high calorie treats to boost their mood [1,16].", [["depression", "DISEASE", 25, 35], ["sugar", "CHEMICAL", 77, 82], ["people", "ORGANISM", 41, 47], ["chocolate", "ORGANISM_SUBDIVISION", 93, 102], ["people", "SPECIES", 41, 47], ["stress", "PROBLEM", 14, 20], ["depression", "PROBLEM", 25, 35]]], ["This desire to eat this unhealthy food will be much enhanced by the people.", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74]]], ["Quarantine-related depression also results in sleep disturbances that, in turn, further increase food intake, thus giving rise to a dangerous vicious cycle [17].", [["Quarantine", "CHEMICAL", 0, 10], ["depression", "DISEASE", 19, 29], ["sleep disturbances", "DISEASE", 46, 64], ["Quarantine", "CHEMICAL", 0, 10], ["depression", "PROBLEM", 19, 29], ["sleep disturbances", "PROBLEM", 46, 64]]], ["Mediouni et al. explained the impact of depression on obesity and this phenomenon was called depreobesity [4].", [["depression", "DISEASE", 40, 50], ["obesity", "DISEASE", 54, 61], ["depreobesity", "DISEASE", 93, 105], ["depression", "PROBLEM", 40, 50], ["obesity", "PROBLEM", 54, 61], ["this phenomenon", "PROBLEM", 66, 81], ["depression", "OBSERVATION", 40, 50], ["obesity", "OBSERVATION", 54, 61]]], ["Besides, physical activity has been reduced because of school closures which have derailed the lives of children [2].", [["children", "ORGANISM", 104, 112], ["children", "SPECIES", 104, 112]]], ["For that purpose, they eat more unhealthy food, have much longer screen time, and have irregular sleep patterns; all of which are linked to obesity [3].", [["obesity", "DISEASE", 140, 147], ["irregular sleep patterns", "PROBLEM", 87, 111], ["irregular", "OBSERVATION_MODIFIER", 87, 96], ["sleep", "OBSERVATION", 97, 102]]], ["In the period of quarantine, reducing energy expenditure contributes to the development of obesity.", [["obesity", "DISEASE", 91, 98], ["reducing energy expenditure", "PROBLEM", 29, 56], ["obesity", "PROBLEM", 91, 98], ["obesity", "OBSERVATION", 91, 98]]], ["Waiting for developing a COVID-19 vaccine, the quarantine will be prolonged and doubled for many countries.", [["a COVID-19 vaccine", "TREATMENT", 23, 41], ["the quarantine", "TREATMENT", 43, 57]]], ["Physical exercises can be a good solution not only for losing weight, but also can be beneficial for the immune system [13].ConclusionIn the period of quarantine, psychiatrists and psychologists will play a crucial role to help peoples to overcome the stress and depression and to create a sense of trust and safety.", [["depression", "DISEASE", 263, 273], ["the stress", "PROBLEM", 248, 258], ["depression", "PROBLEM", 263, 273]]], ["The stressful environment of quarantine has a unfavourable impact on body weight.", [["body", "ANATOMY", 69, 73], ["body", "ORGANISM_SUBDIVISION", 69, 73]]], ["After the disappearance of pandemic (COVID-19), policymakers need to focus more on these challenges and try to predict the upcoming epidemic (depreobesity).", [["depreobesity", "DISEASE", 142, 154], ["pandemic (COVID", "TREATMENT", 27, 42]]], ["Coronavirus will be a lesson for humanity to focus more on the science of prediction [14].", [["Coronavirus", "PROBLEM", 0, 11]]], ["The emerging of new techniques of translational medicine will help researchers to accelerate the treatment of this pandemic [15,18].", [["translational medicine", "TREATMENT", 34, 56], ["new", "OBSERVATION_MODIFIER", 16, 19]]], ["We hereby would like to alert public health officials to minimize as possible the depreobesity and we propose some solutions that can help people to be healthier.Declaration of fundingThis manuscript received no funding.CRediT authorship contribution statement", [["depreobesity", "DISEASE", 82, 94], ["people", "ORGANISM", 139, 145], ["people", "SPECIES", 139, 145], ["the depreobesity", "PROBLEM", 78, 94]]]], "PMC7300489": [["WHY DID SOME RECOVERED COVID\u201019 PATIENTS BECOME RETEST POSITIVE FOR SARS\u2010CoV\u20102 RNA?There are several possibilities why the recovered patients with COVID\u201019 became retest positive for SARS\u2010CoV\u20102 RNA: First, two consecutively RT\u2010PCR tests of pharyngeal swabs might be false\u2010negative before the patient was discharged from the hospital, since overall positivity of RT\u2010PCR for SARS\u2010CoV\u20102 in COVID\u201019 was round 30% to 40%.10The sampling procedures of pharyngeal swabs, quality of sampling tube, sample storage temperature and time, transportation process of samples, and quality of detection reagents (kits) might result in the false\u2010negative tests.", [["pharyngeal swabs", "ANATOMY", 240, 256], ["pharyngeal swabs", "ANATOMY", 446, 462], ["sample", "ANATOMY", 490, 496], ["samples", "ANATOMY", 553, 560], ["SARS", "DISEASE", 183, 187], ["SARS", "DISEASE", 373, 377], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 73, 78], ["patients", "ORGANISM", 133, 141], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 188, 193], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 240, 256], ["patient", "ORGANISM", 292, 299], ["CoV", "ORGANISM", 378, 381], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 446, 462], ["tube", "TISSUE", 484, 488], ["SARS\u2010CoV\u20102 RNA", "RNA", 68, 82], ["CoV\u20102 RNA", "RNA", 188, 197], ["patients", "SPECIES", 133, 141], ["patient", "SPECIES", 292, 299], ["SARS", "PROBLEM", 68, 72], ["COVID\u2010", "TEST", 147, 153], ["SARS", "PROBLEM", 183, 187], ["RT\u2010PCR tests", "TEST", 224, 236], ["pharyngeal swabs", "TEST", 240, 256], ["RT\u2010PCR", "TEST", 362, 368], ["SARS", "PROBLEM", 373, 377], ["CoV", "TEST", 378, 381], ["The sampling procedures of pharyngeal swabs", "TEST", 419, 462], ["sampling tube", "TREATMENT", 475, 488], ["sample storage temperature", "TEST", 490, 516], ["the false\u2010negative tests", "TEST", 619, 643], ["pharyngeal", "ANATOMY", 240, 250], ["pharyngeal", "ANATOMY", 446, 456]]], ["Second, some COVID\u201019 patients did not completely meet the discharge criteria.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["The interval time between the viral RNA tests before discharge and the actual discharge date went too long, and viral test was not repeated right before discharge according to the requirements of the guideline of diagnosis and treatment.", [["the viral RNA tests", "TEST", 26, 45], ["viral test", "TEST", 112, 122], ["treatment", "TREATMENT", 227, 236]]], ["Third, positive signal of viral RNA might be from the \u201cdead\u201d viruses or viral gene fragments without active viral replications.", [["fragments", "ANATOMY", 83, 92], ["viral RNA", "RNA", 26, 35], ["viral gene fragments", "DNA", 72, 92], ["viral RNA", "PROBLEM", 26, 35], ["the \u201cdead\u201d viruses", "PROBLEM", 50, 68], ["viral gene fragments", "PROBLEM", 72, 92], ["active viral replications", "TREATMENT", 101, 126], ["viral RNA", "OBSERVATION", 26, 35], ["viruses", "OBSERVATION", 61, 68], ["viral gene fragments", "OBSERVATION", 72, 92], ["without", "UNCERTAINTY", 93, 100], ["active", "OBSERVATION_MODIFIER", 101, 107], ["viral replications", "OBSERVATION", 108, 126]]], ["Finally, viral clearance might be varied from the patient to patient with pre\u2010existing conditions.", [["patient", "ORGANISM", 50, 57], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 50, 57], ["patient", "SPECIES", 61, 68], ["viral clearance", "TEST", 9, 24], ["pre\u2010existing conditions", "PROBLEM", 74, 97]]], ["For example, 48% COVID\u201019 patients had a comorbidity (such as hypertension, diabetes, etc), 44.9% patients received glucocorticoid therapy, and most COVID\u201019 patients with critical conditions were older than 50 years and above.11,12All these might delay virus clearance.ARE THE PATIENTS WITH RETEST POSITIVE FOR SARS\u2010CoV\u20102 INFECTIOUS?Theoretically, COVID\u201019 patients with active viral replication are infectious.", [["hypertension", "DISEASE", 62, 74], ["diabetes", "DISEASE", 76, 84], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 158, 166], ["patients", "ORGANISM", 358, 366], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 158, 166], ["patients", "SPECIES", 358, 366], ["a comorbidity", "PROBLEM", 39, 52], ["hypertension", "PROBLEM", 62, 74], ["diabetes", "PROBLEM", 76, 84], ["glucocorticoid therapy", "TREATMENT", 116, 138], ["critical conditions", "PROBLEM", 172, 191], ["SARS", "PROBLEM", 312, 316], ["active viral replication", "PROBLEM", 372, 396], ["infectious", "PROBLEM", 401, 411], ["comorbidity", "OBSERVATION", 41, 52], ["hypertension", "OBSERVATION", 62, 74], ["glucocorticoid therapy", "OBSERVATION", 116, 138], ["INFECTIOUS", "OBSERVATION", 323, 333], ["active", "OBSERVATION_MODIFIER", 372, 378], ["viral replication", "OBSERVATION", 379, 396], ["infectious", "OBSERVATION", 401, 411]]], ["As most already know, China has a very powerful and restrictive quarantine and follow\u2010up strategies for all patients with COVID\u201019, suspected cases, and asymptomatic individuals.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["restrictive quarantine", "TREATMENT", 52, 74], ["follow\u2010up strategies", "TREATMENT", 79, 99], ["COVID\u2010", "TREATMENT", 122, 128], ["asymptomatic individuals", "PROBLEM", 153, 177]]], ["In the 13 discharged patients with retest positive for viral RNA in Guangdong province on 25 March 2020, follow\u2010up results demonstrated no new infected cases from 104 close contacts to the original patients.", [["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 198, 206], ["viral RNA", "RNA", 55, 64], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 198, 206], ["viral RNA", "PROBLEM", 55, 64], ["new infected cases", "PROBLEM", 139, 157], ["no", "UNCERTAINTY", 136, 138], ["new", "OBSERVATION_MODIFIER", 139, 142], ["infected", "OBSERVATION", 143, 151]]], ["There was no single family member being infected by the four recovered COVID\u201019 patients with retest positive for SARS\u2010CoV\u20102 RNA, who were discharged from Zhongnan Hospital of Wuhan University,1suggesting a relative low or no infectivity of those recovered patients with retest positive for viral RNA.", [["SARS", "DISEASE", 114, 118], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 257, 265], ["viral RNA", "RNA", 291, 300], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 257, 265], ["SARS\u2010CoV", "SPECIES", 114, 122], ["SARS", "PROBLEM", 114, 118], ["viral RNA", "PROBLEM", 291, 300], ["no", "UNCERTAINTY", 10, 12], ["viral RNA", "OBSERVATION", 291, 300]]], ["Researchers in Hong Kong have followed up more than 10 recovered, discharged COVID\u201019 patients with retest positive for SARS\u2010CoV\u20102 and failed to isolate SARS\u2010CoV\u20102 virus by cell culture in the P3 laboratory due to low viral loads or no live viruses from the samples.", [["cell", "ANATOMY", 173, 177], ["samples", "ANATOMY", 258, 265], ["SARS", "DISEASE", 120, 124], ["SARS", "DISEASE", 153, 157], ["patients", "ORGANISM", 86, 94], ["CoV\u20102 virus", "ORGANISM", 158, 169], ["cell", "CELL", 173, 177], ["patients", "SPECIES", 86, 94], ["CoV\u20102 virus", "SPECIES", 158, 169], ["SARS\u2010CoV\u20102 virus", "SPECIES", 153, 169], ["SARS", "PROBLEM", 120, 124], ["CoV\u20102", "TREATMENT", 125, 130], ["isolate SARS", "PROBLEM", 145, 157], ["CoV\u20102 virus", "PROBLEM", 158, 169], ["cell culture", "TEST", 173, 185], ["low viral loads", "PROBLEM", 214, 229], ["live viruses", "PROBLEM", 236, 248]]], ["A recent study13suggested that the SARS\u2010CoV\u20102 can replicate actively in upper respiratory tract tissues in the early stage with high infectivity.", [["upper respiratory tract tissues", "ANATOMY", 72, 103], ["SARS", "DISEASE", 35, 39], ["SARS\u2010CoV\u20102", "ORGANISM", 35, 45], ["upper respiratory", "ORGANISM_SUBDIVISION", 72, 89], ["tract tissues", "TISSUE", 90, 103], ["SARS\u2010CoV\u20102", "DNA", 35, 45], ["SARS\u2010CoV", "SPECIES", 35, 43], ["A recent study13suggested", "TEST", 0, 25], ["the SARS\u2010CoV\u20102", "PROBLEM", 31, 45], ["high infectivity", "PROBLEM", 128, 144], ["upper", "ANATOMY_MODIFIER", 72, 77], ["respiratory tract", "ANATOMY", 78, 95], ["early stage", "OBSERVATION_MODIFIER", 111, 122], ["high infectivity", "OBSERVATION", 128, 144]]], ["In the later stage, the viral load was relative low in upper respiratory tract.RE\u2010INFECTION WITH SARS\u2010CoV\u20102?Host immune response to pathogens may prevent progression to severe illness or reinfection by the same pathogens.", [["upper respiratory tract", "ANATOMY", 55, 78], ["illness", "DISEASE", 176, 183], ["upper respiratory", "ORGANISM_SUBDIVISION", 55, 72], ["tract", "ORGANISM_SUBDIVISION", 73, 78], ["the viral load", "TEST", 20, 34], ["relative low in upper respiratory tract", "PROBLEM", 39, 78], ["INFECTION", "PROBLEM", 82, 91], ["pathogens", "PROBLEM", 132, 141], ["severe illness", "PROBLEM", 169, 183], ["reinfection", "PROBLEM", 187, 198], ["the same pathogens", "PROBLEM", 202, 220], ["viral load", "OBSERVATION", 24, 34], ["low", "OBSERVATION_MODIFIER", 48, 51], ["upper", "ANATOMY_MODIFIER", 55, 60], ["respiratory tract", "ANATOMY", 61, 78], ["INFECTION", "OBSERVATION", 82, 91], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["illness", "OBSERVATION", 176, 183], ["reinfection", "OBSERVATION", 187, 198]]], ["Many studies have shown that recovered patients with COVID\u201019 have antibodies to SASR\u2010CoV\u20102,14,15,16,17some patients have very low levels of neutralizing antibodies.", [["patients", "ORGANISM", 39, 47], ["SASR\u2010CoV", "ORGANISM", 81, 89], ["patients", "ORGANISM", 108, 116], ["antibodies", "PROTEIN", 67, 77], ["neutralizing antibodies", "PROTEIN", 141, 164], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 108, 116], ["Many studies", "TEST", 0, 12], ["COVID", "TEST", 53, 58], ["antibodies", "TEST", 67, 77], ["SASR", "TEST", 81, 85], ["CoV", "TEST", 86, 89], ["very low levels of neutralizing antibodies", "PROBLEM", 122, 164], ["neutralizing antibodies", "OBSERVATION", 141, 164]]], ["These raised possibilities for possible reinfection of SARS\u2010CoV\u20102 and antibody dependent enhancement.18,19,20As we discussed above, the discharged patients with COVID\u201019 in China and elsewhere were re\u2010testing positive for SARS\u2010CoV\u20102 RNA.", [["SARS", "DISEASE", 55, 59], ["SARS", "DISEASE", 222, 226], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 60, 65], ["patients", "ORGANISM", 147, 155], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 227, 232], ["CoV\u20102 RNA", "RNA", 227, 236], ["patients", "SPECIES", 147, 155], ["reinfection", "PROBLEM", 40, 51], ["SARS", "PROBLEM", 55, 59], ["antibody dependent enhancement", "PROBLEM", 70, 100], ["SARS", "PROBLEM", 222, 226], ["antibody dependent", "OBSERVATION_MODIFIER", 70, 88], ["enhancement", "OBSERVATION_MODIFIER", 89, 100], ["2 RNA", "ANATOMY_MODIFIER", 231, 236]]], ["It remains unclear whether the convalescing patients have risks for an \u201creinfection.\u201d", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["an \u201creinfection", "PROBLEM", 68, 83], ["reinfection", "OBSERVATION", 72, 83]]], ["A recent animal study18may help understanding this situation.", [["A recent animal study", "TEST", 0, 21]]], ["They used the SARS\u2010CoV\u20102\u2010infected monkeys for this study.", [["monkeys", "ORGANISM", 34, 41], ["this study", "TEST", 46, 56]]], ["They found that viral replication in nose, pharynx, lung and gut, moderate interstitial pneumonia at 7 days postinfection.", [["nose", "ANATOMY", 37, 41], ["pharynx", "ANATOMY", 43, 50], ["lung", "ANATOMY", 52, 56], ["gut", "ANATOMY", 61, 64], ["interstitial", "ANATOMY", 75, 87], ["interstitial pneumonia", "DISEASE", 75, 97], ["nose", "ORGANISM_SUBDIVISION", 37, 41], ["pharynx", "ORGAN", 43, 50], ["lung", "ORGAN", 52, 56], ["gut", "ORGAN", 61, 64], ["viral replication in nose, pharynx, lung and gut", "PROBLEM", 16, 64], ["moderate interstitial pneumonia", "PROBLEM", 66, 97], ["viral replication", "OBSERVATION", 16, 33], ["nose", "ANATOMY", 37, 41], ["pharynx", "ANATOMY", 43, 50], ["lung", "ANATOMY", 52, 56], ["gut", "ANATOMY", 61, 64], ["moderate", "OBSERVATION_MODIFIER", 66, 74], ["interstitial", "OBSERVATION_MODIFIER", 75, 87], ["pneumonia", "OBSERVATION", 88, 97], ["7 days", "OBSERVATION_MODIFIER", 101, 107]]], ["After the symptoms were alleviated and the specific antibody tested positively, they rechallenged half of infected monkeys with the same dose of SARS\u2010CoV\u20102 strain.", [["SARS", "DISEASE", 145, 149], ["monkeys", "ORGANISM", 115, 122], ["SARS\u2010CoV", "SPECIES", 145, 153], ["the symptoms", "PROBLEM", 6, 18], ["the specific antibody", "TEST", 39, 60], ["SARS", "PROBLEM", 145, 149], ["CoV\u20102 strain", "TREATMENT", 150, 162]]], ["They did not observe viral loads in nasopharyngeal and anal swabs and viral replication in all primary tissues at 5 days post\u2010reinfection.", [["nasopharyngeal", "ANATOMY", 36, 50], ["anal swabs", "ANATOMY", 55, 65], ["primary tissues", "ANATOMY", 95, 110], ["nasopharyngeal", "CANCER", 36, 50], ["anal swabs", "MULTI-TISSUE_STRUCTURE", 55, 65], ["tissues", "TISSUE", 103, 110], ["viral loads in nasopharyngeal and anal swabs", "PROBLEM", 21, 65], ["viral replication", "TREATMENT", 70, 87], ["nasopharyngeal", "ANATOMY", 36, 50], ["anal swabs", "ANATOMY", 55, 65], ["viral replication", "OBSERVATION", 70, 87]]], ["Thus, SARS\u2010CoV\u20102 infection may protect from subsequent re\u2010exposures.18Previous study showed that immunoglobulin G (IgG) antibody peaked at month 4 after the onset of SARS, IgG antibodies persisted for 16 months in all patients.", [["SARS", "DISEASE", 6, 10], ["CoV\u20102", "CHEMICAL", 11, 16], ["infection", "DISEASE", 17, 26], ["SARS", "DISEASE", 166, 170], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 11, 16], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 97, 113], ["IgG", "GENE_OR_GENE_PRODUCT", 115, 118], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 172, 186], ["patients", "ORGANISM", 218, 226], ["immunoglobulin G (IgG) antibody", "PROTEIN", 97, 128], ["IgG antibodies", "PROTEIN", 172, 186], ["patients", "SPECIES", 218, 226], ["SARS\u2010CoV\u20102 infection", "PROBLEM", 6, 26], ["18Previous study", "TEST", 68, 84], ["immunoglobulin G (IgG) antibody", "TEST", 97, 128], ["SARS", "PROBLEM", 166, 170], ["IgG antibodies", "TEST", 172, 186], ["infection", "OBSERVATION", 17, 26]]], ["In patients with COVID\u201019, antibodies were also detected in patients' blood after being infected by SARS\u2010CoV\u20102, the immunity lasted for at least 7 days following remission of symptoms.21SARS\u2010CoV\u20102\u2010specific neutralizing antibodies were detected in patients from day 10 to 15 after the onset of the disease and remained thereafter.", [["blood", "ANATOMY", 70, 75], ["SARS", "DISEASE", 100, 104], ["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 60, 68], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["21SARS", "GENE_OR_GENE_PRODUCT", 184, 190], ["patients", "ORGANISM", 247, 255], ["antibodies", "PROTEIN", 27, 37], ["21SARS", "PROTEIN", 184, 190], ["CoV\u20102\u2010specific neutralizing antibodies", "PROTEIN", 191, 229], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 247, 255], ["SARS\u2010CoV", "SPECIES", 100, 108], ["COVID", "TEST", 17, 22], ["antibodies", "TEST", 27, 37], ["symptoms", "PROBLEM", 175, 183], ["CoV\u20102\u2010specific neutralizing antibodies", "TEST", 191, 229], ["the disease", "PROBLEM", 293, 304], ["neutralizing antibodies", "OBSERVATION", 206, 229], ["disease", "OBSERVATION", 297, 304]]], ["The titers of these antibodies among these patients correlated with the spike\u2010binding antibodies targeting S1, receptor\u2010binding domain, and S2 regions, although antibody titers were variable in different patients.16Therefore, it is needed for further studies in animal and human for long time follow\u2010up to rule out the possibility for re\u2010infection of SARS\u2010CoV\u20102.MANAGEMENTFirst, the discharge criteria in Novel Coronavirus Pneumonia Diagnosis and Treatment Protocol (7th edition, trial) (http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.) must be strictly followed.", [["SARS", "DISEASE", 351, 355], ["Pneumonia", "DISEASE", 423, 432], ["patients", "ORGANISM", 43, 51], ["S1", "GENE_OR_GENE_PRODUCT", 107, 109], ["S2", "GENE_OR_GENE_PRODUCT", 140, 142], ["patients", "ORGANISM", 204, 212], ["human", "ORGANISM", 273, 278], ["antibodies", "PROTEIN", 20, 30], ["spike\u2010binding antibodies", "PROTEIN", 72, 96], ["S1", "PROTEIN", 107, 109], ["receptor\u2010binding domain", "PROTEIN", 111, 134], ["S2 regions", "PROTEIN", 140, 150], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 204, 212], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 273, 278], ["these antibodies", "TEST", 14, 30], ["the spike\u2010binding antibodies targeting S1, receptor\u2010binding domain, and S2 regions", "PROBLEM", 68, 150], ["antibody titers", "TEST", 161, 176], ["further studies", "TEST", 243, 258], ["re\u2010infection", "PROBLEM", 335, 347], ["SARS", "PROBLEM", 351, 355], ["Novel Coronavirus Pneumonia", "PROBLEM", 405, 432], ["Treatment Protocol", "TREATMENT", 447, 465], ["S2", "ANATOMY", 140, 142], ["regions", "ANATOMY_MODIFIER", 143, 150], ["Coronavirus", "OBSERVATION_MODIFIER", 411, 422], ["Pneumonia", "OBSERVATION", 423, 432]]], ["Patients with COVID\u201019 (who received glucocorticoid therapy, had comorbidities, were older than 65) may extend the length of hospital stay because of the prolonged clearance of viruses.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["glucocorticoid therapy", "TREATMENT", 37, 59], ["comorbidities", "PROBLEM", 65, 78], ["the prolonged clearance of viruses", "PROBLEM", 150, 184], ["viruses", "OBSERVATION", 177, 184]]], ["These discharged patients with COVID\u201019 also should be under quarantine management and health monitoring for 14 days as described in the seventh edition of guidance, instead of \u201cself\u2010monitoring for 14 days\u201d described in previous editions of the Guidance.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["quarantine management", "TREATMENT", 61, 82], ["health monitoring", "TEST", 87, 104]]], ["Finally, combination of serology tests for immunoglobulin M and IgG and viral RNA might be also helpful for surveillance and decision making for discharge of patients with COVID\u201019.17,22", [["COVID\u201019.17,22", "CHEMICAL", 172, 186], ["immunoglobulin M", "GENE_OR_GENE_PRODUCT", 43, 59], ["IgG", "GENE_OR_GENE_PRODUCT", 64, 67], ["patients", "ORGANISM", 158, 166], ["immunoglobulin M and IgG and viral RNA", "RNA", 43, 81], ["patients", "SPECIES", 158, 166], ["serology tests", "TEST", 24, 38], ["immunoglobulin M", "TEST", 43, 59], ["IgG", "TEST", 64, 67], ["viral RNA", "PROBLEM", 72, 81], ["surveillance", "TEST", 108, 120]]]]}